# Patent

## Title
Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels

## Abstract

The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds of formula (I) useful as inhibitors of ion channels:




wherein R1, R2, R3, R4, A, m, n, and o are as defined in the description. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

## Background
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims priority to U.S. provisional patent application Ser. Nos. 61/438,685, filed Feb. 2, 2011, 61/440,987, filed Feb. 9, 2011, and 61/495,538, filed Jun. 10, 2011, the entire contents of all applications are incorporated herein by reference.


TECHNICAL FIELD OF THE INVENTION
The invention relates to compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
BACKGROUND OF THE INVENTION
Pain is a protective mechanism that allows healthy animals to avoid tissue damage and to prevent further damage to injured tissue. Nonetheless there are many conditions where pain persists beyond its usefulness, or where patients would benefit from inhibition of pain. Voltage-gated sodium channels are believed to play a critical role in pain signaling. This belief is based on the known roles of these channels in normal physiology, pathological states arising from mutations in sodium channel genes, preclinical work in animal models of disease, and the clinical usefulness of known sodium channel modulating agents (Cummins, T. R., Sheets, P. L., and Waxman, S. G., The roles of sodium channels in nociception: Implications for mechanisms of pain. Pain 131 (3), 243 (2007); England, S., Voltage-gated sodium channels: the search for subtype-selective analgesics. Expert Opin Investig Drugs 17 (12), 1849 (2008); Krafte, D. S, and Bannon, A. W., Sodium channels and nociception: recent concepts and therapeutic opportunities. Curr Opin Pharmacol 8 (1), 50 (2008)).
Voltage-gated sodium channels (NaV's) are key biological mediators of electrical signaling. NaV's are the primary mediators of the rapid upstroke of the action potential of many excitable cell types (e.g. neurons, skeletal myocytes, cardiac myocytes), and thus are critical for the initiation of signaling in those cells (Hille, Bertil, Ion Channels of Excitable Membranes, Third ed. (Sinauer Associates, Inc., Sunderland, Mass., 2001)). Because of the role NaV's play in the initiation and propagation of neuronal signals, antagonists that reduce NaV currents can prevent or reduce neural signaling. Thus NaV channels are considered likely targets in pathologic states where reduced excitability is predicted to alleviate the clinical symptoms, such as pain, epilepsy, and some cardiac arrhythmias (Chahine, M., Chatelier, A., Babich, O., and Krupp, J. J., Voltage-gated sodium channels in neurological disorders. CNS Neurol Disord Drug Targets 7 (2), 144 (2008)).
The NaV's form a subfamily of the voltage-gated ion channel super-family and comprises 9 isoforms, designated NaV 1.1-NaV 1.9. The tissue localizations of the nine isoforms vary greatly. NaV 1.4 is the primary sodium channel of skeletal muscle, and NaV 1.5 is primary sodium channel of cardiac myocytes. NaV's 1.7, 1.8 and 1.9 are primarily localized to the peripheral nervous system, while NaV's 1.1, 1.2, 1.3, and 1.6 are neuronal channels found in both the central and peripheral nervous systems. The functional behaviors of the nine isoforms are similar but distinct in the specifics of their voltage-dependent and kinetic behavior (Catterall, W. A., Goldin, A. L., and Waxman, S. G., International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev 57 (4), 397 (2005)).
NaV channels have been identified as the primary target for some clinically useful pharmaceutical agents that reduce pain (Cummins, T. R., Sheets, P. L., and Waxman, S. G., The roles of sodium channels in nociception: Implications for mechanisms of pain. Pain 131 (3), 243 (2007)). The local anesthetic drugs such as lidocaine block pain by inhibiting NaV channels. These compounds provide excellent local pain reduction but suffer the drawback of abolishing normal acute pain and sensory inputs. Systemic administration of these compounds results in dose limiting side effects that are generally ascribed to block of neural channels in the CNS (nausea, sedation, confusion, ataxia). Cardiac side effects can also occur, and indeed these compounds are also used as class 1 anti-arrhythmics, presumably due to block of NaV 1.5 channels in the heart. Other compounds that have proven effective at reducing pain have also been suggested to act by sodium channel blockade including carbamazepine, lamotragine, and tricyclic antidepressants (Soderpalm, B., Anticonvulsants: aspects of their mechanisms of action. Eur J Pain 6 Suppl A, 3 (2002); Wang, G. K., Mitchell, J., and Wang, S. Y., Block of persistent late Na+ currents by antidepressant sertraline and paroxetine. J Membr Biol 222 (2), 79 (2008)). These compounds are likewise dose limited by adverse effects similar to those seen with the local anesthetics. Antagonists that specifically block only the isoform(s) critical for nocioception are expected to have increased efficacy since the reduction of adverse effects caused by block of off-target channels should enable higher dosing and thus more complete block of target channels isoforms.
Four NaV isoforms, NaV 1.3, 1.7, 1.8, and 1.9, have been specifically indicated as likely pain targets. NaV 1.3 is normally found in the pain sensing neurons of the dorsal root ganglia (DRG) only early in development and is lost soon after birth both in humans and in rodents. Nonetheless, nerve damaging injuries have been found to result in a return of the NaV 1.3 channels to DRG neurons and this may contribute to the abnormal pain signaling in various chronic pain conditions resulting from nerve damage (neuropathic pain). These data have led to the suggestion that pharmaceutical block of NaV 1.3 could be an effective treatment for neuropathic pain. In opposition to this idea, global genetic knockout of NaV 1.3 in mice does not prevent the development of allodynia in mouse models of neuropathic pain (Nassar, M. A. et al., Nerve injury induces robust allodynia and ectopic discharges in NaV 1.3 null mutant mice. Mol Pain 2, 33 (2006)). It remains unknown whether compensatory changes in other channels allow for normal neuropathic pain in NaV 1.3 knockout mice, though it has been reported that knockout of NaV 1.1 results in drastic upregulation of NaV 1.3. The converse effect in NaV 1.3 knockouts might explain these results.
NaV 1.7, 1.8, and 1.9 are highly expressed in DRG neurons, including the neurons whose axons make up the C-fibers and Aδ nerve fibers that are believed to carry most pain signals from the nociceptive terminals to the central nervous. Like NaV 1.3, NaV 1.7 expression increases after nerve injury and may contribute to neuropathic pain states. The localization of NaV 1.7, 1.8, and 1.9 in nociceptors led to the hypothesis that reducing the sodium currents through these channels might alleviate pain. Indeed, specific interventions that reduce the levels of these channels have proven effective in animal models of pain.
Specific reduction of NaV 1.7 in rodents by multiple different techniques has resulted in the reduction of observable pain behaviors in model animals. Injection of a viral antisense NaV 1.7 cDNA construct greatly reduces normal pain responses due to inflammation or mechanical injury (Yeomans, D. C. et al., Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of NaV 1.7 sodium channels in primary afferents. Hum Gene Ther 16 (2), 271 (2005)). Likewise, a genetic knockout of NaV 1.7 in a subset of nociceptor neurons reduced acute and inflammatory pain in mouse models (Nassar, M. A. et al., Nociceptor-specific gene deletion reveals a major role for NaV 1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci USA 101 (34), 12706 (2004)). Global knockouts of NaV 1.7 in mice lead to animals that die on the first day after birth. These mice fail to feed and this is the presumed cause of death.
Treatments that specifically reduce NaV 1.8 channels in rodent models effectively reduce pain sensitivity. Knockdown of NaV 1.8 in rats by intrathecal injection of antisense oligodeoxynucleotides reduces neuropathic pain behaviors, while leaving acute pain sensation intact (Lai, J. et al., Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain 95 (1-2), 143 (2002); Porreca, F. et al., A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc Natl Acad Sci USA 96 (14), 7640 (1999)). Global genetic knockout of NaV 1.8 in mice or specific destruction of NaV 1.8 expressing neurons greatly reduces perception of acute mechanical, inflammatory, and visceral pain (Akopian, A. N. et al., The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 2 (6), 541 (1999); Abrahamsen, B. et al., The cell and molecular basis of mechanical, cold, and inflammatory pain. Science 321 (5889), 702 (2008); Laird, J. M., Souslova, V., Wood, J. N., and Cervero, F., Deficits in visceral pain and referred hyperalgesia in NaV 1.8 (SNS/PN3)-null mice. J Neurosci 22 (19), 8352 (2002)). In contrast to the antisense experiments in rats, genetic knockout mice appear to develop neuropathic pain behaviors normally after nerve injury (Lai, J. et al., Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8. Pain 95 (1-2), 143 (2002); Akopian, A. N. et al., The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 2 (6), 541 (1999); Abrahamsen, B. et al., The cell and molecular basis of mechanical, cold, and inflammatory pain. Science 321 (5889), 702 (2008); Laird, J. M., Souslova, V., Wood, J. N., and Cervero, F., Deficits in visceral pain and referred hyperalgesia in NaV 1.8 (SNS/PN3)-null mice. J Neurosci 22 (19), 8352 (2002)).
NaV 1.9 global knock out mice have decreased sensitivity to inflammation induced pain, despite normal acute, and neuropathic pain behaviors (Amaya, F. et al., The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. J Neurosci 26 (50), 12852 (2006); Priest, B. T. et al., Contribution of the tetrodotoxin-resistant voltage-gated sodium channel NaV 1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci USA 102 (26), 9382 (2005)). Spinal knockdown of NaV 1.9 had no apparent effect on pain behavior in rats (Porreca, F. et al., A comparison of the potential role of the tetrodotoxin-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc Natl Acad Sci USA 96 (14), 7640 (1999)).
The understanding of the role of NaV channels in human physiology and pathology has been greatly advanced by the discovery and analysis of naturally occurring human mutations. NaV 1.1 and NaV 1.2 mutations result in various forms of epilepsy (Fujiwara, T., Clinical spectrum of mutations in SCN1A gene: severe myoclonic epilepsy in infancy and related epilepsies. Epilepsy Res 70 Suppl 1, S223 (2006); George, A. L., Jr., Inherited disorders of voltage-gated sodium channels. J Clin Invest 115 (8), 1990 (2005); Misra, S, N., Kahlig, K. M., and George, A. L., Jr., Impaired NaV 1.2 function and reduced cell surface expression in benign familial neonatal-infantile seizures. Epilepsia 49 (9), 1535 (2008)). Mutations of the NaV 1.4 cause muscular disorders like paramyotonia congenital (Vicart, S., Sternberg, D., Fontaine, B., and Meola, G., Human skeletal muscle sodium channelopathies. Neurol Sci 26 (4), 194 (2005)). NaV 1.5 mutations result in cardiac abnormalities like Brugada Syndrome and long QT syndrome (Bennett, P. B., Yazawa, K., Makita, N., and George, A. L., Jr., Molecular mechanism for an inherited cardiac arrhythmia. Nature 376 (6542), 683 (1995); Darbar, D. et al., Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 117 (15), 1927 (2008); Wang, Q. et al., SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80 (5), 805 (1995)).
Recent discoveries have demonstrated that mutations in the gene that encodes the NaV 1.7 channel (SCN9A) can cause both enhanced and reduced pain syndromes. Work by Waxman's group and others have identified at least 15 mutations that result in enhanced current through NaV 1.7 and are linked to dominant congenital pain syndromes. Mutations that lower the threshold for NaV 1.7 activation cause inherited erythromelalgia (IEM). IEM patients exhibit abnormal burning pain in their extremities. Mutations that interfere with the normal inactivation properties of NaV 1.7 lead to prolonged sodium currents and cause paroxysmal extreme pain disorder (PEPD). PEPD patients exhibit periocular, perimandibular, and rectal pain symptoms that progresses throughout life (Drenth, J. P. et al., SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol 124 (6), 1333 (2005); Estacion, M. et al., NaV 1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. J Neurosci 28 (43), 11079 (2008)).
NaV 1.7 null mutations in human patients were recently described by several groups (Ahmad, S. et al., A stop codon mutation in SCN9A causes lack of pain sensation. Hum Mol Genet. 16 (17), 2114 (2007); Cox, J. J. et al., An SCN9A channelopathy causes congenital inability to experience pain. Nature 444 (7121), 894 (2006); Goldberg, Y. P. et al., Loss-of-function mutations in the NaV 1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet. 71 (4), 311 (2007)). In all cases patients exhibit congenital indifference to pain. These patients report no pain under any circumstances. Many of these patients suffer dire injuries early in childhood since they do not have the protective, normal pain that helps to prevent tissue damage and develop appropriate protective behaviors. Aside from the striking loss of pain sensation and reduced or absent of smell (Goldberg, Y. P. et al., Loss-of-function mutations in the NaV 1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet. 71 (4), 311 (2007)), these patients appear completely normal. Despite the normally high expression of NaV 1.7 in sympathetic neurons (Toledo-Aral, J. J. et al., Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc Natl Acad Sci USA 94 (4), 1527 (1997)) and adrenal chromafin cells (Klugbauer, N., Lacinova, L., Flockerzi, V., and Hofmann, F., Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J 14 (6), 1084 (1995)), these NaV 1.7-null patients show no sign of neuroendocrine or sympathetic nervous dysfunction.
The gain of NaV 1.7 function mutations that cause pain, coupled with the loss of NaV 1.7 function mutations that abolish pain, provide strong evidence that NaV 1.7 plays an important role in human pain signaling. The relative good health of NaV 1.7-null patients indicates that ablation of NaV 1.7 is well tolerated in these patients.
Unfortunately, the efficacy of currently used sodium channel blockers for the disease states described above has been to a large extent limited by a number of side effects. These side effects include various CNS disturbances such as blurred vision, dizziness, nausea, and sedation as well more potentially life threatening cardiac arrhythmias and cardiac failure. Accordingly, there remains a need to develop additional Na channel antagonists, preferably those with higher potency and fewer side effects.
SUMMARY OF THE INVENTION
It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels. These compounds have the general formula I:




or a pharmaceutically acceptable salt thereof.

These compounds and pharmaceutically acceptable compositions are useful for treating or lessening the severity of a variety of diseases, disorders, or conditions, including, but not limited to, acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, or cancer pain.


DETAILED DESCRIPTION OF THE INVENTION
In one aspect, the invention provides compounds of formula I:




or a pharmaceutically acceptable salt thereof,

wherein, independently for each occurrence:

    R1 is H, C1-C8 alkyl, C3-C8 cycloalkyl, halo, CN, NR8SO2R8, SO2R8, SR8, SOR8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, heterocycloalkyl, or a straight chain, branched, or cyclic (C1-C8)-R1 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8, or two R1 taken together form an oxo group, or a 3 to 7 membered fused cycloalkyl ring, or a 3 to 7 membered spirocyclic ring;
    R2 is H, C1-C8 alkyl, halo, C1-C8 haloalkyl, CN, OH, SO2R8, SR8, SOR8, CO2R8, CON(R8)2, COR8, SO2N(R8)2, CF3, CHF2, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, CF2, or NR8;
    R3 is H, C1-C8 alkyl, C3-C8 cycloalkyl, CO2R8, COR8, COH, CON(R8)2, CF3, CH2CF3, CH2CHF2, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, CF2, or NR8;
    R4 is H, C1-C8 alkyl, halo, C3-C8 cycloalkyl, wherein up to two CH2 units may be replaced by O, CO, S, SO, SO2, or NR8, or 2 R4 taken together form a fused 3 to 7 membered cycloalkyl ring;
    R8 is H, C1-C8 alkyl, CF3, C3-C8 cycloalkyl, fluoroalkyl, aryl, heteroaryl, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR, or 2 R8 taken together with the atoms to which they are attached form a ring;
    R9 is H, CF3, CO2R, OH, aryl, heteroaryl, C3-C8 cycloalkyl, heterocycloalkyl, N(R)2, NRCOR, CON(R)2, CN, halo, or SO2R;
    R is H, C1-C8 alkyl, aryl, heteroaryl, C3-C8 cycloalkyl, or heterocycloalkyl;
    A is an optionally substituted aryl, heteroaryl or heterocyclic;
    m is an integer from 0 to 4 inclusive;
    n is an integer from 0 to 3 inclusive; and
    o is an integer from 0 to 4 inclusive.


In another aspect, the invention provides compounds of formula I,

    or a pharmaceutically acceptable salt thereof, wherein, independently for each occurrence:
    R1 is H, C1-C6 alkyl, C3-C8 cycloalkyl, halo, CN, NR8SO2R8, SO2R8, SR8, SOR8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, heterocycloalkyl, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8, or two R1 taken together form an oxo group, or a 3 to 7 membered fused cycloalkyl ring, or a 3 to 7 membered spirocyclic ring;
    R2 is H, C1-C6 alkyl, C1-C6 haloalkyl, CN, OH, SO2R8, SR8, SOR8, CO2R8, CON(R8)2, SO2N(R8)2, CF3, CHF2, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, CF2, or NR8;
    R3 is H, C1-C6 alkyl, C3-C8 cycloalkyl, CO2R8, CORS, COH, CON(R8)2, CF3, CH2CF3, CH2CHF2, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8;
    R4 is H, C1-C6 alkyl, halo, C3-C8 cycloalkyl, wherein up to two CH2 units may be replaced by O, CO, S, SO, SO2, or NR8, or 2 R4 taken together form a fused 3 to 7 membered cycloalkyl ring;
    R8 is H, C1-C6 alkyl, CF3, C3-C8 cycloalkyl, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR, or 2 R8 taken together with the atoms to which they are attached form a ring;
    R9 is H, CF3, CO2R, OH, aryl, heteroaryl, C3-C8 cycloalkyl, heterocycloalkyl, N(R)2, NRCOR, CON(R)2, CN, or SO2R;
    R is H, C1-C6 alkyl, aryl, heteroaryl, C3-C8 cycloalkyl, or heterocycloalkyl;
    A is an optionally substituted aryl, heteroaryl or heterocyclic;
    m is an integer from 0 to 4 inclusive;
    n is an integer from 0 to 3 inclusive; and
    o is an integer from 0 to 4 inclusive.


For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March's Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
As described herein, compounds of the invention can optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention. The phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” As described herein, the variables R1-R9 in formula I encompass specific groups, such as, for example, alkyl and aryl. Unless otherwise noted, each of the specific groups for the variables R1-R8 can be optionally substituted with one or more substituents of halo, cyano, oxoalkoxy, hydroxy, amino, nitro, aryl, haloalkyl, and alkyl. For instance, an alkyl group can be optionally substituted with one or more of halo, cyano, oxoalkoxy, hydroxy, amino, nitro, aryl, haloalkyl, and alkyl. As an additional example, an aryl group can be optionally substituted with one or more of halo, cyano, alkoxy, hydroxy, nitro, haloalkyl, and alkyl. As one of ordinary skill in the art will recognize, combinations of substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds. The term “stable”, as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week. When two alkoxy groups are bound to the same atom or adjacent atoms, the two alkoxy groups can form a ring together with the atom(s) to which they are bound.
In general, the term “substituted,” whether preceded by the term “optionally” or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. Specific substituents are described above in the definitions and below in the description of compounds and examples thereof. Unless otherwise indicated, an optionally substituted group can have a substituent at each substitutable position of the group, and when more than one position in any given structure can be substituted with more than one substituent selected from a specified group, the substituent can be either the same or different at every position. A ring substituent, such as a heterocycloalkyl, can be bound to another ring, such as a cycloalkyl, to form a spiro-bicyclic ring system, e.g., both rings share one common atom. As one of ordinary skill in the art will recognize, combinations of substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds.
The phrase “up to”, as used herein, refers to zero or any integer number that is equal or less than the number following the phrase. For example, “up to 3” means any one of 0, 1, 2, and 3.
The term “aliphatic”, “aliphatic group” or “alkyl” as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation. Unless otherwise specified, aliphatic groups contain 1-20 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, and in yet other embodiments aliphatic groups contain 1-4 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups. The term “cycloaliphatic” or “cycloalkyl” mean a monocyclic hydrocarbon, bicyclic, or tricyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic and has a single point of attachment to the rest of the molecule. In some embodiments, “cycloaliphatic” refers to a monocyclic C3-C8 hydrocarbon or bicyclic C8-C12 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members.
The term “electron withdrawing group”, as used herein means an atom or a group that is electronegative relative to hydrogen. See, e.g., “Advanced Organic Chemistry: Reactions, Mechanisms, and Structure,” Jerry March, 4th Ed., John Wiley & Sons (1992), e.g., pp. 14-16, 18-19, etc. Exemplary such substituents include halo such as Cl, Br, or F, CN, COOH, CF3, etc.
Unless otherwise specified, the term “heterocycle”, “heterocyclyl”, “heterocycloaliphatic”, “heterocycloalkyl” or “heterocyclic” as used herein means non-aromatic, monocyclic, bicyclic, or tricyclic ring systems in which one or more ring atoms in one or more ring members is an independently selected heteroatom. Heterocyclic ring can be saturated or can contain one or more unsaturated bonds. In some embodiments, the “heterocycle”, “heterocyclyl”, “heterocycloaliphatic”, “heterocycloalkyl” or “heterocyclic” group has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the ring system contains 3 to 7 ring members.
The term “heteroatom” means oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+ (as in N-substituted pyrrolidinyl)).
The term “unsaturated”, as used herein, means that a moiety has one or more units of unsaturation but is not aromatic.
The term “alkoxy”, or “thioalkyl”, as used herein, refers to an aliphatic group, as previously defined, attached to the principal carbon chain through an oxygen (“alkoxy”) or sulfur (“thioalkyl”) atom. As used herein, alkoxy group includes alkenyloxy and aklkynyloxy groups.
The term “aryl” used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring carbon atoms, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring carbon atoms. The term “aryl” may be used interchangeably with the term “aryl ring”.
The term “heteroaryl”, used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members. The term “heteroaryl” may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.
The term “alkylidene chain” refers to a straight or branched carbon chain that may be fully saturated or have one or more units of unsaturation and has two points of attachment to the rest of the molecule.
Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention.
Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Thus, included within the scope of the invention are tautomers of compounds of formula I.
Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds of formula I, wherein one or more hydrogen atoms are replaced deuterium or tritium, or one or more carbon atoms are replaced by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, probes in biological assays, or sodium channel blockers with improved therapeutic profile.
In the formulas and drawings, a line transversing a ring and bonded to an R group such as in




means that the R group can be bonded to any carbon, or if applicable, heteroatom such as N, of that ring as valency allows.

Within a definition of a term as for example, R1, R2, R3, R4, R5, R6, or R7 when a CH2 unit or, interchangeably, methylene unit may be replaced by O, CO, S, SO, SO2 or NR8, it is meant to include any CH2 unit, including a CH2 within a terminal methyl group. For example, —CH2CH2CH2SH is within the definition of C1-C8 alkyl wherein up to two CH2 units may be replaced by S because the CH2 unit of the terminal methyl group has been replaced by S.
In another embodiment, the invention features a compound of formula I and the attendant definitions, wherein R1 is C1-C8 alkyl or two R1 taken together with the atoms to which they are attached form a 3 to 7 membered fused cycloalkyl or spirocyclic ring. In another embodiment, R1 is CH3 or two R1 taken together form a fused cyclohexyl ring.
In another embodiment, the invention features a compound of formula I and the attendant definitions, wherein R2 is H, C1-C8 alkyl, halo, CF3, CN, CON(R8)2, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, CF2, or NR8. In another embodiment, R2 is COCF3, COtBu, Cl, COCH3, CF2CF3, CH2CF3, CF3, CN, Br, COCH(CH3)2, COCH2CH3, CH(OH)CF3, SO2CH3,




COPh,





In another embodiment, the invention features a compound of formula I and the attendant definitions, wherein R3 is H, C1-C8 alkyl, CO2R8, COR8, COH, CON(R8)2 or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, CF2, S, SO, SO2 or NR8. In another embodiment, R3 is H, CH3, CH2CH3, CH2CH2OCH3, benzyl, CH2CH(CH2)2, CH(CH2)2, cyclobutyl, COCH3, CO2CH3, CO2CH2CH3, CH2CF3, CH2CHF2, COH, CON(CH3)2, or CONHCH3.
In another embodiment, the invention features a compound of formula I and the attendant definitions, wherein R4 is H, halo, or C1-C8 alkyl. In another embodiment, R4 is H, F, or CH3.
In another embodiment, the invention features a compound of formula I and the attendant definitions, wherein m is 0, 1, or 2. In another embodiment, n is 0, 1 or 2. In another embodiment, o is 0 or 1.
In another embodiment, the invention features a compound of formula I and the attendant definitions, wherein A is




wherein:

    R5 is H, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, halo, CN, OH, OR8, N(R8)2, NR8SO2R8, SO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R)2, CHF2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8;
    R6 is H, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, C3-C8 cycloalkoxy, halo, CN, OH, OR8N(R8)2, NR8SO2R8, SO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8;
    R7 is H, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, halo, CN, OH, OR8, N(R8)2, NR8SO2R8, SO2R8, OSO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C1-C8)-(R9)p, wherein p is 1 or 2 and wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8; or
    two occurrences of R5 and R6, or R6 and R7 are both C1-C8 alkyl and together with the carbons to which they are attached form an optionally substituted ring comprising up to 2 heteroatoms.


In another embodiment, the invention features a compound of formula I and the attendant definitions, wherein R5 is H, C1-C8 alkyl, C1-C8 alkoxy, halo, OCF3, OCHF2, R9, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR7. In another embodiment, R5 is H, CH3, OCH3, OCF3, OPh, Ph, OCHF2, or F.
In another embodiment, the invention features a compound of formula I and the attendant definitions, wherein R6 is H, C1-C8 alkyl, C1-C8 alkoxy, halo, R9, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8. In another embodiment, R6 is H, CH3, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, CF3, CN, Ph, SO2CH3, OH, CH(CH3)2, OCH2CH2CH2CH3, F, Cl, or CH2OH.
In another embodiment, the invention features a compound of formula I and the attendant definitions, wherein R7 is H, C1-C8 alkyl, C1-C8 alkoxy, SO2R8, OSO2R8, SO2N(R8)2, R9, or a straight chain, branched, or cyclic (C1-C8)-(R9)p, wherein p is 1 or 2 and wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8. In another embodiment, R7 is H, CH2CH3, tBu, Cl, F, OH, C(═CH2)CH3, OC(═CH2)CH3, OCH3, OCH2CH2CH2CH3, CH2OH, OCH2CH2OH, OCH2CH2CH2OH, OtBu, OCH(CH3)(CH2CH3), OCH2C(CH3)2OH, C(CH3)2OH, CH2C(CH3)2OH, CH(OH)CH(CH3)2, C(CH3)2CH2OH, OCH2CH2CH(CH3)2, OCH2CH2CH3, OCH(CH3)2, OCH2CH2OCH3,




SO2CH3, SO2tBu, SO2CH2CH3, SO2CH2CH(CH3)2, SO2CH(CH3)2,





SO2NH(CH3), SO2NH(CH(CH2)2), SO2NH(CH2CH3), SO2NH(CH(CH3)2), SO2N(CH3)2,





Ph,





OCH2CH2OCH3, CH(CH3)2, SO2N(CH2CH3)2, CH2CH2CH2CH3, CH2CH2CH3, OPh, OCH2CH2CH2CH3, CH2OPh,





OCH2Ph, CH2CH2CH2CH2CH3, OCH2CH3, OCH2CH(CH3)2, CH2CH3, CH2Ph,





CCCH2OCH3, SO2CHF2, OCF3,





OCHF2,





CH2CH(CH3)2, OCH2tBu,





OCH2CF3,





CH2OCH2CH2CF3, CH2OCH2CF3, SO2CF3, C(CH3)2CH2CH3, C(CH2CH3)3, CH(OCH2CF3)2,





CF3, OCH2C(CH3)2F,





CH(OH)CH2OCH2CF3, CH(OCH2CF3)CH2OH, OSO2CF3,





or OCH2CH2OCF3.

In another embodiment, the invention features a compound of formula I and the attendant definitions, wherein A is




and is selected from:












































In another embodiment, the invention features a compound of formula I and the attendant definitions, wherein A is heteroaryl or heterocyclic. In another embodiment, A is a monocyclic heteroaryl comprising 1 to 3 heteroatoms independently selected from N, O, or S. In another embodiment, A is selected from a bicyclic heteroaryl comprising from 1 to 3 heteroatoms independently selected from N, O, or S.
In another embodiment, the invention features a compound of formula I and the attendant definitions, wherein A is selected from the following:













In another embodiment, the compounds of the invention have formula IA:




wherein:

    R2 is H, C1-C8 alkyl, halo, C1-C8 haloalkyl, CN, OH, SO2R8, SR8, SOR8, COR8, CO2R8, CON(R8)2, SO2N(R8)2, CF3, CHF2, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 CF2, or NR8;
    R3 is H, C1-C8 alkyl, CO2R8, COR8, COH, CON(R8)2, CF3, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, CF2, S, SO, SO2 or NR8;
    R6 is H, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, C3-C8 cycloalkoxy, halo, CN, OH, OR8N(R8)2, NR8SO2R8, SO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8;
    R7 is H, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, halo, CN, OH, OR8, N(R8)2, NR8SO2R8, SO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8.


In another embodiment, the invention features a compound of formula IA and the attendant definitions, wherein R2 is H, COCF3, COtBu, Cl, COCH3, CF2CF3, CH2CF3, CF3, CN, Br, COCH(CH3)2, COCH2CH3, CH(OH)CF3, SO2CH3,




COPh,





In another embodiment, the invention features a compound of formula IA and the attendant definitions, wherein R3 is H, CH3, CH2CH3, CH2CH2OCH3, CH2CH2OH, CH2CO2CH2CH3, CH2CON(CH3)2, CH2CONH2, CH2CN, benzyl, cyclobutyl, CH2CH(CH2)2, CH(CH2)2, CH2CF3, CH2CHF2, COCH3, COCH2CH3, CO2CH3, CO2CH2CH3, COH, CONH(CH3)2, or CONHCH3.
In another embodiment, the invention features a compound of formula IA and the attendant definitions, wherein R6 is H, CH3, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, CF3, CN, Ph, SO2CH3, OH, CH(CH3)2, OCH2CH2CH2CH3, F, Cl, or CH2OH.
In another embodiment, the invention features a compound of formula IA and the attendant definitions, wherein R7 is H, CH3, CH2CH3, tBu, Cl, F, OH, C(═CH2)CH3, OC(═CH2)CH3, OCH3, OCH2CH2CH2CH3, CH2OH, OCH2CH2OH, OCH2CH2CH2OH, OtBu, OCH(CH3)(CH2CH3), OCH2C(CH3)2OH, C(CH3)2OH, CH2C(CH3)2OH, CH(OH)CH(CH3)2, C(CH3)2CH2OH, OCH2CH2CH(CH3)2, OCH2CH2CH3, OCH(CH3)2, OCH2CH2OCH3,




SO2CH3, SO2tBu, SO2CH2CH3, SO2CH2CH(CH3)2, SO2CH(CH3)2,





SO2NH(CH3), SO2NH(CH(CH2)2), SO2NH(CH2CH3), SO2NH(CH(CH3)2), SO2N(CH3)2,





OPh, Ph,





OCH2CH2OCH3, CH(CH3)2, SO2N(CH2CH2CH3)2, CH2CH2CH2CH3, CH2CH2CH3, OCH2CH2CH2CH3, CH2OPh,





OCH2Ph, CH2CH2CH2CH2CH3, OCH2CH3, OCH2CH(CH3)2, CH2Ph,





CCCH2OCH3, SO2CHF2, OCF3,





OCHF2,





CH2CH(CH3)2, OCH2tBu,





OCH2CF3,





CH2OCH2CH2CF3, CH2OCH2CF3, SO2CF3, C(CH3)2CH2CH3, C(CH2CH3)3, CH(OCH2CF3)2,





CF3, OCH2C(CH3)2F,





CH(OH)CH2OCH2CF3, CH(OCH2CF3)CH2OH, OSO2CF3,





or OCH2CH2OCF3.

In another embodiment, the invention features a compound of formula IA and the attendant definitions, wherein R2 is H, CF3, COCF3, COtBu, Cl, COCH3, CF2CF3, CH2CF3 or CN; R3 is H, CH2CH2OCH3, benzyl, CH3, CH2CH3, CH2CH(CH2)2, cyclobutyl, COCH3, CO2CH3, COH, CH(CH2)2, CH2CF3, CH2CHF2, CO2CH2CH3, CON(CH3)2, or CONHCH3; R6 is CH3, OCH3, OCH2CH3, OCH2CH2CH2CH3, CH2OH, F, or Cl; and R7 is F, CH2CH3, tBu, OH, OCH3, OCH2CH2CH2CH3, OtBu, OCH(CH3)(CH2CH3), OCH2CH2OH, OCH2CH2CH2OH, OCH2C(CH3)2OH, C(CH3)2OH, C(═CH2)CH3, OC(═CH2)CH3, CH2OH, C(CH3)2CH2OH,




OCH2CH2CH(CH3)2, OCH2CH2CH3, OCH(CH3)2, OCH2CH2OCH3, SO2CH3, SO2CH2CH3, SO2CH(CH3)2,





SO2NH(CH3), SO2NH(CH(CH2)2), SO2NH(CH2CH3), SO2NH(CH(CH3)2), SO2N(CH3)2, or OCH2CH2OCF3.

In another embodiment, the invention features a compound of formula IA and the attendant definitions, wherein the




moiety is selected from:






































In another embodiment, the invention features a compound of formula I, wherein the compound is selected from Table 1:

















1


 






2


 






3


 






4


 






5


 






6


 






7


 






8


 






9


 






10


 






11


 






12


 






13


 






14


 






15


 






16


 






17


 






18


 






19


 






20


 






21


 






22


 






23


 






24


 






25


 






26


 






27


 






28


 






29


 






30


 






31


 






32


 






33


 






34


 






35


 






36


 






37


 






38


 






39


 






40


 






41


 






42


 






43


 






44


 






45


 






46


 






47


 






48


 






49


 






50


 






51


 






52


 






53


 






54


 






55


 






56


 






57


 






58


 






59


 






60


 






61


 






62


 






63


 






64


 






65


 






66


 






67


 






68


 






69


 






70


 






71


 






72


 






73


 






74


 






75


 






76


 






77


 






78


 






79


 






80


 






81


 






82


 






83


 






84


 






85


 






86


 






87


 






88


 






89


 






90


 






91


 






92


 






93


 






94


 






95


 






96


 






97


 






98


 






99


 






100


 






101


 






102


 






103


 






104


 






105


 






106


 






107


 






108


 






109


 






110


 






111


 






112


 






113


 






114


 






115


 






116


 






117


 






118


 






119


 






120


 






121


 






122


 






123


 






124


 






125


 






126


 






127


 






128


 






129


 






130


 






131


 






132


 






133


 






134


 






135


 






136


 






137


 






138


 






139


 






140


 






141


 






142


 






143


 






144


 






145


 






146


 






147


 






148


 






149


 






150


 






151


 






152


 






153


 






154


 






155


 






156


 






157


 






158


 






159


 






160


 






161


 






162


 






163


 






164


 






165


 






166


 






167


 






168


 






169


 






170


 






171


 






172


 






173


 






174


 






175


 






176


 






177


 






178


 






179


 






180


 






181


 






182


 






183


 






184


 






185


 






186


 






187


 






188


 






189


 






190


 






191


 






192


 






193


 






194


 






195


 






196


 






197


 






198


 






199


 






200


 






201


 






202


 






203


 






204


 






205


 






206


 






207


 






208


 






209


 






210


 






211


 






212


 






213


 






214


 






215


 






216


 






217


 






218


 






219


 






220


 






221


 






222


 






223


 






224


 






225


 






226


 






227


 






228


 






229


 






230


 






231


 






232


 






233


 






234


 






235


 






236


 






237


 






238


 






239


 






240


 






241


 






242


 






243


 






244


 






245


 






246


 






247


 






248


 






249


 






250


 






251


 






252


 






253


 






254


 






255


 






256


 






257


 






258


 






259


 






260


 






261


 






262


 






263


 






264


 






265


 






266


 






267


 






268


 






269


 






270


 






271


 






272


 






273


 






274


 






275


 






276


 






277


 






278


 






279


 






280


 






281


 






282


 






283


 






284


 






285


 






286


 






287


 






288


 






289


 






290


 






291


 






292


 






293


 






294


 






295


 






296


 






297


 






298


 






299


 






300


 






301


 






302


 






303


 






304


 






305


 






306


 






307


 






308


 






309


 






310


 






311


 






312


 






313


 






314


 






315


 






316


 






317


 






318


 






319


 






320


 






321


 






322


 






323


 






324


 






325


 






326


 






327


 






328


 






329


 






330


 






331


 






332


 






333


 






334


 






335


 






336


 






337


 






338


 






339


 






340


 






341


 






342


 






343


 






344


 






345


 






346


 






347


 






348


 






349


 






350


 






351


 






352


 






353


 






354


 






355


 






356


 






357


 






358


 






359


 






360


 






361


 






362


 






363


 






364


 






365


 






366


 






367


 






368


 






369


 






370


 






371


 






372


 






373


 






374


 






375


 






376


 






377


 






378


 






379


 






380


 






381


 






382


 






383


 






384


 






385


 






386


 






387


 






388


 






389


 






390


 






391


 






392


 






393


 






394


 






395


 






396


 






397


 






398


 






399


 






400


 






401


 






402


 






403


 






404


 






405


 






406


 






407


 






408


 






409


 






410


 






411


 






412


 






413


 






414


 






415


 






416


 






417


 






418


 






419


 






420


 






421


 






422


 






423


 






424


 






425


 






426


 






427


 






428


 






429


 






430


 






431


 






432


 






433


 






434


 






435


 






436


 






437


 






438


 






439


 






440


 






441


 






442


 






443


 






444


 






445


 






446


 






447


 






448


 






449


 






450


 






451


 






452


 






453


 






454


 






455


 






456


 






457


 






458


 






459


 






460


 






461


 






462


 






463


 






464


 






465


 






466


 






467


 






468


 






469


 






470


 






471


 






472


 






473


 






474


 






475


 






476


 






477


 






478


 






479


 






480


 






481


 






482


 






483


 






484


 






485


 






486


 






487


 






488


 






489


 






490


 






491


 






492


 






493


 






494


 






495


 






496


 






497


 






498


 






499


 






500


 






501


 






502


 






503


 






504


 






505


 






506


 






507


 






508


 






509


 






510


 






511


 






512


 






513


 






514


 






515


 






516


 






517


 






518


 






519


 






520


 






521


 






522


 






523


 






524


 






525


 






526


 






527


 






528


 






529


 






530


 






531


 






532


 






533


 






534


 






535


 






536


 






537


 






538


 






539


 






540


 






541


 






542


 






543


 






544


 






545


 






546


 






547


 






548


 






549


 






550


 






551


 






552


 






553


 






554


 






555


 






556


 






557


 






558


 






559


 






560


 






561


 






562


 






563


 






564


 






565


 






566


 






567


 






568


 






569


 






570


 






571


 






572


 






573


 






574


 






575


 






576


 






577


 






578


 






579


 






580


 






581


 






582


 






583


 






584


 






585


 






586


 






587


 






588


 






589


 






590


 






591


 






592


 






593


 






594


 






595


 






596


 






597


 






598


 






599


 






600


 






601


 






602


 






603


 






604


 






605


 






606


 






607


 






608


 






609


 






610


 






611


 






612


 






613


 






614


 






615


 






616


 






617


 






618


 






619


 






620


 






621


 






622


 






623


 






624


 






625


 






626


 






627


 






628


 






629


 






630


 






631


 






632


 






633


 






634


 






635


 






636


 






637


 






638


 






639


 






640


 






641


 






642


 






643


 






644


 






645


 






646


 






647


 






648


 






649


 






650


 






651


 






652


 






653


 






654


 






655


 






656


 






657


 






658


 






659


 






660


 






661


 






662


 






663


 






664


 






665


 






666


 






667


 






668


 






669


 






670


 






671


 






672


 






673


 






674


 






675


 






676


 






677


 






678


 






679


 






680


 






681


 






682


 






683


 






684


 






685


 






686


 






687


 






688


 






689


 






690


 






691


 






692


 






693


 






694


 






695


 






696


 






697


 






698


 






699


 






700


 






701


 






702


 






703


 






704


 






705


 






706


 






707


 






708


 






709


 






710


 






711


 






712


 






713


 






714


 






715


 






716


 






717


 






718


 






719


 






720


 






721


 






722


 






723


 






724


 






725


 






726


 






727


 






728


 






729


 






730


 






731


 






732


 






733


 






734


 






735


 






736


 






737


 






738


 






739


 






740


 






741


 






742


 






743


 






744


 






745


 






746


 






747


 






748


 






749


 






750


 






751


 






752









In another aspect, the invention features a pharmaceutical composition comprising the compound of the invention and a pharmaceutically acceptable carrier.
In another aspect, the invention features a method of inhibiting a voltage-gated sodium ion channel in:

    
    
        a patient; or
        a biological sample;
    
    


comprising administering to the patient, or contacting the biological sample, with the compound or composition of the invention. In another embodiment, the voltage-gated sodium ion channel is NaV 1.7.
In another aspect, the invention features a method of treating or lessening the severity in a subject of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpatic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders, anxiety, depression, dipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, cancer pain, stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress- or exercise induced angina, palpitations, hypertension, migraine, or abnormal gastro-intestinal motility, comprising administering an effective amount of a compound or composition of the invention.
In another embodiment, the method is used for treating or lessening the severity of femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; chronic visceral pain, abdominal pain; pancreatic; IBS pain; chronic and acute headache pain; migraine; tension headache, including, cluster headaches; chronic and acute neuropathic pain, post-herpatic neuralgia; diabetic neuropathy; HIV-associated neuropathy; trigeminal neuralgia; Charcot-Marie Tooth neuropathy; hereditary sensory neuropathies; peripheral nerve injury; painful neuromas; ectopic proximal and distal discharges; radiculopathy; chemotherapy induced neuropathic pain; radiotherapy-induced neuropathic pain; post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; complex regional pain syndrome; phantom pain; intractable pain; acute pain, acute post-operative pain; acute musculoskeletal pain; joint pain; mechanical low back pain; neck pain; tendonitis; injury/exercise pain; acute visceral pain, abdominal pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernias; chest pain, cardiac pain; pelvic pain, renal colic pain, acute obstetric pain, labor pain; cesarean section pain; acute inflammatory, burn and trauma pain; acute intermittent pain, endometriosis; acute herpes zoster pain; sickle cell anemia; acute pancreatitis; breakthrough pain; orofacial pain including sinusitis pain, dental pain; multiple sclerosis (MS) pain; pain in depression; leprosy pain; Behcet's disease pain; adiposis dolorosa; phlebitic pain; Guillain-Barre pain; painful legs and moving toes; Haglund syndrome; erythromelalgia pain; Fabry's disease pain; bladder and urogenital disease, including, urinary incontinence; hyperactivity bladder; painful bladder syndrome; interstitial cyctitis (IC); prostatitis; complex regional pain syndrome (CRPS), type I and type II; widespread pain, paroxysmal extreme pain, pruritis, tinnitis, or angina-induced pain.
The compounds of the invention may be prepared readily using the following methods. Illustrated below in Scheme 1 through Scheme 4 are methods for preparing the compounds of the invention.
















Uses, Formulation and Administration

Pharmaceutically Acceptable Compositions
As discussed above, the invention provides compounds that are inhibitors of voltage-gated sodium ion channels, and thus the present compounds are useful for the treatment of diseases, disorders, and conditions including, but not limited to acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, and incontinence. Accordingly, in another aspect of the invention, pharmaceutically acceptable compositions are provided, wherein these compositions comprise any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents.
It will also be appreciated that certain of the compounds of invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof. According to the invention, a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a subject in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. A “pharmaceutically acceptable salt” means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. As used herein, the term “inhibitorily active metabolite or residue thereof” means that a metabolite or residue thereof is also an inhibitor of a voltage-gated sodium ion channel.
Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1-4alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersable products may be obtained by such quaternization. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.
As described above, the pharmaceutically acceptable compositions of the invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
Uses of Compounds and Pharmaceutically Acceptable Compositions
In yet another aspect, a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, dipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, or cancer pain is provided comprising administering an effective amount of a compound, or a pharmaceutically acceptable composition comprising a compound to a subject in need thereof.
In certain embodiments, a method of treatment or lessening the severity of stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress- or exercise induced angina, palpitations, hypertension, migraine, or abnormal gastro-intestinal motility is provided comprising administering an effective amount of a compound, or a pharmaceutically acceptable composition comprising a compound to a subject in need thereof.
In certain embodiments, a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain is provided comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof. In certain other embodiments, a method for the treatment or lessening the severity of radicular pain, sciatica, back pain, head pain, or neck pain is provided comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof. In still other embodiments, a method for the treatment or lessening the severity of severe or intractable pain, acute pain, postsurgical pain, back pain, tinnitis or cancer pain is provided comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof.
In certain embodiments, a method for the treatment or lessening the severity of femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; chronic visceral pain, including, abdominal; pancreatic; IBS pain; chronic and acute headache pain; migraine; tension headache, including, cluster headaches; chronic and acute neuropathic pain, including, post-herpetic neuralgia; diabetic neuropathy; HIV-associated neuropathy; trigeminal neuralgia; Charcot-Marie Tooth neuropathy; hereditary sensory neuropathies; peripheral nerve injury; painful neuromas; ectopic proximal and distal discharges; radiculopathy; chemotherapy induced neuropathic pain; radiotherapy-induced neuropathic pain; post-mastectomy pain; central pain; spinal cord injury pain; post-stroke pain; thalamic pain; complex regional pain syndrome; phantom pain; intractable pain; acute pain, acute post-operative pain; acute musculoskeletal pain; joint pain; mechanical low back pain; neck pain; tendonitis; injury/exercise pain; acute visceral pain, including, abdominal pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernias; etc; chest pain, including, cardiac Pain; pelvic pain, renal colic pain, acute obstetric pain, including, labor pain; cesarean section pain; acute inflammatory, burn and trauma pain; acute intermittent pain, including, endometriosis; acute herpes zoster pain; sickle cell anemia; acute pancreatitis; breakthrough pain; orofacial pain including sinusitis pain, dental pain; multiple sclerosis (MS) pain; pain in depression; leprosy pain; behcet's disease pain; adiposis dolorosa; phlebitic pain; Guillain-Barre pain; painful legs and moving toes; Haglund syndrome; erythromelalgia pain; Fabry's disease pain; bladder and urogenital disease, including, urinary incontinence; hyperactivity bladder; painful bladder syndrome; interstitial cyctitis (IC); or prostatitis; complex regional pain syndrome (CRPS), type I and type II; angina-induced pain is provided, comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof.
In certain embodiments of the invention an “effective amount” of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, tinnitis or cancer pain.
The compounds and compositions, according to the method of the invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, tinnitis or cancer pain. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression “dosage unit form” as used herein refers to a physically discrete unit of agent appropriate for the subject to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular subject or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term “subject” or “patient”, as used herein, means an animal, preferably a mammal, and most preferably a human.
The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
In order to prolong the effect of a compound of the invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
The active compounds can also be in microencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
As described generally above, the compounds of the invention are useful as inhibitors of voltage-gated sodium ion channels. In one embodiment, the compounds and compositions of the invention are inhibitors of one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, or NaV1.9, and thus, without wishing to be bound by any particular theory, the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, or NaV1.9 is implicated in the disease, condition, or disorder. When activation or hyperactivity of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, or NaV1.9 is implicated in a particular disease, condition, or disorder, the disease, condition, or disorder may also be referred to as a “NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8 or NaV1.9-mediated disease, condition or disorder”. Accordingly, in another aspect, the invention provides a method for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, or NaV1.9 is implicated in the disease state.
The activity of a compound utilized in this invention as an inhibitor of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, or NaV1.9 may be assayed according to methods described generally in the Examples herein, or according to methods available to one of ordinary skill in the art.
In certain exemplary embodiments, compounds of the invention are useful as inhibitors of NaV1.7 and/or NaV1.8.
It will also be appreciated that the compounds and pharmaceutically acceptable compositions of the invention can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects). As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated”. For example, exemplary additional therapeutic agents include, but are not limited to: nonopioid analgesics (indoles such as Etodolac, Indomethacin, Sulindac, Tolmetin; naphthylalkanones such sa Nabumetone; oxicams such as Piroxicam; para-aminophenol derivatives, such as Acetaminophen; propionic acids such as Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Naproxen sodium, Oxaprozin; salicylates such as Aspirin, Choline magnesium trisalicylate, Diflunisal; fenamates such as meclofenamic acid, Mefenamic acid; and pyrazoles such as Phenylbutazone); or opioid (narcotic) agonists (such as Codeine, Fentanyl, Hydromorphone, Levorphanol, Meperidine, Methadone, Morphine, Oxycodone, Oxymorphone, Propoxyphene, Buprenorphine, Butorphanol, Dezocine, Nalbuphine, and Pentazocine). Additionally, nondrug analgesic approaches may be utilized in conjunction with administration of one or more compounds of the invention. For example, anesthesiologic (intraspinal infusion, neural blockade), neurosurgical (neurolysis of CNS pathways), neurostimulatory (transcutaneous electrical nerve stimulation, dorsal column stimulation), physiatric (physical therapy, orthotic devices, diathermy), or psychologic (cognitive methods-hypnosis, biofeedback, or behavioral methods) approaches may also be utilized. Additional appropriate therapeutic agents or approaches are described generally in The Merck Manual, Seventeenth Edition, Ed. Mark H. Beers and Robert Berkow, Merck Research Laboratories, 1999, and the Food and Drug Administration website, www.fda.gov, the entire contents of which are hereby incorporated by reference.
In another embodiment, additional appropriate therapeutic agents are selected from the following:
(1) an opioid analgesic, e.g. morphine, heroin, hydromorphone, oxymorphone, levorphanol, levallorphan, methadone, meperidine, fentanyl, cocaine, codeine, dihydrocodeine, oxycodone, hydrocodone, propoxyphene, nalmefene, nalorphine, naloxone, naltrexone, buprenorphine, butorphanol, nalbuphine or pentazocine;
(2) a nonsteroidal antiinflammatory drug (NSAID), e.g. aspirin, diclofenac, diflusinal, etodolac, fenbufen, fenoprofen, flufenisal, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamic acid, mefenamic acid, meloxicam, nabumetone, naproxen, nimesulide, nitroflurbiprofen, olsalazine, oxaprozin, phenylbutazone, piroxicam, sulfasalazine, sulindac, tolmetin or zomepirac;
(3) a barbiturate sedative, e.g. amobarbital, aprobarbital, butabarbital, butabital, mephobarbital, metharbital, methohexital, pentobarbital, phenobartital, secobarbital, talbutal, theamylal or thiopental;
(4) a benzodiazepine having a sedative action, e.g. chlordiazepoxide, clorazepate, diazepam, flurazepam, lorazepam, oxazepam, temazepam or triazolam;
(5) an H1 antagonist having a sedative action, e.g. diphenhydramine, pyrilamine, promethazine, chlorpheniramine or chlorocyclizine;
(6) a sedative such as glutethimide, meprobamate, methaqualone or dichloralphenazone;
(7) a skeletal muscle relaxant, e.g. baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol or orphrenadine;
(8) an NMDA receptor antagonist, e.g. dextromethorphan ((+)-3-hydroxy-N-methylmorphinan) or its metabolite dextrorphan ((+)-3-hydroxy-N-methylmorphinan), ketamine, memantine, pyrroloquinoline quinine, cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid, budipine, EN-3231 (MorphiDex(R), a combination formulation of morphine and dextromethorphan), topiramate, neramexane or perzinfotel including an NR2B antagonist, e.g. ifenprodil, traxoprodil or (−)-(R)-6-{2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl-3,4-dihydro-2(1H)-quinolinone;
(9) an alpha-adrenergic, e.g. doxazosin, tamsulosin, clonidine, guanfacine, dexmetatomidine, modafinil, or 4-amino-6,7-dimethoxy-2-(5-methane-sulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline;
(10) a tricyclic antidepressant, e.g. desipramine, imipramine, amitriptyline or nortriptyline;
(11) an anticonvulsant, e.g. carbamazepine, lamotrigine, topiratmate or valproate;
(12) a tachykinin (NK) antagonist, particularly an NK-3, NK-2 or NK-I antagonist, e.g. ([alpha]R,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]-naphthyridine-6-13-dione (TAK-637), 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-4-morpholinyl]-methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one (MK-869), aprepitant, lanepitant, dapitant or 3-[[2-methoxy-5-(trifluoromethoxy)phenyl]-methylamino]-2-phenylpiperidine (2S,3S);
(13) a muscarinic antagonist, e.g oxybutynin, tolterodine, propiverine, tropsium chloride, darifenacin, solifenacin, temiverine and ipratropium;
(14) a COX-2 selective inhibitor, e.g. celecoxib, rofecoxib, parecoxib, valdecoxib, deracoxib, etoricoxib, or lumiracoxib;
(15) a coal-tar analgesic, in particular paracetamol;
(16) a neuroleptic such as droperidol, chlorpromazine, haloperidol, perphenazine, thioridazine, mesoridazine, trifluoperazine, fluphenazine, clozapine, olanzapine, risperidone, ziprasidone, quetiapine, sertindole, aripiprazole, sonepiprazole, blonanserin, iloperidone, perospirone, raclopride, zotepine, bifeprunox, asenapine, lurasidone, amisulpride, balaperidone, palindore, eplivanserin, osanetant, rimonabant, meclinertant, Miraxion(R) or sarizotan;
(17) a vanilloid receptor agonist (e.g. resiniferatoxin) or antagonist (e.g. capsazepine);
(18) a beta-adrenergic such as propranolol;
(19) a local anaesthetic such as mexiletine;
(20) a corticosteroid such as dexamethasone;
(21) a 5-HT receptor agonist or antagonist, particularly a 5-HT1B/1D agonist such as eletriptan, sumatriptan, naratriptan, zolmitriptan or rizatriptan;
(22) a 5-HT2A receptor antagonist such as R(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenylethyl)]-4-piperidinemethanol (MDL-100907);
(23) a cholinergic (nicotinic) analgesic, such as ispronicline (TC-1734), (E)-N-methyl-4-(3-pyridinyl)-3-buten-1-amine (RJR-2403), (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594) or nicotine;
(24) Tramadol®;
(25) a PDEV inhibitor, such as 5-[2-ethoxy-5-(4-methyl-1-piperazinyl-sulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil), (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2′,1′:6,1]-pyrido[3,4-b]indole-1,4-dione (IC-351 or tadalafil), 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (vardenafil), 5-(5-acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-(5-acetyl-2-propoxy-3-pyridinyl)-3-ethyl-2-(1-isopropyl-3-azetidinyl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, 4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide, 3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide;
(26) an alpha-2-delta ligand such as gabapentin, pregabalin, 3-methyl gabapentin, (1[alpha],3[alpha],5[alpha])(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-octanoic acid, (2S,4S)-4-(3-chlorophenoxy)proline, (2S,4S)-4-(3-fluorobenzyl)-proline, [(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]-methylamine, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-nonanoic acid, (3S,5R)-3-amino-5-methyl-octanoic acid, (3R,4R,5R)-3-amino-4,5-dimethyl-heptanoic acid and (3R,4R,5R)-3-amino-4,5-dimethyl-octanoic acid;
(27) a cannabinoid;
(28) metabotropic glutamate subtype 1 receptor (mGluR1) antagonist;
(29) a serotonin reuptake inhibitor such as sertraline, sertraline metabolite demethylsertraline, fluoxetine, norfluoxetine (fluoxetine desmethyl metabolite), fluvoxamine, paroxetine, citalopram, citalopram metabolite desmethylcitalopram, escitalopram, d,l-fenfluramine, femoxetine, ifoxetine, cyanodothiepin, litoxetine, dapoxetine, nefazodone, cericlamine and trazodone;
(30) a noradrenaline (norepinephrine) reuptake inhibitor, such as maprotiline, lofepramine, mirtazepine, oxaprotiline, fezolamine, tomoxetine, mianserin, buproprion, buproprion metabolite hydroxybuproprion, nomifensine and viloxazine (Vivalan(R)), especially a selective noradrenaline reuptake inhibitor such as reboxetine, in particular (S,S)-reboxetine;
(31) a dual serotonin-noradrenaline reuptake inhibitor, such as venlafaxine, venlafaxine metabolite O-desmethylvenlafaxine, clomipramine, clomipramine metabolite desmethylclomipramine, duloxetine, milnacipran and imipramine;
(32) an inducible nitric oxide synthase (iNOS) inhibitor such as S-[2-[(1-iminoethyl)amino]ethyl]-L-homocysteine, S-[2-[(1-iminoethyl)-amino]ethyl]-4,4-dioxo-L-cysteine, S-[2-[(1-iminoethyl)amino]ethyl]-2-methyl-L-cysteine, (2S,5Z)-2-amino-2-methyl-7-[(1-iminoethyl)amino]-5-heptenoic acid, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)-butyl]thio]-S-chloro-S-pyridinecarbonitrile; 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-4-chlorobenzonitrile, (2S,4R)-2-amino-4-[[2-chloro-5-(trifluoromethyl)phenyl]thio]-5-thiazolebutanol, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl) butyl]thio]-6-(trifluoromethyl)-3 pyridinecarbonitrile, 2-[[(1R,3S)-3-amino-4-hydroxy-1-(5-thiazolyl)butyl]thio]-5-chlorobenzonitrile, N-[4-[2-(3-chlorobenzylamino)ethyl]phenyl]thiophene-2-carboxamidine, or guanidinoethyldisulfide;
(33) an acetylcholinesterase inhibitor such as donepezil;
(34) a prostaglandin E2 subtype 4 (EP4) antagonist such as 7V-[({2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]ethyl}amino)-carbonyl]-4-methylbenzenesulfonamide or 4-[(15)-1-({[5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl}amino)ethyl]benzoic acid;
(35) a leukotriene B4 antagonist; such as 1-(3-biphenyl-4-ylmethyl-4-hydroxy -chroman-7-yl)-cyclopentanecarboxylic acid (CP-105696), 5-[2-(2-carboxyethyl)-3-[6-(4-methoxyphenyl)-5E-hexenyl]oxyphenoxy]-valeric acid (ONO-4057) or DPC-11870,
(36) a 5-lipoxygenase inhibitor, such as zileuton, 6-[(3-fluoro-5-[4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl])phenoxy-methyl]-1-methyl-2-quinolone (ZD-2138), or 2,3,5-trimethyl-6-(3-pyridylmethyl),1,4-benzoquinone (CV-6504);
(37) a sodium channel blocker, such as lidocaine;
(38) a 5-HT3 antagonist, such as ondansetron; and the pharmaceutically acceptable salts and solvates thereof.
The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
The compounds of this invention or pharmaceutically acceptable compositions thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters. Accordingly, the invention, in another aspect, includes a composition for coating an implantable device comprising a compound of the invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. In still another aspect, the invention includes an implantable device coated with a composition comprising a compound of the invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. Suitable coatings and the general preparation of coated implantable devices are described in U.S. Pat. Nos. 6,099,562; 5,886,026; and 5,304,121. The coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
Another aspect of the invention relates to inhibiting one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, or NaV1.9, activity in a biological sample or a subject, which method comprises administering to the subject, or contacting said biological sample with a compound of formula I or a composition comprising said compound. The term “biological sample”, as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
Inhibition of one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, or NaV1.9, activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of sodium ion channels in biological and pathological phenomena; and the comparative evaluation of new sodium ion channel inhibitors.
EXAMPLES
General methods. 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were obtained as solutions in deuterioacetonitrile (CD3CN), chloroform-d (CDCl3) or dimethyl sulfoxide-D6 (DMSO). Mass spectra (MS) were obtained using an Applied Biosystems API EX LC/MS system equipped with a Phenomenex 50×4.60 mm luna-5μ C18 column. The LC/MS eluting system was 1-99% or 10-99% acetonitrile in H2O with 0.035% v/v trifluoroacetic acid, 0.035% v/v formic acid, 5 mM HCl or 5 mM ammonium formate using a 3 or 15 minute linear gradient and a flow rate of 12 mL/minute. Silica gel chromatography was performed using silica gel-60 with a particle size of 230-400 mesh. Pyridine, dichloromethane (CH2Cl2), tetrahydrofuran (THF), dimethylformamide (DMF), acetonitrile (ACN), methanol (MeOH), and 1,4-dioxane were from Aldrich Sure-Seal bottles kept under dry nitrogen. All reactions were stirred magnetically unless otherwise noted.
trans-5a′,6′,7′,8′,9′,9a′-Hexahydro-5′H-spiro[piperidine-4,4′-pyrrolo[1,2-a]quinoxaline]dihydrochloride




Step 1:
tert-Butyl N-[(1R,2R)-2-aminocyclohexyl]carbamate (1.06 g, 4.93 mmol), sodium acetate (1.70 g, 20.7 mmol) and 2,5-dimethoxytetrahydrofuran (764 μL, 5.91 mmol) were combined in acetic acid (10.6 mL). The reaction mixture was heated at 80° C. for 16 hours. The reaction mixture was then evaporated to dryness and the residue was partitioned between ethyl acetate and a saturated aqueous solution of sodium bicarbonate. The layers were separated, and the organic layer was washed twice with a saturated aqueous solution of sodium chloride, dried over sodium sulfate, and evaporated to dryness to yield a brown solid. This solid was then dissolved in HCl in dioxane (10.3 mL of 4.0 M, 41.1 mmol) and was allowed to stand for 3 hours. The solvent was then removed to yield trans-2-(1H-pyrrol-1-yl)cyclohexanamine hydrogen chloride (989 mg, 99%) as a brown solid. ESI-MS m/z calc. 164.1, found 165.2 (M+1)+; Retention time: 0.27 minutes (4 min run).
Step 2:
trans-2-(1H-Pyrrol-1-yl)cyclohexanamine hydrogen chloride (989 mg, 4.93 mmol), tert-butyl 4-oxopiperidine-1-carboxylate (982 mg, 4.93 mmol), and maleic acid (56.2 mg, 0.493 mmol) were combined in ethanol (12 mL). The reaction mixture was heated at 80° C. for 4 hours. The reaction mixture was cooled to room temperature and the solvent was evaporated. The residue was dissolved in dichloromethane and was then purified on 80 g of silica gel utilizing a gradient of 0-10% methanol in dichloromethane to give trans-tert-butyl 5a′,6′,7′,8′,9′,9a′-hexahydro-5′H-spiro[piperidine-4,4′-pyrrolo[1,2-a]quinoxaline]-1-carboxylate. ESI-MS m/z calc. 345.2, found 346.2 (M+1)+; Retention time: 1.63 minutes (4 min run).
Step 3:
trans-tert-Butyl 5a′,6′,7′,8′,9′,9a′-hexahydro-5′H-spiro[piperidine-4,4′-pyrrolo[1,2-a]quinoxaline]-1-carboxylate (0.311 g, 0.901 mmol) was suspended in hydrogen chloride in dioxane (2.0 mL of 4.0 M, 8.0 mmol). The reaction mixture was allowed to stand for 2 hours. The reaction mixture was then evaporated to dryness to give trans-5a′,6′,7′,8′,9′,9a′-hexahydro-5′H-spiro[piperidine-4,4′-pyrrolo[1,2-a]quinoxaline]. ESI-MS m/z calc. 245.2, found 246.3 (M+1)+; Retention time: 0.32 minutes (3 min run).
2′-Methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride




Step 1:
A mixture of 2,5-dimethoxytetrahydrofuran (15 g, 113.5 mmol), 2-chloroethanamine hydrochloride (44.76 g, 385.9 mmol), and sodium acetate (46.55 g, 567.5 mmol) in acetic acid (55 mL) was heated at 110° C. After 2 h, the reaction was poured into brine and the product was extracted with dichloromethane. The organics were washed with brine, saturated Na2CO3, and brine again. The organics were dried over sodium sulfate and evaporated. The crude material was filtered through a plug of Florisil (80 g) using hexane as the eluent to give 1-(2-chloroethyl)pyrrole (10.1 g, 69%). 1H NMR (400 MHz, CDCl3) δ 6.70 (t, J=1.9 Hz, 2H), 6.18 (t, J=1.9 Hz, 2H), 4.20 (t, J=6.5 Hz, 2H), 3.73 (t, J=6.5 Hz, 2H).
Step 2:
1-(2-Chloroethyl)pyrrole (2.0 g, 15.43 mmol) was combined with a solution of 33% methylamine in ethanol (7.3 mL of 33% w/v, 77.15 mmol). The mixture was heated at 90° C. for 16 h before it was concentrated under reduced pressure to provide N-methyl-2-pyrrol-1-yl-ethanamine (2.19 g, 88%) which was used directly in next reaction. ESI-MS m/z calc. 124.1, found 125.3 (M+1)+; Retention time: 0.22 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 6.73-6.68 (m, 2H), 6.22-6.14 (m, 2H), 4.05 (t, J=5.9 Hz, 2H), 2.94 (t, J=5.9 Hz, 2H), 2.45 (s, 3H).
Step 3:
N-Methyl-2-pyrrol-1-yl-ethanamine (2.19 g, 17.64 mmol), tert-butyl 4-oxopiperidine-1-carboxylate (3.51 g, 17.64 mmol), and pTsOH.H2O (0.334 g, 1.76 mmol) were combined in ethanol (87.60 mL) and heated at 70° C. for 4 h. The reaction was concentrated and the residue was dissolved in dichloromethane. The organics were washed with a saturated NaHCO3 solution and brine. The organics were dried over sodium sulfate and evaporated. The crude material was purified by silica gel chromatography eluting with 0-10% methanol in dichloromethane with 2% triethylamine to give tert-butyl 2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (4.2 g, 78%). ESI-MS m/z calc. 305.4, found 306.3 (M+1)+; Retention time: 0.97 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 6.55-6.52 (m, 1H), 6.15-6.11 (m, 1H), 5.92-5.89 (m, 1H), 3.92 (t, J=6.0 Hz, 2H), 3.91-3.75 (m, 2H), 3.29 (t, J=6.0 Hz, 2H), 3.26-3.12 (m, 2H), 2.36 (s, 3H), 2.10-1.99 (m, 2H), 1.83-1.69 (m, 2H), 1.47 (s, 9H).
Step 4:
Method A: tert-Butyl 2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (1.0 g, 3.27 mmol), potassium carbonate (497.7 mg, 3.60 mmol) and trifluoromethanesulfonate; 5-(trifluoromethyl)dibenzothiophen-5-ium (1.32 g, 3.27 mmol) were combined in acetonitrile (10 mL). The reaction mixture was heated at 60° C. for 16 h. The reaction was evaporated to dryness and the residue was dissolved in dichloromethane. The organics were washed with water and brine, dried over sodium sulfate and evaporated. The crude material was purified by silica gel chromatography eluting with 0-50% ethyl acetate in hexanes to give tert-butyl 2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (812 mg, 66%). ESI-MS m/z calc. 373.2, found 374.5 (M+1)+; Retention time: 1.21 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 6.52 (d, J=3.8 Hz, 1H), 5.91 (d, J=3.8 Hz, 1H), 3.98 (t, J=6.0 Hz, 2H), 3.93-3.76 (m, 2H), 3.32 (t, J=6.0 Hz, 2H), 3.26-3.08 (m, 2H), 2.36 (s, 3H), 2.11-1.99 (m, 2H), 1.81-1.65 (m, 2H), 1.47 (s, 9H).
Method B: To tert-butyl 2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (10.0 g, 32.7 mmol) in DMSO (164 mL) was added ferrous sulfate heptahydrate (9.8 mL of 1.0 M, 9.8 mmol) followed by CF3I (6.41 g, 32.7 mmol) by slow bubbling through the solution and taking the weight difference of the canister. The mixture was cooled with a ice-water bath before H2O2 (3.71 mL of 30% w/v, 32.7 mmol) dropwise over 15 min keeping the internal temperature<20° C. The mixture was poured onto 300 mL of ice water and was extracted with EtOAc (2×400 mL). The combined organic phases were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified column chromatography eluting with 0-10% methanol in dichloromethane with 2% iPr2NEt to give tert-butyl 2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (7.8 g, 64%).
Step 5:
tert-Butyl 2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (7.8 g, 20.89 mmol) was stirred in 4M HCl in dioxane (26.10 mL of 4 M, 104.4 mmol) and methanol (22 mL) at room temperature for 1 h. The reaction mixture was evaporated to dryness and the residue was co-evaporated with 100 mL of MTBE to afford 2′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride as a yellow foam/solid (7.23 g, quantitative). ESI-MS m/z calc. 273.2, found 274.5 (M+1)+; Retention time: 0.44 minutes (3 min run).
2′-Methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-carbonitrile dihydrochloride




Step 1:
A solution of chlorosulfonyl isocyanate (590.9 mg, 363.4 μL, 4.175 mmol) in tetrahydrofuran (2 mL) was slowly added to a solution of tert-butyl 2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (1020 mg, 3.340 mmol) in tetrahydrofuran (9 mL) held at −78° C. (bath temperature) under an atmosphere of argon. The reaction mixture was allowed to stir for 1 hour at −78° C. N,N-dimethylformamide (732.4 mg, 775.8 μL, 10.02 mmol) was then slowly added to the cold reaction mixture. The reaction mixture was then allowed to slowly warm to room temperature. After stirring for 3 hours at room temperature the crude material was diluted with 25 mL of tetrahydrofuran, washed with a 1M solution of sodium hydroxide, followed by three washes of a saturated aqueous solution of sodium chloride. The organic layer was dried over sodium sulfate, filtered, and evaporated to dryness to yield the crude product. The crude material was purified on 80 g of silica gel utilizing a gradient of 0-70% ethyl acetate in hexanes to yield tert-butyl 6-cyano-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (280 mg, 25%) as a white solid. ESI-MS m/z calc. 330.2, found 331.1 (M+1)+; Retention time: 0.94 minutes. 1H NMR (400 MHz, CDCl3) δ 6.76 (d, J=4.0 Hz, 1H), 5.97 (d, J=4.0 Hz, 1H), 4.01 (t, J=6.0 Hz, 2H), 3.98-3.76 (m, 2H), 3.36 (t, J=6.0 Hz, 2H), 3.30-3.08 (m, 2H), 2.36 (s, 3H), 2.09-1.98 (m, 2H), 1.84-1.66 (m, 2H), 1.47 (s, 9H).
Step 2:
tert-Butyl 6-cyano-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (280 mg, 0.8474 mmol) was dissolved in a mixture of hydrochloric acid in dioxane (8 mL of 4 M, 32.00 mmol) and dioxane (8 mL). The reaction mixture was allowed to stir for 30 minutes and then evaporated to dryness to yield 2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-carbonitrile dihydrochloride (258 mg, 99%) as a white solid. ESI-MS m/z calc. 230.2, found 231.5 (M+1)+; Retention time: 0.50 minutes (3 min run). 1H NMR (400 MHz, D2O) δ 7.10 (d, J=4.2 Hz, 1H), 6.59 (d, J=4.3 Hz, 1H), 4.51 (t, J=6.4 Hz, 2H), 4.02 (t, J=6.3 Hz, 2H), 3.66-3.56 (m, 2H), 3.49-3.36 (m, 2H), 2.95 (s, 3H), 2.69-2.59 (m, 2H), 2.54-2.40 (m, 2H).
N-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-2′-carboxamide hydrochloride




Step 1:
To tert-butyl 6-(trifluoromethyl)spiro[3,4-dihydro-2H-pyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (600 mg, 1.67 mmol), THF (3 mL) and Et3N (698 μL, 5.01 mmol) was added methyl isocyanate (199 μL, 3.34 mmol). The mixture was allowed to stir at room temperature for 2 h. The mixture was charged with additional Et3N (698 μL, 5.01 mmol) and methyl isocyanate (199 μL, 3.34 mmol), and the reaction was stirred at room temperature for 3 d. The solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (40 mL) and washed with water (3×10 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo to yield tert-butyl 2-(methylcarbamoyl)-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (680 mg, 97%). ESI-MS m/z calc. 416.2, found 417.4 (M+1)+; Retention time: 1.73 minutes (3 min run). 1H NMR (400 MHz, DMSO) δ 7.14 (q, J=4.3 Hz, 1H), 6.56 (d, J=3.4 Hz, 1H), 6.03 (d, J=3.9 Hz, 1H), 3.88 (t, J=5.4 Hz, 2H), 3.73 (t, J=5.4 Hz, 2H), 3.69-3.55 (m, 2H), 3.23-3.03 (m, 2H), 2.78-2.62 (m, 2H), 2.56 (d, J=4.4 Hz, 3H), 1.76-1.60 (m, 2H), 1.40 (s, 9H).
Step 2:
To tert-butyl 2-(methylcarbamoyl)-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (0.66 g, 1.6 mmol) and acetonitrile (5 mL) was added a solution of HCl in dioxane (5.2 mL of 4.0 M, 21 mmol). The reaction mixture was stirred at room temperature for 60 minutes. The solvent was evaporated under reduced pressure to yield N-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-2-carboxamide hydrochloride as a brown solid (99%). ESI-MS m/z calc. 316.2, found 317.2 (M+1)+; Retention time: 0.77 minutes (3 min run).
The following compounds were synthesized using the procedures described above:

    2′-(2-methoxyethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    2′-benzyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    2′-(2-methoxyethyl)-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    2′-ethyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    3′,3′-dimethyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    3′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    4′,4′-dimethyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    2′,3′-dimethyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    3-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    2′-cyclopropyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    2′-(cyclopropylmethyl)-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    2′,3-dimethyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    2′-methyl-6′-(2,2,2-trifluoroethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    2′-methyl-6′-(perfluoroethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    2′-methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride, 3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    N,N-dimethyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-2′-carboxamide,
    2′-(2,2,2-trifluoroethyl)-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]hydrochloride,
    3-fluoro-2′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    2,2′-dimethyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    methyl 2′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-4′-carboxylate,
    2′-(2,2-difluoroethyl)-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]hydrochloride,
    2′-cyclobutyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride,
    ethyl 2-(6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-2′-yl)acetate, and
    methyl 6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-2′-carboxylate.


2,2,2-Trifluoro-1-(2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl)ethanone dihydrochloride




Step 1:
(2,2,2-Trifluoroacetyl) 2,2,2-trifluoroacetate (910 μL, 6.55 mmol) was added dropwise to a solution of tert-butyl 2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (1.0 g, 3.27 mmol), pyridine (1.06 mL, 13.10 mmol) and CH2Cl2 (6.5 mL) at room temperature. The mixture was heated at 35° C. for 2 h. The reaction mixture was partitioned between 1N HCl and CH2Cl2. The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×). The combined organics were dried over sodium sulfate and filtered. The filtrate was concentrated to give tert-butyl 2-methyl-6-(2,2,2-trifluoroacetyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (1.38 g, 94%) as a yellowish solid. ESI-MS m/z calc. 401.2, found 402.5 (M+1)+; Retention time: 1.36 minutes. 1H NMR (400 MHz, CDCl3) δ 7.21 (dd, J=4.4, 2.1 Hz, 1H), 6.14 (d, J=4.5 Hz, 1H), 4.34 (t, J=6.0 Hz, 2H), 3.93 (s, 2H), 3.33 (t, J=6.0 Hz, 2H), 3.19 (s, 2H), 2.39 (s, 3H), 2.13-2.05 (m, 2H), 1.79 (t, J=11.6 Hz, 2H), 1.48 (s, 9H).
Step 2:
Hydrogen chloride (6.01 mL of 4 M, 24.07 mmol) was added to a solution of tert-butyl 2-methyl-6-(2,2,2-trifluoroacetyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]1′-carboxylate (1.38 g, 3.44 mmol) in CH2Cl2 (9.7 mL) at room temperature. The mixture was stirred at room temperature for 1.5 h. The reaction mixture was concentrated under reduced pressure to give 2,2,2-trifluoro-1-(2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl)ethanone dihydrochloride (1.34 g, 99%) as a tan solid. ESI-MS m/z calc. 301.1, found 302.5 (M+1)+; Retention time: 1.02 minutes.
2,2-Dimethyl-1-(2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl)propan-1-one dihydrochloric acid




Step 1:
2,2-Dimethylpropanoyl chloride (1.22 mL, 9.90 mmol) was added to a mixture of tert-butyl 2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (2.75 g, 9.0 mmol), DBN (1.22 mL, 9.90 mmol) and dichloroethane (6.9 mL) at room temperature. The mixture was allowed to stir for 18 h at 115° C. The mixture was cooled to room temperature before it was partitioned between CH2Cl2 and 1N HCl. The layers were separated and the organic layer was washed with 1N NaOH. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (0-100% ethyl acetate/hexanes) to give tert-butyl dimethylpropanoyl)-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (1.8 g, 41%) as an off-white solid. ESI-MS m/z calc. 389.3, found 390.5 (M+1)+; Retention time: 1.46 minutes.
Step 2:
Hydrogen chloride (5.1 mL of 4 M, 20.22 mmol) was added to a solution of tert-butyl 6-(2,2-dimethylpropanoyl)-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (1.75 g, 4.49 mmol) in CH2Cl2 (12.3 mL) at room temperature. The mixture was stirred at room temperature for 1.5 h. The reaction mixture was concentrated under reduced pressure to give 2,2-dimethyl-1-(2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl)propan-1-one dihydrochloride (1.8 g, 99%) as a tan solid. ESI-MS m/z calc. 289.2, found 290.5 (M+1)+; Retention time: 0.97 minutes.
1-(2′-Methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)ethanone dihydrochloride




Step 1:
To tert-butyl 2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (10 g, 32.74 mmol) in methylene chloride (73.5 mL) at 0° C. was added N-bromosuccinimide (5.53 g, 31.10 mmol) portionwise. The reaction was stirred at 0° C. After 30 minutes, additional N-bromosuccinimide (291.4 mg, 1.64 mmol) was added and the reaction was stirred for 1 hour. The reaction was diluted with 0.5 M Na2S2O3 (135 mL) and the aqueous phase was removed. The organic layer was washed with brine (135 mL). The organic layer was dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure to yield tert-butyl 6-bromo-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate as a red viscous liquid that was used in the next step without further purification. 1H NMR (400 MHz, DMSO) δ 6.09 (d, J=3.7 Hz, 1H), 5.99 (d, J=3.7 Hz, 1H), 3.78-3.65 (m, 4H), 3.27 (t, J=6.0 Hz, 2H), 3.17-2.92 (m, 2H), 2.21 (s, 3H), 2.03-1.93 (m, 2H), 1.65-1.53 (m, 2H), 1.40 (s, 9H). ESI-MS m/z calc. 383.1, found 386.0 (M+1)+; Retention time: 1.13 minutes (3 minute run).
Step 2:
A solution of tert-butyl 6-bromo-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (2 g, 5.2 mmol) and N-cyclohexyl-N-methyl-cyclohexanamine (1.67 mL, 7.81 mmol) in 1,4-dioxane (8.0 mL) was purged with N2 for 5 minutes. 1-Vinyloxybutane (7.04 mL, 52.04 mmol), Pd(dba)3 (1.078 g, 1.04 mmol) and tri tert-butylphosphane (642.0 μL, 2.60 mmol) were added and the reaction was heated at 80° C. for 5 hours in a pressure vessel. The reaction was filtered through a plug of celite using ethyl acetate. The solvent was evaporated under reduced pressure. The crude product was purified by silica gel chromatography utilizing a gradient of 1-100% ethyl acetate in hexane to yield tert-butyl 6-acetyl-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (672.1 mg, 1.93 mmol, 37%) as a yellow solid. 1H NMR (400 MHz, DMSO) δ 7.04 (d, J=4.1 Hz, 1H), 6.12 (d, J=4.2 Hz, 1H), 4.17 (t, J=6.0 Hz, 2H), 3.83-3.68 (m, 2H), 3.21 (t, J=6.0 Hz, 2H), 3.17-2.91 (m, 2H), 2.31 (s, 3H), 2.24 (s, 3H), 2.07-1.97 (m, 2H), 1.72-1.59 (m, 2H), 1.41 (s, 9H). ESI-MS m/z calc. 347.2, found 348.5 (M+1)+; Retention time: 0.95 minutes (3 minute run).
Step 3:
To tert-butyl 6-acetyl-2-methyl-Spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (300 mg, 0.86 mmol) and methylene chloride (1.7 mL) was added hydrogen chloride in dioxane (1.60 mL of 4 M, 6.40 mmol) The reaction was stirred at room temperature for 0.5 hours. The solvent was evaporated under reduced pressure to yield 1-(2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl)ethanone dihydrochloride as a light green solid in quantitative yield. ESI-MS m/z calc. 247.2, found 248.2 (M+1)+; Retention time: 0.17 minutes (3 minute run).
The following compounds were synthesized using the procedures described above:

    1-(2′-methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)propan-1-one dihydrochloride,
    2-methyl-1-(2′-methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)propan-1-one dihydrochloride,
    cyclopropyl(2′-methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)methanone dihydrochloride,
    (2′-methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)(phenyl)methanone dihydrochloride,
    1-(3′,3′-dimethyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)-2,2,2-trifluoroethanone dihydrochloride,
    1-(3′,3′-dimethyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)ethanone dihydrochloride,
    1-(3′,3′-dimethyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-7′-yl)ethanone dihydrochloride,
    2,2,2-trifluoro-1-(2′,4′,4′-trimethyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)ethanone dihydrochloride,
    2,2,2-trifluoro-1-(2′,4′,4′-trimethyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-7′-yl)ethanone dihydrochloride,
    1-(2′,4′,4′-trimethyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)ethanone dihydrochloride,
    1-(2′,3′-dimethyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)-2,2,2-trifluoroethanone dihydrochloride,
    2,2,2-trifluoro-1-(3′-methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)ethanone dihydrochloride,
    2,2,2-trifluoro-1-(4′-methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)ethanone dihydrochloride,
    1-(2′,4′-dimethyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)-2,2,2-trifluoroethanone dihydrochloride, and
    (2′-methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)(1-methylcyclopropyl)methanone.


2′-Methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-8′-carbonitrile dihydrochloride




Step 1:
To a solution of tert-butyl 2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (1.86 g, 5.0 mmol) in acetonitrile (50 mL) was added N-bromosuccinimide (930.4 mg, 5.25 mmol). The mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure. The residue was partitioned between ethyl acetate and water. The layers were separated and the aqueous layer was extracted with ethyl acetate (2×). The combined organic layers were washed with brine, dried over MgSO4 and concentrated to dryness. The crude material was purified by column chromatography (10-20% Ethyl acetate-Hexanes) to provide a the product as light yellow solid (1.7 g, 75%). ESI-MS m/z calc. 451.1, found 452.1 (M+1)+; Retention time: 1.59 minutes (3 minute run).
Step 2:
A mixture of tert-butyl 8-bromo-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (1.67 g, 3.7 mmol) and dicyanozinc (234.9 μL, 3.7 mmol) in DMF (10 mL) was purged with N2 for 5 min. Pd(PPh3)4 (427.6 mg, 0.37 mmol) was added. The mixture was heated in a sealed microwave vial at 150° C. overnight. The mixture was partitioned between ethyl acetate and water. The layers were separated. The aqueous layer was extracted with ethyl acetate (3×). All organic layers were combined, washed with water (3×), brine, dried over MgSO4, filtered and concentrated to dryness. The crude material was purified by column chromatography (10-20% EtOAc/hexanes) to provide tert-butyl 8-cyano-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (510 mg, 35%) as a white solid. ESI-MS m/z calc. 398.2, found 399.3 (M+1)+; Retention time: 1.56 minutes (3 minute run).
Step 3:
To a solution of tert-butyl 8-cyano-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (278.9 mg, 0.7 mmol) in DCM (4 mL) was added HCl in dioxane (2 mL of 4 M, 8.0 mmol). The mixture was stirred at room temperature for 30 min. The solvent was evaporated and the crude material was used directly in next step without further purification. ESI-MS m/z calc. 298.1, found 299.5 (M+1)+; Retention time: 0.88 minutes (3 minute run).
6′-Chloro-2′-methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride




Step 1:
To tert-butyl 2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (5 g, 16.37 mmol) in dichloromethane (50.00 mL) at 0° C. was added trifluoromethanesulfonyl chloride (3.64 mL, 34.38 mmol) and the reaction was stirred from 0° C. to room temperature overnight. The reaction was diluted with dichloromethane and washed with water. The layers were separated and the organics were dried over sodium sulfate, filtered and concentrated. Purification of the residue by silica gel chromatography eluting with 10-100% ethylacetate in hexanes afforded tert-butyl 6-chloro-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (4.3 g, 77%), as a yellow solid. ESI-MS m/z calc. 339.2, found 340.3 (M+1)+; Retention time: 1.13 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 6.01 (d, J=3.8 Hz, 1H), 5.91 (d, J=3.7 Hz, 1H), 3.77 (t, J=6.1 Hz, 2H), 3.34 (s, 2H), 3.24 (s, 2H), 2.34 (s, 3H), 2.03 (d, J=13.1 Hz, 2H), 1.74 (t, J=11.1 Hz, 2H), 1.47 (s, 9H).
Step 2:
HCl (1.84 mL of 4 M in dioxanes, 7.34 mmol) was added to a solution of tert-butyl 6-chloro-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (624 mg, 1.84 mmol) in dichloromethane (2 mL) and was stirred at 40° C. for 1 hour. The reaction was evaporated to dryness to yield 6′-chloro-2′-methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride (quantitative) that was used without further purification. ESI-MS m/z calc. 239.1, found 240.3 (M+1)+; Retention time: 0.22 minutes (3 min run).
Ethyl 6′-cyano-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-2′-carboxylate hydrochloride




Step 1:
Ethyl chloroformate (328.2 μL, 3.43 mmol) was added to a solution of tert-butyl spiro[3,4-dihydro-2H-pyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (500 mg, 1.72 mmol) and K2CO3 (474.3 mg, 3.43 mmol) in acetonitrile (5.0 mL) and the reaction was stirred at room temperature overnight. The reaction was filtered using acetonitrile and the solvent was evaporated under reduced pressure. The compound was dissolved in ethyl acetate and washed with 1N hydrochloric acid and brine. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to yield 1-tert-butyl 2′-ethyl 3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-1,2′-dicarboxylate (395 mg, 63%) as an amber oil that was used in the next step without further purification. ESI-MS m/z calc. 363.2, found 364.3 (M+1)+; Retention time: 1.78 minutes (3 minute run).
Step 2:
A solution of N-(oxomethylene)sulfamoyl chloride (23.9 μL, 0.27 mmol) in THF (200.0 μL) was slowly added to a solution of 1-tert-butyl 2′-ethyl 3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-1,2′-dicarboxylate (100 mg, 0.27 mmol) in THF (1.0 mL) at −78° C. under nitrogen. The reaction mixture was stirred for 1 hour at −78° C. N,N-dimethylformamide (39.9 μL, 0.51 mmol) was then slowly added to the cold reaction mixture. The reaction mixture was then allowed to slowly warm to room temperature. The reaction was filtered and purified by reverse phase preparatory-LC-MS (10-99% CH3CN/H2O) using HCl modifier to give 1-tert-butyl 2′-ethyl 6′-cyano-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-1,2′-dicarboxylate. ESI-MS m/z calc. 388.2, found 389.3 (M+1)+; Retention time: 1.82 minutes (3 minute run).
Step 3:
4 N HCl in dioxane (8.7 mL, 34.7 mmol) was added to a solution of 1-tert-butyl 2′-ethyl 6′-cyano-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-1,2′-dicarboxylate (0.27 mmol) in dichloromethane (5 mL) and the mixture was stirred at 40° C. for 1 hour. The reaction mixture was evaporated to dryness to give ethyl 6′-cyano-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-2′-carboxylate hydrochloride. ESI-MS m/z calc. 288.2, found 289.3 (M+1)+; Retention time: 0.75 minutes (3 minute run).
8′-Fluoro-2′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride




Step 1:
To a solution of tert-butyl 2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (5.60 g, 15.0 mmol) in acetonitrile (50 mL) was added NBS (2.80 g, 15.8 mmol). The mixture was stirred at room temperature overnight. The solvent was removed and the residue was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc (2×). The combined organic layers were washed with brine, dried over MgSO4 and concentrated to dryness. The crude material was purified by column chromatography (10-20% EtOAc-Hex) to provide tert-butyl 8-bromo-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (5.40 g, 73%) as a light yellow solid. ESI-MS m/z calc. 452.3. found 454.5 (M+1)+; Retention time: 1.60 minutes (3 minute run).
Step 2:
A solution of tert-butyl 8-bromo-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (15.0 g, 33.2 mmol) in THF (200 mL) was purged with Argon for 5 min. The mixture was cooled to −78° C. before nBuLi (42.5 mL of 1.6 M, 68 mmol) was added dropwise. The mixture was stirred at −78° C. for 30 min before a solution of N-(benzenesulfonyl)-N-fluoro-benzenesulfonamide (20.9 g, 66.3 mmol) in THF (100 mL) was added dropwise. The mixture was allowed to warm to room temperature overnight. The reaction mixture was quenched with sat. aq. NH4Cl. The layers were separated and the aqueous layer was extracted with EtOAc (2×). The organic layers were combined and washed with brine, dried over MgSO4, filtered and concentrated to dryness. CH2Cl2 was added and the solid was removed via filtration. The filtrate was concentrated to dryness and the residue was purified by column chromatography (10-20% EtOAc-Hex) to provide tert-butyl 8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (5.52 g, 43%) as a light brown oil that solidified upon standing. ESI-MS m/z calc. 391.4, found 392.5 (M+1)+; Retention time: 1.35 minutes (3 minute run).
Step 3:
To tert-butyl 8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (310 mg, 0.80 mmol) in CH2Cl2 (2 mL) was added a solution of HCl (2.0 mL of 4 M, 8.0 mmol) in 1,4-dioxane. The reaction mixture was allowed to stir at room temperature for 1 hour. The volatiles were removed under reduced pressure providing 8-fluoro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]dihydrochloride (290 mg, 99%) as a pink solid. ESI-MS m/z calc. 291.1, found 292.3 (M+1)+; Retention time: 0.75 minutes (3 minute run).
8′-Chloro-2′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride




Step 1:
To a solution of tert-butyl 8-bromo-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (5.00 g, 11.1 mmol) in anhydrous THF (125 mL) at −78° C. was added nBuLi (8.84 mL of 2.5 M, 22.1 mmol) slowly. The reaction mixture was allowed to stir at −78 for 20 minutes before 1,1,1,2,2,2-hexachloroethane (5.36 g, 22.7 mmol) was added dropwise as a solution in THF (12 mL). The reaction mixture was allowed to slowly warm to room temperature and was stirred overnight. The reaction mixture was quenched with the addition of saturated aqueous ammonium chloride (100 mL). The volatiles were removed under reduced pressure to half volume. The remaining aqueous suspension was extracted with EtOAc (2×100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to afford a thick brown oil. The crude product was purified by silica gel column chromatography: 10-20% EtOAc/hexane gradient to provide tert-butyl 8-chloro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (2.40 g, 53%) as a yellow oil that crystallized upon standing. ESI-MS m/z calc. 407.2, found 407.9 (M+1)+; Retention time: 1.70 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 6.47 (s, 1H), 3.97 (t, J=5.5 Hz, 4H), 3.28 (s, 2H), 3.13 (s, 2H), 2.51-2.28 (m, 5H), 1.93 (d, J=13.7 Hz, 2H), 1.47 (d, J=9.5 Hz, 9H).
Step 2:
To a solution of tert-butyl 8-chloro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (750 mg, 1.84 mmol) in CH2Cl2 (2 mL) was added a prepared solution of 1:1 trifluoroacetic acid (2.0 mL, 26 mmol) in CH2Cl2 (2 mL). After stirring at room temperature for 2 hours, saturated aqueous sodium bicarbonate solution (75 mL) was slowly added. The mixture was extracted with EtOAc (2×75 mL). The organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to provide 8-chloro-2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine] (555 mg, 98%) as a yellow-brown solid. ESI-MS m/z calc. 307.1, found 307.9 (M+1)+; Retention time: 1.12 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 9.72 (s, 1H), 9.38 (s, 1H), 6.49 (s, 1H), 3.98 (t, J=5.6 Hz, 2H), 3.36 (d, J=11.6 Hz, 2H), 3.26 (d, J=6.1 Hz, 4H), 2.78 (s, 2H), 2.40 (s, 3H), 2.11 (d, J=14.4 Hz, 2H), 1.69 (s, 2H).
2′-Methyl-6′,7′-bis(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]




Step 1:
Ferrous sulfate heptahydrate (803 μL of 1.00 M, 0.803 mmol) was added to a mixture of tert-butyl 2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (1.00 g, 2.68 mmol) and DMSO (15 mL) at room temperature. The vessel was then charged with CF3I (gas) before H2O2 (304 μL of 30% w/v, 2.68 mmol) was added dropwise. The mixture was allowed to stir overnight at room temperature before it was partitioned between ethyl acetate and water. The layers were separated and the aqueous layer was extracted with ethyl acetate (3×). The combined organics were washed with brine, dried over sodium sulfate, filtered and concentrated. The reside was purified by column chromatography (0-100% ethyl acetate/hexanes) to give tert-butyl 2-methyl-6,7-bis(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate. ESI-MS m/z calc. 441.2, found 442.5 (M+1)+; Retention time: 1.36 minutes (3 min run).
Step 2:
tert-Butyl 2-methyl-6,7-bis(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (from step 1) was taken up in CH2Cl2 (2 mL) and HCl (1.7 mL of 4 M, 6.8 mmol) was added. The mixture was allowed to stir for 30 min before it was concentrated under reduced pressure. The residue was taken up in ethyl acetate and was washed with sat. aq. NaHCO3, then brine. The organic layer was dried over sodium sulfate, filtered and concentrated to give 2-methyl-6,7-bis(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine] (22 mg, 2% over 2 steps). ESI-MS m/z calc. 341.1, found 342.3 (M+1)+; Retention time: 1.29 minutes.
2′-Methyl-6′-(methylsulfonyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]




Step 1:
To benzyl 2-methylspiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (3.00 g, 8.84 mmol) in CH2Cl2 (30 mL) at 0° C. was added NBS (1.57 g, 8.84 mmol) portionwise. The reaction mixture was stirred at 0° C. for 2 h. Additional NBS (157 mg) was added and the reaction mixture was stirred at 0° C. for 15 minutes (repeated 6 additional times until starting material was consumed). The reaction mixture was diluted with 0.5 M Na2S2O3 (30 mL) and the aqueous phase was removed. The organic phase was washed with brine (30 mL). The organic layer was dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography utilizing a gradient of 0-30% ethyl acetate in CH2Cl2 to yield benzyl 6-bromo-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (2.34 g, 63%) as a cream solid. ESI-MS m/z calc. 417.1, found 418.1 (M+1)+; Retention time: 1.49 minutes (3 min run). 1H NMR (400 MHz, DMSO) δ 7.43-7.26 (m, 5H), 6.09 (d, J=3.7 Hz, 1H), 5.99 (d, J=3.7 Hz, 1H), 5.08 (s, 2H), 3.89-3.74 (m, 2H), 3.68 (t, J=5.8 Hz, 2H), 3.27 (t, J=5.8 Hz, 2H), 3.22-2.99 (m, 2H), 2.21 (s, 3H), 2.09-1.94 (m, 2H), 1.73-1.52 (m, 2H).
Step 2:
A mixture of sodium methanesulfinate (293 mg, 2.87 mmol), benzyl 6-bromo-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (1.00 g, 2.39 mmol), CuI (296 mg, 1.55 mmol) and DMSO (5 mL) was heated at 90° C. in a pressure vessel for 20 hours. The mixture was cooled and was partitioned between ether (10 mL) and water (10 mL). The organic layer was separated and the aqueous layer was extracted with ether (3×5 mL). The combined organic layers were washed with brine (2×10 mL), dried over sodium sulfate, filtered and concentrated in vacuo. The crude product was purified by column chromatography utilizing a gradient of 0-50% ethyl acetate in CH2Cl2 to yield benzyl 2-methyl-6-methylsulfonyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (520 mg, 52%) as a white solid. ESI-MS m/z calc. 417.2, found 418.3 (M+1)+; Retention time: 1.27 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 7.45-7.30 (m, 5H), 6.88 (d, J=4.1 Hz, 1H), 6.01 (d, J=3.9 Hz, 1H), 5.15 (s, 2H), 4.28-4.15 (m, 2H), 4.09-3.89 (m, 2H), 3.40-3.16 (m, 4H), 3.10 (s, 3H), 2.37 (s, 3H), 2.20-2.02 (m, 2H), 1.89-1.66 (m, 2H).
Step 3:
To a solution of benzyl 2-methyl-6-methylsulfonyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carboxylate (520 mg, 1.25 mmol) in EtOH (13 mL) was added 10% palladium-carbon (66 mg, 0.062 mmol) under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 16 h under a hydrogen atmosphere. The mixture was filtered through a plug of celite and the solvent was evaporated under reduced pressure to yield 2-methyl-6-methylsulfonyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine] (342 mg, 97%) as an off-white solid. ESI-MS m/z calc. 283.1, found 284.3 (M+1)+; Retention time: 0.30 minutes (3 min run).
3-Methyl-4-(methylsulfamoyl)benzoic acid




Step 1:
A solution of 4-amino-3-methyl-benzoic acid (4.00 g, 26.5 mmol) in conc. HCl (15 mL) was cooled to 0° C. in an ice bath before a solution of sodium nitrite (1.97 g, 910 μL, 28.6 mmol) in water (5 mL) was added dropwise while keeping the temperature below 5° C. SO2 was bubbled through a solution of acetic acid (60 mL) and CuCl2 (889 mg, 6.62 mmol) for 20 min before the cold diazonium solution was added. The reaction mixture was stirred for 1 h before it was poured onto ice. The solid was collected by filtration and was washed with water. The solid was further dried to give 4-chlorosulfonyl-3-methyl-benzoic acid (2.30 g, 37%). 1H NMR (400 MHz, DMSO) δ 7.81 (d, J=7.8 Hz, 1H), 7.74-7.66 (m, 2H), 2.57 (s, 3H).
Step 2:
4-Chlorosulfonyl-3-methyl-benzoic acid (0.99 g, 4.2 mmol), methanamine (2.0 mL of 33% w/v, 21 mmol), and triethylamine (1.8 mL, 13 mmol) were stirred for 45 min at rt. The reaction mixture was evaporated and the resultant oil was partitioned between ethyl acetate and 1N HCl. The organics were separated and washed with another portion of 1N HCl and then brine. The organics were dried over sodium sulfate and evaporated to give 3-methyl-4-(methylsulfamoyl)benzoic acid (841 mg, 87%). ESI-MS m/z calc. 229.0, found 230.5 (M+1)+; Retention time: 0.64 minutes (3 min run).
The following compounds were synthesized using the procedures described above:
4-(N-ethylsulfamoyl)-3-methylbenzoic acid, 4-(N-cyclopropylsulfamoyl)-3-methylbenzoic acid, 4-(N-isopropylsulfamoyl)-3-methylbenzoic acid, and 4-(N,N-dimethylsulfamoyl)-3-methylbenzoic acid.
7-(Ethyl(methyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid




Step 1:
To a stirred suspension ethyl 7-hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylate (0.95 g, 4.6 mmol) in POCl3 (8.0 mL, 86 mmol) was added dimethyl aniline (0.8 μL, 0.006 mmol) and the mixture was heated at 80° C. for 2 hours. The mixture was slowly poured onto ice, and the pH was carefully adjusted to  ̃7 with 1N NaOH, then to pH 10 with solid Na2CO3. The mixture was then extracted with dichloromethane (3×). The organics were combined, washed with brine, dried (MgSO4) and evaporated to dryness. Trituration of the solids with hexanes gave ethyl 7-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (260 mg, 25%) as a tan solid. ESI-MS m/z calc. 225.0, found 226.5 (M+1)+; Retention time: 0.87 minutes (3 min run).
Step 2:
To a solution of ethyl 7-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (68 mg, 0.30 mmol) in CH3CN (1 mL) was added N-methylethanamine (18 mg, 0.30 mmol) and the mixture was stirred at ambient temperature for 16 h. The mixture was evaporated and the residue was purified by column chromatography (0-10% MeOH in dichloromethane) to give a solid. The solid was taken up in EtOH (0.5 mL) and water (0.1 mL) before NaOH (12 mg, 0.30 mmol) was added. The mixture was stirred at 50° C. for 4 h. The pH of the mixture was adjusted to 4 with conc. HCl, and the solvents were removed. The residue was co-evaporated with MeOH (3×) to provide 7-(ethyl(methyl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid. ESI-MS m/z calc. 220.1, found 221.5 (M+1)+; Retention time: 0.29 minutes (3 min run).
The following compounds were synthesized using the procedures described above:
7-(ethylamino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 7-(isopropylamino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 7-(ethyl(methyl)amino)-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid, 5-methyl-7-(pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid, and 7-(ethylamino)-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid.
4-(1-Hydroxy-1-methyl-ethyl)-3-methyl-benzoic acid




4-Bromo-3-methyl-benzoic acid (3.96 g, 18.4 mmol) was dissolved in tetrahydrofuran (100 mL) and the solution was cooled to −78° C. n-Butyllithium in hexanes (16.2 mL of 2.5 M, 41 mmol) was added dropwise over 20 minutes. The reaction mixture was allowed to stir for 30 minutes at −78° C. and then acetone (1.35 mL, 18.4 mmol) was added in a drop-wise manner. The reaction mixture was allowed to stir for 30 minutes at −78° C., and then it was allowed to warm to room temperature. The reaction mixture was then diluted with 100 mL of 1M aqueous sodium hydroxide. The organic layer was discarded and then the aqueous layer was made acidic with 4M aqueous hydrochloric acid. The aqueous layer was then extracted 3 times with ethyl acetate. The combined extracts were dried over sodium sulfate and then evaporated to dryness. The crude material was further purified on silica gel utilizing a gradient of 0-10% methanol in dichloromethane to give 4-(1-hydroxy-1-methyl-ethyl)-3-methyl-benzoic acid (1.51 g, 42%). 1H NMR (400 MHz, DMSO) δ 12.74 (s, 1H), 7.68 (dd, J=3.9, 2.5 Hz, 2H), 7.55 (d, J=8.7 Hz, 1H), 5.06 (s, 1H), 2.56 (s, 3H), 1.51 (s, 6H).
The following compounds were synthesized using the procedures described above:
4-(1-hydroxycyclopentyl)-3-methylbenzoic acid, 4-(1-hydroxycyclopentyl)benzoic acid, 4-(1-hydroxycyclohexyl)-3-methylbenzoic acid, 4-(1-hydroxycyclohexyl)benzoic acid, 3-fluoro-4-(1-hydroxycyclohexyl)benzoic acid, and 4-(1-hydroxycyclohexyl)-3-methoxybenzoic acid.
5-Isopropoxy-6-methylpicolinic acid




Step 1:
2-Methyl-3-pyridinol (8.3 g, 76.1 mmol) was suspended in acetonitrile (125 mL). A solution of NBS (27.7 g, 155.6 mmol, 2.05 equiv) in acetonitrile (275 mL) was added to the suspension drop-wise over 1 hour. The mixture was heated at reflux for 1.5 h. The mixture was concentrated and the residue was purified by column chromatography (DCM) to give 4,6-dibromo-2-methylpyridin-3-ol (15.8 g, 78%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) 2.41 (s, 3H), 7.70 (s, 1H), 9.98 (s, 1H).
Step 2:
4,6-Dibromo-2-methylpyridin-3-ol (15.8 g, 59.4 mmol) was dissolved in THF (200 mL). The solution was cooled to −78° C. and n-BuLi (50 mL, 125 mmol, 2.5 M in hexane) was added drop-wise keeping the temperature below −78° C. The mixture was allowed to stir at that temperature for 2 h. The mixture was quenched with water (50 mL) and was neutralized with 2 N HCl. The aqueous mixture was extracted with dichloromethane (2×). The combined organic layers were dried (Na2SO4) and concentrated to give 6-bromo-2-methylpyridin-3-ol (10.5 g, 95%) as a yellow oil. 1H-NMR (300 MHz, DMSO-d6) 2.29 (s, 3H), 7.08 (d, 1H), 7.26 (d, 1H), 10.08 (s, 1H).
Step 3:
6-Bromo-2-methylpyridin-3-ol (10.5 g, 55.9 mmol) was dissolved in DMF (100 mL). K2CO3 (19.3 g, 139.6 mmol) and 2-bromopropane (13.1 ml, 139.6 mmol) were added to the solution and the mixture was heated at 100° C. overnight. The mixture was poured into a mixture of water and EtOAc (200 mL). The layers were separated and the aqueous layer was extracted with EtOAc (2×). The combined organic layers were dried (Na2SO4) and concentrated. The crude oil was purified by column chromatography (0-20% ethyl acetate/heptanes) to give 6-bromo-3-isopropoxy-2-methylpyridine (10.9 g, 85) as a yellow oil. 1H-NMR (300 MHz, CDCl3) 1.42 (d, 6H), 2.48 (s, 3H), 4.65 (m, 1H), 7.20 (d, 1H), 8.04 (d, 1H).
Step 4:
6-Bromo-3-isopropoxy-2-methylpyridine (2.00 g, 8.70 mmol), PdCl2(PPh3)2 (0.18 g, 0.26 mmol) and Et3N (1.8 ml, 13.04 mmol) were added to MeOH (5.2 mL) and acetonitrile (20 mL) in a Berghoff reactor. The reactor was charged with 10 bar CO (g) and was heated at 60° C. overnight. The mixture was concentrated and the residue was partitioned between DCM and water. The layers were separated and the organic layer was washed with brine and dried (Na2SO4). The mixture was concentrated and purified by column chromatography to give methyl 5-isopropoxy-6-methylpicolinate (1.3 g, 71%) as a yellow oil. 1H-NMR (300 MHz, CDCl3) 1.40 (d, 6H), 2.53 (s, 3H), 3.98 (s, 3H), 4.62 (m, 1H), 7.12 (d, 1H), 7.98 (d, 1H).
Step 5:
5-Isopropoxy-6-methylpicolinate (1.3 g, 6.22 mmol) was dissolved in THF/water 2:1 (9 mL). LiOH*H2O (0.26 g, 6.22 mmol) was added and the mixture was stirred at room temperature overnight. The mixture was poured into a mixture of water and EtOAc and the layers were separated. The aqueous layer was acidified to pH 4 with 2 N HCl and was extracted with EtOAc (2×). The combined organics were dried (Na2SO4) and concentrated to give 5-isopropoxy-6-methylpicolinic acid (860 mg, 74%) as a beige solid. 1H-NMR (300 MHz, DMSO-d6) 1.31 (d, 6H), 4.73 (m, 1H), 7.44 (d, 1H), 7.86 (d, 1H). 1H NMR (400 MHz, DMSO) δ 12.61 (s, 1H), 7.88 (d, J=8.5 Hz, 1H), 7.44 (d, J=8.7 Hz, 1H), 4.74 (dt, J=12.0, 6.0 Hz, 1H), 2.37 (s, 3H), 1.32 (d, J=6.0 Hz, 6H).
The following compound was synthesized using the procedures described above:
5-methoxy-6-methylpicolinic acid.
4-Isopropoxy-3-methoxybenzoic acid




Step 1:
Under a balloon of N2, tert-butyllithium (2.14 mL of 1.6 M, 3.43 mmol) was added drop-wise to a solution of 4-bromo-1-isopropoxy-2-methoxy-benzene (400 mg, 1.63 mmol) in THF (6.0 mL) at −78° C. The mixture was allowed to stir for 1 h at −78° C. before it was added drop-wise to a flask containing CO2 (1.80 g, 40.8 mmol)(solid, dry ice) in THF (2.0 mL). The mixture was allowed to stir for 30 min as it warmed to room temperature (caution: CO2 gas evolution). Water (20 mL) was added and the volatiles were removed under reduced pressure. The resultant aqueous layer was acidified with 1N HCl to pH  ̃1-2 and the mixture was extracted with ethyl acetate (3×15 mL). The combined organics were washed with brine, dried over sodium sulfate, filtered and concentrated to give 4-isopropoxy-3-methoxy-benzoic acid (≧94% pure, 310 mg, 85%) as a white solid. ESI-MS m/z calc. 210.1, found 210.9 (M+1)+; Retention time: 1.23 min. 1H NMR (400 MHz, DMSO) δ 12.63 (s, 1H), 7.53 (dd, J=8.4, 2.0 Hz, 1H), 7.44 (d, J=2.0 Hz, 1H), 7.04 (d, J=8.7 Hz, 1H), 4.67 (dt, J=12.1, 6.0 Hz, 1H), 3.78 (s, 3H), 1.28 (d, J=6.0 Hz, 6H).
3-Methoxy-4-(2-(trifluoromethoxy)ethoxy)benzoic acid




Step 1:
To sodium hydride (200 mg, 5.0 mmol) in DMF (6 mL) under N2 was added methyl 4-hydroxy-3-methoxy-benzoate (920 mg, 5.0 mmol) and the mixture was stirred for 10 min. 2-(trifluoromethoxy)ethyl trifluoromethanesulfonate (1.2 g, 4.6 mmol) was then added dropwise and the solution was stirred at room temperature for 2 h, then at 50° C. for 2 h. The mixture was concentrated to a solid, and the residue was taken up in 50 mL of CH2Cl2 before it was washed with brine (20 mL), dried over MgSO4 and purified by column chromatography (0-25% EtOAc/hexane) to give methyl 3-methoxy-4-(2-(trifluoromethoxy)ethoxy)benzoate as a white solid. ESI-MS m/z calc. 294.1, found 295.3 (M+1)+; Retention time: 1.63 minutes (3 min run).
Step 2:
Methyl 3-methoxy-4-(2-(trifluoromethoxy)ethoxy)benzoate (obtained in Step 1) was dissolved in THF (5 mL) and a suspension of LiOH (550 mg, 23 mmol) in water (5 mL) was added. The mixture was stirred vigorously and heated at 60° C. for 6 h before it was concentrated to half volume. Water (5 mL) was added and the mixture was extracted with diethyl ether (1×10 mL). The aqueous layer was acidified with 4N HCl to pH 2. The resulting mixture was extracted with ethyl acetate (3×10 mL) and the combined organics were washed (1×10 mL H2O, 1×10 mL brine), dried over MgSO4 and evaporated to give 3-methoxy-4-(2-(trifluoromethoxy)ethoxy)benzoic acid (1.0 g, 82%) as a white solid. ESI-MS m/z calc. 280.1, found 281.3 (M+1)+; Retention time: 1.34 minutes (3 min run).
4-tert-Butoxy-3-methoxybenzoic acid




Step 1:
4-Hydroxy-3-methoxy-benzaldehyde (500 mg, 3.29 mmol), Boc2O (1.74 g, 7.97 mmol), and Sc(OTf)3 (0.080 g, 0.16 mmol) were combined in dichloromethane (5 mL). The reaction mixture was allowed to stir at room temperature for 24 h. Water (5 mL) and dichloromethane (5 mL) were added and the two phases were separated. The aqueous layer was extracted with dichloromethane (3×5 mL) and the combined organics were stirred with 10% aqueous potassium hydroxide until all remaining starting material was not observed in the organic phase (TLC, 40% ethyl acetate in hexanes). The two phases were separated and the dichloromethane layer was then washed twice with a saturated aqueous solution of sodium chloride, dried over sodium sulfate, filtered, and evaporated to dryness to give 4-tert-butoxy-3-methoxybenzaldehyde (130 mg, 19%) as a yellow oil. Rf=0.66 (SiO2, 40% ethyl acetate in hexanes); ESI-MS m/z calc. 208.1, found 209.2 (M+1)+. Retention time: 0.96 minutes (6 min run).
Step 2:
4-tert-Butoxy-3-methoxybenzaldehyde (130 mg, 0.62 mmol) was suspended in a mixture of dioxane (520 μL) and potassium hydroxide (6.5 mL of 0.20 M, 1.3 mmol). KMnO4 (150 mg, 0.93 mmol) was added and the reaction was stirred vigorously for 16 h. The reaction mixture was filtered and then concentrated to 3 mL. Hydrochloric acid (1M, 4 mL) was added and the resulting precipitate was filtered (after standing for 15 minutes) and washed with 1M HCl and a small amount of water to yield 4-tert-butoxy-3-methoxy-benzoic acid (68 mg, 49%) as a white solid. Rf=0.23 (SiO2, 40% ethyl acetate in hexanes); ESI-MS m/z calc. 224.1, found 225.2 (M+1)+. Retention time: 1.66 minutes (3 min run). 1H NMR (400 MHz, DMSO) δ 12.80 (s, 1H), 7.66-7.41 (m, 2H), 7.09 (d, J=8.8 Hz, 1H), 3.78 (s, 3H), 1.32 (s, 9H).
The following compounds were synthesized using the procedures described above:
4-tert-butoxy-3-methylbenzoic acid from 4-hydroxy-3-methylbenzaldehyde, 2-fluoro-4,5-dimethoxybenzoic acid from 2-fluoro-4,5-dimethoxybenzaldehyde, 4-tert-butoxy-2-methoxybenzoic acid from 4-hydroxy-2-methoxybenzaldehyde, 4-tert-butoxy-2-fluorobenzoic acid from 2-fluoro-4-hydroxybenzaldehyde, and 4-tert-butoxybenzoic acid from 4-hydroxybenzaldehyde.
4-Ethyl-3-methoxybenzoic acid




A mixture of 4-bromo-3-methoxy-benzoic acid (2.49 g, 10.9 mmol) and Pd(dppf)Cl2 (158 mg, 0.216 mmol) were stirred in dioxane (25 mL) and Et2Zn (22 mL, 1 M in hexanes, 22 mmol) was added. The reaction mixture was heated at 70° C. for 1 h. The mixture was cooled to room temperature and was quenched with MeOH (1.1 mL). The solution was diluted with ethyl acetate (20 mL) and was washed with 1 N HCl (10 mL). The combined organics were washed with brine, dried over sodium sulfate and evaporated to dryness to give 4-ethyl-3-methoxybenzoic acid. ESI-MS m/z calc. 180.1, found 179.1 (M−1)−; Retention time: 1.77 minutes (3 min run).
4-(Isopropylsulfonyl)-3-methylbenzoic acid




Step 1:
Butyllithium (16 mL of 1.6 M, 26 mmol) was added drop-wise to a mixture of 4-bromo-3-methyl-benzoic acid (2.5 g, 12 mmol) and THF (63 mL) at −78° C. The mixture was allowed to stir at −78° C. for 30 minutes before a solution of 2-isopropyldisulfanylpropane (1.7 g, 12 mmol) in THF (2 mL) was added drop-wise. The mixture was allowed to stir at −78° C. for 30 min, then 30 min at rt. The reaction mixture was then diluted with 100 mL of 1M aqueous sodium hydroxide. The organic layer was discarded and the aqueous layer was made acidic with 4M aqueous hydrochloric acid. The aqueous layer was then extracted 3 times with ethyl acetate. The combined extracts were dried over sodium sulfate and then evaporated to dryness. The crude material was purified by column chromatography using a gradient of 0-5% MeOH in dichloromethane to give 4-(isopropylthio)-3-methylbenzoic acid (870 mg, 18%). MS m/z calc. 210.3, found 211.2 (M+1)+. Retention time: 2.32 minutes (3 min run).
Step 2:
3-Chlorobenzenecarboperoxoic acid (930 mg, 4.2 mmol) was added to a mixture of 4-(isopropylthio)-3-methylbenzoic acid (250 mg, 1.2 mmol) and dichloromethane (5.0 mL) at 25° C. The mixture was allowed to stir at 25° C. for 2 h before it was concentrated in vacuo. The white solid material was taken up in dichloromethane and was subjected to column chromatography (0-2% MeOH/dichloromethane) to give 4-isopropylsulfonyl-3-methyl-benzoic acid (90 mg, 31%) as a white solid. ESI-MS m/z calc. 242.3, found 243.2 (M+1)+. Retention time: 1.57 minutes (3 min run). 1H NMR (400 MHz, DMSO) δ 13.50 (s, 1H), 8.50-7.66 (m, 3H), 3.50-3.47 (m, 1H), 2.67 (s, 3H), 1.19 (d, J=1.16 Hz, 6H).
The following compounds were synthesized using the procedures described above:
4-(isopropylsulfonyl)-2-methylbenzoic acid and 4-(ethylsulfonyl)-3-methylbenzoic acid,
4-(2-Hydroxypropan-2-yl)-3-methoxybenzoic acid




4-Bromo-3-methoxy-benzoic acid (2.00 g, 8.67 mmol) was dissolved in THF (50 mL) and the solution was cooled to −78° C. n-BuLi in hexanes (7.6 mL of 2.5 M, 19 mmol) was added dropwise over 15 minutes. The reaction mixture was allowed to stir for 30 minutes at −78° C. and then acetone (640 μL, 8.9 mmol) was added in a dropwise manner. The reaction mixture was allowed to stir for 30 minutes at −78° C., and then it was allowed to warm to room temperature. The reaction mixture was then diluted with 100 mL of 1M aqueous sodium hydroxide. The organic layer was discarded and the aqueous layer was made acidic with 4M aqueous hydrochloric acid. The aqueous layer was then extracted 3 times with ethyl acetate. The combined extracts were dried over sodium sulfate and then evaporated to dryness. The crude material was purified by column chromatography utilizing a gradient of 0-5% methanol in dichloromethane to give 4-(2-hydroxypropan-2-yl)-3-methoxybenzoic acid (618 mg, 34%). ESI-MS m/z calc. 210.1, found 209.1 (M−1)−; Retention time: 0.68 minutes (3 min run).
3-Fluoro-4-isopropoxybenzoic acid




Step 1:
To methyl 3-fluoro-4-hydroxy-benzoate (2.00 g, 11.8 mmol) in DMF (12.5 mL) was added K2CO3 (6.50 g, 47.0 mmol) followed by 2-iodopropane (2.35 mL, 23.5 mmol). The mixture was heated at 60° C. for 1.5 h. The mixture was filtered using EtOAc and the filtrate was evaporated under reduced pressure. The residue was dissolved in EtOAc and was washed with water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give methyl 3-fluoro-4-isopropoxybenzoate. ESI-MS m/z calc 212.1, found 213.3 (M+1)+. Retention time: 1.70 minutes (3 min run).
Step 2:
Methyl 3-fluoro-4-isopropoxybenzoate (from step 1), 1,4-dioxane (31 mL), and NaOH (31 mL of 1.0 M, 31 mmol) were combined and the mixture was heated at 80° C. for 20 min. The solvent was evaporated under reduced pressure. The crude mixture was dissolved in water and was washed with EtOAc (3×). The combined organics were discarded. The aqueous layer was acidified and was extracted with EtOAc (3×). The organic layer was dried over sodium sulfate, filtered and the concentrated under reduced pressure to yield 3-fluoro-4-isopropoxy-benzoic acid (1.25 g, 72%) as a white solid. ESI-MS m/z calc 198.1, found 199.3 (M+1)+. Retention time: 1.34 minutes (3 min run).
The following compounds were synthesized using the procedures described above:
2-fluoro-4-isopropoxybenzoic acid and 4-isopropoxy-3-methylbenzoic acid, 3-cyano-4-isopropoxybenzoic acid and 4-isopropoxy-3-(trifluoromethyl)benzoic acid.
4-(tert-Butylsulfonyl)benzoic acid




Step 1:
Ethyl 4-fluorobenzoate (1.5 g, 8.9 mmol) and tert-butylsulfanylsodium (2.00 g, 17.8 mmol) were combined in DMF (10 mL). The reaction mixture was heated at 80° C. for 2 hours. A large amount of precipitate formed and an additional 15 mL of DMF was added and the reaction mixture was stirred for an additional 20 hours at 80° C. The reaction mixture was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic layer was discarded, and the water layer was made acidic with 4M hydrochloric acid. The water layer was extracted two times with ethyl acetate. The combined extracts were dried over sodium sulfate, filtered, and evaporated to dryness to yield 4-(tert-butylthio)benzoic acid as a colorless oil. ESI-MS m/z calc. 210.3, found 211.1 (M+1)+. Retention time: 1.74 minutes (3 min run).
Step 2:
4-(tert-Butylthio)benzoic acid (from Step 1) was dissolved in AcOH (10 mL) and hydrogen peroxide (5.0 mL of 30% w/w, 52 mmol) was added to the reaction mixture. The resulting mixture was heated at 80° C. for 2 hours. The reaction mixture was then allowed to cool to room temperature, and was diluted with 50 mL of water and 100 mL of ethyl acetate. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined ethyl acetate extracts were dried over sodium sulfate, filtered, and evaporated to dryness to yield a white solid. The white solid was then dissolved in dichloromethane and was evaporated to dryness. The solid was then dried under vacuum for 16 hours to give 4-tert-butylsulfonylbenzoic acid (2.2 g, 92%) as a white solid. ESI-MS m/z calc. 242.1, found 243.1 (M+1)+. Retention time: 1.15 minutes (3 min run). 1H NMR (400 MHz, DMSO) δ 8.18 (d, J=8.0 Hz, 2H), 7.94 (d, J=7.6 Hz, 2H), 1.25 (s, 9H).
The following compound was synthesized using the procedures described above:
4-(ethylsulfonyl)benzoic acid.
4-(Isobutylsulfonyl)benzoic acid




Step 1:
K2CO3 (1.23 g, 8.92 mmol) was added to a mixture of methyl 4-sulfanylbenzoate (1.00 g, 5.95 mmol), 1-bromo-2-methyl-propane (970 μL, 8.92 mmol), and DMF (10 mL) at rt. The mixture was allowed to stir for 4 h at rt before the solids were filtered off. The solids were washed with ethyl acetate, and then were discarded. The combined filtrates were partitioned between ethyl acetate (100 mL) and water (100 mL). The layers were separated and the organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated to give methyl 4-(isobutylthio)benzoate (82%) as a clear oil. ESI-MS m/z calc. 224.1, found 225.2 (M+1)+. Retention time: 1.59 minutes (3 min run).
Step 2:
m-CPBA (3.59 g, 15.6 mmol) was added to a solution of methyl 4-(isobutylsulfanyl)benzoate (1.00 g, 4.46 mmol) in CH2Cl2 (20 mL) at rt. The mixture was allowed to stir for 2 h before it was concentrated in vacuo. Column chromatography (0-100% ethyl acetate/hexanes) on the residue gave methyl 4-(isobutylsulfonyl)benzoate. ESI-MS m/z calc. 256.1, found 257.2 (M+1)+; Retention time: 1.96 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 8.23 (d, J=8.4 Hz, 2H), 8.00 (d, J=8.3 Hz, 2H), 3.98 (s, 3H), 3.02 (d, J=6.5 Hz, 2H), 2.25 (dp, J=13.3, 6.6 Hz, 1H), 1.07 (d, J=6.7 Hz, 6H).
Step 3:
A mixture of methyl 4-isobutylsulfonylbenzoate (1.00 g, 3.90 mmol), NaOH (10 mL of 1.0 M, 10 mmol), and 1,4-dioxane (10 mL) was heated at 80° C. for 1.5 h. The mixture was cooled to rt before it was concentrated in vacuo. The solid residue was taken up in water and was washed with ethyl acetate which was discarded. The aqueous layer was acidified with 1N HCl and was extracted with ethyl acetate (2×). The combined organics were washed with brine, dried over sodium sulfate, and were concentrated in vacuo. Column chromatography (0-100% ethyl acetate/hexanes) on the residue gave 4-(isobutylsulfonyl)benzoic acid (98%). ESI-MS m/z calc. 242.1, found 243.2 (M+1)+; Retention time: 1.73 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 8.30 (d, J=8.3 Hz, 2H), 8.05 (d, J=8.3 Hz, 2H), 3.03 (d, J=6.5 Hz, 2H), 2.27 (dt, J=13.3, 6.6 Hz, 1H), 1.08 (d, J=6.7 Hz, 6H).
3-(Hydroxymethyl)-4-isopropoxy-benzoic acid




Step 1:
To methyl 3-formyl-4-hydroxy-benzoate (10.0 g, 55.5 mmol), potassium carbonate (30.7 g, 222 mmol) and DMF (63 mL) was added 2-iodopropane (11.1 mL, 111 mmol). The mixture was heated at 60° C. for 18 hours. The mixture was filtered using ethyl acetate (200 mL) and the solvent was evaporated under reduced pressure. The residue was dissolved in ethyl acetate (150 mL) and was washed with water (3×75 mL) and a saturated aqueous solution of sodium chloride (1×75 mL). The organic layer was dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure to yield methyl 3-formyl-4-isopropoxy-benzoate (98%) as a yellow viscous liquid. ESI-MS m/z calc. 222.2, found 223.3 (M+1)+; Retention time: 1.51 minutes (3 min run). 1H NMR (400 MHz, DMSO) δ 10.35 (s, 1H), 8.23 (d, J=2.3 Hz, 1H), 8.17 (dd, J=8.8, 2.3 Hz, 1H), 7.39 (d, J=8.9 Hz, 1H), 4.98-4.83 (m, 1H), 3.85 (s, 3H), 1.38 (d, J=6.0 Hz, 6H).
Step 2:
Methyl 3-formyl-4-isopropoxy-benzoate (180 mg, 0.81 mmol) was dissolved in tetrahydrofuran (4.8 mL) and LiBH4 (35 mg, 1.6 mmol) was added. The reaction was stirred at room temperature for 30 minutes before it was quenched with methanol (3 mL). The reaction was neutralized by the addition of a saturated aqueous solution of sodium bicarbonate (3 mL) and was then extracted with ethyl acetate (3×10 mL). The combined organics were washed with a saturated aqueous solution of sodium chloride (1×10 mL), dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure to yield methyl 3-(hydroxymethyl)-4-isopropoxy-benzoate (99%) as a viscous liquid. ESI-MS m/z calc. 224.3, found 225.3 (M+1)+; Retention time: 1.26 minutes (3 min run). 1H NMR (400 MHz, DMSO) δ 8.09 (s, 1H), 7.89 (d, J=8.6 Hz, 1H), 7.13 (d, J=8.6 Hz, 1H), 5.25 (t, J=5.6 Hz, 1H), 4.86-4.68 (m, 1H), 4.54 (d, J=5.6 Hz, 2H), 3.87 (s, 3H), 1.35 (d, J=6.0 Hz, 6H).
Step 3:
To methyl 3-(hydroxymethyl)-4-isopropoxy-benzoate (180 mg, 0.80 mmol) and 1,4-dioxane (1.895 mL) was added sodium hydroxide (2.1 mL of 1.0 M, 2.1 mmol) and the mixture was heated at 80° C. for 50 minutes. The solvent was evaporated under reduced pressure. The crude mixture was dissolved in water (10 mL) and was washed with ethyl acetate (3×10 mL) which was discarded. The aqueous layer was acidified with hydrochloric acid. The aqueous layer was extracted with ethyl acetate (3×10 mL). The combined organics were dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure to yield 3-(hydroxymethyl)-4-isopropoxy-benzoic acid (89%) as a white solid. ESI-MS m/z calc. 210.2, found 211.3 (M+1)+; Retention time: 1.01 minutes (3 min run).
The following compounds were synthesized using the procedures described above:
4-ethoxy-3-(hydroxymethyl)benzoic acid, 4-(2-hydroxy-2-methylpropoxy)-3-methylbenzoic acid, 4-isopropoxy-3-methoxy-5-methylbenzoic acid, 5-isobutoxypicolinic acid, 5-(isopentyloxy)picolinic acid, 5-isopropoxy-4-methylpicolinic acid.
3-Methyl-4-(oxetan-3-yl)benzoic acid




Step 1:
(4-Cyano-2-methyl-phenyl)boronic acid (1.75 g, 10.87 mmol), diiodonickel (102 mg, 0.326 mmol), (1S,2S)-2-aminocyclohexan-1-ol hydrochloride (50 mg, 0.33 mmol) and NaHMDS (2.01 g, 11.0 mmol) were combined in isopropanol (10 mL) under N2 in a pressure vial. A solution of 3-iodooxetane (1.00 g, 5.44 mmol) in isopropanol (1 mL) was added. The vial was immersed in a pre-heated 90° C. oil bath and stirred for 2 h, then cooled, diluted with ethanol (20 mL), filtered over Celite, concentrated, then absorbed onto Celite and purified by silica gel column chromatography (0-60% EtOAc/hexane) to give 3-methyl-4-(oxetan-3-yl)benzonitrile (616 mg, 3.556 mmol, 65.42%) as a white solid. ESI-MS m/z calc. 173.1, found 174.3 (M+1)+; Retention time: 1.09 minutes (3 min run).
Step 2:
To 3-methyl-4-(oxetan-3-yl)benzonitrile (500 mg, 2.89 mmol) in ethanol (7.5 mL) was added NaOH (3.0 mL of 5 M, 15 mmol) and the mixture immersed in a 85° C. oil bath. The mixture was heated and stirred for 1 h, concentrated, then diluted with ethyl acetate (20 mL). 6N HCl ( ̃3 mL) was added to adjust pH to 6. The aqueous layer was extracted with ethyl acetate (2×20 mL), then the combined organics washed with brine (10 mL), dried over MgSO4 and concentrated to give a white solid, which was triturated with ether to give a mixture (2:3 by NMR) of acid 3-methyl-4-(oxetan-3-yl)benzoic acid (500 mg, 14%) and amide. ESI-MS m/z calc. 192.2, found 193.3 (M+1)+; Retention time: 0.87 minutes (3 min run).
5-Isopropoxy-6-methoxypicolinic acid




Step 1:
To a solution of 2-chloro-6-iodo-pyridin-3-ol (5.00 g, 19.57 mmol) in DMF was added finely ground potassium carbonate (5.409 g, 39.14 mmol) followed by 2-bromopropane (4.814 g, 3.675 mL, 39.14 mmol). The reaction mixture was allowed to stir at 70° C. overnight. The reaction mixture was concentrated under reduced pressure. The residue was dissolved/suspended in EtOAc (75 mL) and washed with water (1×75 mL). The aqueous layer was further extracted with EtOAc (1×75 mL). Both organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain a yellow oil which was purified by silica gel column chromatography: 0-30% EtOAc/hexane gradient to provide 2-chloro-6-iodo-3-isopropoxy-pyridine (5.68 g, 97. %) as a clear colourless thin oil. ESI-MS m/z calc. 296.9, found 298.4 (M+1)+; Retention time: 1.74 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J=8.3 Hz, 1H), 6.90 (d, J=8.3 Hz, 1H), 4.53 (dt, J=12.1, 6.1 Hz, 1H), 1.39 (d, J=6.1 Hz, 6H).
Step 2:
2-Chloro-6-iodo-3-isopropoxy-pyridine (2.00 g, 6.722 mmol) was dissolved in DMF (15 mL). Zn(CN)2 (592 mg, 5.04 mmol) was added, and the mixture was bubbled with nitrogen gas prior to the addition of Pd(PPh3)4 (600 mg, 0.519 mmol). The reaction system was sealed and heated under microwave irradiation at 100° C. for 30 minutes. The reaction mixture was diluted with EtOAc (75 mL) and washed with saturated aqueous sodium bicarbonate solution (75 mL) followed by brine (75 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to obtain a clear oil which was purified by silica gel column chromatography: 0-30% EtOAc/hexane gradient to provide 6-chloro-5-isopropoxy-pyridine-2-carbonitrile (1.17 g, 88%) as a clear colourless oil that crystallized upon standing. ESI-MS m/z calc. 196.0, found 197.3 (M+1)+; Retention time: 1.46 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J=8.4 Hz, 1H), 7.21 (d, J=8.4 Hz, 1H), 4.67 (dt, J=12.1, 6.1 Hz, 1H), 1.45 (d, J=6.1 Hz, 6H).
Step 3:
6-Chloro-5-isopropoxy-pyridine-2-carbonitrile (1.10 g, 5.59 mmol) was dissolved in methanol (11 mL). To the solution was added a solution of HCl (11 mL of 4 M, 44.00 mmol) in 1,4-dioxane. The reaction mixture was allowed to stir at 70° C. overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The remaining solids were suspended in EtOAc (75 mL) and washed with saturated aqueous sodium bicarbonate solution (1×75 mL). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. It was purified by silica gel column chromatography: 0-50% EtOAc/hexane to provide methyl 6-chloro-5-isopropoxy-pyridine-2-carboxylate (894 mg, 69%) as a clear colourless oil that crystallized upon standing. ESI-MS m/z calc. 229.1, found 230.3 (M+1)+; Retention time: 1.23 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 8.06 (d, J=8.4 Hz, 1H), 7.25 (d, J=8.5 Hz, 1H), 4.68 (dt, J=12.1, 6.1 Hz, 1H), 3.97 (s, 3H), 1.44 (d, J=6.1 Hz, 6H).
Step 4:
Methyl 6-chloro-5-isopropoxy-pyridine-2-carboxylate (330 mg, 1.44 mmol) was dissolved in dioxane (12 mL), and a solution of sodium methoxide (5.75 mL of 0.5 M, 2.87 mmol) in methanol was added. The reaction was heated under microwave irradiation at 140° C. for 1.5 hours. Water (52 μL, 2.9 mmol) was added, and the reaction mixture was heated by microwave irradiation at 100° C. for 30 minutes. The reaction mixture was diluted with 1 N HCl solution (50 mL) and extracted with EtOAc (2×50 mL). Organic layers were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to provide 5-isopropoxy-6-methoxy-pyridine-2-carboxylic acid (300 mg, 98%) as a beige solid. ESI-MS m/z calc. 211.1, found 211.9 (M+1)+; Retention time: 0.97 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 7.83 (d, J=8.1 Hz, 1H), 7.17 (d, J=8.1 Hz, 1H), 4.72-4.61 (m, 1H), 4.06 (s, 3H), 1.45 (t, J=7.4 Hz, 7H).
5-tert-Butoxypicolinic acid




Step 1:
To NaOtBu (1.57 g, 16.4 mmol) in HMPA (6 mL) was added DMF (6 mL) (to facilitate stirring). 5-Fluoropyridine-2-carbonitrile (1.00 g, 8.19 mmol) was added and the dark mixture was stirred overnight. The mixture was diluted with water (100 mL), extracted with DCM (3×50 mL) and the organics were washed with water (50 mL) and sat. aq. NaHCO3 (50 mL), dried over MgSO4, evaporated and purified by column chromatography (0-50% EtOAc/hex) to give 5-tert-butoxypyridine-2-carbonitrile (0.90 g, 62%) as a yellow solid. ESI-MS m/z calc. 211.1, found 211.9 (M+1)+; Retention time: 0.97 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 8.38 (dd, J=2.7, 0.5 Hz, 1H), 7.67-7.56 (m, 1H), 7.41-7.31 (m, 1H), 1.52-1.38 (m, 10H).
Step 2:
To 5-tert-butoxypyridine-2-carbonitrile (751 mg, 4.26 mmol) in ethanol (10 mL) was added NaOH (4.262 mL of 5 M, 21.31 mmol) and the mixture immersed in a 85° C. heated bath. The mixture was heated and stirred for 1 h, concentrated, then diluted with ethyl acetate (50 mL). 10 mL brine and  ̃3 mL of 6N HCl (to adjust to pH 6) was added. The organic layer was separated, dried over MgSO4 and concentrated to give 5-tert-butoxypyridine-2-carboxylic acid (820 mg, 98%) as a yellow solid. ESI-MS m/z calc. 195.1, found 196.1 (M+1)+; Retention time: 0.62 minutes (3 min run). 1H NMR (400 MHz, DMSO) δ 12.74 (s, 1H), 8.29 (d, J=32.6 Hz, 1H), 7.99 (s, 1H), 7.60 (d, J=6.5 Hz, 1H), 3.37 (s, 1H), 1.39 (s, 11H).
4-(N-Methyl-N-(thiazol-2-yl)sulfamoyl)benzoic acid




Step 1:
To methyl 4-chlorosulfonylbenzoate (4 g, 17.05 mmol), N-methylthiazol-2-amine (1.95 g, 17.05 mmol), 1,2-dichloroethane (20 mL), and triethylamine (2.38 mL, 17.05 mmol) were added and the reaction was heated at 100° C. in a pressure vessel for 20.5 hours on a heat block. The solvent was evaporated under reduced pressure. The crude compound was dissolved in dichloromethane and filtered. The filtrate was purified by silica gel chromatography utilizing a gradient of 0-30% ethyl acetate in dichloromethane to yield methyl 4-[methyl(thiazol-2-yl)sulfamoyl]benzoate (4.22 g, 79.2%). 1H NMR (400 MHz, DMSO) δ 8.16 (d, J=8.5 Hz, 2H), 7.95 (d, J=8.5 Hz, 2H), 7.46 (d, J=3.6 Hz, 1H), 7.44 (d, J=3.6 Hz, 1H), 3.89 (s, 3H), 3.39 (s, 3H). ESI-MS m/z calc. 312.0, found 313.3 (M+1)+; Retention time: 1.52 minutes (3 min run).
Step 2:
To methyl 4-[methyl(thiazol-2-yl)sulfamoyl]benzoate (4.22 g, 13.5 mmol) and 1,4-dioxane (32 mL) was added aq. NaOH (62 mL of 2.5 M, 155 mmol) and the mixture was stirred at 50° C. for 1 hour. The reaction mixture was cooled to room temperature. Ethyl acetate (135 mL) was added before acidifying it to pH 1 with HCl (37%). The organic and aqueous layers were separated. The aqueous layer was extracted with ethyl acetate (1×50 mL). The organic layers were dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure to yield 4-[methyl(thiazol-2-yl)sulfamoyl]benzoic acid (3.63 g, 87%) as a white solid. ESI-MS m/z calc. 298.0, found 299.1 (M+1)+; Retention time: 1.31 minutes (3 minutes run). 1H NMR (400 MHz, DMSO) δ 13.56 (s, 1H), 8.14 (d, J=8.6 Hz, 2H), 7.92 (d, J=8.5 Hz, 2H), 7.46 (d, J=3.6 Hz, 1H), 7.44 (d, J=3.6 Hz, 1H), 3.39 (s, 3H).
4-(2-Fluoro-2-methylpropoxy)-3-methoxybenzoic acid




Step 1:
To a solution of methyl 4-(2-hydroxy-2-methyl-propoxy)-3-methoxy-benzoate (509 mg, 2.00 mmol) in DCM (5 mL) at 0° C. was added 2-methoxy-N-(2-methoxyethyl)-N-(trifluoro-sulfanyl)ethanamine (406 μL, 2.20 mmol) dropwise. The mixture was stirred at 0° C. for 1 h before the cooling bath was removed and the mixture was stirred for 1 h at room temperature. The mixture was poured into water and was extracted with EtOAc (3×). The organics were combined, washed with water, brine, dried (Na2SO4) and evaporated to dryness. Purification of the residue by column chromatography (0-20% EtOAc in Hex) gave methyl 4-(2-fluoro-2-methyl-propoxy)-3-methoxy-benzoate (450 mg, 70%). ESI-MS m/z calc. 256.1, found 257.1 (M+1)+; Retention time: 1.57 minutes (3 min run).
Step 2:
To a solution of methyl 4-(2-fluoro-2-methyl-propoxy)-3-methoxy-benzoate (450 mg, 1.76 mmol) in MeOH (3.6 mL) and water (900 μL) was added NaOH (210 mg, 5.27 mmol) and the mixture was stirred at 40° C. for 1 hour. The MeOH was evaporated and the pH of the solution was adjusted to 3 with 1N HCl. The precipitate was filtered, washed with water, and desiccated to give 4-(2-fluoro-2-methylpropoxy)-3-methoxybenzoic acid. ESI-MS m/z calc. 242.2, found 243.7 (M+1)+; Retention time: 1.25 minutes (3 min run).
3-Methoxy-4-((2,2,2-trifluoroethoxy)methyl)benzoic acid




To a solution of 2,2,2-trifluoroethanol (874 μL, 12.0 mmol) at 0° C. was added NaH (60%, 520 mg, 13.0 mmol) and the mixture was stirred at this temp for 10 min, then at room temperature for 10 min. The mixture was cooled to 0° C. before methyl 4-(bromomethyl)-3-methoxybenzoate (2.59 g, 10.0 mmol) was added. The cooling bath was removed and the mixture was stirred at room temperature for 3 hours. The mixture was poured into water and extracted with EtOAc (3×). The organics were combined, washed with water, brine, dried (MgSO4) and evaporated to dryness. Crushed NaOH was added to the residue, followed by water (4 mL) and MeOH (20 mL). The mixture was stirred at room temperature for 1 hour. The MeOH was evaporated and the residue was taken up in 1N NaOH (30 ml) and the pH was adjusted to pH 2 with conc HCl. The precipitate was filtered, washed with water (2×) then hexanes (2×) and desiccated to give 3-methoxy-4-((2,2,2-trifluoroethoxy)methyl)benzoic acid. 1H NMR (400 MHz, CDCl3) δ 7.79 (dd, J=7.8, 1.4 Hz, 1H), 7.61 (d, J=1.4 Hz, 1H), 7.53 (d, J=7.8 Hz, 1H), 4.80 (s, 2H), 4.00-3.91 (m, 5H).
The following compound was synthesized using the procedures described above:
methyl 3-methoxy-4-((3,3,3-trifluoropropoxy)methyl)benzoate.
4-(1-Hydroxy-2-methylpropan-2-yl)-3-methoxybenzoic acid




Step 1:
4-Bromo-3-methoxy-benzoic acid (1.50 g, 6.49 mmol), K2CO3 (2.69 g, 19.5 mmol), and DMF (10 mL) were combined and the mixture was allowed to stir for 10 minutes. Bromomethylbenzene (849 gL, 7.14 mmol) was added dropwise and the mixture was allowed to stir at room temperature for 1 h. The reaction mixture was quenched with brine and was extracted with EtOAc (3×). The organic layers were dried over sodium sulfate, filter and concentrated. The residue was purified using silica gel chromatography (5%-70% EtOAc in hexanes) to provide benzyl 4-bromo-3-methoxybenzoate (91%). ESI-MS m/z calc 320.0, found 321.0/323.0 (M+I)+. Retention time: 3.24 minutes (4 min run).
Step 2:
To a flask purged with nitrogen was added Pd(tBu3P)2 (26 mg, 0.050 mmol), ZnF2 (52 mg, 0.50 mmol) and DMF (4 mL). The reaction mixture was allowed to stir for 10 minutes before benzyl 4-bromo-3-methoxy-benzoate (323 mg, 1.01 mmol) was added followed by trimethyl(2-methylprop-1-enoxy)silane (277 μL, 1.51 mmol). The reaction was heated at 80° C. overnight. The crude mixture was quenched with brine and extracted with EtOAc 3 times. The organic layer was dried over sodium sulfate and the solvent was evaporated to give benzyl 3-methoxy-4-(2-methyl-1-oxopropan-2-yl)benzoate. ESI-MS m/z calc. 312.4, found 313.4 (M+1)+; Retention time: 3.27 minutes (4 min run).
Step 3:
Benzyl 3-methoxy-4-(2-methyl-1-oxopropan-2-yl)benzoate (crude, from step 2) was then treated with MeOH (2 mL) followed by NaBH4 (190 mg, 5.03 mmol). The reaction mixture was stirred for 1 h before it was quenched with brine and extracted with EtOAc. The organic layers were combined, dried over sodium sulfate, and evaporated to give benzyl 4-(1-hydroxy-2-methylpropan-2-yl)-3-methoxybenzoate.
Step 4:
To the crude benzyl 4-(1-hydroxy-2-methylpropan-2-yl)-3-methoxybenzoate (from step 3) was added THF (2 mL) followed by aqueous NaOH (1.7 mL of 3.0 M, 5.0 mmol). The reaction mixture was stirred for 3 h. The reaction mixture was acidified to pH 3 and was extracted with EtOAc 3 times. The organic layers were dried over sodium sulfate and the solvent was evaporated to give 4-(1-hydroxy-2-methylpropan-2-yl)-3-methoxybenzoic acid. ESI-MS m/z calc. 224.1, found 224.2 (M+1)+; Retention time: 2.46 minutes (4 min run).
3-Fluoro-4-(2-hydroxy-2-methylpropyl)benzoic acid




Step 1:
Diazomethyl-trimethyl-silane (11.6 mL of 2.0 M, 23.2 mmol) was added dropwise to a solution of 2-(4-bromo-2-fluoro-phenyl)acetic acid (4.50 g, 19.3 mmol) in toluene (7.7 mL) and MeOH (7.7 mL) under a nitrogen atmosphere at room temperature. A persistent yellow color remained after complete addition of diazomethane. The reaction was then quenched with a few drops of acetic acid and the solvents were removed under reduced pressure. The residue was purified by silica gel flash column chromatography using 0-10% EtOAc in hexanes to yield methyl 2-(4-bromo-2-fluoro-phenyl)acetate (4.32 g, 91%). 1H NMR (400 MHz, CDCl3) δ 7.28-7.22 (m, 2H), 7.15 (t, J=8.0 Hz, 1H), 3.71 (s, 3H), 3.63 (d, J=1.0 Hz, 2H).
Step 2:
Methyl 2-(4-bromo-2-fluoro-phenyl)acetate (4.00 g, 16.2 mmol) in THF (56 mL) was cooled in an ice water bath under a nitrogen atmosphere upon which bromo-methyl-magnesium (16.2 mL of 3 M, 48.6 mmol) was added dropwise over 30 minutes. The reaction mixture was continued to stir for 2 hours under ice water bath cooling. The reaction mixture was then quenched with saturated aqueous ammonium chloride and diluted with EtOAc. The layers were separated, and the aqueous layer was extracted with EtOAc. The combined organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography using 0-15% EtOAc in hexanes to yield 1-(4-bromo-2-fluoro-phenyl)-2-methyl-propan-2-ol (3.0 g, 75%) as a clear colorless oil. ESI-MS m/z calc. 246.0, found 231.1 (M+1)+; Retention time: 1.53 minutes (3 min run). LC/MS observed m/z does not show parent mass, but the −17 fragment. 1H NMR (400 MHz, CDCl3) δ 7.26-7.21 (m, 2H), 7.14 (t, J=8.1 Hz, 1H), 2.78 (d, J=1.4 Hz, 2H), 1.24 (d, J=0.8 Hz, 6H).
Step 3:
1-(4-Bromo-2-fluoro-phenyl)-2-methyl-propan-2-ol (2.35 g, 9.51 mmol), diacetoxypalladium (214 mg, 0.951 mmol), 3-diphenylphosphanylpropyl-diphenyl-phosphane (404 mg, 0.951 mmol), and Et3N (4.24 mL, 30.4 mmol) in DMF (26 mL) were treated with MeOH (20.0 mL, 495 mmol). The vessel was charged to 50 psi with CO (266 mg, 9.51 mmol) and then vented. This operation was repeated twice. The reaction was charged to 50 psi and heated at 80° C. for 15 h. The reaction mixture was allowed to cool, vented and partitioned between EtOAc/brine. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organics were washed twice with brine, dried over Na2SO4, filtered and concentrated to an orange oil. The residue was purified by silica gel flash column chromatography using 0-30% EtOAc in hexanes to yield methyl 3-fluoro-4-(2-hydroxy-2-methyl-propyl)benzoate (1.83 g, 85%) ESI-MS m/z calc. 226.1, found 227.5 (M+1)+; Retention time: 1.29 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 7.78 (dd, J=7.9, 1.7 Hz, 1H), 7.71 (dd, J=10.3, 1.6 Hz, 1H), 7.34 (t, J=7.6 Hz, 1H), 3.92 (s, 3H), 2.88 (d, J=1.3 Hz, 2H), 1.26 (s, 6H).
Step 4:
Methyl 3-fluoro-4-(2-hydroxy-2-methyl-propyl)benzoate (1.59 g, 7.03 mmol) was dissolved in THF (40 mL), water (200 mL) and MeOH (21 mL) before LiOH (1.01 g, 42.2 mmol) was added. The reaction mixture was heated at 55° C. for 30 minutes. The reaction mixture was cooled to room temperature and the solvents were removed under reduced pressure. The residue was dissolved in water and cooled in an ice water bath and treated with HCl 1M to pH 3. The resulting precipitate was collected by vacuum filtration, washed with water and dried under high vacuum to yield 3-fluoro-4-(2-hydroxy-2-methyl-propyl)benzoic acid (999 mg, 67%) as a white solid. ESI-MS m/z calc. 212.1, found 211.1 (M+1)+; Retention time: 0.98 minutes (3 min run, scanned using negative ionization mode). 1H NMR (400 MHz, CDCl3) δ 7.84 (dd, J=7.9, 1.6 Hz, 1H), 7.77 (dd, J=10.1, 1.6 Hz, 1H), 7.39 (d, J=15.1 Hz, 1H), 2.91 (s, 2H), 1.28 (s, 6H).
3-Fluoro-4-(3-methoxyprop-1-ynyl)benzoic acid




Step 1:
To methyl 4-bromo-3-fluoro-benzoate (2.50 g, 10.7 mmol), copper (I) iodide (204 mg, 1.07 mmol) and Pd(PPh3)2Cl2 (753 mg, 1.07 mmol) in a flask under Argon was added DMF (degassed for 30 min) and reaction cooled to 0 C. Et3N (1.95 mL, 14.0 mmol) was added followed by 3-methoxyprop-1-yne (997 μL, 11.8 mmol) and the mixture was allowed to stir at 60° C. for 70 min. The mixture was cooled, diluted with ethyl acetate and filtered. The filtrate was washed sequentially with 1 M HCl, 10% NH4OH and brine solutions. The organic layer was separated, dried and purified with silica gel using ethyl acetate-hexanes to give methyl 3-fluoro-4-(3-methoxyprop-1-ynyl)benzoate. ESI-MS m/z calc. 222.2, found 223.2 (M+1)+; Retention time: 1.53 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 7.75 (ddd, J=11.2, 8.8, 1.5 Hz, 2H), 7.50 (dd, J=7.9, 7.0 Hz, 1H), 4.37 (s, 2H), 3.92 (s, 3H), 3.47 (s, 3H).
Step 2:
To methyl 3-fluoro-4-(3-methoxyprop-1-ynyl)benzoate (1.40 g, 6.30 mmol) in 15 ml of 2:1 THF:MeOH at room temperature was added NaOH (1.89 mL of 4 M, 7.56 mmol). The mixture was stirred at room temperature for 1 h before the volatile solvents were removed. The remainder was extracted with ether. The aqueous layer was acidified with 1M HCl and was extracted with ether (3×). The combined ether extracts were dried and concentrated to give 3-fluoro-4-(3-methoxyprop-1-ynyl)benzoic acid as a white solid. ESI-MS m/z calc. 208.2, found 209.2 (M+1)+; Retention time: 1.22 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 7.85 (dd, J=8.0, 1.4 Hz, 1H), 7.80 (dd, J=9.5, 1.3 Hz, 1H), 7.59-7.49 (m, 1H), 4.39 (s, 2H), 3.48 (s, 3H).
4-(Bis(2,2,2-trifluoroethoxy)methyl)-3-chlorobenzoic acid




To a solution of methyl 3-chloro-4-methyl-benzoate (2.00 g, 10.8 mmol) and NBS (2.05 g, 11.5 mmol) in CCl4 (9 mL) at reflux was added AIBN (178 mg, 1.08 mmol). The mixture was heated at reflux for 16 h before additional AIBN (178 mg, 1.08 mmol) was added. The mixture was heated at reflux for 72 h before it was cooled. The mixture was concentrated to dryness, the residue was partitioned between Et2O and water, the layers were separated, and the aqueous layer was extracted with Et2O (2×). The organics were combined, washed with water, brine, dried (MgSO4) and concentrated to dryness. Purification of the residue by column chromatography (0-30% EtOAc in Hex) gave methyl 3-chloro-4-(dibromomethyl)benzoate. ESI-MS m/z calc. 342.5, found 342.9 (M+1)+; Retention time: 1.96 minutes (3 min run).
Step 2:
To a solution of 2,2,2-trifluoroethanol (109 μL, 1.50 mmol) in DMF (2.63 mL) was added NaH (64 mg, 1.6 mmol). The mixture was stirred at room temperature for 1 h before methyl 3-chloro-4-(dibromomethyl)benzoate (342 mg, 1.00 mol) was added. The mixture was stirred at room temperature for 2 h before it was poured into water and was extracted with EtOAc (3×). The organics were combined, washed with water, brine, dried (Na2SO4) and evaporated to dryness. The material was taken up in MeOH and powdered NaOH (160 mg, 4.00 mol) was added and the mixture was stirred at room temperature for 1 h. The mixture was evaporated and treated with 1N HCl (until the solution was strongly acidic). The precipitated product was washed with water and dried to give 4-(bis(2,2,2-trifluoroethoxy)methyl)-3-chlorobenzoic acid. ESI-MS m/z calc. 394.4, found 394.5 (M+1)+; Retention time: 1.74 minutes (3 min run).
4-(1-Hydroxy-2-(2,2,2-trifluoroethoxy)ethyl)benzoic acid and 4-(2-hydroxy-1-(2,2,2-trifluoroethoxy)ethyl)benzoic acid




Step 1:
To a solution of methyl 4-acetylbenzoate (8.91 g, 50.0 mmol) in AcOH (80 mL) was added Br2 (2.71 mL, 52.5 mmol) dropwise. The mixture was stirred at room temperature for 2 h. The mixture was cooled to 0° C. and the solid was filtered. The precipitate was washed with 1:1 MeOH in water and was desiccated to give methyl 4-(2-bromoacetyl)benzoate (10.6 g, 82%) as a tan solid. 1H NMR (400 MHz, CDCl3) δ 8.19-8.12 (m, 2H), 8.04 (d, J=8.5 Hz, 2H), 4.47 (s, 2H), 3.96 (s, 3H).
Step 2:
To a stirred solution of methyl 4-(2-bromoacetyl)benzoate (0.59 g, 2.3 mmol) in MeOH (6 mL) at 0° C. was added NaBH4 (92 mg, 2.4 mmol) in portions. The cooling bath was removed and the mixture was stirred at room temperature for 1 h. K2CO3 (317 mg, 2.30 mmol) was added and the mixture was stirred at room temperature for 72 h. The mixture was poured into water and was extracted with Et2O (3×). The organics were combined, washed with water, brine, dried (MgSO4) and evaporated to dryness to give methyl 4-(oxiran-2-yl)benzoate (370 mg, 90%) as a white solid. ESI-MS m/z calc. 178.2, found 179.1 (M+1)+; Retention time: 1.14 minutes (3 min run).
Step 3:
To 2,2,2-trifluoroethanol (0.50 mL, 6.9 mmol) was added NaH (10 mg, 0.24 mmol). The mixture was stirred for 5 min before the addition of methyl 4-(oxiran-2-yl)benzoate (36 mg, 0.20 mmol) and heating at 70° C. for 2 h. Crushed NaOH (40 mg, 1.0 mmol) was added followed by water (0.1 mL) and the mixture was stirred at 40° C. for 3 h. The mixture was evaporated and the residue was partitioned between 1N HCl and EtOAc. The layers were separated, and aqueous layer was extracted with EtOAc (2×). The organics were combined and evaporated to dryness to give a mixture of 4-[1-hydroxy-2-(2,2,2-trifluoroethoxy)ethyl]benzoic acid and 4-(2-hydroxy-1-(2,2,2-trifluoroethoxy)ethyl)benzoic acid (30 mg, 57%) as an oil. ESI-MS m/z calc. 264.1, found 265.1 (M+1)+; Retention time: 1.07 minutes (3 min run).
(4-Isopropoxy-3-methoxyphenyl)(2′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-1-yl)methanone




A mixture of 2′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]dihydrochloride (69 mg, 0.20 mmol), 4-isopropoxy-3-methoxybenzoic acid (42 mg, 0.20 mmol), HATU (76 mg, 0.20 mmol), Et3N (112 μL, 0.80 mmol) and DMF (2 mL) was allowed to stir at room temperature for 3 h. The mixture was filtered and purified by reverse-phase preparatory HPLC (10-99% ACN/water). The desired fractions were concentrated to give (4-isopropoxy-3-methoxyphenyl)(2′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-1-yl)methanone as an amorphous white solid. ESI-MS m/z calc. 465.2, found 466.3 (M+1)+; Retention time: 1.23 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 7.01 (d, J=1.7 Hz, 1H), 6.97 (dd, J=8.2, 1.7 Hz, 1H), 6.88 (d, J=8.3 Hz, 1H), 6.53 (d, J=3.0 Hz, 1H), 5.94 (d, J=3.5 Hz, 1H), 4.57 (dt, J=12.2, 6.1 Hz, 1H), 4.52 (s, 1H), 3.99 (s, 2H), 3.87 (s, 3H), 3.69 (s, 1H), 3.40 (s, 1H), 3.34 (t, J=5.4 Hz, 3H), 2.39 (s, 3H), 2.11 (s, 2H), 1.82 (s, 2H), 1.38 (d, J=6.1 Hz, 6H).
(4-Isopropoxy-3-methoxyphenyl)(6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-1-yl)methanone




To a stirred solution of 6-(trifluoromethyl)spiro[3,4-dihydro-2H-pyrrolo[1,2-a]pyrazine-1,4′-piperidine]dihydrochloride (475 mg, 1.43 mmol), 4-isopropoxy-3-methoxy-benzoic acid (361 mg, 1.72 mmol) and 1-hydroxybenzotriazole (232 mg, 1.72 mmol) in CH2Cl2 (5.5 mL) at ambient temperature was added 3-(ethyliminomethyleneamino)-N,N-dimethyl-propan-1-amine (266 mg, 1.72 mmol) followed by 4-methylmorpholine (786 μL, 7.15 mmol). The mixture was stirred for 16 h at room temperature. The mixture was poured into water and was extracted with EtOAc (3×). The organics were combined, washed with 0.1 N HCl, 1N NaOH, water, brine, dried (Na2SO4) and evaporated to dryness. The residue was purified by column chromatography (0-100% ethyl acetate/hexanes) to give (4-isopropoxy-3-methoxy-phenyl)-[6-(trifluoromethyl)spiro[3,4-dihydro-2H-pyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-yl]methanone (623 mg, 96%). ESI-MS m/z calc. 451.2, found 452.3 (M+1)+; Retention time: 1.30 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 7.03 (d, J=1.9 Hz, 1H), 6.98 (dd, J=8.2, 1.9 Hz, 1H), 6.88 (d, J=8.3 Hz, 1H), 6.54 (d, J=3.7 Hz, 1H), 5.93 (d, J=3.8 Hz, 1H), 4.56 (dd, J=12.2, 6.1 Hz, 1H), 4.52 (s, 1H), 3.94 (s, 2H), 3.88 (s, 3H), 3.69 (s, 1H), 3.47 (s, 2H), 3.27 (s, 2H), 1.87 (s, 4H), 1.38 (d, J=6.1 Hz, 6H).
The following compounds were made using the procedures described above:












Compound name
Amine name
Acid name







[(5aR,9aR)-spiro[5a,6,7,8,9,9a-
(5aR,9aR)-
4-tert-butyl-3-methoxy-


hexahydro-5H-pyrrolo[1,2-
spiro[5a,6,7,8,9,9a-
benzoic acid


a]quinoxaline-4,4′-piperidine]-1′-yl]-
hexahydro-5H-


(4-tert-butyl-3-methoxy-
pyrrolo[1,2-a]quinoxaline-


phenyl)methanone
4,4′-piperidine]


[(5aS,9aS)-spiro[5a,6,7,8,9,9a-
(5aS,9aS)-
4-tert-butyl-3-methoxy-


hexahydro-5H-pyrrolo[1,2-
spiro[5a,6,7,8,9,9a-
benzoic acid


a]quinoxaline-4,4′-piperidine]-1′-yl]-
hexahydro-5H-


(4-tert-butyl-3-methoxy-
pyrrolo[1,2-a]quinoxaline-


phenyl)methanone
4,4′-piperidine]


(4-isopropoxy-3-methyl-phenyl)-[2-
2-(2-
4-isopropoxy-3-methyl-


(2-methoxyethyl)spiro[3,4-
methoxyethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(2-benzylspiro[3,4-
2-benzylspiro[3,4-
4-isopropoxy-3-methyl-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
benzoic acid


piperidine]-1′-yl)-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methyl-phenyl)methanone


(4-ethyl-3-methoxy-phenyl)-[2-
2-methyl-6-
4-ethyl-3-methoxy-benzoic


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


[3-(hydroxymethyl)-4-isopropoxy-
2-methyl-6-
3-(hydroxymethyl)-4-


phenyl]-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
isopropoxy-benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[2-methyl-6-
2-methyl-6-
2-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
(trifluoromethoxy)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-yl]-[2-
a]pyrazine-1,4′-piperidine]


(trifluoromethoxy)phenyl]methanone


(4-isopropoxy-3-methoxy-phenyl)-
2-methyl-6-
4-isopropoxy-3-methoxy-


[2-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[4-(1-hydroxy-1-methyl-
2-methyl-6-
4-(1-hydroxy-1-methyl-


ethyl)phenyl]-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
ethyl)benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-ethyl-3-methoxy-phenyl)-[2-(2-
2-(2-methoxyethyl)-6-
4-ethyl-3-methoxy-benzoic


methoxyethyl)-6-
(trifluoromethyl)spiro[3,4-
acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[3-(hydroxymethyl)-4-isopropoxy-
2-(2-methoxyethyl)-6-
3-(hydroxymethyl)-4-


phenyl]-[2-(2-methoxyethyl)-6-
(trifluoromethyl)spiro[3,4-
isopropoxy-benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[2-(2-methoxyethyl)-6-
2-(2-methoxyethyl)-6-
2-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
(trifluoromethoxy)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-yl]-[2-
a]pyrazine-1,4′-piperidine]


(trifluoromethoxy)phenyl]methanone


(4-isopropoxy-3-methoxy-phenyl)-
2-(2-methoxyethyl)-6-
4-isopropoxy-3-methoxy-


[2-(2-methoxyethyl)-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[4-(1-hydroxy-1-methyl-
2-(2-methoxyethyl)-6-
4-(1-hydroxy-1-methyl-


ethyl)phenyl]-[2-(2-methoxyethyl)-6-
(trifluoromethyl)spiro[3,4-
ethyl)benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-isopropoxy-3-methoxy-phenyl)-
6-
4-isopropoxy-3-methoxy-


[6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydro-2H-pyrrolo[1,2-a]pyrazine-
dihydro-2H-pyrrolo[1,2-


1,4′-piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


[3-(hydroxymethyl)-4-isopropoxy-
6-
3-(hydroxymethyl)-4-


phenyl]-[6-
(trifluoromethyl)spiro[3,4-
isopropoxy-benzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[2-ethyl-6-(trifluoromethyl)spiro[3,4-
2-ethyl-6-
4-isopropoxy-3-methoxy-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-
benzoic acid


piperidine]-1′-yl]-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


(3-methyl-4-methylsulfonyl-phenyl)-
2-methyl-6-
3-methyl-4-


[2-methyl-6-
(trifluoromethyl)spiro[3,4-
methylsulfonyl-benzoic


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


N-methyl-4-[2-methyl-6-
2-methyl-6-
4-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
(methylsulfamoyl)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


(4-isopropoxy-3-methyl-phenyl)-[2-
2-methyl-6-
4-isopropoxy-3-methyl-


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(4-tert-butoxy-3-methoxy-phenyl)-
2-methyl-6-
4-tert-butoxy-3-methoxy-


[2-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-tert-butoxy-3-methoxy-phenyl)-
6-
4-tert-butoxy-3-methoxy-


[6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydro-2H-pyrrolo[1,2-a]pyrazine-
dihydro-2H-pyrrolo[1,2-


1,4′-piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


1′-(4-isopropoxy-3-methyl-benzoyl)-
2-methylspiro[3,4-
4-isopropoxy-3-methyl-


2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-carbonitrile
piperidine]-6-carbonitrile


(4-tert-butylsulfonylphenyl)-[2-
2-methyl-6-
4-tert-butylsulfonylbenzoic


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


N-cyclopropyl-4-[6-
6-
4-(cyclopropylsulfamoyl)-


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


(4-isopropoxy-3-methyl-phenyl)-[6-
6-
4-isopropoxy-3-methyl-


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


N-cyclopropyl-4-[2-methyl-6-
2-methyl-6-
4-(cyclopropylsulfamoyl)-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


N,2-dimethyl-4-[2-methyl-6-
2-methyl-6-
3-methyl-4-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
(methylsulfamoyl)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


(3-ethoxy-4-methoxy-phenyl)-[6-
6-
3-ethoxy-4-methoxy-


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(4-isopropoxyphenyl)-[6-
6-
4-isopropoxybenzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


8-quinolyl-[6-
6-
quinoline-8-carboxylic


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(3-butoxy-4-methoxy-phenyl)-[6-
6-
3-butoxy-4-methoxy-


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(4-butoxy-3-methoxy-phenyl)-[6-
6-
4-butoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(4-methoxyphenyl)-[6-
6-
4-methoxybenzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


4-quinolyl-[6-
6-
quinoline-4-carboxylic


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(3,4-dimethoxyphenyl)-[2-methyl-6-
2-methyl-6-
3,4-dimethoxybenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(3-ethoxy-4-methoxy-phenyl)-[2-
2-methyl-6-
3-ethoxy-4-methoxy-


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(3-methoxy-4-propoxy-phenyl)-[2-
2-methyl-6-
3-methoxy-4-propoxy-


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(3-methoxyphenyl)-[2-methyl-6-
2-methyl-6-
3-methoxybenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(4-isopropoxyphenyl)-[2-methyl-6-
2-methyl-6-
4-isopropoxybenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


[2-methyl-6-
2-methyl-6-
quinoline-8-carboxylic


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(8-
a]pyrazine-1,4′-piperidine]


quinolyl)methanone


(3-butoxy-4-methoxy-phenyl)-[2-
2-methyl-6-
3-butoxy-4-methoxy-


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


[4-(1-hydroxy-1-methyl-ethyl)-3-
2-methyl-6-
4-(1-hydroxy-1-methyl-


methoxy-phenyl]-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
ethyl)-3-methoxy-benzoic


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[4-(1-hydroxy-1-methyl-ethyl)-3-
2-methyl-6-
4-(1-hydroxy-1-methyl-


methyl-phenyl]-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
ethyl)-3-methyl-benzoic


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-butoxy-3-methoxy-phenyl)-[2-
2-methyl-6-
4-butoxy-3-methoxy-


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


[2-methyl-6-
2-methyl-6-
3-methylbenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(m-tolyl)methanone
a]pyrazine-1,4′-piperidine]


[2-methyl-6-
2-methyl-6-
2-(1-piperidyl)pyridine-4-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
carboxylic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[2-(1-piperidyl)-4-
a]pyrazine-1,4′-piperidine]


pyridyl]methanone


(3-chlorophenyl)-[2-methyl-6-
2-methyl-6-
3-chlorobenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(2-methoxyphenyl)-[2-methyl-6-
2-methyl-6-
2-methoxybenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


[4-(2-hydroxyethoxy)-3-methoxy-
2-methyl-6-
4-(2-hydroxyethoxy)-3-


phenyl]-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
methoxy-benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-methoxyphenyl)-[2-methyl-6-
2-methyl-6-
4-methoxybenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(4-fluoro-3-methyl-phenyl)-[2-
2-methyl-6-
4-fluoro-3-methyl-benzoic


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


[2-methyl-6-
2-methyl-6-
quinoline-4-carboxylic


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-
a]pyrazine-1,4′-piperidine]


quinolyl)methanone


[4-(1-hydroxy-1-methyl-ethyl)-3-
6-
4-(1-hydroxy-1-methyl-


methoxy-phenyl]-[6-
(trifluoromethyl)spiro[3,4-
ethyl)-3-methoxy-benzoic


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-
acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(3-methoxy-4-propoxy-phenyl)-[6-
6-
3-methoxy-4-propoxy-


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


[4-(1-hydroxy-1-methyl-ethyl)-3-
6-
4-(1-hydroxy-1-methyl-


methyl-phenyl]-[6-
(trifluoromethyl)spiro[3,4-
ethyl)-3-methyl-benzoic


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-
acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


N-ethyl-2-methyl-4-[2-methyl-6-
2-methyl-6-
4-(ethylsulfamoyl)-3-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
methyl-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


N-cyclopropyl-2-methyl-4-[2-methyl-
2-methyl-6-
4-(cyclopropylsulfamoyl)-


6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
3-methyl-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


N-isopropyl-2-methyl-4-[2-methyl-6-
2-methyl-6-
4-(isopropylsulfamoyl)-3-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
methyl-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


N,N,2-trimethyl-4-[2-methyl-6-
2-methyl-6-
4-(dimethylsulfamoyl)-3-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
methyl-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


N,2-dimethyl-4-[6-
6-
3-methyl-4-


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
(methylsulfamoyl)benzoic


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-
acid


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


(2-phenoxyphenyl)-[6-
6-
2-phenoxybenzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(4-phenoxyphenyl)-[6-
6-
4-phenoxybenzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(2-phenylphenyl)-[6-
6-
2-phenylbenzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


[2-methyl-6-
2-methyl-6-
2-phenoxybenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(2-
a]pyrazine-1,4′-piperidine]


phenoxyphenyl)methanone


(4-chlorophenyl)-[2-methyl-6-
2-methyl-6-
4-chlorobenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


[2-methyl-6-
2-methyl-6-
4-phenoxybenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-
a]pyrazine-1,4′-piperidine]


phenoxyphenyl)methanone


[2-methyl-6-
2-methyl-6-
4-phenylbenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-
a]pyrazine-1,4′-piperidine]


phenylphenyl)methanone


[2-methyl-6-
2-methyl-6-
2-phenylbenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(2-
a]pyrazine-1,4′-piperidine]


phenylphenyl)methanone


[2-methyl-6-
2-methyl-6-
4-methylbenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(p-tolyl)methanone
a]pyrazine-1,4′-piperidine]


N,N,2-trimethyl-4-[6-
6-
4-(dimethylsulfamoyl)-3-


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
methyl-benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


(2′-(cyclopropylmethyl)-6′-
2′-(cyclopropylmethyl)-6′-
4-isopropoxy-3-methoxy-


(trifluoromethyl)-3′,4′-dihydro-2′H-
(trifluoromethyl)-3′,4′-
benzoic acid


spiro[piperidine-4,1′-pyrrolo[1,2-
dihydro-2′H-


a]pyrazine]-1-yl)(4-isopropoxy-3-
spiro[piperidine-4,1′-


methoxyphenyl)methanone
pyrrolo[1,2-a]pyrazine]


(2-fluoro-4-isopropoxy-phenyl)-[6-
6-
2-fluoro-4-isopropoxy-


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(3-fluoro-4-isopropoxy-phenyl)-[6-
6-
3-fluoro-4-isopropoxy-


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(3-chloro-4-isopropoxy-phenyl)-[6-
6-
3-chloro-4-isopropoxy-


(trifluoromethyl)spiro[3,4-dihydro-
(trifluoromethyl)spiro[3,4-
benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
dihydro-2H-pyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(2-fluoro-4-isopropoxy-phenyl)-[2-
2-methyl-6-
2-fluoro-4-isopropoxy-


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(3-fluoro-4-isopropoxy-phenyl)-[2-
2-methyl-6-
3-fluoro-4-isopropoxy-


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(3-chloro-4-isopropoxy-phenyl)-[2-
2-methyl-6-
3-chloro-4-isopropoxy-


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


[3,3-dimethyl-6-
3,3-dimethyl-6-
4-isopropoxy-3-methyl-


(trifluoromethyl)spiro[2,4-
(trifluoromethyl)spiro[2,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methyl-phenyl)methanone


[3,3-dimethyl-6-
3,3-dimethyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[2,4-
(trifluoromethyl)spiro[2,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[3,3-dimethyl-6-
3,3-dimethyl-6-
2-fluoro-4-isopropoxy-


(trifluoromethyl)spiro[2,4-
(trifluoromethyl)spiro[2,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(2-fluoro-4-
a]pyrazine-1,4′-piperidine]


isopropoxy-phenyl)methanone


(3-chloro-4-isopropoxy-phenyl)-[3,3-
3,3-dimethyl-6-
3-chloro-4-isopropoxy-


dimethyl-6-
(trifluoromethyl)spiro[2,4-
benzoic acid


(trifluoromethyl)spiro[2,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-tert-butoxy-3-methoxy-phenyl)-
3,3-dimethyl-6-
4-tert-butoxy-3-methoxy-


[3,3-dimethyl-6-
(trifluoromethyl)spiro[2,4-
benzoic acid


(trifluoromethyl)spiro[2,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[3,3-dimethyl-6-
3,3-dimethyl-6-
3-fluoro-4-isopropoxy-


(trifluoromethyl)spiro[2,4-
(trifluoromethyl)spiro[2,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(3-fluoro-4-
a]pyrazine-1,4′-piperidine]


isopropoxy-phenyl)methanone


(2-fluoro-4-isopropoxy-phenyl)-[3-
3-methyl-6-
2-fluoro-4-isopropoxy-


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydro-2H-pyrrolo[1,2-a]pyrazine-
dihydro-2H-pyrrolo[1,2-


1,4′-piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(4-isopropoxy-3-methoxy-phenyl)-
3-methyl-6-
4-isopropoxy-3-methoxy-


[3-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-isopropoxy-3-methyl-phenyl)-[3-
3-methyl-6-
4-isopropoxy-3-methyl-


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydro-2H-pyrrolo[1,2-a]pyrazine-
dihydro-2H-pyrrolo[1,2-


1,4′-piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


(3-fluoro-4-isopropoxy-phenyl)-[3-
3-methyl-6-
3-fluoro-4-isopropoxy-


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydro-2H-pyrrolo[1,2-a]pyrazine-
dihydro-2H-pyrrolo[1,2-


1,4′-piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


[4,4-dimethyl-6-
4,4-dimethyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[2,3-
(trifluoromethyl)spiro[2,3-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[7-(difluoromethyl)-5-methyl-
2-methyl-6-
7-(difluoromethyl)-5-


pyrazolo[1,5-a]pyrimidin-3-yl]-[2-
(trifluoromethyl)spiro[3,4-
methyl-pyrazolo[1,5-


methyl-6-(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
a]pyrimidine-3-carboxylic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]
acid


piperidine]-1′-yl]methanone


[7-(difluoromethyl)-5-methyl-
6-
7-(difluoromethyl)-5-


pyrazolo[1,5-a]pyrimidin-3-yl]-[6-
(trifluoromethyl)spiro[3,4-
methyl-pyrazolo[1,5-


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-
a]pyrimidine-3-carboxylic


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]
acid


piperidine]-1′-yl]methanone


[2,3-dimethyl-6-
2,3-dimethyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[4,4-dimethyl-6-
4,4-dimethyl-6-
3-fluoro-4-isopropoxy-


(trifluoromethyl)spiro[2,3-
(trifluoromethyl)spiro[2,3-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(3-fluoro-4-
a]pyrazine-1,4′-piperidine]


isopropoxy-phenyl)methanone


[4,4-dimethyl-6-
4,4-dimethyl-6-
4-isopropoxy-3-methyl-


(trifluoromethyl)spiro[2,3-
(trifluoromethyl)spiro[2,3-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methyl-phenyl)methanone


(3-chloro-4-isopropoxy-phenyl)-[4,4-
4,4-dimethyl-6-
3-chloro-4-isopropoxy-


dimethyl-6-
(trifluoromethyl)spiro[2,3-
benzoic acid


(trifluoromethyl)spiro[2,3-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


N-cyclopropyl-4-[4,4-dimethyl-6-
4,4-dimethyl-6-
4-(cyclopropylsulfamoyl)-


(trifluoromethyl)spiro[2,3-
(trifluoromethyl)spiro[2,3-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


[7-(difluoromethyl)-5-methyl-
4,4-dimethyl-6-
7-(difluoromethyl)-5-


pyrazolo[1,5-a]pyrimidin-3-yl]-[4,4-
(trifluoromethyl)spiro[2,3-
methyl-pyrazolo[1,5-


dimethyl-6-
dihydropyrrolo[1,2-
a]pyrimidine-3-carboxylic


(trifluoromethyl)spiro[2,3-
a]pyrazine-1,4′-piperidine]
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-


piperidine]-1′-yl]methanone


[7-[ethyl(methyl)amino]-5-methyl-
2-methyl-6-
7-[ethyl(methyl)amino]-5-


pyrazolo[1,5-a]pyrimidin-3-yl]-[2-
(trifluoromethyl)spiro[3,4-
methyl-pyrazolo[1,5-


methyl-6-(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
a]pyrimidine-3-carboxylic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]
acid


piperidine]-1′-yl]methanone


[4,4-dimethyl-6-
4,4-dimethyl-6-
4-(1-hydroxy-1-methyl-


(trifluoromethyl)spiro[2,3-
(trifluoromethyl)spiro[2,3-
ethyl)-3-methyl-benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-yl]-[4-(1-hydroxy-1-
a]pyrazine-1,4′-piperidine]


methyl-ethyl)-3-methyl-


phenyl]methanone


[3-methoxy-4-[(1S)-1-
2-methyl-6-
3-methoxy-4-[(1S)-1-


methylpropoxy]phenyl]-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
methylpropoxy]benzoic


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[3-methoxy-4-[(1R)-1-
2-methyl-6-
3-methoxy-4-[(1R)-1-


methylpropoxy]phenyl]-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
methylpropoxy]benzoic


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[3-methoxy-4-[(1S)-1-
6-
3-methoxy-4-[(1S)-1-


methylpropoxy]phenyl]-[6-
(trifluoromethyl)spiro[3,4-
methylpropoxy]benzoic


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-
acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[3-methoxy-4-[(1R)-1-
6-
3-methoxy-4-[(1R)-1-


methylpropoxy]phenyl]-[6-
(trifluoromethyl)spiro[3,4-
methylpropoxy]benzoic


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-
acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(5,7-dimethylpyrazolo[1,5-
2-methyl-6-
5,7-dimethylpyrazolo[1,5-


a]pyrimidin-3-yl)-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
a]pyrimidine-3-carboxylic


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[7-[ethyl(methyl)amino]pyrazolo[1,5-
2-methyl-6-
7-[ethyl(methyl)amino]-


a]pyrimidin-3-yl]-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
pyrazolo[1,5-a]pyrimidine-


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
3-carboxylic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(5-methyl-7-pyrrolidin-1-yl-
2-methyl-6-
5-methyl-7-pyrrolidin-1-


pyrazolo[1,5-a]pyrimidin-3-yl)-[2-
(trifluoromethyl)spiro[3,4-
yl-pyrazolo[1,5-


methyl-6-(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
a]pyrimidine-3-carboxylic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]
acid


piperidine]-1′-yl]methanone


[7-(ethylamino)-5-methyl-
2-methyl-6-
7-(ethylamino)-5-methyl-


pyrazolo[1,5-a]pyrimidin-3-yl]-[2-
(trifluoromethyl)spiro[3,4-
pyrazolo[1,5-a]pyrimidine-


methyl-6-(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
3-carboxylic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-isopropoxy-3-methoxy-phenyl)-
3′-methyl-6-
4-isopropoxy-3-methoxy-


[3′-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(7-methylpyrazolo[1,5-a]pyrimidin-3-
2-methyl-6-
7-methylpyrazolo[1,5-


yl)-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
a]pyrimidine-3-carboxylic


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[7-(ethylamino)pyrazolo[1,5-
2-methyl-6-
7-


a]pyrimidin-3-yl]-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
(ethylamino)pyrazolo[1,5-


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
a]pyrimidine-3-carboxylic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]
acid


piperidine]-1′-yl]methanone


[7-(isopropylamino)pyrazolo[1,5-
2-methyl-6-
7-


a]pyrimidin-3-yl]-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
(isopropylamino)pyrazolo[1,


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
5-a]pyrimidine-3-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]
carboxylic acid


piperidine]-1′-yl]methanone


[5-cyclopropyl-7-
2-methyl-6-
5-cyclopropyl-7-


(difluoromethyl)pyrazolo[1,5-
(trifluoromethyl)spiro[3,4-
(difluoromethyl)pyrazolo[1,


a]pyrimidin-3-yl]-[2-methyl-6-
dihydropyrrolo[1,2-
5-a]pyrimidine-3-


(trifluoromethyl)spiro[3,4-
a]pyrazine-1,4′-piperidine]
carboxylic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-


piperidine]-1′-yl]methanone


[2-cyclopropyl-6-
2-cyclopropyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[2-cyclopropyl-6-
2-cyclopropyl-6-
4-isopropoxy-3-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methyl-phenyl)methanone


[2,3′-dimethyl-6-
2,3′-dimethyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[4-(2-hydroxy-1,1-dimethyl-ethyl)-3-
2-methyl-6-
4-(2-hydroxy-1,1-


methoxy-phenyl]-[2-methyl-6-
(trifluoromethyl)spiro[3,4-
dimethyl-ethyl)-3-


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
methoxy-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[4-(2-hydroxy-1,1-dimethyl-ethyl)-3-
6-
4-(2-hydroxy-1,1-


methoxy-phenyl]-[6-
(trifluoromethyl)spiro[3,4-
dimethyl-ethyl)-3-


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-
methoxy-benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


1′-(4-isopropoxy-3-methoxy-
N-methyl-6-
4-isopropoxy-3-methoxy-


benzoyl)-N-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-2-carboxamide
piperidine]-2-carboxamide


1′-(4-isopropoxy-3-methyl-benzoyl)-
N-methyl-6-
4-isopropoxy-3-methyl-


N-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-2-carboxamide
piperidine]-2-carboxamide


1′-(3-chloro-4-isopropoxy-benzoyl)-
N-methyl-6-
3-chloro-4-isopropoxy-


N-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-2-carboxamide
piperidine]-2-carboxamide


1′-(2-fluoro-4-isopropoxy-benzoyl)-
N-methyl-6-
2-fluoro-4-isopropoxy-


N-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-2-carboxamide
piperidine]-2-carboxamide


(5-isopropoxy-6-methyl-2-pyridyl)-
2-methyl-6-
5-isopropoxy-6-methyl-


[2-methyl-6-
(trifluoromethyl)spiro[3,4-
pyridine-2-carboxylic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


2,2,2-trifluoro-1-[1′-(4-
2,2,2-trifluoro-1-(2-
4-isopropylsulfonyl-3-


isopropylsulfonyl-3-methyl-benzoyl)-
methylspiro[3,4-
methyl-benzoic acid


2-methyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-
2,2,2-trifluoro-1-(2-
4-isopropylsulfonyl-2-


isopropylsulfonyl-2-methyl-benzoyl)-
methylspiro[3,4-
methyl-benzoic acid


2-methyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[3-fluoro-4-(1-
2,2,2-trifluoro-1-(2-
3-fluoro-4-(1-hydroxy-1-


hydroxy-1-methyl-ethyl)benzoyl]-2-
methylspiro[3,4-
methyl-ethyl)benzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[4-(3-
2,2,2-trifluoro-1-(2-
4-(3-hydroxypropoxy)-3-


hydroxypropoxy)-3-methyl-benzoyl]-
methylspiro[3,4-
methyl-benzoic acid


2-methyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-tert-butoxy-3-methoxy-
2,2,2-trifluoro-1-(2-
4-tert-butoxy-3-methoxy-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


N,2-dimethyl-4-[2-methyl-6-(2,2,2-
2,2,2-trifluoro-1-(2-
3-methyl-4-


trifluoroacetyl)spiro[3,4-
methylspiro[3,4-
(methylsulfamoyl)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-
a]pyrazine-1,4′-


carbonyl]benzenesulfonamide
piperidine]-6-yl)ethanone


N-cyclopropyl-4-[2-methyl-6-(2,2,2-
2,2,2-trifluoro-1-(2-
4-(cyclopropylsulfamoyl)-


trifluoroacetyl)spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-
a]pyrazine-1,4′-


carbonyl]benzenesulfonamide
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[4-(1-hydroxy-
2,2,2-trifluoro-1-(2-
4-(1-hydroxy-1-methyl-


1-methyl-ethyl)-3-methyl-benzoyl]-2-
methylspiro[3,4-
ethyl)-3-methyl-benzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-tert-butylsulfonylbenzoyl)-2-
2,2,2-trifluoro-1-(2-
4-tert-butylsulfonylbenzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-isopropoxy-
2,2,2-trifluoro-1-(2-
4-isopropoxy-3-methyl-


3-methyl-benzoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-isopropoxy-
2,2,2-trifluoro-1-(2-
4-isopropoxy-3-methoxy-


3-methoxy-benzoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-isopropylsulfonyl-2-methyl-
2,2-dimethyl-1-(2-
4-isopropylsulfonyl-2-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
methyl-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-[3-fluoro-4-(1-hydroxy-1-
2,2-dimethyl-1-(2-
3-fluoro-4-(1-hydroxy-1-


methyl-ethyl)benzoyl]-2-methyl-
methylspiro[3,4-
methyl-ethyl)benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-yl]-2,2-
a]pyrazine-1,4′-


dimethyl-propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-[4-(3-hydroxypropoxy)-3-
2,2-dimethyl-1-(2-
4-(3-hydroxypropoxy)-3-


methyl-benzoyl]-2-methyl-spiro[3,4-
methylspiro[3,4-
methyl-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(4-tert-butoxy-3-methoxy-
2,2-dimethyl-1-(2-
4-tert-butoxy-3-methoxy-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


4-[6-(2,2-dimethylpropanoyl)-2-
2,2-dimethyl-1-(2-
3-methyl-4-


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
(methylsulfamoyl)benzoic


a]pyrazine-1,4′-piperidine]-1′-
dihydropyrrolo[1,2-
acid


carbonyl]-N,2-dimethyl-
a]pyrazine-1,4′-


benzenesulfonamide
piperidine]-6-yl)propan-1-



one


1-[1′-[4-(1-hydroxy-1-methyl-ethyl)-
2,2-dimethyl-1-(2-
4-(1-hydroxy-1-methyl-


3-methyl-benzoyl]-2-methyl-
methylspiro[3,4-
ethyl)-3-methyl-benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-2,2-
a]pyrazine-1,4′-


dimethyl-propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(4-isopropoxy-3-methyl-
2,2-dimethyl-1-(2-
4-isopropoxy-3-methyl-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(4-isopropoxy-3-methoxy-
2,2-dimethyl-1-(2-
4-isopropoxy-3-methoxy-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(3-chloro-4-isopropoxy-
2,2,2-trifluoro-1-(2-
3-chloro-4-isopropoxy-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-isopropylsulfonyl-3-methyl-
2,2-dimethyl-1-(2-
4-isopropylsulfonyl-3-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
methyl-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


N-cyclopropyl-4-[6-(2,2-
2,2-dimethyl-1-(2-
4-(cyclopropylsulfamoyl)-


dimethylpropanoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-1′-
a]pyrazine-1,4′-


carbonyl]benzenesulfonamide
piperidine]-6-yl)propan-1-



one


1-[1′-(4-tert-butylsulfonylbenzoyl)-2-
2,2-dimethyl-1-(2-
4-tert-butylsulfonylbenzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-2,2-
dihydropyrrolo[1,2-


dimethyl-propan-1-one
a]pyrazine-1,4′-



piperidine]-6-yl)propan-1-



one


1-[1′-(3-chloro-4-isopropoxy-
2,2-dimethyl-1-(2-
3-chloro-4-isopropoxy-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-isopropylsulfonyl-3-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
methyl-benzoic acid


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


isopropylsulfonyl-3-methyl-
a]pyrazine-1,4′-piperidine]


phenyl)methanone


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-(1-hydroxy-1-methyl-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
ethyl)-3-methyl-benzoic


piperidine]-1′-yl)-[4-(1-hydroxy-1-
dihydropyrrolo[1,2-
acid


methyl-ethyl)-3-methyl-
a]pyrazine-1,4′-piperidine]


phenyl]methanone


(3-chloro-4-isopropoxy-phenyl)-(6-
6-chloro-2-methyl-
3-chloro-4-isopropoxy-


chloro-2-methyl-spiro[3,4-
spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl)methanone
a]pyrazine-1,4′-piperidine]


4-(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-(cyclopropylsulfamoyl)-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
benzoic acid


piperidine]-1′-carbonyl)-N-
dihydropyrrolo[1,2-


cyclopropyl-benzenesulfonamide
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
5-isopropoxy-6-methyl-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
pyridine-2-carboxylic acid


piperidine]-1′-yl)-(5-isopropoxy-6-
dihydropyrrolo[1,2-


methyl-2-pyridyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-isopropoxy-3-methoxy-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
benzoic acid


piperidine]-1′-yl)-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-isopropoxy-3-methyl-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
benzoic acid


piperidine]-1′-yl)-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methyl-phenyl)methanone
a]pyrazine-1,4′-piperidine]


[3-methoxy-4-[(1R)-1-
2-methyl-6-(1,1,2,2,2-
3-methoxy-4-[(1R)-1-


methylpropoxy]phenyl]-[2-methyl-6-
pentafluoroethyl)spiro[3,4-
methylpropoxy]benzoic


(1,1,2,2,2-
dihydropyrrolo[1,2-
acid


pentafluoroethyl)spiro[3,4-
a]pyrazine-1,4′-piperidine]


dihydropyrrolo[1,2-a]pyrazine-1,4′-


piperidine]-1′-yl]methanone


N,2-dimethyl-4-[2-methyl-6-
2-methyl-6-(1,1,2,2,2-
3-methyl-4-


(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
(methylsulfamoyl)benzoic


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-


carbonyl]benzenesulfonamide


[4-(3-hydroxypropoxy)-3-methyl-
2-methyl-6-(1,1,2,2,2-
4-(3-hydroxypropoxy)-3-


phenyl]-[2-methyl-6-(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
methyl-benzoic acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[3-fluoro-4-(2-hydroxy-2-methyl-
2-methyl-6-(1,1,2,2,2-
3-fluoro-4-(2-hydroxy-2-


propyl)phenyl]-[2-methyl-6-
pentafluoroethyl)spiro[3,4-
methyl-propyl)benzoic


(1,1,2,2,2-
dihydropyrrolo[1,2-
acid


pentafluoroethyl)spiro[3,4-
a]pyrazine-1,4′-piperidine]


dihydropyrrolo[1,2-a]pyrazine-1,4′-


piperidine]-1′-yl]methanone


N-methyl-4-[2-methyl-6-(1,1,2,2,2-
2-methyl-6-(1,1,2,2,2-
4-


pentafluoroethyl)spiro[3,4-
pentafluoroethyl)spiro[3,4-
(methylsulfamoyl)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


[3-methoxy-4-[(1S)-1-
2-methyl-6-(1,1,2,2,2-
3-methoxy-4-[(1S)-1-


methylpropoxy]phenyl]-[2-methyl-6-
pentafluoroethyl)spiro[3,4-
methylpropoxy]benzoic


(1,1,2,2,2-
dihydropyrrolo[1,2-
acid


pentafluoroethyl)spiro[3,4-
a]pyrazine-1,4′-piperidine]


dihydropyrrolo[1,2-a]pyrazine-1,4′-


piperidine]-1′-yl]methanone


(4-tert-butoxy-3-methoxy-phenyl)-
2-methyl-6-(1,1,2,2,2-
4-tert-butoxy-3-methoxy-


[2-methyl-6-(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
benzoic acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-cyclopropylsulfonylphenyl)-[2-
2-methyl-6-(1,1,2,2,2-
4-cyclopropylsulfonyl-


methyl-6-(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
benzoic acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-tert-butylsulfonylphenyl)-[2-
2-methyl-6-(1,1,2,2,2-
4-tert-butylsulfonylbenzoic


methyl-6-(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[3-methoxy-4-(2-
2-methyl-6-(1,1,2,2,2-
3-methoxy-4-(2-


methoxyethoxy)phenyl]-[2-methyl-6-
pentafluoroethyl)spiro[3,4-
methoxyethoxy)benzoic


(1,1,2,2,2-
dihydropyrrolo[1,2-
acid


pentafluoroethyl)spiro[3,4-
a]pyrazine-1,4′-piperidine]


dihydropyrrolo[1,2-a]pyrazine-1,4′-


piperidine]-1′-yl]methanone


[3-(hydroxymethyl)-4-isopropoxy-
2-methyl-6-(1,1,2,2,2-
3-(hydroxymethyl)-4-


phenyl]-[2-methyl-6-(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
isopropoxy-benzoic acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[4-(1-hydroxycyclopentyl)phenyl]-[2-
2-methyl-6-(1,1,2,2,2-
4-(1-hydroxycyclopentyl)-


methyl-6-(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
benzoic acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[3-fluoro-4-(1-hydroxy-1-methyl-
2-methyl-6-(1,1,2,2,2-
3-fluoro-4-(1-hydroxy-1-


ethyl)phenyl]-[2-methyl-6-(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
methyl-ethyl)benzoic acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[4-(1-hydroxy-1-methyl-
2-methyl-6-(1,1,2,2,2-
4-(1-hydroxy-1-methyl-


ethyl)phenyl]-[2-methyl-6-(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
ethyl)benzoic acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


N-cyclopropyl-4-[2-methyl-6-
2-methyl-6-(1,1,2,2,2-
4-(cyclopropylsulfamoyl)-


(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
benzoic acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-


carbonyl]benzenesulfonamide


(3-chloro-4-isopropoxy-phenyl)-[2-
2-methyl-6-(1,1,2,2,2-
3-chloro-4-isopropoxy-


methyl-6-(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
benzoic acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[4-(1-hydroxy-1-methyl-ethyl)-3-
2-methyl-6-(1,1,2,2,2-
4-(1-hydroxy-1-methyl-


methyl-phenyl]-[2-methyl-6-
pentafluoroethyl)spiro[3,4-
ethyl)-3-methyl-benzoic


(1,1,2,2,2-
dihydropyrrolo[1,2-
acid


pentafluoroethyl)spiro[3,4-
a]pyrazine-1,4′-piperidine]


dihydropyrrolo[1,2-a]pyrazine-1,4′-


piperidine]-1′-yl]methanone


(4-isopropylsulfonyl-3-methyl-
2-methyl-6-(1,1,2,2,2-
4-isopropylsulfonyl-3-


phenyl)-[2-methyl-6-(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
methyl-benzoic acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-isopropoxy-3-methoxy-phenyl)-
2-methyl-6-(1,1,2,2,2-
4-isopropoxy-3-methoxy-


[2-methyl-6-(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
benzoic acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-isopropoxy-3-methyl-phenyl)-[2-
2-methyl-6-(1,1,2,2,2-
4-isopropoxy-3-methyl-


methyl-6-(1,1,2,2,2-
pentafluoroethyl)spiro[3,4-
benzoic acid


pentafluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


ethyl 1′-(3-chloro-4-isopropoxy-
ethyl 6-cyanospiro[3,4-
3-chloro-4-isopropoxy-


benzoyl)-6-cyano-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-2-carboxylate
piperidine]-2-carboxylate


ethyl 6-cyano-1′-(4-isopropoxy-3-
ethyl 6-cyanospiro[3,4-
4-isopropoxy-3-methyl-


methyl-benzoyl)spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-2-carboxylate
piperidine]-2-carboxylate


ethyl 6-cyano-1′-(5-isopropoxy-6-
ethyl 6-cyanospiro[3,4-
5-isopropoxy-6-methyl-


methyl-pyridine-2-
dihydropyrrolo[1,2-
pyridine-2-carboxylic acid


carbonyl)spiro[3,4-
a]pyrazine-1,4′-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-2-carboxylate


piperidine]-2-carboxylate


4-(6-acetyl-2-methyl-spiro[3,4-
1-(2-methylspiro[3,4-
4-(cyclopropylsulfamoyl)-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
benzoic acid


piperidine]-1′-carbonyl)-N-
a]pyrazine-1,4′-


cyclopropyl-benzenesulfonamide
piperidine]-6-yl)ethanone


1-[1′-(4-isopropylsulfonyl-3-methyl-
1-(2-methylspiro[3,4-
4-isopropylsulfonyl-3-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
methyl-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-isopropoxy-3-methyl-
1-(2-methylspiro[3,4-
4-isopropoxy-3-methyl-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(3-chloro-4-isopropoxy-
1-(2-methylspiro[3,4-
3-chloro-4-isopropoxy-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-(1-hydroxy-1-methyl-ethyl)-
1-(2-methylspiro[3,4-
4-(1-hydroxy-1-methyl-


3-methyl-benzoyl]-2-methyl-
dihydropyrrolo[1,2-
ethyl)-3-methyl-benzoic


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-
acid


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


1-[1′-(4-isopropoxy-3-methoxy-
1-(2-methylspiro[3,4-
4-isopropoxy-3-methoxy-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


[4-(1-hydroxy-1-methyl-ethyl)-3-
2-methylspiro[3,4-
4-(1-hydroxy-1-methyl-


methyl-phenyl]-(2-methylspiro[3,4-
dihydropyrrolo[1,2-
ethyl)-3-methyl-benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]
acid


piperidine]-1′-yl)methanone


(4-isopropoxy-3-methyl-phenyl)-(2-
2-methylspiro[3,4-
4-isopropoxy-3-methyl-


methylspiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
benzoic acid


a]pyrazine-1,4′-piperidine]-1′-
a]pyrazine-1,4′-piperidine]


yl)methanone


(3-chloro-4-isopropoxy-phenyl)-[2-
2-methyl-6-(2,2,2-
3-chloro-4-isopropoxy-


methyl-6-(2,2,2-
trifluoroethyl)spiro[3,4-
benzoic acid


trifluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[4-(1-hydroxy-1-methyl-ethyl)-3-
2-methyl-6-(2,2,2-
4-(1-hydroxy-1-methyl-


methyl-phenyl]-[2-methyl-6-(2,2,2-
trifluoroethyl)spiro[3,4-
ethyl)-3-methyl-benzoic


trifluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-isopropylsulfonyl-3-methyl-
2-methyl-6-(2,2,2-
4-isopropylsulfonyl-3-


phenyl)-[2-methyl-6-(2,2,2-
trifluoroethyl)spiro[3,4-
methyl-benzoic acid


trifluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-isopropoxy-3-methoxy-phenyl)-
2-methyl-6-(2,2,2-
4-isopropoxy-3-methoxy-


[2-methyl-6-(2,2,2-
trifluoroethyl)spiro[3,4-
benzoic acid


trifluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-isopropoxy-3-methyl-phenyl)-[2-
2-methyl-6-(2,2,2-
4-isopropoxy-3-methyl-


methyl-6-(2,2,2-
trifluoroethyl)spiro[3,4-
benzoic acid


trifluoroethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


1′-(4-isopropoxy-3-methoxy-
2-methyl-6-
4-isopropoxy-3-methoxy-


benzoyl)-2-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-8-carbonitrile
piperidine]-8-carbonitrile


[(5aR,9aR)-spiro[5a,6,7,8,9,9a-
(5aR,9aR)-
4-isopentyloxy-3-


hexahydro-5H-pyrrolo[1,2-
spiro[5a,6,7,8,9,9a-
methoxy-benzoic acid


a]quinoxaline-4,4′-piperidine]-1′-yl]-
hexahydro-5H-


(4-isopentyloxy-3-methoxy-
pyrrolo[1,2-a]quinoxaline-


phenyl)methanone
4,4′-piperidine]


[(5aS,9aS)-spiro[5a,6,7,8,9,9a-
(5aS,9aS)-
4-isopentyloxy-3-


hexahydro-5H-pyrrolo[1,2-
spiro[5a,6,7,8,9,9a-
methoxy-benzoic acid


a]quinoxaline-4,4′-piperidine]-1′-yl]-
hexahydro-5H-


(4-isopentyloxy-3-methoxy-
pyrrolo[1,2-a]quinoxaline-


phenyl)methanone
4,4′-piperidine]


(4-isopropoxy-3-methoxy-phenyl)-
(3S)-3-methyl-6-
4-isopropoxy-3-methoxy-


[(3S)-3-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-isopropoxy-3-methoxy-phenyl)-
(3R)-3-methyl-6-
4-isopropoxy-3-methoxy-


[(3R)-3-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[(3S)-2,3-dimethyl-6-
(3S)-2,3-dimethyl-6-
2-fluoro-4-isopropoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(2-fluoro-4-
a]pyrazine-1,4′-piperidine]


isopropoxy-phenyl)methanone


[(3R)-2,3-dimethyl-6-
(3R)-2,3-dimethyl-6-
2-fluoro-4-isopropoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(2-fluoro-4-
a]pyrazine-1,4′-piperidine]


isopropoxy-phenyl)methanone


[(3S)-2,3-dimethyl-6-
(3S)-2,3-dimethyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[(3R)-2,3-dimethyl-6-
(3R)-2,3-dimethyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


(4-isopropoxy-3-methyl-phenyl)-
(3S)-3-methyl-6-
4-isopropoxy-3-methyl-


[(3S)-3-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-isopropoxy-3-methyl-phenyl)-
(3R)-3-methyl-6-
4-isopropoxy-3-methyl-


[(3R)-3-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(3-fluoro-4-isopropoxy-phenyl)-
(3S)-3-methyl-6-
3-fluoro-4-isopropoxy-


[(3S)-3-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(3-fluoro-4-isopropoxy-phenyl)-
(3R)-3-methyl-6-
3-fluoro-4-isopropoxy-


[(3R)-3-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-dihydro-
dihydro-2H-pyrrolo[1,2-


2H-pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[(1S,3′R)-3′-fluoro-2-methyl-6-
(1S,3′R)-3′-fluoro-2-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
methyl-6-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-


piperidine]-1′-yl]-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


[(1R,3′R)-3′-fluoro-2-methyl-6-
(1R,3′R)-3′-fluoro-2-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
methyl-6-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-


piperidine]-1′-yl]-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


[(1R,2′S)-2,2′-dimethyl-6-
(1R,2′S)-2,2′-dimethyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[(1R,3′R)-3′-fluoro-2-methyl-6-
(1R,3′R)-3′-fluoro-2-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
methyl-6-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-


piperidine]-1′-yl]-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


[(1R,3′S)-3′-fluoro-2-methyl-6-
(1R,3′S)-3′-fluoro-2-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
methyl-6-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-


piperidine]-1′-yl]-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


[(1S,3′R)-3′-fluoro-2-methyl-6-
(1S,3′R)-3′-fluoro-2-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
methyl-6-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-


piperidine]-1′-yl]-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


[(1S,3′S)-2,3′-dimethyl-6-
(1S,3′S)-2,3′-dimethyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[(1S,3′S)-3′-fluoro-2-methyl-6-
(1S,3′S)-3′-fluoro-2-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
methyl-6-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-


piperidine]-1′-yl]-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


[(1S,3′R)-3′-fluoro-2-methyl-6-
(1S,3′R)-3′-fluoro-2-
4-(1-hydroxy-1-methyl-


(trifluoromethyl)spiro[3,4-
methyl-6-
ethyl)-3-methyl-benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-
acid


piperidine]-1′-yl]-[4-(1-hydroxy-1-
dihydropyrrolo[1,2-


methyl-ethyl)-3-methyl-
a]pyrazine-1,4′-piperidine]


phenyl]methanone


[(1S,3′R)-3′-fluoro-2-methyl-6-
(1S,3′R)-3′-fluoro-2-
3-(hydroxymethyl)-4-


(trifluoromethyl)spiro[3,4-
methyl-6-
isopropoxy-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-


piperidine]-1′-yl]-[3-
dihydropyrrolo[1,2-


(hydroxymethyl)-4-isopropoxy-
a]pyrazine-1,4′-piperidine]


phenyl]methanone


N-cyclopropyl-4-[(1S,3′R)-3′-fluoro-
(1S,3′R)-3′-fluoro-2-
4-(cyclopropylsulfamoyl)-


2-methyl-6-
methyl-6-
benzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


[(1S,3′R)-3′-fluoro-2-methyl-6-
(1S,3′R)-3′-fluoro-2-
4-isopropoxy-3-methyl-


(trifluoromethyl)spiro[3,4-
methyl-6-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-


piperidine]-1′-yl]-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methyl-phenyl)methanone
a]pyrazine-1,4′-piperidine]


[(1R,2′S)-2,2′-dimethyl-6-
(1R,2′S)-2,2′-dimethyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[(1S,2′R)-2,2′-dimethyl-6-
(1S,2′R)-2,2′-dimethyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[(1S,3′R)-3′-fluoro-2-methyl-6-
(1S,3′R)-3′-fluoro-2-
4-(1-hydroxy-1-methyl-


(trifluoromethyl)spiro[3,4-
methyl-6-
ethyl)-3-methyl-benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-
acid


piperidine]-1′-yl]-[4-(1-hydroxy-1-
dihydropyrrolo[1,2-


methyl-ethyl)-3-methyl-
a]pyrazine-1,4′-piperidine]


phenyl]methanone


[(1R,3′S)-3′-fluoro-2-methyl-6-
(1R,3′S)-3′-fluoro-2-
4-(1-hydroxy-1-methyl-


(trifluoromethyl)spiro[3,4-
methyl-6-
ethyl)-3-methyl-benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-
acid


piperidine]-1′-yl]-[4-(1-hydroxy-1-
dihydropyrrolo[1,2-


methyl-ethyl)-3-methyl-
a]pyrazine-1,4′-piperidine]


phenyl]methanone


[(1S,3′R)-3′-fluoro-2-methyl-6-
(1S,3′R)-3′-fluoro-2-
4-isopropoxy-3-methyl-


(trifluoromethyl)spiro[3,4-
methyl-6-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-


piperidine]-1′-yl]-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methyl-phenyl)methanone
a]pyrazine-1,4′-piperidine]


[(1R,3′S)-3′-fluoro-2-methyl-6-
(1R,3′S)-3′-fluoro-2-
4-isopropoxy-3-methyl-


(trifluoromethyl)spiro[3,4-
methyl-6-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
(trifluoromethyl)spiro[3,4-


piperidine]-1′-yl]-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methyl-phenyl)methanone
a]pyrazine-1,4′-piperidine]


ethyl 2-[1′-(4-isopropoxy-3-methoxy-
ethyl 2-(2-
4-isopropoxy-3-methoxy-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2-oxo-acetate
a]pyrazine-1,4′-



piperidine]-6-yl)-2-oxo-



acetate


ethyl 2-[1′-(4-isopropoxy-3-methyl-
ethyl 2-(2-
4-isopropoxy-3-methyl-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2-oxo-acetate
a]pyrazine-1,4′-



piperidine]-6-yl)-2-oxo-



acetate


ethyl 2-[1′-[4-(1-hydroxy-1-methyl-
ethyl 2-(2-
4-(1-hydroxy-1-methyl-


ethyl)-3-methyl-benzoyl]-2-methyl-
methylspiro[3,4-
ethyl)-3-methyl-benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-2-
a]pyrazine-1,4′-


oxo-acetate
piperidine]-6-yl)-2-oxo-



acetate


ethyl 2-[1′-(3-chloro-4-isopropoxy-
ethyl 2-(2-
3-chloro-4-isopropoxy-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2-oxo-acetate
a]pyrazine-1,4′-



piperidine]-6-yl)-2-oxo-



acetate


ethyl 2-[1′-(4-isopropylsulfonyl-3-
ethyl 2-(2-
4-isopropylsulfonyl-3-


methyl-benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
methyl-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2-oxo-acetate
a]pyrazine-1,4′-



piperidine]-6-yl)-2-oxo-



acetate


ethyl 2-[1′-[4-
ethyl 2-(2-
4-(cyclopropylsulfamoyl)-


(cyclopropylsulfamoyl)benzoyl]-2-
methylspiro[3,4-
benzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-yl]-2-
a]pyrazine-1,4′-


oxo-acetate
piperidine]-6-yl)-2-oxo-



acetate


[8-bromo-2-methyl-6-
8-bromo-2-methyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[8-bromo-2-methyl-6-
8-bromo-2-methyl-6-
4-isopropoxy-3-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methyl-phenyl)methanone


1′-(4-isopropoxy-3-methyl-benzoyl)-
2-methyl-6-
4-isopropoxy-3-methyl-


2-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-8-carbonitrile
piperidine]-8-carbonitrile


1′-(3-chloro-4-isopropoxy-benzoyl)-
2-methyl-6-
3-chloro-4-isopropoxy-


2-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-8-carbonitrile
piperidine]-8-carbonitrile


1′-[4-(1-hydroxy-1-methyl-ethyl)-3-
2-methyl-6-
4-(1-hydroxy-1-methyl-


methyl-benzoyl]-2-methyl-6-
(trifluoromethyl)spiro[3,4-
ethyl)-3-methyl-benzoic


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-8-carbonitrile
piperidine]-8-carbonitrile


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
4-(1-hydroxy-1-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
ethyl)-3-methyl-benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-yl]-[4-(1-hydroxy-1-
a]pyrazine-1,4′-piperidine]


methyl-ethyl)-3-methyl-


phenyl]methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
5-isopropoxy-6-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
pyridine-2-carboxylic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(5-isopropoxy-6-
a]pyrazine-1,4′-piperidine]


methyl-2-pyridyl)methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-isopropoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
4-isopropoxy-3-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methyl-phenyl)methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-isopropoxy-3-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


methyl-phenyl)methanone


2,2,2-trifluoro-1-[1′-(4-
2,2,2-trifluoro-1-(2-
4-isopropylbenzoic acid


isopropylbenzoyl)-2-methyl-
methylspiro[3,4-


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[4-(2-
2,2,2-trifluoro-1-(2-
4-(2-


methoxyethoxy)benzoyl]-2-methyl-
methylspiro[3,4-
methoxyethoxy)benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[2-methyl-1′-(4-
2,2,2-trifluoro-1-(2-
4-propoxybenzoic acid


propoxybenzoyl)spiro[3,4-
methylspiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


4-[2-methyl-6-(2,2,2-
2,2,2-trifluoro-1-(2-
4-(dipropylsulfamoyl)-


trifluoroacetyl)spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-carbonyl]-N,N-
a]pyrazine-1,4′-


dipropyl-benzenesulfonamide
piperidine]-6-yl)ethanone


1-[1′-(4-butylbenzoyl)-2-methyl-
2,2,2-trifluoro-1-(2-
4-butylbenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[2-methyl-1′-(4-
2,2,2-trifluoro-1-(2-
4-phenylbenzoic acid


phenylbenzoyl)spiro[3,4-
methylspiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[2-methyl-1′-(4-
2,2,2-trifluoro-1-(2-
4-propylbenzoic acid


propylbenzoyl)spiro[3,4-
methylspiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[2-methyl-1′-(4-
2,2,2-trifluoro-1-(2-
4-phenoxybenzoic acid


phenoxybenzoyl)spiro[3,4-
methylspiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-
2,2,2-trifluoro-1-(2-
4-isopentyloxybenzoic


isopentyloxybenzoyl)-2-methyl-
methylspiro[3,4-
acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-butoxybenzoyl)-2-methyl-
2,2,2-trifluoro-1-(2-
4-butoxybenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[1′-(4-tert-butylbenzoyl)-2-methyl-
2,2,2-trifluoro-1-(2-
4-tert-butylbenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[2-methyl-1′-[4-
2,2,2-trifluoro-1-(2-
4-(phenoxymethyl)benzoic


(phenoxymethyl)benzoyl]spiro[3,4-
methylspiro[3,4-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[2-methyl-1′-[4-(1-
2,2,2-trifluoro-1-(2-
4-(1-piperidyl)benzoic acid


piperidyl)benzoyl]spiro[3,4-
methylspiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[1′-(4-tert-butoxybenzoyl)-2-
2,2,2-trifluoro-1-(2-
4-tert-butoxybenzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[1′-(4-benzyloxybenzoyl)-2-methyl-
2,2,2-trifluoro-1-(2-
4-benzyloxybenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[1′-(3-chloro-4-isopropoxy-
2-methyl-1-(2-
3-chloro-4-isopropoxy-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2-methyl-propan-1-
a]pyrazine-1,4′-


one
piperidine]-6-yl)propan-1-



one


1-[1′-(4-isopropoxy-3-methyl-
2-methyl-1-(2-
4-isopropoxy-3-methyl-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2-methyl-propan-1-
a]pyrazine-1,4′-


one
piperidine]-6-yl)propan-1-



one


1-[1′-(4-isopropoxy-3-methoxy-
2-methyl-1-(2-
4-isopropoxy-3-methoxy-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2-methyl-propan-1-
a]pyrazine-1,4′-


one
piperidine]-6-yl)propan-1-



one


2,2,2-trifluoro-1-[2-methyl-1′-(4-
2,2,2-trifluoro-1-(2-
4-pentylbenzoic acid


pentylbenzoyl)spiro[3,4-
methylspiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[1′-(3,4-diethoxybenzoyl)-2-
2,2,2-trifluoro-1-(2-
3,4-diethoxybenzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[1′-(4-tert-butyl-3-methoxy-
2,2,2-trifluoro-1-(2-
4-tert-butyl-3-methoxy-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-methoxy-3-
2,2,2-trifluoro-1-(2-
4-methoxy-3-propoxy-


propoxy-benzoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-butoxy-3-methoxy-benzoyl)-
2,2,2-trifluoro-1-(2-
4-butoxy-3-methoxy-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(3-methoxy-4-
2,2,2-trifluoro-1-(2-
3-methoxy-4-propoxy-


propoxy-benzoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(3-isopropoxy-
2,2,2-trifluoro-1-(2-
3-isopropoxy-4-methoxy-


4-methoxy-benzoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[4-(2-hydroxy-
2,2,2-trifluoro-1-(2-
4-(2-hydroxy-2-methyl-


2-methyl-propoxy)-3-methyl-
methylspiro[3,4-
propoxy)-3-methyl-


benzoyl]-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(3-butoxy-4-methoxy-benzoyl)-
2,2,2-trifluoro-1-(2-
3-butoxy-4-methoxy-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[4-(1-hydroxy-
2,2,2-trifluoro-1-(2-
4-(1-hydroxy-1-methyl-


1-methyl-ethyl)benzoyl]-2-methyl-
methylspiro[3,4-
ethyl)benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-isobutoxy-3-
2,2,2-trifluoro-1-(2-
4-isobutoxy-3-methoxy-


methoxy-benzoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-ethylbenzoyl)-2-methyl-
2,2,2-trifluoro-1-(2-
4-ethylbenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(3-fluoro-4-
2,2,2-trifluoro-1-(2-
3-fluoro-4-isopropoxy-


isopropoxy-benzoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-ethoxy-3-fluoro-benzoyl)-2-
2,2,2-trifluoro-1-(2-
4-ethoxy-3-fluoro-benzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[1′-(4-ethyl-3-methoxy-benzoyl)-2-
2,2,2-trifluoro-1-(2-
4-ethyl-3-methoxy-benzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-
2,2,2-trifluoro-1-(2-
4-isopropoxybenzoic acid


isopropoxybenzoyl)-2-methyl-
methylspiro[3,4-


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-benzylbenzoyl)-2-methyl-
2,2,2-trifluoro-1-(2-
4-benzylbenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[4-isopropoxy-
2,2,2-trifluoro-1-(2-
4-isopropoxy-3-


3-(trifluoromethyl)benzoyl]-2-
methylspiro[3,4-
(trifluoromethyl)benzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-isopropylbenzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


isopropylphenyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-propoxybenzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


propoxyphenyl)methanone
a]pyrazine-1,4′-piperidine]


4-(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-(dipropylsulfamoyl)-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
benzoic acid


piperidine]-1′-carbonyl)-N,N-
dihydropyrrolo[1,2-


dipropyl-benzenesulfonamide
a]pyrazine-1,4′-piperidine]


(4-butylphenyl)-(6-chloro-2-methyl-
6-chloro-2-methyl-
4-butylbenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
spiro[3,4-


a]pyrazine-1,4′-piperidine]-1′-
dihydropyrrolo[1,2-


yl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-phenylbenzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


phenylphenyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-propylbenzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


propylphenyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-phenoxybenzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


phenoxyphenyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-isopentyloxybenzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
acid


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


isopentyloxyphenyl)methanone
a]pyrazine-1,4′-piperidine]


(4-butoxyphenyl)-(6-chloro-2-
6-chloro-2-methyl-
4-butoxybenzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
spiro[3,4-


a]pyrazine-1,4′-piperidine]-1′-
dihydropyrrolo[1,2-


yl)methanone
a]pyrazine-1,4′-piperidine]


(4-tert-butylphenyl)-(6-chloro-2-
6-chloro-2-methyl-
4-tert-butylbenzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
spiro[3,4-


a]pyrazine-1,4′-piperidine]-1′-
dihydropyrrolo[1,2-


yl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-(phenoxymethyl)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
acid


piperidine]-1′-yl)-[4-
dihydropyrrolo[1,2-


(phenoxymethyl)phenyl]methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-(1-piperidyl)benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-


piperidine]-1′-yl)-[4-(1-
dihydropyrrolo[1,2-


piperidyl)phenyl]methanone
a]pyrazine-1,4′-piperidine]


(4-benzyloxyphenyl)-(6-chloro-2-
6-chloro-2-methyl-
4-benzyloxybenzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
spiro[3,4-


a]pyrazine-1,4′-piperidine]-1′-
dihydropyrrolo[1,2-


yl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-pentylbenzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


pentylphenyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-cyclohexylbenzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


cyclohexylphenyl)methanone
a]pyrazine-1,4′-piperidine]


(4-tert-butyl-3-methoxy-phenyl)-(6-
6-chloro-2-methyl-
4-tert-butyl-3-methoxy-


chloro-2-methyl-spiro[3,4-
spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-methoxy-3-propoxy-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
benzoic acid


piperidine]-1′-yl)-(4-methoxy-3-
dihydropyrrolo[1,2-


propoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


(4-butoxy-3-methoxy-phenyl)-(6-
6-chloro-2-methyl-
4-butoxy-3-methoxy-


chloro-2-methyl-spiro[3,4-
spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
3-methoxy-4-propoxy-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
benzoic acid


piperidine]-1′-yl)-(3-methoxy-4-
dihydropyrrolo[1,2-


propoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


(3-butoxy-4-methoxy-phenyl)-(6-
6-chloro-2-methyl-
3-butoxy-4-methoxy-


chloro-2-methyl-spiro[3,4-
spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
3-methoxy-4-[2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
(trifluoromethoxy)ethoxy]benzoic


piperidine]-1′-yl)-[3-methoxy-4-[2-
dihydropyrrolo[1,2-
acid


(trifluoromethoxy)ethoxy]phenyl]methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
3-fluoro-4-(3-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
methoxyprop-1-


piperidine]-1′-yl)-[3-fluoro-4-(3-
dihydropyrrolo[1,2-
ynyl)benzoic acid


methoxyprop-1-
a]pyrazine-1,4′-piperidine]


ynyl)phenyl]methanone


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
3-fluoro-4-isopropoxy-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
benzoic acid


piperidine]-1′-yl)-(3-fluoro-4-
dihydropyrrolo[1,2-


isopropoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


4-(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-(ethylsulfamoyl)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
acid


piperidine]-1′-carbonyl)-N-ethyl-
dihydropyrrolo[1,2-


benzenesulfonamide
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
3-fluoro-4-(1-hydroxy-1-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
methyl-ethyl)benzoic acid


piperidine]-1′-yl)-[3-fluoro-4-(1-
dihydropyrrolo[1,2-


hydroxyl-1-methyl-
a]pyrazine-1,4′-piperidine]


ethyl)phenyl]methanone


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-isopropoxy-3-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
(trifluoromethyl)benzoic


piperidine]-1′-yl)-[4-isopropoxy-3-
dihydropyrrolo[1,2-
acid


(trifluoromethyl)phenyl]methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-isopropoxybenzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


isopropoxyphenyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-isobutoxy-3-methoxy-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
benzoic acid


piperidine]-1′-yl)-(4-isobutoxy-3-
dihydropyrrolo[1,2-


methoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
(difluoromethylsulfonyl)-


piperidine]-1′-yl)-[4-
dihydropyrrolo[1,2-
benzoic acid


(difluoromethylsulfonyl)phenyl]methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
quinoline-8-carboxylic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
acid


piperidine]-1′-yl)-(8-
dihydropyrrolo[1,2-


quinolyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-(1-hydroxycyclopentyl)-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
benzoic acid


piperidine]-1′-yl)-[4-(1-
dihydropyrrolo[1,2-


hydroxycyclopentyl)phenyl]methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
3-methoxy-4-[(1S)-1-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
methylpropoxy]benzoic


piperidine]-1′-yl)-[3-methoxy-4-
dihydropyrrolo[1,2-
acid


[(1S)-1-
a]pyrazine-1,4′-piperidine]


methylpropoxy]phenyl]methanone


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-ethyl-3-methoxy-benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
acid


piperidine]-1′-yl)-(4-ethyl-3-
dihydropyrrolo[1,2-


methoxy-phenyl)methanone
a]pyrazine-1,4′-piperidine]


(4-benzylphenyl)-(6-chloro-2-methyl-
6-chloro-2-methyl-
4-benzylbenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
spiro[3,4-


a]pyrazine-1,4′-piperidine]-1′-
dihydropyrrolo[1,2-


yl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
3,4-diethoxybenzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-


piperidine]-1′-yl)-(3,4-
dihydropyrrolo[1,2-


diethoxyphenyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-(2-hydroxy-2-methyl-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
propoxy)-3-methyl-


piperidine]-1′-yl)-[4-(2-hydroxy-2-
dihydropyrrolo[1,2-
benzoic acid


methyl-propoxy)-3-methyl-
a]pyrazine-1,4′-piperidine]


phenyl]methanone


1-[1′-(4-isopropylbenzoyl)-2-methyl-
1-(2-methylspiro[3,4-
4-isopropylbenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[2-methyl-1′-(4-
1-(2-methylspiro[3,4-
4-propoxybenzoic acid


propoxybenzoyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


4-(6-acetyl-2-methyl-spiro[3,4-
1-(2-methylspiro[3,4-
4-(dipropylsulfamoyl)-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
benzoic acid


piperidine]-1′-carbonyl)-N,N-
a]pyrazine-1,4′-


dipropyl-benzenesulfonamide
piperidine]-6-yl)ethanone


1-[1′-(4-butylbenzoyl)-2-methyl-
1-(2-methylspiro[3,4-
4-butylbenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[2-methyl-1′-(4-
1-(2-methylspiro[3,4-
4-phenylbenzoic acid


phenylbenzoyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[2-methyl-1′-(4-
1-(2-methylspiro[3,4-
4-propylbenzoic acid


propylbenzoyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[2-methyl-1′-(4-
1-(2-methylspiro[3,4-
4-phenoxybenzoic acid


phenoxybenzoyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-isopentyloxybenzoyl)-2-
1-(2-methylspiro[3,4-
4-isopentyloxybenzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-butoxybenzoyl)-2-methyl-
1-(2-methylspiro[3,4-
4-butoxybenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-tert-butylbenzoyl)-2-methyl-
1-(2-methylspiro[3,4-
4-tert-butylbenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[2-methyl-1′-[4-
1-(2-methylspiro[3,4-
4-(phenoxymethyl)benzoic


(phenoxymethyl)benzoyl]spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[2-methyl-1′-[4-(1-
1-(2-methylspiro[3,4-
4-(1-piperidyl)benzoic acid


piperidyl)benzoyl]spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-benzyloxybenzoyl)-2-methyl-
1-(2-methylspiro[3,4-
4-benzyloxybenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[2-methyl-1′-(4-
1-(2-methylspiro[3,4-
4-pentylbenzoic acid


pentylbenzoyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-cyclohexylbenzoyl)-2-
1-(2-methylspiro[3,4-
4-cyclohexylbenzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-tert-butyl-3-methoxy-
1-(2-methylspiro[3,4-
4-tert-butyl-3-methoxy-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-methoxy-3-propoxy-
1-(2-methylspiro[3,4-
4-methoxy-3-propoxy-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-butoxy-3-methoxy-benzoyl)-
1-(2-methylspiro[3,4-
4-butoxy-3-methoxy-


2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(3-methoxy-4-propoxy-
1-(2-methylspiro[3,4-
3-methoxy-4-propoxy-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-[3-methoxy-4-[2-
1-(2-methylspiro[3,4-
3-methoxy-4-[2-


(trifluoromethoxy)ethoxy]benzoyl]-
dihydropyrrolo[1,2-
(trifluoromethoxy)ethoxy]benzoic


2-methyl-spiro[3,4-
a]pyrazine-1,4′-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)ethanone


piperidine]-6-yl]ethanone


1-[1′-[3-fluoro-4-(3-methoxyprop-1-
1-(2-methylspiro[3,4-
3-fluoro-4-(3-


ynyl)benzoyl]-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
methoxyprop-1-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-
ynyl)benzoic acid


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-ethylbenzoyl)-2-methyl-
1-(2-methylspiro[3,4-
4-ethylbenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(3-fluoro-4-isopropoxy-
1-(2-methylspiro[3,4-
3-fluoro-4-isopropoxy-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


4-(6-acetyl-2-methyl-spiro[3,4-
1-(2-methylspiro[3,4-
4-(ethylsulfamoyl)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-carbonyl)-N-ethyl-
a]pyrazine-1,4′-


benzenesulfonamide
piperidine]-6-yl)ethanone


1-[1′-[3-fluoro-4-(1-hydroxy-1-
1-(2-methylspiro[3,4-
3-fluoro-4-(1-hydroxy-1-


methyl-ethyl)benzoyl]-2-methyl-
dihydropyrrolo[1,2-
methyl-ethyl)benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


1-[1′-[4-isopropoxy-3-
1-(2-methylspiro[3,4-
4-isopropoxy-3-


(trifluoromethyl)benzoyl]-2-methyl-
dihydropyrrolo[1,2-
(trifluoromethyl)benzoic


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-
acid


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


1-[1′-(4-isopropoxybenzoyl)-2-
1-(2-methylspiro[3,4-
4-isopropoxybenzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-isobutoxy-3-methoxy-
1-(2-methylspiro[3,4-
4-isobutoxy-3-methoxy-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-
1-(2-methylspiro[3,4-
4-


(difluoromethylsulfonyl)benzoyl]-2-
dihydropyrrolo[1,2-
(difluoromethylsulfonyl)-


methyl-spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-
benzoic acid


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


1-[2-methyl-1′-(quinoline-8-
1-(2-methylspiro[3,4-
quinoline-8-carboxylic


carbonyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-(1-
1-(2-methylspiro[3,4-
4-(1-hydroxycyclopentyl)-


hydroxycyclopentyl)benzoyl]-2-
dihydropyrrolo[1,2-
benzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


1-[1′-[3-methoxy-4-[(1S)-1-
1-(2-methylspiro[3,4-
3-methoxy-4-[(1S)-1-


methylpropoxy]benzoyl]-2-methyl-
dihydropyrrolo[1,2-
methylpropoxy]benzoic


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-
acid


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


1-[1′-(4-ethyl-3-methoxy-benzoyl)-2-
1-(2-methylspiro[3,4-
4-ethyl-3-methoxy-benzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-benzylbenzoyl)-2-methyl-
1-(2-methylspiro[3,4-
4-benzylbenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(3,4-diethoxybenzoyl)-2-
1-(2-methylspiro[3,4-
3,4-diethoxybenzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-(2-hydroxy-2-methyl-
1-(2-methylspiro[3,4-
4-(2-hydroxy-2-methyl-


propoxy)-3-methyl-benzoyl]-2-
dihydropyrrolo[1,2-
propoxy)-3-methyl-


methyl-spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-
benzoic acid


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
3-methoxy-4-[(1R)-1-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
methylpropoxy]benzoic


piperidine]-1′-yl)-[3-methoxy-4-
dihydropyrrolo[1,2-
acid


[(1R)-1-
a]pyrazine-1,4′-piperidine]


methylpropoxy]phenyl]methanone


1-[1′-[3-methoxy-4-[(1R)-1-
1-(2-methylspiro[3,4-
3-methoxy-4-[(1R)-1-


methylpropoxy]benzoyl]-2-methyl-
dihydropyrrolo[1,2-
methylpropoxy]benzoic


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-
acid


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


2-isopropoxy-5-[2-methyl-6-(2,2,2-
2,2,2-trifluoro-1-(2-
3-cyano-4-isopropoxy-


trifluoroacetyl)spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-carbonyl]benzonitrile
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[4-methoxy-3-
2,2,2-trifluoro-1-(2-
4-methoxy-3-


(trifluoromethyl)benzoyl]-2-methyl-
methylspiro[3,4-
(trifluoromethyl)benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[2-methyl-1′-[4-
2,2,2-trifluoro-1-(2-
4-


(trifluoromethoxy)benzoyl]spiro[3,4-
methylspiro[3,4-
(trifluoromethoxy)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[3-
2,2,2-trifluoro-1-(2-
3-(hydroxymethyl)-4-


(hydroxymethyl)-4-isopropoxy-
methylspiro[3,4-
isopropoxy-benzoic acid


benzoyl]-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[4-(2-hydroxy-
2,2,2-trifluoro-1-(2-
4-(2-hydroxy-2-methyl-


2-methyl-propyl)benzoyl]-2-methyl-
methylspiro[3,4-
propyl)benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[3-methoxy-4-
2,2,2-trifluoro-1-(2-
3-methoxy-4-(2-


(2-methoxyethoxy)benzoyl]-2-
methylspiro[3,4-
methoxyethoxy)benzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-isopropoxybenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-
a]pyrazine-1,4′-piperidine]


isopropoxyphenyl)methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-propoxybenzoic acid


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-
a]pyrazine-1,4′-piperidine]


propoxyphenyl)methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-(2-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
methoxyethoxy)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-yl]-[4-(2-
a]pyrazine-1,4′-piperidine]


methoxyethoxy)phenyl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-(1-hydroxy-1-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
ethyl)benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[4-(1-hydroxy-1-
a]pyrazine-1,4′-piperidine]


methyl-ethyl)phenyl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-(1-hydroxy-2-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
propyl)benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[4-(1-hydroxy-2-
a]pyrazine-1,4′-piperidine]


methyl-propyl)phenyl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-(1-hydroxy-1-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
ethyl)-3-methyl-benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-yl]-[4-(1-hydroxy-1-
a]pyrazine-1,4′-piperidine]


methyl-ethyl)-3-methyl-


phenyl]methanone


[3-fluoro-4-(1-hydroxy-1-methyl-
8-fluoro-2-methyl-6-
3-fluoro-4-(1-hydroxy-1-


ethyl)phenyl]-[8-fluoro-2-methyl-6-
(trifluoromethyl)spiro[3,4-
methyl-ethyl)benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-(2-hydroxy-2-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
propoxy)-3-methyl-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
benzoic acid


piperidine]-1′-yl]-[4-(2-hydroxy-2-
a]pyrazine-1,4′-piperidine]


methyl-propoxy)-3-methyl-


phenyl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-(1-hydroxycyclobutyl)-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[4-(1-
a]pyrazine-1,4′-piperidine]


hydroxycyclobutyl)phenyl]methanone


(3-fluoro-4-isopropoxy-phenyl)-[8-
8-fluoro-2-methyl-6-
3-fluoro-4-isopropoxy-


fluoro-2-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
3-methoxy-4-propoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(3-methoxy-4-
a]pyrazine-1,4′-piperidine]


propoxy-phenyl)methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
3-methoxy-4-[(1S)-1-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
methylpropoxy]benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-yl]-[3-methoxy-4-
a]pyrazine-1,4′-piperidine]


[(1S)-1-


methylpropoxy]phenyl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
3-methoxy-4-(2-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
methoxyethoxy)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-yl]-[3-methoxy-4-(2-
a]pyrazine-1,4′-piperidine]


methoxyethoxy)phenyl]methanone


(4-tert-butoxy-3-methoxy-phenyl)-
8-fluoro-2-methyl-6-
4-tert-butoxy-3-methoxy-


[8-fluoro-2-methyl-6-
(trifluoromethyl)spiro[3,4-
benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-isobutoxy-3-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-isobutoxy-3-
a]pyrazine-1,4′-piperidine]


methoxy-phenyl)methanone


[4-(difluoromethoxy)-3-methoxy-
8-fluoro-2-methyl-6-
4-(difluoromethoxy)-3-


phenyl]-[8-fluoro-2-methyl-6-
(trifluoromethyl)spiro[3,4-
methoxy-benzoic acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-(3-hydroxypropoxy)-3-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
methyl-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[4-(3-
a]pyrazine-1,4′-piperidine]


hydroxypropoxy)-3-methyl-


phenyl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
3-(hydroxymethyl)-4-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
isopropoxy-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[3-
a]pyrazine-1,4′-piperidine]


(hydroxymethyl)-4-isopropoxy-


phenyl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-methoxy-3-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
(trifluoromethyl)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-yl]-[4-methoxy-3-
a]pyrazine-1,4′-piperidine]


(trifluoromethyl)phenyl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-(2-hydroxyethoxy)-3-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
methoxy-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[4-(2-
a]pyrazine-1,4′-piperidine]


hydroxyethoxy)-3-methoxy-


phenyl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
5-isopropoxy-6-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
pyridine-2-carboxylic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(5-isopropoxy-6-
a]pyrazine-1,4′-piperidine]


methyl-2-pyridyl)methanone


N-cyclopropyl-4-[8-fluoro-2-methyl-
8-fluoro-2-methyl-6-
4-(cyclopropylsulfamoyl)-


6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-
a]pyrazine-1,4′-piperidine]


carbonyl]benzenesulfonamide


4-[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
(methylsulfamoyl)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-carbonyl]-N-methyl-
a]pyrazine-1,4′-piperidine]


benzenesulfonamide


[4-(difluoromethylsulfonyl)phenyl]-
8-fluoro-2-methyl-6-
4-


[8-fluoro-2-methyl-6-
(trifluoromethyl)spiro[3,4-
(difluoromethylsulfonyl)-


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-isopropylsulfonylbenzoic


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-
a]pyrazine-1,4′-piperidine]


isopropylsulfonylphenyl)methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-isopropylsulfonyl-3-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
methyl-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-
a]pyrazine-1,4′-piperidine]


isopropylsulfonyl-3-methyl-


phenyl)methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
6-isopropoxypyridine-3-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
carboxylic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(6-isopropoxy-3-
a]pyrazine-1,4′-piperidine]


pyridyl)methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-(2-hydroxy-2-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
propyl)benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[4-(2-hydroxy-2-
a]pyrazine-1,4′-piperidine]


methyl-propyl)phenyl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
3-methoxy-4-[(1R)-1-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
methylpropoxy]benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-yl]-[3-methoxy-4-
a]pyrazine-1,4′-piperidine]


[(1R)-1-


methylpropoxy]phenyl]methanone


1-[1′-[4-(1-hydroxy-1-methyl-ethyl)-
1-(2-methylspiro[3,4-
4-(1-hydroxy-1-methyl-


3-methyl-benzoyl]-2-methyl-
dihydropyrrolo[1,2-
ethyl)-3-methyl-benzoic


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-
acid


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)propan-1-


yl]propan-1-one
one


1-[1′-(4-isopropoxy-3-methoxy-
1-(2-methylspiro[3,4-
4-isopropoxy-3-methoxy-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(3-chloro-4-isopropoxy-
1-(2-methylspiro[3,4-
3-chloro-4-isopropoxy-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(4-isopropoxy-3-methyl-
1-(2-methylspiro[3,4-
4-isopropoxy-3-methyl-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]propan-1-one
piperidine]-6-yl)propan-1-



one


1-[2-methyl-1′-[4-(1-
1-(2-methylspiro[3,4-
4-(1-piperidyl)benzoic acid


piperidyl)benzoyl]spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(4-cyclopropylbenzoyl)-2-
2,2,2-trifluoro-1-(2-
4-cyclopropylbenzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-
2,2,2-trifluoro-1-(2-
4-isobutylbenzoic acid


isobutylbenzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[2-methyl-1′-(3-
2,2,2-trifluoro-1-(2-
3-methyl-4-phenyl-benzoic


methyl-4-phenyl-benzoyl)spiro[3,4-
methylspiro[3,4-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[1′-[4-(2,2-
2,2,2-trifluoro-1-(2-
4-(2,2-


dimethylpropoxy)benzoyl]-2-methyl-
methylspiro[3,4-
dimethylpropoxy)benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-
a]pyrazine-1,4′-


2,2,2-trifluoro-ethanone
piperidine]-6-yl)ethanone


5-[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
3-cyano-4-isopropoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-carbonyl]-2-
a]pyrazine-1,4′-piperidine]


isopropoxy-benzonitrile


(4-ethyl-3-methoxy-phenyl)-[8-
8-fluoro-2-methyl-6-
4-ethyl-3-methoxy-benzoic


fluoro-2-methyl-6-
(trifluoromethyl)spiro[3,4-
acid


(trifluoromethyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


(4-cyclopropylphenyl)-[8-fluoro-2-
8-fluoro-2-methyl-6-
4-cyclopropylbenzoic acid


methyl-6-(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]methanone
a]pyrazine-1,4′-piperidine]


1-[1′-[4-
2,2,2-trifluoro-1-(2-
4-(cyclopropylmethoxy)-


(cyclopropylmethoxy)benzoyl]-2-
methylspiro[3,4-
benzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-yl]-
a]pyrazine-1,4′-


2,2,2-trifluoro-ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[2-methyl-1′-[4-
2,2,2-trifluoro-1-(2-
4-(2,2,2-


(2,2,2-
methylspiro[3,4-
trifluoroethoxy)benzoic


trifluoroethoxy)benzoyl]spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-methoxy-3-
2,2,2-trifluoro-1-(2-
4-methoxy-3-phenyl-


phenyl-benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-isopropyl-3-
2,2,2-trifluoro-1-(2-
4-isopropyl-3-


methylsulfonyl-benzoyl)-2-methyl-
methylspiro[3,4-
methylsulfonyl-benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-cyclohexylbenzoyl)-2-
2,2,2-trifluoro-1-(2-
4-cyclohexylbenzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[4-(1-
2,2,2-trifluoro-1-(2-
4-(1-hydroxycyclopentyl)-


hydroxycyclopentyl)-3-methyl-
methylspiro[3,4-
3-methyl-benzoic acid


benzoyl]-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
3-(hydroxymethyl)-4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
isopropoxy-benzoic acid


piperidine]-1′-yl)-[3-
dihydropyrrolo[1,2-


(hydroxymethyl)-4-isopropoxy-
a]pyrazine-1,4′-piperidine]


phenyl]methanone


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-(cyclopropylmethoxy)-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
benzoic acid


piperidine]-1′-yl)-[4-
dihydropyrrolo[1,2-


(cyclopropylmethoxy)phenyl]methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-(2,2,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
trifluoroethoxy)benzoic


piperidine]-1′-yl)-[4-(2,2,2-
dihydropyrrolo[1,2-
acid


trifluoroethoxy)phenyl]methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-(2,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
dimethylpropoxy)benzoic


piperidine]-1′-yl)-[4-(2,2-
dihydropyrrolo[1,2-
acid


dimethylpropoxy)phenyl]methanone
a]pyrazine-1,4′-piperidine]


5-(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
3-cyano-4-isopropoxy-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
benzoic acid


piperidine]-1′-carbonyl)-2-
dihydropyrrolo[1,2-


isopropoxy-benzonitrile
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
3-methyl-4-phenyl-benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
acid


piperidine]-1′-yl)-(3-methyl-4-phenyl-
dihydropyrrolo[1,2-


phenyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
(trifluoromethoxy)benzoic


piperidine]-1′-yl)-[4-
dihydropyrrolo[1,2-
acid


(trifluoromethoxy)phenyl]methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-cyclopropylbenzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


cyclopropylphenyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-isobutylbenzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


isobutylphenyl)methanone
a]pyrazine-1,4′-piperidine]


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-methoxy-3-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
(trifluoromethyl)benzoic


piperidine]-1′-yl)-[4-methoxy-3-
dihydropyrrolo[1,2-
acid


(trifluoromethyl)phenyl]methanone
a]pyrazine-1,4′-piperidine]


1-[1′-[3-(hydroxymethyl)-4-
1-(2-methylspiro[3,4-
3-(hydroxymethyl)-4-


isopropoxy-benzoyl]-2-methyl-
dihydropyrrolo[1,2-
isopropoxy-benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


1-[1′-[4-
1-(2-methylspiro[3,4-
4-(cyclopropylmethoxy)-


(cyclopropylmethoxy)benzoyl]-2-
dihydropyrrolo[1,2-
benzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


1-[1′-(4-methoxy-3-phenyl-benzoyl)-
1-(2-methylspiro[3,4-
4-methoxy-3-phenyl-


2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[2-methyl-1′-[4-(2,2,2-
1-(2-methylspiro[3,4-
4-(2,2,2-


trifluoroethoxy)benzoyl]spiro[3,4-
dihydropyrrolo[1,2-
trifluoroethoxy)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-
acid


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-(2,2-
1-(2-methylspiro[3,4-
4-(2,2-


dimethylpropoxy)benzoyl]-2-methyl-
dihydropyrrolo[1,2-
dimethylpropoxy)benzoic


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-
acid


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


5-(6-acetyl-2-methyl-spiro[3,4-
1-(2-methylspiro[3,4-
3-cyano-4-isopropoxy-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
benzoic acid


piperidine]-1′-carbonyl)-2-
a]pyrazine-1,4′-


isopropoxy-benzonitrile
piperidine]-6-yl)ethanone


1-[2-methyl-1′-(3-methyl-4-phenyl-
1-(2-methylspiro[3,4-
3-methyl-4-phenyl-benzoic


benzoyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[2-methyl-1′-[4-
1-(2-methylspiro[3,4-
4-


(trifluoromethoxy)benzoyl]spiro[3,4-
dihydropyrrolo[1,2-
(trifluoromethoxy)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-
acid


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-cyclopropylbenzoyl)-2-
1-(2-methylspiro[3,4-
4-cyclopropylbenzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-isobutylbenzoyl)-2-methyl-
1-(2-methylspiro[3,4-
4-isobutylbenzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


(6-chloro-2-methyl-spiro[3,4-
6-chloro-2-methyl-
4-[(4-methyl-1-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[3,4-
piperidyl)sulfonyl]benzoic


piperidine]-1′-yl)-[4-[(4-methyl-1-
dihydropyrrolo[1,2-
acid


piperidyl)sulfonyl]phenyl]methanone
a]pyrazine-1,4′-piperidine]


2,2,2-trifluoro-1-[1′-(5-isopropoxy-
2,2,2-trifluoro-1-(2-
5-isopropoxy-6-methyl-


6-methyl-pyridine-2-carbonyl)-2-
methylspiro[3,4-
pyridine-2-carboxylic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[2-methyl-1′-[4-[(4-
2,2,2-trifluoro-1-(2-
4-[(4-methyl-1-


methyl-1-
methylspiro[3,4-
piperidyl)sulfonyl]benzoic


piperidyl)sulfonyl]benzoyl]spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(3-chloro-4-methoxy-benzoyl)-
2,2,2-trifluoro-1-(2-
3-chloro-4-methoxy-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(3-fluoro-4-
2,2,2-trifluoro-1-(2-
3-fluoro-4-methoxy-


methoxy-benzoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-
2,2,2-trifluoro-1-(2-
4-isobutoxybenzoic acid


isobutoxybenzoyl)-2-methyl-
methylspiro[3,4-


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


(4-cyclohexylphenyl)-[2-methyl-6-
2,2,2-trifluoro-1-(2-
4-cyclohexylbenzoic acid


(2,2,2-trifluoro-1-hydroxy-
methylspiro[3,4-


ethyl)spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-1′-
a]pyrazine-1,4′-


yl]methanone
piperidine]-6-yl)ethanol


2,2,2-trifluoro-1-[1′-(4-methoxy-3-
2,2,2-trifluoro-1-(2-
4-methoxy-3-methyl-


methyl-benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[1′-(4-cyclohexylbenzoyl)-3,3-
1-(3,3-dimethylspiro[2,4-
4-cyclohexylbenzoic acid


dimethyl-spiro[2,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(3-fluoro-4-
1-(3,3-dimethylspiro[2,4-
3-fluoro-4-isopropoxy-


isopropoxy-benzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(5-isopropoxy-
1-(3,3-dimethylspiro[2,4-
5-isopropoxy-6-methyl-


6-methyl-pyridine-2-carbonyl)-3,3-
dihydropyrrolo[1,2-
pyridine-2-carboxylic acid


dimethyl-spiro[2,4-
a]pyrazine-1,4′-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(4-isopropoxy-
1-(3,3-dimethylspiro[2,4-
4-isopropoxy-3-methoxy-


3-methoxy-benzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(2-fluoro-4-
1-(3,3-dimethylspiro[2,4-
2-fluoro-4-isopropoxy-


isopropoxy-benzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


1-[1′-(3-chloro-4-isopropoxy-
1-(3,3-dimethylspiro[2,4-
3-chloro-4-isopropoxy-


benzoyl)-3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(4-isopentyloxy-
1-(3,3-dimethylspiro[2,4-
4-isopentyloxy-3-


3-methoxy-benzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
methoxy-benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(4-isopropoxy-
1-(3,3-dimethylspiro[2,4-
4-isopropoxy-3-methyl-


3-methyl-benzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(4-
1-(3,3-dimethylspiro[2,4-
4-isopentyloxybenzoic


isopentyloxybenzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


[3-fluoro-4-(1-
8-fluoro-2-methyl-6-
3-fluoro-4-(1-


hydroxycyclobutyl)phenyl]-[8-fluoro-
(trifluoromethyl)spiro[3,4-
hydroxycyclobutyl)-


2-methyl-6-
dihydropyrrolo[1,2-
benzoic acid


(trifluoromethyl)spiro[3,4-
a]pyrazine-1,4′-piperidine]


dihydropyrrolo[1,2-a]pyrazine-1,4′-


piperidine]-1′-yl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-(1-hydroxycyclobutyl)-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
3-methyl-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[4-(1-
a]pyrazine-1,4′-piperidine]


hydroxycyclobutyl)-3-methyl-


phenyl]methanone


[8-fluoro-2-methyl-6-
8-fluoro-2-methyl-6-
4-(1-hydroxycyclobutyl)-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
3-methoxy-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[4-(1-
a]pyrazine-1,4′-piperidine]


hydroxycyclobutyl)-3-methoxy-


phenyl]methanone


2,2,2-trifluoro-1-[1′-(4-hydroxy-3-
2,2,2-trifluoro-1-(2-
4-hydroxy-3-methyl-


methyl-benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[1′-(3-chloro-4-hydroxy-benzoyl)-
2,2,2-trifluoro-1-(2-
3-chloro-4-hydroxy-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


(4-isopropoxy-3-methoxy-phenyl)-
2-methyl-6,7-
4-isopropoxy-3-methoxy-


[2-methyl-6,7-
bis(trifluoromethyl)spiro[3,
benzoic acid


bis(trifluoromethyl)spiro[3,4-
4-dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-piperidine]


piperidine]-1′-yl]methanone


1-[2-methyl-1′-[4-(3,3,3-
1-(2-methylspiro[3,4-
4-(3,3,3-


trifluoropropoxymethyl)benzoyl]spiro[3,
dihydropyrrolo[1,2-
trifluoropropoxymethyl)-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-
benzoic acid


1,4′-piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[2-methyl-1′-[4-(2,2,2-
1-(2-methylspiro[3,4-
4-(2,2,2-


trifluoroethoxymethyl)benzoyl]spiro[3,
dihydropyrrolo[1,2-
trifluoroethoxymethyl)-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-
benzoic acid


1,4′-piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


(4-isopropoxy-3-methyl-phenyl)-(2-
2-methyl-6-
4-isopropoxy-3-methyl-


methyl-6-methylsulfonyl-spiro[3,4-
methylsulfonyl-spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl)methanone
a]pyrazine-1,4′-piperidine]


(4-cyclohexylphenyl)-(2-methyl-6-
2-methyl-6-
4-cyclohexylbenzoic acid


methylsulfonyl-spiro[3,4-
methylsulfonyl-spiro[3,4-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl)methanone
a]pyrazine-1,4′-piperidine]


(3-chloro-4-isopropoxy-phenyl)-(2-
2-methyl-6-
3-chloro-4-isopropoxy-


methyl-6-methylsulfonyl-spiro[3,4-
methylsulfonyl-spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl)methanone
a]pyrazine-1,4′-piperidine]


2,2,2-trifluoro-1-[1′-(4-methoxy-3-
1-(3,3-dimethylspiro[2,4-
4-methoxy-3-methyl-


methyl-benzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-[4-methoxy-3-
1-(3,3-dimethylspiro[2,4-
4-methoxy-3-


(trifluoromethyl)benzoyl]-3,3-
dihydropyrrolo[1,2-
(trifluoromethyl)benzoic


dimethyl-spiro[2,4-
a]pyrazine-1,4′-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-[3-fluoro-4-(1-
1-(3,3-dimethylspiro[2,4-
3-fluoro-4-(1-hydroxy-1-


hydroxy-1-methyl-ethyl)benzoyl]-
dihydropyrrolo[1,2-
methyl-ethyl)benzoic acid


3,3-dimethyl-spiro[2,4-
a]pyrazine-1,4′-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


1-[1′-(3-chloro-4-methoxy-benzoyl)-
1-(3,3-dimethylspiro[2,4-
3-chloro-4-methoxy-


3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(4-methoxy-2-
1-(3,3-dimethylspiro[2,4-
4-methoxy-2-methyl-


methyl-benzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(2-fluoro-4-
1-(3,3-dimethylspiro[2,4-
2-fluoro-4-methoxy-


methoxy-benzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


1-[1′-(3-chloro-4-ethoxy-benzoyl)-
1-(3,3-dimethylspiro[2,4-
3-chloro-4-ethoxy-benzoic


3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


1-[1′-(4-tert-butyl-3-methoxy-
1-(3,3-dimethylspiro[2,4-
4-tert-butyl-3-methoxy-


benzoyl)-3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


1-[1′-(4-isopropoxy-3-methyl-
1-(3,3-dimethylspiro[2,4-
4-isopropoxy-3-methyl-


benzoyl)-3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-7-yl]ethanone
piperidine]-7-yl)ethanone


1-[1′-(4-isopropoxy-3-methyl-
1-(3,3-dimethylspiro[2,4-
4-isopropoxy-3-methyl-


benzoyl)-3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-cyclohexylbenzoyl)-3,3-
1-(3,3-dimethylspiro[2,4-
4-cyclohexylbenzoic acid


dimethyl-spiro[2,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-7-yl]ethanone
piperidine]-7-yl)ethanone


1-[1′-(4-cyclohexylbenzoyl)-3,3-
1-(3,3-dimethylspiro[2,4-
4-cyclohexylbenzoic acid


dimethyl-spiro[2,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-methoxy-3-methyl-benzoyl)-
1-(3,3-dimethylspiro[2,4-
4-methoxy-3-methyl-


3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-methoxy-3-
1-(3,3-dimethylspiro[2,4-
4-methoxy-3-


(trifluoromethyl)benzoyl]-3,3-
dihydropyrrolo[1,2-
(trifluoromethyl)benzoic


dimethyl-spiro[2,4-
a]pyrazine-1,4′-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)ethanone


piperidine]-6-yl]ethanone


1-[1′-(3-chloro-4-methoxy-benzoyl)-
1-(3,3-dimethylspiro[2,4-
3-chloro-4-methoxy-


3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(2-fluoro-4-isopropoxy-
1-(3,3-dimethylspiro[2,4-
2-fluoro-4-isopropoxy-


benzoyl)-3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-isopropoxy-3-
1-(3,3-dimethylspiro[2,4-
4-isopropoxy-3-


(trifluoromethyl)benzoyl]-3,3-
dihydropyrrolo[1,2-
(trifluoromethyl)benzoic


dimethyl-spiro[2,4-
a]pyrazine-1,4′-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-7-yl)ethanone


piperidine]-7-yl]ethanone


1-[1′-[4-isopropoxy-3-
1-(3,3-dimethylspiro[2,4-
4-isopropoxy-3-


(trifluoromethyl)benzoyl]-3,3-
dihydropyrrolo[1,2-
(trifluoromethyl)benzoic


dimethyl-spiro[2,4-
a]pyrazine-1,4′-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)ethanone


piperidine]-6-yl]ethanone


1-[1′-(3-chloro-4-isopropoxy-
1-(3,3-dimethylspiro[2,4-
3-chloro-4-isopropoxy-


benzoyl)-3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-7-yl]ethanone
piperidine]-7-yl)ethanone


1-[1′-(3-chloro-4-isopropoxy-
1-(3,3-dimethylspiro[2,4-
3-chloro-4-isopropoxy-


benzoyl)-3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-tert-butyl-3-
1-(3,3-
4-tert-butyl-3-methoxy-


methoxy-benzoyl)-3,3-dimethyl-
dimethylspiro[2,4-
benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-7-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-7-yl)ethanone


1-[1′-(4-tert-butyl-3-methoxy-
1-(3,3-dimethylspiro[2,4-
4-tert-butyl-3-methoxy-


benzoyl)-3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(2-fluoro-4-
2,2,2-trifluoro-1-(2,4,4-
2-fluoro-4-methoxy-


methoxy-benzoyl)-2,4,4-trimethyl-
trimethylspiro[3H-
benzoic acid


spiro[3H-pyrrolo[1,2-a]pyrazine-
pyrrolo[1,2-a]pyrazine-


1,4′-piperidine]-7-yl]ethanone
1,4′-piperidine]-7-



yl)ethanone


2,2,2-trifluoro-1-[1′-[4-(1-hydroxy-
2,2,2-trifluoro-1-(2,4,4-
4-(1-hydroxy-1-methyl-


1-methyl-ethyl)-3-methyl-benzoyl]-
trimethylspiro[3H-
ethyl)-3-methyl-benzoic


2,4,4-trimethyl-spiro[3H-
pyrrolo[1,2-a]pyrazine-
acid


pyrrolo[1,2-a]pyrazine-1,4′-
1,4′-piperidine]-7-


piperidine]-7-yl]ethanone
yl)ethanone


2,2,2-trifluoro-1-[1′-(4-isopropoxy-
2,2,2-trifluoro-1-(2,4,4-
4-isopropoxy-3-methyl-


3-methyl-benzoyl)-2,4,4-trimethyl-
trimethylspiro[3H-
benzoic acid


spiro[3H-pyrrolo[1,2-a]pyrazine-
pyrrolo[1,2-a]pyrazine-


1,4′-piperidine]-7-yl]ethanone
1,4′-piperidine]-7-



yl)ethanone


1-[1′-(3-chloro-4-methoxy-benzoyl)-
2,2,2-trifluoro-1-(2,4,4-
3-chloro-4-methoxy-


2,4,4-trimethyl-spiro[3H-
trimethylspiro[3H-
benzoic acid


pyrrolo[1,2-a]pyrazine-1,4′-
pyrrolo[1,2-a]pyrazine-


piperidine]-7-yl]-2,2,2-trifluoro-
1,4′-piperidine]-7-


ethanone
yl)ethanone


2,2,2-trifluoro-1-[1′-(2-fluoro-4-
2,2,2-trifluoro-1-(2,4,4-
2-fluoro-4-isopropoxy-


isopropoxy-benzoyl)-2,4,4-trimethyl-
trimethylspiro[3H-
benzoic acid


spiro[3H-pyrrolo[1,2-a]pyrazine-
pyrrolo[1,2-a]pyrazine-


1,4′-piperidine]-7-yl]ethanone
1,4′-piperidine]-7-



yl)ethanone


2,2,2-trifluoro-1-[1′-(4-methoxy-3-
2,2,2-trifluoro-1-(2,4,4-
4-methoxy-3-methyl-


methyl-benzoyl)-2,4,4-trimethyl-
trimethylspiro[3H-
benzoic acid


spiro[3H-pyrrolo[1,2-a]pyrazine-
pyrrolo[1,2-a]pyrazine-


1,4′-piperidine]-7-yl]ethanone
1,4′-piperidine]-7-



yl)ethanone


2,2,2-trifluoro-1-[1′-(5-isopropoxy-
2,2,2-trifluoro-1-(2,4,4-
5-isopropoxy-6-methyl-


6-methyl-pyridine-2-carbonyl)-2,4,4-
trimethylspiro[3H-
pyridine-2-carboxylic acid


trimethyl-spiro[3H-pyrrolo[1,2-
pyrrolo[1,2-a]pyrazine-


a]pyrazine-1,4′-piperidine]-7-
1,4′-piperidine]-7-


yl]ethanone
yl)ethanone


1-[1′-(3-chloro-4-isopropoxy-
2,2,2-trifluoro-1-(2,4,4-
3-chloro-4-isopropoxy-


benzoyl)-2,4,4-trimethyl-spiro[3H-
trimethylspiro[3H-
benzoic acid


pyrrolo[1,2-a]pyrazine-1,4′-
pyrrolo[1,2-a]pyrazine-


piperidine]-7-yl]-2,2,2-trifluoro-
1,4′-piperidine]-7-


ethanone
yl)ethanone


2,2,2-trifluoro-1-[1′-(3-fluoro-4-
2,2,2-trifluoro-1-(2,4,4-
3-fluoro-4-isopropoxy-


isopropoxy-benzoyl)-2,4,4-trimethyl-
trimethylspiro[3H-
benzoic acid


spiro[3H-pyrrolo[1,2-a]pyrazine-
pyrrolo[1,2-a]pyrazine-


1,4′-piperidine]-7-yl]ethanone
1,4′-piperidine]-7-



yl)ethanone


1-[1′-[4-(cyclopropylmethoxy)-3-
2,2,2-trifluoro-1-(2-
4-(cyclopropylmethoxy)-


fluoro-benzoyl]-2-methyl-spiro[3,4-
methylspiro[3,4-
3-fluoro-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-(cyclopropylmethoxy)-3-
1-(2-methylspiro[3,4-
4-(cyclopropylmethoxy)-


fluoro-benzoyl]-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
3-fluoro-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-(cyclopropylmethoxy)-3-
1-(3,3-dimethylspiro[2,4-
4-(cyclopropylmethoxy)-


fluoro-benzoyl]-3,3-dimethyl-
dihydropyrrolo[1,2-
3-fluoro-benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-yl]-
piperidine]-6-yl)-2,2,2-


2,2,2-trifluoro-ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(4-isopropoxy-
2,2,2-trifluoro-1-(2,4,4-
4-isopropoxy-3-methyl-


3-methyl-benzoyl)-2,4,4-trimethyl-
trimethylspiro[3H-
benzoic acid


spiro[3H-pyrrolo[1,2-a]pyrazine-
pyrrolo[1,2-a]pyrazine-


1,4′-piperidine]-6-yl]ethanone
1,4′-piperidine]-6-



yl)ethanone


2,2,2-trifluoro-1-[1′-[4-methoxy-3-
2,2,2-trifluoro-1-(2,4,4-
4-methoxy-3-


(trifluoromethyl)benzoyl]-2,4,4-
trimethylspiro[3H-
(trifluoromethyl)benzoic


trimethyl-spiro[3H-pyrrolo[1,2-
pyrrolo[1,2-a]pyrazine-
acid


a]pyrazine-1,4′-piperidine]-6-
1,4′-piperidine]-6-


yl]ethanone
yl)ethanone


2,2,2-trifluoro-1-[1′-(3-fluoro-4-
2,2,2-trifluoro-1-(2,4,4-
3-fluoro-4-isopropoxy-


isopropoxy-benzoyl)-2,4,4-trimethyl-
trimethylspiro[3H-
benzoic acid


spiro[3H-pyrrolo[1,2-a]pyrazine-
pyrrolo[1,2-a]pyrazine-


1,4′-piperidine]-6-yl]ethanone
1,4′-piperidine]-6-



yl)ethanone


(7,8-difluoro-3,3-dimethyl-spiro[2,4-
7,8-difluoro-3,3-dimethyl-
4-isopropoxy-3-methyl-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[2,4-
benzoic acid


piperidine]-1′-yl)-(4-isopropoxy-3-
dihydropyrrolo[1,2-


methyl-phenyl)methanone
a]pyrazine-1,4′-piperidine]


(7,8-difluoro-3,3-dimethyl-spiro[2,4-
7,8-difluoro-3,3-dimethyl-
4-isopentyloxybenzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
spiro[2,4-
acid


piperidine]-1′-yl)-(4-
dihydropyrrolo[1,2-


isopentyloxyphenyl)methanone
a]pyrazine-1,4′-piperidine]


2,2,2-trifluoro-1-[1′-(4-methoxy-3-
2,2,2-trifluoro-1-(2,4,4-
4-methoxy-3-methyl-


methyl-benzoyl)-2,4,4-trimethyl-
trimethylspiro[3H-
benzoic acid


spiro[3H-pyrrolo[1,2-a]pyrazine-
pyrrolo[1,2-a]pyrazine-


1,4′-piperidine]-6-yl]ethanone
1,4′-piperidine]-6-



yl)ethanone


1-[1′-[4-isopropoxy-3-
1-(2,4,4-
4-isopropoxy-3-


(trifluoromethyl)benzoyl]-2,4,4-
trimethylspiro[3H-
(trifluoromethyl)benzoic


trimethyl-spiro[3H-pyrrolo[1,2-
pyrrolo[1,2-a]pyrazine-
acid


a]pyrazine-1,4′-piperidine]-6-
1,4′-piperidine]-6-


yl]ethanone
yl)ethanone


1-[1′-[3-fluoro-4-(1-hydroxy-1-
1-(2,4,4-
3-fluoro-4-(1-hydroxy-1-


methyl-ethyl)benzoyl]-2,4,4-
trimethylspiro[3H-
methyl-ethyl)benzoic acid


trimethyl-spiro[3H-pyrrolo[1,2-
pyrrolo[1,2-a]pyrazine-


a]pyrazine-1,4′-piperidine]-6-
1,4′-piperidine]-6-


yl]ethanone
yl)ethanone


2,2,2-trifluoro-1-[1′-(4-isopropoxy-
2,2,2-trifluoro-1-(2,4,4-
4-isopropoxy-3-methoxy-


3-methoxy-benzoyl)-2,4,4-trimethyl-
trimethylspiro[3H-
benzoic acid


spiro[3H-pyrrolo[1,2-a]pyrazine-
pyrrolo[1,2-a]pyrazine-


1,4′-piperidine]-6-yl]ethanone
1,4′-piperidine]-6-



yl)ethanone


2,2,2-trifluoro-1-[1′-[3-fluoro-4-(1-
2,2,2-trifluoro-1-(2,4,4-
3-fluoro-4-(1-hydroxy-1-


hydroxy-1-methyl-ethyl)benzoyl]-
trimethylspiro[3H-
methyl-ethyl)benzoic acid


2,4,4-trimethyl-spiro[3H-
pyrrolo[1,2-a]pyrazine-


pyrrolo[1,2-a]pyrazine-1,4′-
1,4′-piperidine]-6-


piperidine]-6-yl]ethanone
yl)ethanone


1-[1′-(4-isopropoxy-3-methyl-
1-(2,4,4-
4-isopropoxy-3-methyl-


benzoyl)-2,4,4-trimethyl-spiro[3H-
trimethylspiro[3H-
benzoic acid


pyrrolo[1,2-a]pyrazine-1,4′-
pyrrolo[1,2-a]pyrazine-


piperidine]-6-yl]ethanone
1,4′-piperidine]-6-



yl)ethanone


1-[1′-(4-cyclohexylbenzoyl)-2,4,4-
1-(2,4,4-
4-cyclohexylbenzoic acid


trimethyl-spiro[3H-pyrrolo[1,2-
trimethylspiro[3H-


a]pyrazine-1,4′-piperidine]-6-
pyrrolo[1,2-a]pyrazine-


yl]ethanone
1,4′-piperidine]-6-



yl)ethanone


1-[1′-(4-hydroxy-3-methyl-benzoyl)-
2,2-dimethyl-1-(2-
4-hydroxy-3-methyl-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(3-chloro-4-hydroxy-benzoyl)-
2,2-dimethyl-1-(2-
3-chloro-4-hydroxy-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(4-methoxy-3-methyl-benzoyl)-
2,2-dimethyl-1-(2-
4-methoxy-3-methyl-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(3-chloro-4-methoxy-benzoyl)-
2,2-dimethyl-1-(2-
3-chloro-4-methoxy-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-[4-methoxy-3-
2,2-dimethyl-1-(2-
4-methoxy-3-


(trifluoromethyl)benzoyl]-2-methyl-
methylspiro[3,4-
(trifluoromethyl)benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-2,2-
a]pyrazine-1,4′-


dimethyl-propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-[4-isopropoxy-3-
2,2-dimethyl-1-(2-
4-isopropoxy-3-


(trifluoromethyl)benzoyl]-2-methyl-
methylspiro[3,4-
(trifluoromethyl)benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-2,2-
a]pyrazine-1,4′-


dimethyl-propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(2-fluoro-4-isopropoxy-
2,2-dimethyl-1-(2-
2-fluoro-4-isopropoxy-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(2-fluoro-4-methoxy-benzoyl)-
2,2-dimethyl-1-(2-
2-fluoro-4-methoxy-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


2,2-dimethyl-1-[2-methyl-1′-(3-
2,2-dimethyl-1-(2-
3-methyl-4-


methyl-4-methylsulfonyl-
methylspiro[3,4-
methylsulfonyl-benzoic


benzoyl)spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(3-fluoro-4-isopropoxy-
2,2-dimethyl-1-(2-
3-fluoro-4-isopropoxy-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(4-isopropylsulfonylbenzoyl)-2-
2,2-dimethyl-1-(2-
4-isopropylsulfonylbenzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-2,2-
dihydropyrrolo[1,2-


dimethyl-propan-1-one
a]pyrazine-1,4′-



piperidine]-6-yl)propan-1-



one


1-[1′-(4-isopentyloxybenzoyl)-2-
2,2-dimethyl-1-(2-
4-isopentyloxybenzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-2,2-
dihydropyrrolo[1,2-


dimethyl-propan-1-one
a]pyrazine-1,4′-



piperidine]-6-yl)propan-1-



one


1-[1′-(4-ethylsulfonyl-3-methyl-
2,2-dimethyl-1-(2-
4-ethylsulfonyl-3-methyl-


benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2-dimethyl-
a]pyrazine-1,4′-


propan-1-one
piperidine]-6-yl)propan-1-



one


2,2-dimethyl-1-[2-methyl-1′-[4-
2,2-dimethyl-1-(2-
4-


(trifluoromethylsulfonyl)benzoyl]spiro[3,
methylspiro[3,4-
(trifluoromethylsulfonyl)-


4-dihydropyrrolo[1,2-a]pyrazine-
dihydropyrrolo[1,2-
benzoic acid


1,4′-piperidine]-6-yl]propan-1-one
a]pyrazine-1,4′-



piperidine]-6-yl)propan-1-



one


1-[1′-[7-(difluoromethyl)-5-methyl-
2,2-dimethyl-1-(2-
7-(difluoromethyl)-5-


pyrazolo[1,5-a]pyrimidine-3-
methylspiro[3,4-
methyl-pyrazolo[1,5-


carbonyl]-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
a]pyrimidine-3-carboxylic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-
acid


piperidine]-6-yl]-2,2-dimethyl-
piperidine]-6-yl)propan-1-


propan-1-one
one


1-[1′-(4-isobutylsulfonylbenzoyl)-2-
2,2-dimethyl-1-(2-
4-isobutylsulfonylbenzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-2,2-
dihydropyrrolo[1,2-


dimethyl-propan-1-one
a]pyrazine-1,4′-



piperidine]-6-yl)propan-1-



one


1-[1′-[4-(1,1-
1-(3,3-dimethylspiro[2,4-
4-(1,1-


dimethylpropyl)benzoyl]-3,3-
dihydropyrrolo[1,2-
dimethylpropyl)benzoic


dimethyl-spiro[2,4-
a]pyrazine-1,4′-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)-2,2,2-


piperidine]-6-yl]-2,2,2-trifluoro-
trifluoro-ethanone


ethanone


1-[1′-[4-(1,1-
2,2,2-trifluoro-1-(2-
4-(1,1-


dimethylpropyl)benzoyl]-2-methyl-
methylspiro[3,4-
dimethylpropyl)benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-
a]pyrazine-1,4′-


2,2,2-trifluoro-ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-(1,1-diethylpropyl)benzoyl]-
1-(2-methylspiro[3,4-
4-(1,1-


2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
diethylpropyl)benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-(1,1-
1-(2-methylspiro[3,4-
4-(1,1-


dimethylpropyl)benzoyl]-2-methyl-
dihydropyrrolo[1,2-
dimethylpropyl)benzoic


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-
acid


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


1-[1′-[3-methoxy-4-(3,3,3-
1-(2-methylspiro[3,4-
3-methoxy-4-(3,3,3-


trifluoropropoxymethyl)benzoyl]-2-
dihydropyrrolo[1,2-
trifluoropropoxymethyl)-


methyl-spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-
benzoic acid


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


1-[1′-[3-methoxy-4-(2,2,2-
1-(2-methylspiro[3,4-
3-methoxy-4-(2,2,2-


trifluoroethoxymethyl)benzoyl]-2-
dihydropyrrolo[1,2-
trifluoroethoxymethyl)-


methyl-spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-
benzoic acid


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


2,2,2-trifluoro-1-[2-methyl-1′-[4-
2,2,2-trifluoro-1-(2-
4-(3,3,3-


(3,3,3-
methylspiro[3,4-
trifluoropropoxymethyl)-


trifluoropropoxymethyl)benzoyl]spiro[3,
dihydropyrrolo[1,2-
benzoic acid


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-


1,4′-piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[2-methyl-1′-[4-
2,2,2-trifluoro-1-(2-
4-(2,2,2-


(2,2,2-
methylspiro[3,4-
trifluoroethoxymethyl)-


trifluoroethoxymethyl)benzoyl]spiro[3,
dihydropyrrolo[1,2-
benzoic acid


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-


1,4′-piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[3-methoxy-4-
2,2,2-trifluoro-1-(2-
3-methoxy-4-(3,3,3-


(3,3,3-
methylspiro[3,4-
trifluoropropoxymethyl)-


trifluoropropoxymethyl)benzoyl]-2-
dihydropyrrolo[1,2-
benzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


2,2,2-trifluoro-1-[1′-[3-methoxy-4-
2,2,2-trifluoro-1-(2-
3-methoxy-4-(2,2,2-


(2,2,2-
methylspiro[3,4-
trifluoroethoxymethyl)-


trifluoroethoxymethyl)benzoyl]-2-
dihydropyrrolo[1,2-
benzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


1-[3,3-dimethyl-1′-[4-(3,3,3-
1-(3,3-dimethylspiro[2,4-
4-(3,3,3-


trifluoropropoxymethyl)benzoyl]spiro[2,
dihydropyrrolo[1,2-
trifluoropropoxymethyl)-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-
benzoic acid


1,4′-piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


1-[3,3-dimethyl-1′-[4-(2,2,2-
1-(3,3-dimethylspiro[2,4-
4-(2,2,2-


trifluoroethoxymethyl)benzoyl]spiro[2,
dihydropyrrolo[1,2-
trifluoroethoxymethyl)-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-
benzoic acid


1,4′-piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-[3-methoxy-4-
1-(3,3-dimethylspiro[2,4-
3-methoxy-4-(3,3,3-


(3,3,3-
dihydropyrrolo[1,2-
trifluoropropoxymethyl)-


trifluoropropoxymethyl)benzoyl]-
a]pyrazine-1,4′-
benzoic acid


3,3-dimethyl-spiro[2,4-
piperidine]-6-yl)-2,2,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
trifluoro-ethanone


piperidine]-6-yl]ethanone


2,2,2-trifluoro-1-[1′-[3-methoxy-4-
1-(3,3-dimethylspiro[2,4-
3-methoxy-4-(2,2,2-


(2,2,2-
dihydropyrrolo[1,2-
trifluoroethoxymethyl)-


trifluoroethoxymethyl)benzoyl]-3,3-
a]pyrazine-1,4′-
benzoic acid


dimethyl-spiro[2,4-
piperidine]-6-yl)-2,2,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
trifluoro-ethanone


piperidine]-6-yl]ethanone


1-[1′-[4-[bis(2,2,2-
1-(2-methylspiro[3,4-
4-[bis(2,2,2-


trifluoroethoxy)methyl]-3-chloro-
dihydropyrrolo[1,2-
trifluoroethoxy)methyl]-3-


benzoyl]-2-methyl-spiro[3,4-
a]pyrazine-1,4′-
chloro-benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)ethanone


piperidine]-6-yl]ethanone


2,2,2-trifluoro-1-[1′-(4-hydroxy-3-
1-(3,3-dimethylspiro[2,4-
4-hydroxy-3-methyl-


methyl-benzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


1-[1′-(3-chloro-4-hydroxy-benzoyl)-
1-(3,3-dimethylspiro[2,4-
3-chloro-4-hydroxy-


3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-[4-hydroxy-3-
1-(3,3-dimethylspiro[2,4-
4-hydroxy-3-


(trifluoromethyl)benzoyl]-3,3-
dihydropyrrolo[1,2-
(trifluoromethyl)benzoic


dimethyl-spiro[2,4-
a]pyrazine-1,4′-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-[4-hydroxy-3-
2,2,2-trifluoro-1-(2-
4-hydroxy-3-


(trifluoromethyl)benzoyl]-2-methyl-
methylspiro[3,4-
(trifluoromethyl)benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-hydroxy-3-
2,2-dimethyl-1-(2-
4-hydroxy-3-


(trifluoromethyl)benzoyl]-2-methyl-
methylspiro[3,4-
(trifluoromethyl)benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-2,2-
a]pyrazine-1,4′-


dimethyl-propan-1-one
piperidine]-6-yl)propan-1-



one


2,2,2-trifluoro-1-[1′-(3-hydroxy-4-
2,2,2-trifluoro-1-(2-
3-hydroxy-4-methyl-


methyl-benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-hydroxy-3,5-
2,2,2-trifluoro-1-(2-
4-hydroxy-3,5-dimethyl-


dimethyl-benzoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(2-fluoro-5-
2,2,2-trifluoro-1-(2-
2-fluoro-5-hydroxy-


hydroxy-benzoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[2-methyl-1′-(4-
2,2,2-trifluoro-1-(2-
4-tetrahydropyran-4-


tetrahydropyran-4-
methylspiro[3,4-
yloxybenzoic acid


yloxybenzoyl)spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(4-chloro-3-hydroxy-benzoyl)-
2,2,2-trifluoro-1-(2-
4-chloro-3-hydroxy-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(3-hydroxy-2-
2,2,2-trifluoro-1-(2-
3-hydroxy-2-methyl-


methyl-benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-fluoro-3-
2,2,2-trifluoro-1-(2-
4-fluoro-3-hydroxy-


hydroxy-benzoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-fluoro-3-
2,2,2-trifluoro-1-(2-
4-fluoro-3-methyl-benzoic


methyl-benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[1′-(4-chloro-3-methyl-benzoyl)-2-
2,2,2-trifluoro-1-(2-
4-chloro-3-methyl-benzoic


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3 4-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
4-(1-hydroxy-1-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
ethyl)benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[4-(1-hydroxy-1-
a]pyrazine-1,4′-piperidine]


methyl-ethyl)phenyl]methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
3-fluoro-4-(1-hydroxy-1-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
methyl-ethyl)benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[3-fluoro-4-(1-
a]pyrazine-1,4′-piperidine]


hydroxy-1-methyl-


ethyl)phenyl]methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
4-(1-hydroxycyclobutyl)-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-[4-(1-
a]pyrazine-1,4′-piperidine]


hydroxycyclobutyl)phenyl]methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
3-fluoro-4-(2-hydroxy-2-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
methyl-propyl)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-1′-yl]-[3-fluoro-4-(2-
a]pyrazine-1,4′-piperidine]


hydroxy-2-methyl-


propyl)phenyl]methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
4-methoxy-3-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-methoxy-3-
a]pyrazine-1,4′-piperidine]


methyl-phenyl)methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
4-ethoxy-3-methyl-benzoic


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(4-ethoxy-3-
a]pyrazine-1,4′-piperidine]


methyl-phenyl)methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
2-fluoro-4-isopropoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(2-fluoro-4-
a]pyrazine-1,4′-piperidine]


isopropoxy-phenyl)methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
4-(2,2,2-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
trifluoroethoxymethyl)-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
benzoic acid


piperidine]-1′-yl]-[4-(2,2,2-
a]pyrazine-1,4′-piperidine]


trifluoroethoxymethyl)phenyl]methanone


2,2,2-trifluoro-1-[2-methyl-1′-(5-
2,2,2-trifluoro-1-(2-
5-phenylpyridine-2-


phenylpyridine-2-carbonyl)spiro[3,4-
methylspiro[3,4-
carboxylic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[3,3-dimethyl-1′-(5-phenylpyridine-
1-(3,3-dimethylspiro[2,4-
5-phenylpyridine-2-


2-carbonyl)spiro[2,4-
dihydropyrrolo[1,2-
carboxylic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(3-methoxy-4-
2,2,2-trifluoro-1-(2-
3-methoxy-4-phenyl-


phenyl-benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(3-methoxy-4-
1-(3,3-dimethylspiro[2,4-
3-methoxy-4-phenyl-


phenyl-benzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(3-hydroxy-4-
2,2,2-trifluoro-1-(2-
3-hydroxy-4-phenyl-


phenyl-benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(3-hydroxy-4-
1-(3,3-dimethylspiro[2,4-
3-hydroxy-4-phenyl-


phenyl-benzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
benzoic acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(3-fluoro-4-
2,2,2-trifluoro-1-(2-
3-fluoro-4-phenyl-benzoic


phenyl-benzoyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(3-fluoro-4-
1-(3,3-dimethylspiro[2,4-
3-fluoro-4-phenyl-benzoic


phenyl-benzoyl)-3,3-dimethyl-
dihydropyrrolo[1,2-
acid


spiro[2,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[(3R)-1′-(2-fluoro-
1-[(3R)-2,3-
2-fluoro-4-isopropoxy-


4-isopropoxy-benzoyl)-2,3-dimethyl-
dimethylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


1-[(3R)-1′-(3-chloro-4-methoxy-
1-[(3R)-2,3-
3-chloro-4-methoxy-


benzoyl)-2,3-dimethyl-spiro[3,4-
dimethylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


2,2,2-trifluoro-1-[(3R)-1′-(4-
1-[(3R)-2,3-
4-methoxy-3-methyl-


methoxy-3-methyl-benzoyl)-2,3-
dimethylspiro[3,4-
benzoic acid


dimethyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


2,2,2-trifluoro-1-[(3R)-1′-[4-
1-[(3R)-2,3-
4-methoxy-3-


methoxy-3-
dimethylspiro[3,4-
(trifluoromethyl)benzoic


(trifluoromethyl)benzoyl]-2,3-
dihydropyrrolo[1,2-
acid


dimethyl-spiro[3,4-
a]pyrazine-1,4′-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl]-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[2-methyl-1′-[3-
2,2,2-trifluoro-1-(2-
3-methyl-4-


methyl-4-
methylspiro[3,4-
(trifluoromethyl)benzoic


(trifluoromethyl)benzoyl]spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-[4-ethoxy-3-
2,2,2-trifluoro-1-(2-
4-ethoxy-3-


(trifluoromethyl)benzoyl]-2-methyl-
methylspiro[3,4-
(trifluoromethyl)benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-
a]pyrazine-1,4′-


2,2,2-trifluoro-ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(5-isopropoxy-
2,2,2-trifluoro-1-(2-
5-isopropoxy-4-methyl-


4-methyl-pyridine-2-carbonyl)-2-
methylspiro[3,4-
pyridine-2-carboxylic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


[6-(cyclopropanecarbonyl)-2-methyl-
cyclopropyl-(2-
4-methoxy-3-


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
(trifluoromethyl)benzoic


a]pyrazine-1,4′-piperidine]-1′-yl]-[4-
dihydropyrrolo[1,2-
acid


methoxy-3-
a]pyrazine-1,4′-


(trifluoromethyl)phenyl]methanone
piperidine]-6-



yl)methanone


(3-chloro-4-methoxy-phenyl)-[6-
cyclopropyl-(2-
3-chloro-4-methoxy-


(cyclopropanecarbonyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-1′-
a]pyrazine-1,4′-


yl]methanone
piperidine]-6-



yl)methanone


(4-cyclohexylphenyl)-[6-
cyclopropyl-(2-
4-cyclohexylbenzoic acid


(cyclopropanecarbonyl)-2-methyl-
methylspiro[3,4-


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-1′-
a]pyrazine-1,4′-


yl]methanone
piperidine]-6-



yl)methanone


[6-(cyclopropanecarbonyl)-2-methyl-
cyclopropyl-(2-
4-isopropoxy-3-


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
(trifluoromethyl)benzoic


a]pyrazine-1,4′-piperidine]-1′-yl]-[4-
dihydropyrrolo[1,2-
acid


isopropoxy-3-
a]pyrazine-1,4′-



piperidine]-6-


(trifluoromethyl)phenyl]methanone
yl)methanone


2,2,2-trifluoro-1-[(3S)-1′-[4-
1-[(3S)-2,3-
4-methoxy-3-


methoxy-3-
dimethylspiro[3,4-
(trifluoromethyl)benzoic


(trifluoromethyl)benzoyl]-2,3-
dihydropyrrolo[1,2-
acid


dimethyl-spiro[3,4-
a]pyrazine-1,4′-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl]-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[(3S)-1′-(4-
1-[(3S)-2,3-
4-methoxy-3-methyl-


methoxy-3-methyl-benzoyl)-2,3-
dimethylspiro[3,4-
benzoic acid


dimethyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


1-[(3S)-1′-(3-chloro-4-methoxy-
1-[(3S)-2,3-
3-chloro-4-methoxy-


benzoyl)-2,3-dimethyl-spiro[3,4-
dimethylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


2,2,2-trifluoro-1-[(3S)-1′-(2-fluoro-
1-[(3S)-2,3-
2-fluoro-4-isopropoxy-


4-isopropoxy-benzoyl)-2,3-dimethyl-
dimethylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
4-(3,3,3-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
trifluoropropoxymethyl)-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
benzoic acid


piperidine]-1′-yl]-[4-(3,3,3-
a]pyrazine-1,4′-piperidine]


trifluoropropoxymethyl)phenyl]methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
3-methoxy-4-(2,2,2-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
trifluoroethoxymethyl)-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
benzoic acid


piperidine]-1′-yl]-[3-methoxy-4-
a]pyrazine-1,4′-piperidine]


(2,2,2-


trifluoroethoxymethyl)phenyl]methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
3-methoxy-4-(3,3,3-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
trifluoropropoxymethyl)-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
benzoic acid


piperidine]-1′-yl]-[3-methoxy-4-
a]pyrazine-1,4′-piperidine]


(3,3,3-


trifluoropropoxymethyl)phenyl]methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
4-(2-fluoro-2-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
propoxy)-3-methoxy-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
benzoic acid


piperidine]-1′-yl]-[4-(2-fluoro-2-
a]pyrazine-1,4′-piperidine]


methyl-propoxy)-3-methoxy-


phenyl]methanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
5-isopropoxy-4-methyl-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
pyridine-2-carboxylic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(5-isopropoxy-4-
a]pyrazine-1,4′-piperidine]


methyl-2-pyridyl)methanone


[6-(cyclopropanecarbonyl)-2-methyl-
cyclopropyl-(2-
4-methoxy-3-methyl-


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
benzoic acid


a]pyrazine-1,4′-piperidine]-1′-yl]-(4-
dihydropyrrolo[1,2-


methoxy-3-methyl-phenyl)methanone
a]pyrazine-1,4′-



piperidine]-6-



yl)methanone


[6-(cyclopropanecarbonyl)-2-methyl-
cyclopropyl-(2-
2-fluoro-4-isopropoxy-


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
benzoic acid


a]pyrazine-1,4′-piperidine]-1′-yl]-(2-
dihydropyrrolo[1,2-


fluoro-4-isopropoxy-
a]pyrazine-1,4′-


phenyl)methanone
piperidine]-6-



yl)methanone


[6-(cyclopropanecarbonyl)-2-methyl-
cyclopropyl-(2-
3-fluoro-4-(1-hydroxy-1-


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
methyl-ethyl)benzoic acid


a]pyrazine-1,4′-piperidine]-1′-yl]-[3-
dihydropyrrolo[1,2-


fluoro-4-(1-hydroxy-1-methyl-
a]pyrazine-1,4′-


ethyl)phenyl]methanone
piperidine]-6-



yl)methanone


[6-(cyclopropanecarbonyl)-2-methyl-
cyclopropyl-(2-
4-(3,3,3-


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
trifluoropropoxymethyl)-


a]pyrazine-1,4′-piperidine]-1′-yl-[4-
dihydropyrrolo[1,2-
benzoic acid


(3,3,3-
a]pyrazine-1,4′-


trifluoropropoxymethyl)phenyl]methanone
piperidine]-6-



yl)methanone


[6-(cyclopropanecarbonyl)-2-methyl-
cyclopropyl-(2-
4-isopropoxy-3-methyl-


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
benzoic acid


a]pyrazine-1,4′-piperidine]-1′-yl]-(4-
dihydropyrrolo[1,2-


isopropoxy-3-methyl-
a]pyrazine-1,4′-


phenyl)methanone
piperidine]-6-



yl)methanone


[6-(cyclopropanecarbonyl)-2-methyl-
cyclopropyl-(2-
3-fluoro-4-isopropoxy-


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
benzoic acid


a]pyrazine-1,4′-piperidine]-1′-yl]-(3-
dihydropyrrolo[1,2-


fluoro-4-isopropoxy-
a]pyrazine-1,4′-


phenyl)methanone
piperidine]-6-



yl)methanone


(3-chloro-4-hydroxy-phenyl)-[6-
cyclopropyl-(2-
3-chloro-4-hydroxy-


(cyclopropanecarbonyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-1′-
a]pyrazine-1,4′-


yl]methanone
piperidine]-6-



yl)methanone


(3-chloro-4-isopropoxy-phenyl)-[6-
cyclopropyl-(2-
3-chloro-4-isopropoxy-


(cyclopropanecarbonyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-1′-
a]pyrazine-1,4′-


yl]methanone
piperidine]-6-



yl)methanone


[6-(cyclopropanecarbonyl)-2-methyl-
cyclopropyl-(2-
4-hydroxy-3-methyl-


spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
benzoic acid


a]pyrazine-1,4′-piperidine]-1′-yl]-(4-
dihydropyrrolo[1,2-


hydroxy-3-methyl-phenyl)methanone
a]pyrazine-1,4′-



piperidine]-6-



yl)methanone


1-[1′-(4-methoxy-3-methyl-benzoyl)-
2-methyl-1-(2-
4-methoxy-3-methyl-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2-methyl-propan-1-
a]pyrazine-1,4′-


one
piperidine]-6-yl)propan-1-



one


1-[1′-[4-methoxy-3-
2-methyl-1-(2-
4-methoxy-3-


(trifluoromethyl)benzoyl]-2-methyl-
methylspiro[3,4-
(trifluoromethyl)benzoic


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-2-
a]pyrazine-1,4′-


methyl-propan-1-one
piperidine]-6-yl)propan-1-



one


1-[1′-(3-chloro-4-methoxy-benzoyl)-
2-methyl-1-(2-
3-chloro-4-methoxy-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2-methyl-propan-1-
a]pyrazine-1,4′-


one
piperidine]-6-yl)propan-1-



one


1-[1′-(4-hydroxy-3-methyl-benzoyl)-
2-methyl-1-(2-
4-hydroxy-3-methyl-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2-methyl-propan-1-
a]pyrazine-1,4′-


one
piperidine]-6-yl)propan-1-



one


1-[1′-(3-chloro-4-hydroxy-benzoyl)-
2-methyl-1-(2-
3-chloro-4-hydroxy-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2-methyl-propan-1-
a]pyrazine-1,4′-


one
piperidine]-6-yl)propan-1-



one


1-[1′-[3-fluoro-4-(1-hydroxy-1-
2-methyl-1-(2-
3-fluoro-4-(1-hydroxy-1-


methyl-ethyl)benzoyl]-2-methyl-
methylspiro[3,4-
methyl-ethyl)benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-yl]-2-
a]pyrazine-1,4′-


methyl-propan-1-one
piperidine]-6-yl)propan-1-



one


2-methyl-1-[2-methyl-1′-[4-(3,3,3-
2-methyl-1-(2-
4-(3,3,3-


trifluoropropoxymethyl)benzoyl]spiro[3,
methylspiro[3,4-
trifluoropropoxymethyl)-


4-dihydropyrrolo[1,2-a]pyrazine-
dihydropyrrolo[1,2-
benzoic acid


1,4′-piperidine]-6-yl]propan-1-one
a]pyrazine-1,4′-



piperidine]-6-yl)propan-1-



one


[1′-(4-methoxy-3-methyl-benzoyl)-2-
(2-methylspiro[3,4-
4-methoxy-3-methyl-


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
benzoic acid


a]pyrazine-1,4′-piperidine]-6-yl]-
a]pyrazine-1,4′-


phenyl-methanone
piperidine]-6-yl)-phenyl-



methanone


[1′-[4-methoxy-3-
(2-methylspiro[3,4-
4-methoxy-3-


(trifluoromethyl)benzoyl]-2-methyl-
dihydropyrrolo[1,2-
(trifluoromethyl)benzoic


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-
acid


a]pyrazine-1,4′-piperidine]-6-yl]-
piperidine]-6-yl)-phenyl-


phenyl-methanone
methanone


[1′-(3-chloro-4-methoxy-benzoyl)-2-
(2-methylspiro[3,4-
3-chloro-4-methoxy-


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
benzoic acid


a]pyrazine-1,4′-piperidine]-6-yl]-
a]pyrazine-1,4′-


phenyl-methanone
piperidine]-6-yl)-phenyl-



methanone


[1′-(4-hydroxy-3-methyl-benzoyl)-2-
(2-methylspiro[3,4-
4-hydroxy-3-methyl-


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
benzoic acid


a]pyrazine-1,4′-piperidine]-6-yl]-
a]pyrazine-1,4′-


phenyl-methanone
piperidine]-6-yl)-phenyl-



methanone


2,2,2-trifluoro-1-[1′-(6-isopropoxy-
2,2,2-trifluoro-1-(2-
6-isopropoxy-5-methyl-


5-methyl-pyridine-3-carbonyl)-2-
methylspiro[3,4-
pyridine-3-carboxylic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-hydroxy-3-
2,2,2-trifluoro-1-(2-
4-hydroxy-3-isopropyl-


isopropyl-benzoyl)-2-methyl-
methylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(5-ethylpyridine-2-carbonyl)-2-
2,2,2-trifluoro-1-(2-
5-ethylpyridine-2-


methyl-spiro[3,4-dihydropyrrolo[1,2-
methylspiro[3,4-
carboxylic acid


a]pyrazine-1,4′-piperidine]-6-yl]-
dihydropyrrolo[1,2-


2,2,2-trifluoro-ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[(3S)-1′-(3-chloro-4-hydroxy-
1-[(3S)-2,3-
3-chloro-4-hydroxy-


benzoyl)-2,3-dimethyl-spiro[3,4-
dimethylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


2,2,2-trifluoro-1-[(3S)-1′-(4-
1-[(3S)-2,3-
4-hydroxy-3-methyl-


hydroxy-3-methyl-benzoyl)-2,3-
dimethylspiro[3,4-
benzoic acid


dimethyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


2,2,2-trifluoro-1-[(3S)-1′-[3-fluoro-
1-[(3S)-2,3-
3-fluoro-4-(1-hydroxy-1-


4-(1-hydroxy-1-methyl-
dimethylspiro[3,4-
methyl-ethyl)benzoic acid


ethyl)benzoyl]-2,3-dimethyl-
dihydropyrrolo[1,2-


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl]-2,2,2-


yl]ethanone
trifluoro-ethanone


1-[(3S)-1′-(4-tert-
1-[(3S)-2,3-
4-tert-butylsulfonylbenzoic


butylsulfonylbenzoyl)-2,3-dimethyl-
dimethylspiro[3,4-
acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-yl]-
a]pyrazine-1,4′-


2,2,2-trifluoro-ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


1-[(3S)-1′-[2-
1-[(3S)-2,3-
2-


(difluoromethoxy)benzoyl]-2,3-
dimethylspiro[3,4-
(difluoromethoxy)benzoic


dimethyl-spiro[3,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl]-2,2,2-


ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[(3S)-1′-(3-fluoro-
1-[(3S)-2,3-
3-fluoro-4-isopropoxy-


4-isopropoxy-benzoyl)-2,3-dimethyl-
dimethylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


2,2,2-trifluoro-1-[(3S)-1′-(2-
1-[(3S)-2,3-
2-methoxy-3-methyl-


methoxy-3-methyl-benzoyl)-2,3-
dimethylspiro[3,4-
benzoic acid


dimethyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


1-[(3S)-2,3-dimethyl-1′-[4-(2,2,2-
1-[(3S)-2,3-
4-(2,2,2-


trifluoroethoxy)benzoyl]spiro[3,4-
dimethylspiro[3,4-
trifluoroethoxy)benzoic


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-
acid


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


1-[(3S)-2,3-dimethyl-1′-[4-(3,3,3-
1-[(3S)-2,3-
4-(3,3,3-


trifluoropropoxymethyl)benzoyl]spiro[3,
dimethylspiro[3,4-
trifluoropropoxymethyl)-


4-dihydropyrrolo[1,2-a]pyrazine-
dihydropyrrolo[1,2-
benzoic acid


1,4′-piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


2,2,2-trifluoro-1-[(3S)-1′-(3-fluoro-
1-[(3S)-2,3-
3-fluoro-2-methoxy-


2-methoxy-benzoyl)-2,3-dimethyl-
dimethylspiro[3,4-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


2,2,2-trifluoro-1-[(3S)-1′-(5-
1-[(3S)-2,3-
5-methoxy-6-methyl-


methoxy-6-methyl-pyridine-2-
dimethylspiro[3,4-
pyridine-2-carboxylic acid


carbonyl)-2,3-dimethyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(5-methoxy-6-
2,2,2-trifluoro-1-(2-
5-methoxy-6-methyl-


methyl-pyridine-2-carbonyl)-2-
methylspiro[3,4-
pyridine-2-carboxylic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(5-hydroxy-6-
2,2,2-trifluoro-1-(2-
5-hydroxy-6-methyl-


methyl-pyridine-2-carbonyl)-2-
methylspiro[3,4-
pyridine-2-carboxylic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(5-isopropoxy-6-methyl-
1-(2-methylspiro[3,4-
5-isopropoxy-6-methyl-


pyridine-2-carbonyl)-2-methyl-
dihydropyrrolo[1,2-
pyridine-2-carboxylic acid


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


1-[1′-(2-fluoro-4-isopropoxy-
1-(2-methylspiro[3,4-
2-fluoro-4-isopropoxy-


benzoyl)-2-methyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(5-
2,2,2-trifluoro-1-(2-
5-isobutoxypyridine-2-


isobutoxypyridine-2-carbonyl)-2-
methylspiro[3,4-
carboxylic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(5-
2,2,2-trifluoro-1-(2-
5-isopentyloxypyridine-2-


isopentyloxypyridine-2-carbonyl)-2-
methylspiro[3,4-
carboxylic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


[4-methoxy-3-
(1-methylcyclopropyl)-(2-
4-methoxy-3-


(trifluoromethyl)phenyl]-[2-methyl-6-
methylspiro[3,4-
(trifluoromethyl)benzoic


(1-
dihydropyrrolo[1,2-
acid


methylcyclopropanecarbonyl)spiro[3,
a]pyrazine-1,4′-


4-dihydropyrrolo[1,2-a]pyrazine-
piperidine]-6-


1,4′-piperidine]-1′-yl]methanone
yl)methanone


[2-methyl-6-(1-
(1-methylcyclopropyl)-(2-
4-(3,3,3-


methylcyclopropanecarbonyl)spiro[3,
methylspiro[3,4-
trifluoropropoxymethyl)-


4-dihydropyrrolo[1,2-a]pyrazine-
dihydropyrrolo[1,2-
benzoic acid


1,4′-piperidine]-1′-yl]-[4-(3,3,3-
a]pyrazine-1,4′-


trifluoropropoxymethyl)phenyl]methanone
piperidine]-6-



yl)methanone


2,2,2-trifluoro-1-[1′-[4-[1-hydroxy-
2,2,2-trifluoro-1-(2-
4-[1-hydroxy-2-(2,2,2-


2-(2,2,2-
methylspiro[3,4-
trifluoroethoxy)ethyl]-


trifluoroethoxy)ethyl]benzoyl]-2-
dihydropyrrolo[1,2-
benzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


2,2,2-trifluoro-1-[1′-[4-[2-hydroxy-
2,2,2-trifluoro-1-(2-
4-[2-hydroxy-1-(2,2,2-


1-(2,2,2-
methylspiro[3,4-
trifluoroethoxy)ethyl]-


trifluoroethoxy)ethyl]benzoyl]-2-
dihydropyrrolo[1,2-
benzoic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


2,2,2-trifluoro-1-[1′-(4-
1-(3,3-dimethylspiro[2,4-
4-isopropylsulfonylbenzoic


isopropylsulfonylbenzoyl)-3,3-
dihydropyrrolo[1,2-
acid


dimethyl-spiro[2,4-
a]pyrazine-1,4′-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


1-[3,3-dimethyl-1′-[4-
1-(3,3-dimethylspiro[2,4-
4-


(trifluoromethylsulfonyl)benzoyl]spiro[2,
dihydropyrrolo[1,2-
(trifluoromethylsulfonyl)-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-
benzoic acid


1,4′-piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


N-cyclopropyl-4-[3,3-dimethyl-6-
1-(3,3-dimethylspiro[2,4-
4-(cyclopropylsulfamoyl)-


(2,2,2-trifluoroacetyl)spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-1′-
piperidine]-6-yl)-2,2,2-


carbonyl]benzenesulfonamide
trifluoro-ethanone


1-[1′-(4-tert-butylsulfonylbenzoyl)-
1-(3,3-dimethylspiro[2,4-
4-tert-butylsulfonylbenzoic


3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[(3S)-1′-(4-
1-[(3S)-2,3-
4-isopropylsulfonylbenzoic


isopropylsulfonylbenzoyl)-2,3-
dimethylspiro[3,4-
acid


dimethyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


1-[(3S)-2,3-dimethyl-1′-[4-
1-[(3S)-2,3-
4-


(trifluoromethylsulfonyl)benzoyl]spiro[3,
dimethylspiro[3,4-
(trifluoromethylsulfonyl)-


4-dihydropyrrolo[1,2-a]pyrazine-
dihydropyrrolo[1,2-
benzoic acid


1,4′-piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


N-cyclopropyl-4-[(3S)-2,3-dimethyl-
1-[(3S)-2,3-
4-(cyclopropylsulfamoyl)-


6-(2,2,2-trifluoroacetyl)spiro[3,4-
dimethylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-
a]pyrazine-1,4′-


carbonyl]benzenesulfonamide
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


1-[1′-(5-cyclohexylpyridine-2-
2,2,2-trifluoro-1-(2-
5-cyclohexylpyridine-2-


carbonyl)-2-methyl-spiro[3,4-
methylspiro[3,4-
carboxylic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[5-(2-
2,2,2-trifluoro-1-(2-
5-(2-


fluorophenyl)pyridine-2-carbonyl]-2-
methylspiro[3,4-
fluorophenyl)pyridine-2-


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-
carboxylic acid


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[(3S)-1′-[4-(1-
1-[(3S)-2,3-
4-(1-hydroxy-1-methyl-


hydroxy-1-methyl-ethyl)benzoyl]-
dimethylspiro[3,4-
ethyl)benzoic acid


2,3-dimethyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl]-2,2,2-



trifluoro-ethanone


[4-(1-hydroxy-1-methyl-
(1-methylcyclopropyl)-(2-
4-(1-hydroxy-1-methyl-


ethyl)phenyl]-[2-methyl-6-(1-
methylspiro[3,4-
ethyl)benzoic acid


methylcyclopropanecarbonyl)spiro[3,
dihydropyrrolo[1,2-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-


1,4′-piperidine]-1′-yl]methanone
piperidine]-6-



yl)methanone


(5-methoxy-6-methyl-2-pyridyl)-[2-
(1-methylcyclopropyl)-(2-
5-methoxy-6-methyl-


methyl-6-(1-
methylspiro[3,4-
pyridine-2-carboxylic acid


methylcyclopropanecarbonyl)spiro[3,
dihydropyrrolo[1,2-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-


1,4′-piperidine]-1′-yl]methanone
piperidine]-6-



yl)methanone


(3-chloro-4-methoxy-phenyl)-[2-
(1-methylcyclopropyl)-(2-
3-chloro-4-methoxy-


methyl-6-(1-
methylspiro[3,4-
benzoic acid


methylcyclopropanecarbonyl)spiro[3,
dihydropyrrolo[1,2-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-


1,4′-piperidine]-1′-yl]methanone
piperidine]-6-



yl)methanone


(4-hydroxy-3-methyl-phenyl)-[2-
(1-methylcyclopropyl)-(2-
4-hydroxy-3-methyl-


methyl-6-(1-
methylspiro[3,4-
benzoic acid


methylcyclopropanecarbonyl)spiro[3,
dihydropyrrolo[1,2-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-


1,4′-piperidine]-1′-yl]methanone
piperidine]-6-



yl)methanone


N-cyclopropyl-4-[2-methyl-6-(1-
(1-methylcyclopropyl)-(2-
4-(cyclopropylsulfamoyl)-


methylcyclopropanecarbonyl)spiro[3,
methylspiro[3,4-
benzoic acid


4-dihydropyrrolo[1,2-a]pyrazine-
dihydropyrrolo[1,2-


1,4′-piperidine]-1′-
a]pyrazine-1,4′-


carbonyl]benzenesulfonamide
piperidine]-6-



yl)methanone


(3-chloro-4-hydroxy-phenyl)-[2-
(1-methylcyclopropyl)-(2-
3-chloro-4-hydroxy-


methyl-6-(1-
methylspiro[3,4-
benzoic acid


methylcyclopropanecarbonyl)spiro[3,
dihydropyrrolo[1,2-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-


1,4′-piperidine]-1′-yl]methanone
piperidine]-6-



yl)methanone


[2-methyl-6-(1-
(1-methylcyclopropyl)-(2-
4-


methylcyclopropanecarbonyl)spiro[3,
methylspiro[3,4-
(trifluoromethylsulfonyl)-


4-dihydropyrrolo[1,2-a]pyrazine-
dihydropyrrolo[1,2-
benzoic acid


1,4′-piperidine]-1′-yl]-[4-
a]pyrazine-1,4′-


(trifluoromethylsulfonyl)phenyl]methanone
piperidine]-6-



yl)methanone


[3-(hydroxymethyl)-4-isopropoxy-
(1-methylcyclopropyl)-(2-
3-(hydroxymethyl)-4-


phenyl]-[2-methyl-6-(1-
methylspiro[3,4-
isopropoxy-benzoic acid


methylcyclopropanecarbonyl)spiro[3,
dihydropyrrolo[1,2-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-


1,4′-piperidine]-1′-yl]methanone
piperidine]-6-



yl)methanone


(2-fluoro-4-isopropoxy-phenyl)-[2-
(1-methylcyclopropyl)-(2-
2-fluoro-4-isopropoxy-


methyl-6-(1-
methylspiro[3,4-
benzoic acid


methylcyclopropanecarbonyl)spiro[3,
dihydropyrrolo[1,2-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-


1,4′-piperidine]-1′-yl]methanone
piperidine]-6-



yl)methanone


(4-methoxy-3-methyl-phenyl)-[2-
(1-methylcyclopropyl)-(2-
4-methoxy-3-methyl-


methyl-6-(1-
methylspiro[3,4-
benzoic acid


methylcyclopropanecarbonyl)spiro[3,
dihydropyrrolo[1,2-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-


1,4′-piperidine]-1′-yl]methanone
piperidine]-6-



yl)methanone


[4-hydroxy-3-
(1-methylcyclopropyl)-(2-
4-hydroxy-3-


(trifluoromethyl)phenyl]-[2-methyl-6-
methylspiro[3,4-
(trifluoromethyl)benzoic


(1-
dihydropyrrolo[1,2-
acid


methylcyclopropanecarbonyl)spiro[3,
a]pyrazine-1,4′-


4-dihydropyrrolo[1,2-a]pyrazine-
piperidine]-6-


1,4′-piperidine]-1′-yl]methanone
yl)methanone


2,2,2-trifluoro-1-[1′-(5-methoxy-6-
1-(3,3-dimethylspiro[2,4-
5-methoxy-6-methyl-


methyl-pyridine-2-carbonyl)-3,3-
dihydropyrrolo[1,2-
pyridine-2-carboxylic acid


dimethyl-spiro[2,4-
a]pyrazine-1,4′-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


(4-tert-butylsulfonylphenyl)-[2-
(1-methylcyclopropyl)-(2-
4-tert-butylsulfonylbenzoic


methyl-6-(1-
methylspiro[3,4-
acid


methylcyclopropanecarbonyl)spiro[3,
dihydropyrrolo[1,2-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-


1,4′-piperidine]-1′-yl]methanone
piperidine]-6-



yl)methanone


1-[1′-(4-cyclopropylsulfonylbenzoyl)-
2,2,2-trifluoro-1-(2-
4-cyclopropylsulfonyl-


2-methyl-spiro[3,4-
methylspiro[3,4-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


1-[(3S)-1′-(4-
1-[(3S)-2,3-
4-cyclopropylsulfonyl-


cyclopropylsulfonylbenzoyl)-2,3-
dimethylspiro[3,4-
benzoic acid


dimethyl-spiro[3,4-
dihydropyrrolo[1,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl]-2,2,2-


ethanone
trifluoro-ethanone


1-[1′-(4-cyclopropylsulfonylbenzoyl)-
1-(3,3-dimethylspiro[2,4-
4-cyclopropylsulfonyl-


3,3-dimethyl-spiro[2,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


[4-[2-methyl-6-(2,2,2-
2,2,2-trifluoro-1-(2-
4-(trifluoromethyl-


trifluoroacetyl)spiro[3,4-
methylspiro[3,4-
sulfonyloxy)benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-carbonyl]phenyl]trifluoromethanesulfonate
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-methoxy-3-
1-(2,4-dimethylspiro[3,4-
4-methoxy-3-methyl-


methyl-benzoyl)-2,4-dimethyl-
dihydropyrrolo[1,2-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


1-[1′-(3-chloro-4-methoxy-benzoyl)-
1-(2,4-dimethylspiro[3,4-
3-chloro-4-methoxy-


2,4-dimethyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-[4-methoxy-3-
1-(2,4-dimethylspiro[3,4-
4-methoxy-3-


(trifluoromethyl)benzoyl]-2,4-
dihydropyrrolo[1,2-
(trifluoromethyl)benzoic


dimethyl-spiro[3,4-
a]pyrazine-1,4′-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(4-
1-(2,4-dimethylspiro[3,4-
4-isopentyloxybenzoic


isopentyloxybenzoyl)-2,4-dimethyl-
dihydropyrrolo[1,2-
acid


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(4-isopropoxy-
1-(2,4-dimethylspiro[3,4-
4-isopropoxy-3-methyl-


3-methyl-benzoyl)-2,4-dimethyl-
dihydropyrrolo[1,2-
benzoic acid


spiro[3,4-dihydropyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)-2,2,2-


yl]ethanone
trifluoro-ethanone


1-[2,4-dimethyl-1′-[4-(3,3,3-
1-(2,4-dimethylspiro[3,4-
4-(3,3,3-


trifluoropropoxymethyl)benzoyl]spiro[3,
dihydropyrrolo[1,2-
trifluoropropoxymethyl)-


4-dihydropyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-
benzoic acid


1,4′-piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


1-[1′-(3-chloro-4-isopropoxy-
1-(2,4-dimethylspiro[3,4-
3-chloro-4-isopropoxy-


benzoyl)-2,4-dimethyl-spiro[3,4-
dihydropyrrolo[1,2-
benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]-2,2,2-trifluoro-
piperidine]-6-yl)-2,2,2-


ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(5-isopropoxy-
1-(2,4-dimethylspiro[3,4-
5-isopropoxy-6-methyl-


6-methyl-pyridine-2-carbonyl)-2,4-
dihydropyrrolo[1,2-
pyridine-2-carboxylic acid


dimethyl-spiro[3,4-
a]pyrazine-1,4′-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(5-
1-(2,4-dimethylspiro[3,4-
5-isopentyloxypyridine-2-


isopentyloxypyridine-2-carbonyl)-
dihydropyrrolo[1,2-
carboxylic acid


2,4-dimethyl-spiro[3,4-
a]pyrazine-1,4′-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-(4-methoxy-3-
2,2,2-trifluoro-1-(4-
4-methoxy-3-methyl-


methyl-benzoyl)-4-methyl-spiro[3,4-
methylspiro[3,4-dihydro-
benzoic acid


dihydro-2H-pyrrolo[1,2-a]pyrazine-
2H-pyrrolo[1,2-


1,4′-piperidine]-6-yl]ethanone
a]pyrazine-1,4′-



piperidine]-6-yl)ethanone


1-[1′-(3-chloro-4-methoxy-benzoyl)-
2,2,2-trifluoro-1-(4-
3-chloro-4-methoxy-


4-methyl-spiro[3,4-dihydro-2H-
methylspiro[3,4-dihydro-
benzoic acid


pyrrolo[1,2-a]pyrazine-1,4′-
2H-pyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-
2,2,2-trifluoro-1-(4-
4-isopentyloxybenzoic


isopentyloxybenzoyl)-4-methyl-
methylspiro[3,4-dihydro-
acid


spiro[3,4-dihydro-2H-pyrrolo[1,2-
2H-pyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(4-isopropoxy-
2,2,2-trifluoro-1-(4-
4-isopropoxy-3-methyl-


3-methyl-benzoyl)-4-methyl-
methylspiro[3,4-dihydro-
benzoic acid


spiro[3,4-dihydro-2H-pyrrolo[1,2-
2H-pyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[4-methyl-1′-[4-
2,2,2-trifluoro-1-(4-
4-(3,3,3-


(3,3,3-
methylspiro[3,4-dihydro-
trifluoropropoxymethyl)-


trifluoropropoxymethyl)benzoyl]spiro[3,
2H-pyrrolo[1,2-
benzoic acid


4-dihydro-2H-pyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl)ethanone


yl]ethanone


2,2,2-trifluoro-1-[1′-(5-methoxy-6-
2,2,2-trifluoro-1-(4-
5-methoxy-6-methyl-


methyl-pyridine-2-carbonyl)-4-
methylspiro[3,4-dihydro-
pyridine-2-carboxylic acid


methyl-spiro[3,4-dihydro-2H-
2H-pyrrolo[1,2-


pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


1-[1′-(3-chloro-4-isopropoxy-
2,2,2-trifluoro-1-(4-
3-chloro-4-isopropoxy-


benzoyl)-4-methyl-spiro[3,4-dihydro-
methylspiro[3,4-dihydro-
benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
2H-pyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(5-
2,2,2-trifluoro-1-(4-
5-isopentyloxypyridine-2-


isopentyloxypyridine-2-carbonyl)-4-
methylspiro[3,4-dihydro-
carboxylic acid


methyl-spiro[3,4-dihydro-2H-
2H-pyrrolo[1,2-


pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(5-methoxy-6-
1-(2,4-dimethylspiro[3,4-
5-methoxy-6-methyl-


methyl-pyridine-2-carbonyl)-2,4-
dihydropyrrolo[1,2-
pyridine-2-carboxylic acid


dimethyl-spiro[3,4-
a]pyrazine-1,4′-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-[4-methoxy-3-
2,2,2-trifluoro-1-(4-
4-methoxy-3-


(trifluoromethyl)benzoyl]-4-methyl-
methylspiro[3,4-dihydro-
(trifluoromethyl)benzoic


spiro[3,4-dihydro-2H-pyrrolo[1,2-
2H-pyrrolo[1,2-
acid


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(5-isopropoxy-
2,2,2-trifluoro-1-(4-
5-isopropoxy-6-methyl-


6-methyl-pyridine-2-carbonyl)-4-
methylspiro[3,4-dihydro-
pyridine-2-carboxylic acid


methyl-spiro[3,4-dihydro-2H-
2H-pyrrolo[1,2-


pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-[4-(1-hydroxy-
1-(2,4-dimethylspiro[3,4-
4-(1-hydroxy-1-methyl-


1-methyl-ethyl)-3-methyl-benzoyl]-
dihydropyrrolo[1,2-
ethyl)-3-methyl-benzoic


2,4-dimethyl-spiro[3,4-
a]pyrazine-1,4′-
acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)-2,2,2-


piperidine]-6-yl]ethanone
trifluoro-ethanone


2,2,2-trifluoro-1-[1′-[4-(1-hydroxy-
2,2,2-trifluoro-1-(4-
4-(1-hydroxy-1-methyl-


1-methyl-ethyl)-3-methyl-benzoyl]-4-
methylspiro[3,4-dihydro-
ethyl)-3-methyl-benzoic


methyl-spiro[3,4-dihydro-2H-
2H-pyrrolo[1,2-
acid


pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl)ethanone


2,2,2-trifluoro-1-[1′-(5-isopropoxy-
2,2,2-trifluoro-1-(2-
5-isopropoxy-6-methoxy-


6-methoxy-pyridine-2-carbonyl)-2-
methylspiro[3,4-
pyridine-2-carboxylic acid


methyl-spiro[3,4-dihydropyrrolo[1,2-
dihydropyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl)ethanone


[8-chloro-2-methyl-6-
8-chloro-2-methyl-6-
5-isopropoxy-6-methoxy-


(trifluoromethyl)spiro[3,4-
(trifluoromethyl)spiro[3,4-
pyridine-2-carboxylic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-yl]-(5-isopropoxy-6-
a]pyrazine-1,4′-piperidine]


methoxy-2-pyridyl)methanone


2,2,2-trifluoro-1-[1′-[3-methoxy-4-
1-(2,4-dimethylspiro[3,4-
3-methoxy-4-[2-


[2-
dihydropyrrolo[1,2-
(trifluoromethoxy)ethoxy]benzoic


(trifluoromethoxy)ethoxy]benzoyl]-
a]pyrazine-1,4′-
acid


2,4-dimethyl-spiro[3,4-
piperidine]-6-yl)-2,2,2-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
trifluoro-ethanone


piperidine]-6-yl]ethanone


2,2,2-trifluoro-1-[1′-[3-methoxy-4-
2,2,2-trifluoro-1-(4-
3-methoxy-4-[2-


[2-
methylspiro[3,4-dihydro-
(trifluoromethoxy)ethoxy]benzoic


(trifluoromethoxy)ethoxy]benzoyl]-
2H-pyrrolo[1,2-
acid


4-methyl-spiro[3,4-dihydro-2H-
a]pyrazine-1,4′-


pyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)ethanone


piperidine]-6-yl]ethanone


2,2,2-trifluoro-1-[1′-[3-methoxy-4-
2,2,2-trifluoro-1-(2-
3-methoxy-4-[2-


[2-
methylspiro[3,4-
(trifluoromethoxy)ethoxy]benzoic


(trifluoromethoxy)ethoxy]benzoyl]-
dihydropyrrolo[1,2-
acid


2-methyl-spiro[3,4-
a]pyrazine-1,4′-


dihydropyrrolo[1,2-a]pyrazine-1,4′-
piperidine]-6-yl)ethanone


piperidine]-6-yl]ethanone


[4-[2,4-dimethyl-6-(2,2,2-
1-(2,4-dimethylspiro[3,4-
4-(trifluoromethyl-


trifluoroacetyl)spiro[3,4-
dihydropyrrolo[1,2-
sulfonyloxy)benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-1′-carbonyl]phenyl]trifluoromethanesulfonate
piperidine]-6-yl)-2,2,2-



trifluoro-ethanone


2,2,2-trifluoro-1-[(3S)-1′-(4-
2,2,2-trifluoro-1-[(3S)-3-
4-methoxy-3-methyl-


methoxy-3-methyl-benzoyl)-3-
methylspiro[3,4-dihydro-
benzoic acid


methyl-spiro[3,4-dihydro-2H-
2H-pyrrolo[1,2-


pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl]ethanone


1-[(3S)-1′-(3-chloro-4-methoxy-
2,2,2-trifluoro-1-[(3S)-3-
3-chloro-4-methoxy-


benzoyl)-3-methyl-spiro[3,4-dihydro-
methylspiro[3,4-dihydro-
benzoic acid


2H-pyrrolo[1,2-a]pyrazine-1,4′-
2H-pyrrolo[1,2-


piperidine]-6-yl]-2,2,2-trifluoro-
a]pyrazine-1,4′-


ethanone
piperidine]-6-yl]ethanone


2,2,2-trifluoro-1-[(3S)-1′-[4-
2,2,2-trifluoro-1-[(3S)-3-
4-methoxy-3-


methoxy-3-
methylspiro[3,4-dihydro-
(trifluoromethyl)benzoic


(trifluoromethyl)benzoyl]-3-methyl-
2H-pyrrolo[1,2-
acid


spiro[3,4-dihydro-2H-pyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl]ethanone


yl]ethanone


2,2,2-trifluoro-1-[(3S)-1′-(3-fluoro-
2,2,2-trifluoro-1-[(3S)-3-
3-fluoro-4-isopropoxy-


4-isopropoxy-benzoyl)-3-methyl-
methylspiro[3,4-dihydro-
benzoic acid


spiro[3,4-dihydro-2H-pyrrolo[1,2-
2H-pyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl]ethanone


1-[(3S)-1′-(4-tert-
2,2,2-trifluoro-1-[(3S)-3-
4-tert-butylsulfonylbenzoic


butylsulfonylbenzoyl)-3-methyl-
methylspiro[3,4-dihydro-
acid


spiro[3,4-dihydro-2H-pyrrolo[1,2-
2H-pyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-yl]-
a]pyrazine-1,4′-


2,2,2-trifluoro-ethanone
piperidine]-6-yl]ethanone


2,2,2-trifluoro-1-[(3S)-3-methyl-1′-
2,2,2-trifluoro-1-[(3S)-3-
4-(3,3,3-


[4-(3,3,3-
methylspiro[3,4-dihydro-
trifluoropropoxymethyl)-


trifluoropropoxymethyl)benzoyl]spiro[3,
2H-pyrrolo[1,2-
benzoic acid


4-dihydro-2H-pyrrolo[1,2-
a]pyrazine-1,4′-


a]pyrazine-1,4′-piperidine]-6-
piperidine]-6-yl]ethanone


yl]ethanone


2,2,2-trifluoro-1-[(3S)-1′-(5-
2,2,2-trifluoro-1-[(3S)-3-
5-methoxy-6-methyl-


methoxy-6-methyl-pyridine-2-
methylspiro[3,4-dihydro-
pyridine-2-carboxylic acid


carbonyl)-3-methyl-spiro[3,4-
2H-pyrrolo[1,2-


dihydro-2H-pyrrolo[1,2-a]pyrazine-
a]pyrazine-1,4′-


1,4′-piperidine]-6-yl]ethanone
piperidine]-6-yl]ethanone


2,2,2-trifluoro-1-[(3S)-1′-(2-fluoro-
2,2,2-trifluoro-1-[(3S)-3-
2-fluoro-4-isopropoxy-


4-isopropoxy-benzoyl)-3-methyl-
methylspiro[3,4-dihydro-
benzoic acid


spiro[3,4-dihydro-2H-pyrrolo[1,2-
2H-pyrrolo[1,2-


a]pyrazine-1,4′-piperidine]-6-
a]pyrazine-1,4′-


yl]ethanone
piperidine]-6-yl]ethanone


2,2,2-trifluoro-1-[(3S)-1′-(5-
2,2,2-trifluoro-1-[(3S)-3-
5-isopentyloxypyridine-2-


isopentyloxypyridine-2-carbonyl)-3-
methylspiro[3,4-dihydro-
carboxylic acid


methyl-spiro[3,4-dihydro-2H-
2H-pyrrolo[1,2-


pyrrolo[1,2-a]pyrazine-1,4′-
a]pyrazine-1,4′-


piperidine]-6-yl]ethanone
piperidine]-6-yl]ethanone


N-methyl-4-[2-methyl-6-(2,2,2-
2,2,2-trifluoro-1-(2-
4-[methyl(thiazol-2-


trifluoroacetyl)spiro[3,4-
methylspiro[3,4-
yl)sulfamoyl]benzoic acid


dihydropyrrolo[1,2-a]pyrazine-1,4′-
dihydropyrrolo[1,2-


piperidine]-1′-carbonyl]-N-thiazol-2-
a]pyrazine-1,4′-


yl-benzenesulfonamide
piperidine]-6-yl)ethanone


1-(1-(4-bromo-3-methylbenzoyl)-2′-
2,2,2-trifluoro-1-(2′-
4-bromo-3-methylbenzoic


methyl-3′,4′-dihydro-2′H-
methyl-3′,4′-dihydro-2′H-
acid


spiro[piperidine-4,1′-pyrrolo[1,2-
spiro[piperidine-4,1′-


a]pyrazine]-6′-yl)-2,2,2-
pyrrolo[1,2-a]pyrazine]-6′-


trifluoroethanone
yl)ethanone


(2-chloropyridin-3-yl)(2′-methyl-6′-
2′-methyl-6′-
2-chloronicotinic acid


(trifluoromethyl)-3′,4′-dihydro-2′H-
(trifluoromethyl)-3′,4′-


spiro[piperidine-4,1′-pyrrolo[1,2-
dihydro-2′H-


a]pyrazine]-1-yl)methanone
spiro[piperidine-4,1′-



pyrrolo[1,2-a]pyrazine]









1-(1-(4-Isopropoxy-3-methoxybenzoyl)-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-2′-yl)ethanone




Acetyl chloride (158 μL, 2.22 mmol) was added drop-wise to a mixture of (4-isopropoxy-3-methoxy-phenyl)-[6-(trifluoromethyl)spiro[3,4-dihydro-2H-pyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-yl]methanone (100 mg, 0.222 mmol) and pyridine (1 mL) at room temperature. The mixture was allowed to stir for 16 h at room temperature before it was partitioned between ethyl acetate and 1N HCl. The layers were separated and the organic layer was washed with 1N HCl, water, and then brine. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The residue was taken up in DMF and was purified by preparatory-HPLC (10-99% ACN/water with ammonium formate modifier) to give 1-[1′-(4-isopropoxy-3-methoxy-benzoyl)-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-2-yl]ethanone (60 mg, 53%) as a white solid. ESI-MS m/z calc. 493.2, found 494.7 (M+1)+; Retention time: 1.70 minutes (3 min run). 1H NMR (400 MHz, CDCl3) δ 7.06 (d, J=1.8 Hz, 1H), 7.05-6.98 (m, 1H), 6.88 (d, J=8.2 Hz, 1H), 6.55 (d, J=3.3 Hz, 1H), 6.15 (d, J=3.9 Hz, 1H), 4.57 (d, J=6.1 Hz, 1H), 4.19-4.10 (m, 2H), 3.88 (m, s, 5H), 3.79 (s, 2H), 3.70-3.52 (m, J=31.5 Hz, 2H), 3.11 (s, 2H), 2.24 (s, 3H), 1.92-1.75 (m, 2H), 1.38 (d, J=6.1 Hz, 6H).
The following compounds were synthesized using the procedure described above: methyl 1-(4-isopropoxy-3-methoxybenzoyl)-6′-(trifluoromethyl)-3′,4′-dihydro-2′H -spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-2′-carboxylate and ethyl 1-(4-isopropoxy-3-methoxybenzoyl)-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-2′-carboxylate.
2,2,2-Trifluoro-1-[1′-[4-(2-methoxy-3-pyridyl)-3-methyl-benzoyl]-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl]ethanone




To a microtube with Pd(dppf)Cl2 (5.5 mg, 0.075 mmol) was added 2-methoxypyridin-3-ylboronic acid (0.10 mmol) in NMP (0.2 mL), followed by a solution of 1-(1-(4-bromo-3-methylbenzoyl)-2′-methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)-2,2,2-trifluoroethanone (0.75 mmol) in DMF (0.3 mL) and aq. Na2CO3 (2M, 4 mmol). The reaction mixture was shaken at 80° C. for 16 h. Filtration followed by purification using preparatory-HPLC (1-99% ACN in water (HCl modifier)) gave 2,2,2-trifluoro-1-[1′-[4-(2-methoxy-3-pyridyl)-3-methyl-benzoyl]-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl]ethanone. ESI-MS m/z calc. 526.2, found 527.3 (M+1)+; Retention time: 1.38 minutes (3 min run).
The following compounds were synthesized using the procedure described above:

    5-[2-methyl-4-[2-methyl-6-(2,2,2-trifluoroacetyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carbonyl]phenyl]pyridine-2-carbonitrile,
    1-[1′-[4-(1-ethylimidazol-4-yl)-3-methyl-benzoyl]-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl]-2,2,2-trifluoro-ethanone,
    2,2,2-trifluoro-1-[2-methyl-1′-[3-methyl-4-(2-methyl-4-pyridyl)benzoyl]spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl]ethanone,
    2,2,2-trifluoro-1-[2-methyl-1′-[3-methyl-4-(1-methylpyrazol-3-yl)benzoyl]spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl]ethanone,
    2,2,2-trifluoro-1-[2-methyl-1′-[3-methyl-4-(1-methylpyrazol-4-yl)benzoyl]spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl]ethanone,
    2,2,2-trifluoro-1-[1′-[4-(4-methoxyphenyl)-3-methyl-benzoyl]-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl]ethanone,
    1-[1′-[4-(3-chlorophenyl)-3-methyl-benzoyl]-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl]-2,2,2-trifluoro-ethanone,
    2,2,2-trifluoro-1-[2-methyl-1′-[3-methyl-4-(2-methylpyrazol-3-yl)benzoyl]spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl]ethanone,
    N-[5-[2-methyl-4-[2-methyl-6-(2,2,2-trifluoroacetyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-carbonyl]phenyl]-2-pyridyl]acetamide,
    1-[1′-[4-[2-(dimethylamino)pyrimidin-5-yl]-3-methyl-benzoyl]-2-methyl-spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl]-2,2,2-trifluoro-ethanone,
    2,2,2-trifluoro-1-[2-methyl-1′-[3-methyl-4-[3-(trifluoromethyl)-1H-pyrazol-4-yl]benzoyl]spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl]ethanone, and
    2,2,2-trifluoro-1-[2-methyl-1′-(3-methyl-4-pyrimidin-5-yl-benzoyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-6-yl]ethanone.


(2-(3-Hydroxypyrrolidin-1-yl)pyridin-3-yl)(2′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-1-yl)methanone




A mixture of (2-Chloro-3-pyridyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-yl]methanone (0.1 mol) and pyrrolidin-3-ol (0.3 mmol) DMF (0.5 mL) was stirred at 80° C. for 16 h. Additional pyrrolidin-3-ol (0.5 mmol) was added and the mixture was stirred at 150° C. for 16 h. The mixture was filtered and was subjected to preparatory-HPLC (10-90% ACN in water) to give (2-(3-hydroxypyrrolidin-1-yl)pyridin-3-yl)(2′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-1-yl)methanone. ESI-MS m/z calc. 463.5, found 464.3 (M+1)+; Retention time: 0.75 minutes (3 min run).
The following compounds were synthesized using the procedure described above:
(2-(3-fluoropyrrolidin-1-yl)pyridin-3-yl)(2′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-1-yl)methanone and (2-(3,3-difluoropyrrolidin-1-yl)pyridin-3-yl)(2′-methyl-6′-(trifluoromethyl)-3′,4′-dihydro-2′H -spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-1-yl)methanone.
2,2,2-Trifluoro-1-(1-(3-methoxy-4-(prop-1-en-2-yloxy)benzoyl)-2′-methyl-3′,4′-dihydro-2′H-spiro[piperidine-4,1′-pyrrolo[1,2-a]pyrazine]-6′-yl)ethanone




Step 1:
4-Methyl morpholine (1.59 mL, 14.4 mmol) was added to a mixture of 2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]dihydrochloride (1.00 g, 2.89 mmol), 4-hydroxy-3-methoxy-benzoic acid (486 mg, 2.89 mmol), EDCI (831 mg, 4.33 mmol), HOBt (585 mg, 4.33 mmol) and DMF (10 mL) at room temperature. The mixture was heated at 60° C. overnight before it was cooled to room temperature and partitioned between ethyl acetate and 1N HCl. The layers were separated and the aqueous layer was extracted with ethyl acetate (3×). The combined organics were washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was subjected to column chromatography (0-100% ethyl acetate/hexanes) to give (4-hydroxy-3-methoxy-phenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-yl]methanone (690 mg, 58%). ESI-MS m/z calc. 423.2, found 424.1 (M+1)+; Retention time: 1.16 minutes (3 min run). 1H NMR (400 MHz, CD3CN) δ 7.04 (d, J=1.8 Hz, 1H), 6.94 (dd, J=8.1, 1.9 Hz, 1H), 6.87 (d, J=8.1 Hz, 1H), 6.82 (s, 1H), 6.62-6.56 (m, 1H), 6.05 (d, J =3.9 Hz, 1H), 4.35 (s, 1H), 4.00 (t, J=6.0 Hz, 2H), 3.89 (s, 3H), 3.64 (s, 2H), 3.36 (t, J=6.0 Hz, 2H), 3.29 (s, 1H), 2.36 (s, 3H), 2.16-2.04 (m, 2H), 1.81 (dd, J=17.1, 7.3 Hz, 2H).26-7.21 (m, 2H), 7.14 (t, J=8.1 Hz, 1H), 2.78 (d, J=1.4 Hz, 2H), 1.24 (d, J=0.8 Hz, 6H).
Step 2:
A mixture of Cs2CO3 (115 mg, 0.354 mmol), acetylacetone (12 μL, 0.12 mmol), CuCl (5.8 mg, 0.059 mmol) and THF (2.5 mL) in a vial was stirred at room temperature for 5 min before (4-hydroxy-3-methoxy-phenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-yl]methanone (100 mg, 0.236 mmol) then 2-bromoprop-1-ene (27 μL, 0.31 mmol) were added. The vial was capped and heated at 70° C. overnight. The mixture was cooled to room temperature, filtered and concentrated under reduced pressure. The residue was subjected to column chromatography (0-100% ethyl acetate/hexanes) to give (4-isopropenyloxy-3-methoxy-phenyl)-[2-methyl-6-(trifluoromethyl)spiro[3,4-dihydropyrrolo[1,2-a]pyrazine-1,4′-piperidine]-1′-yl]methanone (8.9 mg, 8%). ESI-MS m/z calc. 463.2, found 464.3 (M+1)+; Retention time: 1.47 minutes (3 min run). 1H NMR (400 MHz, CD3CN) δ 7.12 (d, J=1.8 Hz, 1H), 7.07 (d, J=8.0 Hz, 1H), 7.01 (dd, J=8.0, 1.8 Hz, 1H), 6.60 (d, J=3.4 Hz, 1H), 6.07 (d, J=3.7 Hz, 1H), 4.42 (s, 1H), 4.12 (dd, J=1.6, 0.9 Hz, 1H), 4.01 (t, J=6.0 Hz, 2H), 3.85 (s, 3H), 3.79 (d, J=1.7 Hz, 1H), 3.67-3.40 (m, 2H), 3.36 (t, J=5.6 Hz, 2H), 3.20 (s, 1H), 2.36 (s, 3H), 2.18 (s, 2H), 2.00 (d, J=0.7 Hz, 3H), 1.83 (s, 2H).
Table 2 below recites the analytical data for the compounds of Table 1.










TABLE 2





Cmpd.
LC/MS
LC/RT



No.
M + 1
min
NMR


















1
454.50
1.61
1H NMR (400 MHz, DMSO) δ 7.89 (d, J = 8.0 Hz, 1H),





7.59-7.45 (m, 2H), 6.58 (d, J = 3.7 Hz, 1H), 6.12 (d, J = 3.9 Hz,





1H), 4.45-4.27 (m, 1H), 3.93 (t, J = 5.8 Hz,





2H), 3.57-3.43 (m, 1H), 3.43-3.01 (m, 5H), 2.65 (s,





3H), 2.27 (s, 3H), 2.23-1.65 (m, 4H), 1.17 (d, J = 6.8 Hz,





6H).


2
498.20
2.57
1H NMR (400 MHz, DMSO) δ 7.11-6.97 (m, 3H),





6.65 (d, J = 3.5 Hz, 1H), 6.33 (d, J = 3.9 Hz, 1H),





4.98-4.69 (m, 1H), 4.67-4.54 (m, 1H), 4.09-3.98 (m, 1H),





3.90-3.81 (m, 1H), 3.77 (s, 3H), 3.74-3.52 (m, 2H),





3.46-3.35 (m, 1H), 3.34-3.30 (m, 2H), 3.26-3.08 (m, 1H),





2.32 (s, 3H), 2.14-1.82 (m, 2H), 1.27 (d, J = 6.0 Hz,





6H).


3
484.40
2.83


4
466.30
1.63


5
408.20
2.38


6
478.50
1.55
1H NMR (400 MHz, DMSO) δ 7.83 (d, J = 8.0 Hz, 1H),





7.63-7.54 (m, 1H), 7.52-7.39 (m, 2H), 6.58 (d, J = 3.7 Hz,





1H), 6.12 (d, J = 3.9 Hz, 1H), 4.43-4.26 (m, 1H),





3.93 (t, J = 5.6 Hz, 2H), 3.48-3.19 (m, 4H),





3.19-3.01 (m, 1H), 2.59 (s, 3H), 2.45 (d, J = 4.6 Hz, 3H), 2.27 (s,





3H), 2.23-2.12 (m, 1H), 2.06-1.96 (m, 1H),





1.85-1.70 (m, 2H).


7
485.50
1.24


8
546.70
1.64


9
500.50
1.51


10
416.50
1.05
1H NMR (400 MHz, DMSO) δ 7.50 (d, J = 2.1 Hz, 1H),





7.36 (dd, J = 8.5, 2.1 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H),





5.99 (d, J = 3.5 Hz, 1H), 5.93 (d, J = 3.6 Hz, 1H),





4.78-4.64 (m, 1H), 4.38-4.03 (m, 1H), 3.78 (t, J = 5.8 Hz,





2H), 3.63 (q, J = 11.2 Hz, 2H), 3.55-3.03 (m, 5H),





2.24 (s, 3H), 2.12-1.91 (m, 2H), 1.79-1.62 (m, 2H),





1.31 (d, J = 6.0 Hz, 6H).


11
484.50
1.32


12
462.50
1.64
1H NMR (400 MHz, DMSO) δ 7.83 (d, J = 8.0 Hz, 1H),





7.57 (q, J = 4.9 Hz, 1H), 7.50-7.41 (m, 2H), 6.57 (s,





1H), 6.19 (d, J = 4.0 Hz, 1H), 4.36 (d, J = 12.5 Hz, 1H),





3.98 (t, J = 5.7 Hz, 2H), 3.44-3.33 (m, 2H),





3.31-3.22 (m, 2H), 3.11 (t, J = 12.6 Hz, 1H), 2.59 (s, 3H), 2.45 (d,





J = 4.9 Hz, 3H), 2.28 (s, 3H), 2.19 (d, J = 12.9 Hz, 1H),





2.06-1.99 (m, 1H), 1.80 (t, J = 12.6 Hz, 2H).


13
535.50
1.40


14
464.50
1.47


15
465.50
1.35


16
510.70
1.74


17
548.50
1.73


18
454.50
2.97


19
442.50
1.26


20
414.18
2.84


21
509.50
1.36


22
437.10
1.27


23
510.50
2.68


24
451.20
1.73


25
420.22
2.21


26
434.50
1.54


27
470.50
1.70
1H NMR (400 MHz, DMSO) δ 8.10 (d, J = 1.7 Hz, 1H),





7.91 (d, J = 7.9 Hz, 1H), 7.50-7.39 (m, 2H), 6.59 (d, J = 3.6 Hz,





1H), 6.13 (d, J = 3.8 Hz, 1H), 4.36 (d, J = 12.3 Hz,





1H), 3.93 (t, J = 5.2 Hz, 2H), 3.48-3.25 (m, 4H),





3.12 (t, J = 11.7 Hz, 1H), 2.59 (s, 3H), 2.28 (s, 3H),





2.23-2.10 (m, 2H), 2.07-1.95 (m, 1H), 1.86-1.68 (m, 2H),





0.51-0.42 (m, 2H), 0.38-0.30 (m, 2H).


28
511.70
1.23
1H NMR (400 MHz, CDCl3) δ 7.04-7.00 (m, 1H),





6.97 (dd, J = 8.2, 1.6 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H),





6.52 (d, J = 3.6 Hz, 1H), 5.98-5.86 (m, 1H), 4.72-4.26 (m,





2H), 3.88 (s, 3H), 3.86-3.07 (m, 6H), 2.46-1.88 (m,





6H), 1.71-1.46 (m, 1H), 1.38 (d, J = 6.1 Hz, 6H),





1.34-1.12 (m, 3H).


29
480.30
1.70


30
458.30
1.45


31
428.50
1.22


32
430.23
2.75
1H NMR (400 MHz, CDCl3) δ 8.00-7.94 (m, 2H),





7.61-7.55 (m, 2H), 7.22 (dd, J = 4.3, 2.1 Hz, 1H), 6.17 (d, J = 4.4 Hz,





1H), 4.91 (s, 1H), 4.63 (d, J = 12.5 Hz, 1H),





4.36 (t, J = 5.8 Hz, 2H), 3.64-3.41 (m, 2H), 3.34 (t, J = 5.7 Hz,





2H), 3.31-3.21 (m, 1H), 2.41 (s, 3H),





2.32-2.18 (m, 2H), 2.08 (d, J = 10.2 Hz, 1H), 1.95 (t, J = 12.2 Hz,





1H), 1.74 (t, J = 11.1 Hz, 1H), 0.68-0.60 (m, 4H).


33
525.50
1.41


34
424.24
2.33
1H NMR (400 MHz, DMSO) δ 7.54-7.39 (m, 1H),





7.22-7.09 (m, 2H), 6.60 (d, J = 3.6 Hz, 1H), 6.10 (s, 1H),





5.20-4.36 (m, 3H), 4.19-3.99 (m, 1H), 3.92-3.37 (m,





4H), 3.20-2.93 (m, 2H), 2.54 (s, 3H), 2.35-2.14 (m,





4H), 1.95-1.64 (m, 1H), 1.51 (s, 6H).


35
468.20
4.64


36
430.19
2.11
1H NMR (400 MHz, DMSO) δ 7.51 (d, J = 2.0 Hz, 1H),





7.37 (dd, J = 8.5, 2.0 Hz, 1H), 7.21 (d, J = 8.6 Hz, 1H),





6.60 (d, J = 3.8 Hz, 1H), 6.16 (d, J = 3.9 Hz, 1H),





4.86-4.60 (m, 1H), 4.48-4.08 (m, 1H), 3.70 (s, 2H),





3.62-2.81 (m, 3H), 2.09 (s, 1H), 1.89-1.61 (m, 4H), 1.31 (d,





J = 6.0 Hz, 6H), 1.09 (s, 6H).


37
484.40
1.54


38
446.26
2.26


39
458.70
1.53


40
482.50
1.56


41
532.50
1.62


42
408.50
1.24


43
456.50
1.42


44
450.30
1.10


45
436.20
2.13


46
494.30
1.69


47
476.50
1.52


48
534.20
1.25


49
429.70
1.17


50
464.50
1.42


51
489.50
1.54


52
510.70
1.64


53
511.70
1.28


54
476.50
1.76


55
496.20
1.79


56
438.28
2.52


57
454.50
1.51


58
458.40
1.55


59
534.50
2.04
1H NMR (400 MHz, DMSO) δ 7.04-6.87 (m, 3H),





6.57 (d, J = 3.5 Hz, 1H), 6.07 (d, J = 3.9 Hz, 1H),





4.66-4.52 (m, 1H), 4.04-3.83 (m, 2H), 3.77 (s, 3H),





3.60-3.12 (m, 5H), 2.33-2.21 (m, 4H), 2.17-1.65 (m, 3H),





1.42 (d, J = 7.0 Hz, 3H), 1.26 (d, J = 6.0 Hz, 6H).


60
480.40
3.01


61
518.20
1.17


62
476.50
1.81


63
393.50
0.99


64
518.30
1.66


65
446.17
2.37


66
460.50
1.64


67
422.50
1.51


68
450.14
2.52


69
504.50
1.54


70
450.50
1.46


71
496.70
1.69


72
548.30
1.28


73
400.20
2.57


74
478.20
0.98
1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.2 Hz, 2H),





7.40 (d, J = 8.2 Hz, 2H), 6.49 (s, 1H), 4.71 (s, 2H),





4.63 (s, 1H), 3.98 (s, 2H), 3.86 (q, J = 8.7 Hz, 2H), 3.57 (s,





1H), 3.47 (s, 1H), 3.30 (s, 2H), 3.19 (s, 1H), 2.47 (s,





1H), 2.41 (d, J = 24.3 Hz, 4H), 2.16-2.02 (m, 1H),





2.01 (s, 1H), 1.91 (s, 1H), 1.56 (s, 2H), 1.25 (s, 1H).


75
524.00
1.69
1H NMR (400 MHz, DMSO) δ 8.07-7.95 (m, 1H),





7.95-7.81 (m, 2H), 7.76-7.61 (m, 2H), 6.62 (d, J = 4.0 Hz,





1H), 6.12 (d, J = 4.0 Hz, 1H), 4.45-4.30 (m, 1H),





3.57-3.08 (m, 3H), 2.97-2.85 (m, 2H), 2.85-2.74 (m, 1H),





2.20-2.07 (m, 1H), 2.01-1.66 (m, 4H), 1.43 (d, J = 6.7 Hz,





6H), 0.56-0.32 (m, 4H).


76
511.50
4.41
1H NMR (400 MHz, DMSO) δ 7.51 (d, J = 2.0 Hz, 1H),





7.37 (dd, J = 8.5, 2.0 Hz, 1H), 7.21 (d, J = 8.6 Hz, 1H),





6.61 (d, J = 4.0 Hz, 1H), 6.11 (d, J = 4.0 Hz, 1H),





4.81-4.66 (m, 1H), 4.41-4.16 (m, 1H), 3.58-2.99 (m, 3H),





2.91 (d, J = 5.8 Hz, 2H), 2.77 (t, J = 7.1 Hz, 1H),





1.99-1.68 (m, 4H), 1.43 (s, 6H), 1.31 (d, J = 6.0 Hz, 6H).


77
484.50
6.20


78
444.20
2.34


79
446.50
1.59
1H NMR (400 MHz, DMSO) δ 7.19 (d, J = 7.6 Hz, 1H),





6.96 (s, 1H), 6.93 (d, J = 7.8 Hz, 1H), 6.56 (d, J = 3.7 Hz,





1H), 6.09 (d, J = 3.9 Hz, 1H), 4.33-4.15 (m, 1H),





3.97-3.87 (m, 2H), 3.81 (s, 3H), 3.48 (t, J = 5.5 Hz,





2H), 3.46-3.32 (m, 4H), 3.25 (s, 3H), 3.23-3.08 (m,





1H), 2.70-2.61 (m, 2H), 2.57 (q, J = 7.5 Hz, 2H),





2.29-1.98 (m, 2H), 1.90-1.63 (m, 2H), 1.13 (t, J = 7.5 Hz,





3H).


80
480.50
1.57
1H NMR (400 MHz, DMSO) δ 7.07-6.91 (m, 3H),





6.60 (d, J = 3.7 Hz, 1H), 6.18-6.04 (m, 1H), 5.14-4.73 (m,





1H), 4.66-4.58 (m, 1H), 4.57-4.19 (m, 1H),





4.19-3.99 (m, 1H), 3.93-3.71 (m, 5H), 3.59-3.43 (m, 1H),





3.40-3.26 (m, 2H), 3.14-2.97 (m, 1H), 2.30 (s, 3H),





2.26-2.12 (m, 1H), 1.94-1.75 (m, 1H), 1.27 (d, J = 6.0 Hz,





6H).


81
484.40
5.39


82
446.26
2.37


83
452.20
1.16


84
436.50
1.06
1H NMR (400 MHz, CDCl3) δ 7.06-6.98 (m, 3H),





6.91 (dd, J = 8.1, 1.9 Hz, 1H), 6.00 (d, J = 4.3 Hz, 1H),





4.57 (s, 1H), 4.31 (t, J = 6.0 Hz, 2H), 3.83 (s, 3H), 3.65 (s,





1H), 3.53 (s, 1H), 3.26 (t, J = 6.0 Hz, 2H), 3.26 (s, 1H),





2.42-2.37 (m, 3H), 2.27-2.00 (m, 2H), 1.90 (s, 1H),





1.73 (s, 1H), 1.36 (s, 9H), 1.35 (s, 9H).


85
496.70
1.51


86
432.26
2.02


87
448.20
1.69
1H NMR (400 MHz, DMSO) δ 7.07-6.90 (m, 3H),





6.60 (d, J = 3.8 Hz, 1H), 6.18-6.03 (m, 1H), 5.14-4.74 (m,





1H), 4.67-4.52 (m, 1H), 4.54-4.14 (m, 1H),





4.18-3.94 (m, 1H), 3.89-3.69 (m, 5H), 3.60-3.37 (m, 1H),





3.37-3.27 (m, 2H), 3.17-2.99 (m, 1H), 2.30 (s, 3H),





2.25-2.08 (m, 1H), 1.96-1.71 (m, 1H), 1.27 (d, J = 6.0 Hz,





6H).


88
484.40
5.32
1H NMR (400 MHz, DMSO) δ 7.30 (d, J = 8.8 Hz, 2H),





7.05 (d, J = 4.2 Hz, 1H), 6.92 (d, J = 8.8 Hz, 2H),





6.16 (d, J = 4.2 Hz, 1H), 4.19 (t, J = 5.9 Hz, 2H),





4.12-3.56 (m, 1H), 3.38-3.29 (m, 2H), 3.27-3.16 (m, 7H),





2.73 (q, J = 7.4 Hz, 2H), 2.27 (s, 3H), 2.15-1.98 (m, 2H),





1.85-1.66 (m, 2H), 1.66-1.50 (m, 6H), 1.04 (t, J = 7.4 Hz,





3H).


89
449.20
1.07
1H NMR (400 MHz, CDCl3) δ 7.25-7.18 (m, 1H),





7.08-6.98 (m, 2H), 6.97-6.88 (m, 1H), 6.25-6.10 (m, 1H),





4.59 (s, 1H), 4.37 (s, 2H), 3.84 (s, 3H), 3.75 (s, 1H),





3.51 (s, 1H), 3.35 (s, 1H), 3.35 (s, 2H), 2.42 (s, 3H),





2.16 (s, 2H), 1.87 (s, 2H), 1.37 (s, 9H).


90
508.70
1.52


91
470.50
1.49


92
422.29
2.67


93
526.30
1.65


94
515.29
2.43
1H NMR (400 MHz, CDCl3) δ 7.63 (t, J = 8.1 Hz, 1H),





7.19 (dd, J = 8.0, 1.6 Hz, 1H), 7.12 (dd, J = 11.9, 1.6 Hz,





1H), 6.49 (s, 1H), 4.60 (s, 1H), 3.99 (s, 2H), 3.72 (q,





J = 7.0 Hz, 3H), 3.37 (t, J = 80.3 Hz, 5H), 2.43 (d, J = 16.6 Hz,





5H), 2.25-1.83 (m, 3H), 1.65 (d, J = 0.8 Hz,





7H), 1.29-1.20 (m, 5H).


95
488.50
1.46
1H NMR (400 MHz, DMSO) δ 7.28-7.22 (m, 2H),





6.95 (d, J = 8.5 Hz, 1H), 6.58-6.52 (m, 1H), 6.18 (d, J = 4.0 Hz,





1H), 4.54 (t, J = 5.2 Hz, 1H), 4.47-4.13 (m, 1H),





4.07 (t, J = 6.2 Hz, 2H), 3.97 (t, J = 5.7 Hz, 2H), 3.62 (s,





1H), 3.62-3.54 (m, 2H), 3.33 (s, 2H), 3.30-3.03 (m,





2H), 2.28 (s, 3H), 2.16 (s, 3H), 2.14-2.00 (m, 2H),





1.88 (q, J = 6.2 Hz, 2H), 1.81-1.67 (m, 2H).


96
516.50
1.44


97
478.20
1.01
1H NMR (400 MHz, DMSO) δ 7.47 (d, J = 8.7 Hz, 1H),





7.24-7.09 (m, 2H), 6.57 (d, J = 3.2 Hz, 1H), 6.12 (d, J = 3.9 Hz,





1H), 4.97 (s, 1H), 4.45-4.25 (m, 1H), 3.92 (t,





J = 5.2 Hz, 2H), 3.60-2.97 (m, 5H), 2.54 (s, 3H),





2.27 (s, 3H), 2.21-1.95 (m, 2H), 1.85-1.63 (m, 2H), 1.50 (s,





6H).


98
450.50
1.21


99
408.10
1.20


100
470.50
1.58
1H NMR (400 MHz, DMSO) δ 7.36 (d, J = 8.2 Hz, 2H),





7.28 (d, J = 8.2 Hz, 2H), 7.27-7.18 (m, 1H), 6.49 (d, J = 4.6 Hz,





1H), 4.50-4.18 (m, 3H), 3.54-2.99 (m, 5H),





2.58-2.47 (m, 1H), 2.30 (s, 3H), 2.26-1.91 (m, 2H),





1.91-1.65 (m, 7H), 1.50-1.16 (m, 5H).


101
488.50
1.84
1H NMR (400 MHz, CDCl3) δ 7.47-7.41 (m, 2H),





7.38 (d, J = 8.2 Hz, 2H), 6.48 (s, 1H), 4.64 (d, J = 10.0 Hz,





1H), 4.56 (s, 2H), 3.98 (s, 2H), 3.71 (t, J = 6.6 Hz, 2H),





3.58 (s, 1H), 3.46 (s, 1H), 3.29 (s, 2H), 3.18 (s, 1H),





2.61-2.28 (m, 7H), 2.17-2.02 (m, 1H), 2.01 (s, 1H),





1.88 (d, J = 12.1 Hz, 1H), 1.60 (s, 1H).


102
538.00
1.81


103
546.70
1.63


104
420.10
2.45
1H NMR (400 MHz, DMSO) δ 7.06-6.90 (m, 3H),





6.60 (d, J = 3.5 Hz, 1H), 6.17-6.05 (m, 1H), 5.11-4.71 (m,





1H), 4.65-4.55 (m, 1H), 4.53-4.25 (m, 1H),





4.14-4.03 (m, 1H), 3.88-3.69 (m, 5H), 3.58-3.43 (m, 1H),





3.41-3.28 (m, 2H), 3.15-3.06 (m, 1H), 2.30 (s, 3H),





2.27-2.10 (m, 1H), 2.00-1.69 (m, 1H), 1.27 (d, J = 6.0 Hz,





6H).


105
484.60
4.79
1H NMR (400 MHz, DMSO) δ 7.26-7.19 (m, 2H),





6.96 (d, J = 9.2 Hz, 1H), 6.57 (d, J = 3.8 Hz, 1H), 6.13 (d, J = 3.9 Hz,





1H), 4.71-4.56 (m, 1H), 4.32-3.90 (m, 1H),





3.79 (t, J = 6.0 Hz, 2H), 3.70-3.18 (m, 5H),





3.18-3.02 (m, 1H), 2.19-1.68 (m, 11H), 1.57-1.36 (m, 2H),





1.29 (d, J = 6.0 Hz, 6H).


106
490.40
4.35
1H NMR (400 MHz, DMSO) δ 7.51 (d, J = 2.1 Hz, 1H),





7.38 (dd, J = 8.5, 2.1 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H),





7.06 (d, J = 4.2 Hz, 1H), 6.17 (d, J = 4.2 Hz, 1H),





4.74 (hept, J = 6.0 Hz, 1H), 4.48-4.12 (m, 3H),





3.65-3.28 (m, 2H), 3.28-2.94 (m, 3H), 2.73 (q, J = 7.4 Hz, 2H),





2.27 (s, 3H), 2.17-1.90 (m, 2H), 1.86-1.68 (m, 2H),





1.31 (d, J = 6.0 Hz, 6H), 1.04 (t, J = 7.4 Hz, 3H).


107
458.20
1.49


108
454.50
1.51


109
392.50
1.31


110
436.20
1.92
1H NMR (400 MHz, DMSO) δ 7.51 (d, J = 2.1 Hz, 1H),





7.38 (dd, J = 8.5, 2.1 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H),





6.73 (d, J = 4.0 Hz, 1H), 6.22 (d, J = 4.1 Hz, 1H),





4.80-4.65 (m, 1H), 4.46-4.20 (m, 1H), 4.13 (t, J = 5.8 Hz,





2H), 3.62-3.24 (m, 4H), 3.20 (s, 3H), 3.18-2.93 (m,





1H), 2.29 (s, 3H), 2.23-1.90 (m, 2H), 1.87-1.70 (m,





2H), 1.31 (d, J = 6.0 Hz, 6H).


111
480.30
1.37
1H NMR (400 MHz, CDCl3) δ 7.42 (t, J = 7.8 Hz, 1H),





7.17 (ddd, J = 12.5, 9.5, 1.5 Hz, 2H), 6.29 (s, 1H),





4.57 (s, 1H), 3.93 (s, 2H), 3.53 (d, J = 31.9 Hz, 2H), 3.25 (d,





J = 38.8 Hz, 3H), 2.65 (dt, J = 11.8, 8.8 Hz, 2H),





2.50-2.33 (m, 6H), 2.27-2.07 (m, 3H), 2.01 (s, 2H),





1.84-1.67 (m, 1H).


112
484.30
1.34


113
492.50
2.82


114
578.50
1.62


115
508.70
1.58


116
464.30
0.75
1H NMR (400 MHz, CDCl3) δ 7.28-7.20 (m, 3H),





6.82 (d, J = 8.1 Hz, 1H), 6.16 (d, J = 4.5 Hz, 1H), 4.56 (dt, J = 12.1,





6.0 Hz, 1H), 4.56 (s, 1H), 4.35 (t, J = 5.9 Hz,





2H), 3.80 (s, 1H), 3.37 (s, 2H), 3.34 (t, J = 5.9 Hz, 2H),





2.41 (s, 3H), 2.21 (s, 3H), 2.11 (s, 2H), 1.84 (s, 2H),





1.35 (d, J = 6.0 Hz, 6H).


117
478.30
1.64


118
484.70
1.32
1H NMR (400 MHz, CDCl3) δ 7.19-7.00 (m, 2H),





6.91 (d, J = 8.0 Hz, 1H), 6.56 (d, J = 3.8 Hz, 1H), 6.02 (d, J = 3.8 Hz,





1H), 5.92 (s, 1H), 4.71-4.50 (m, 1H),





4.46-4.23 (m, 2H), 4.16 (t, J = 6.5 Hz, 2H), 3.88 (s, 3H),





3.88-3.62 (m, 2H), 3.41 (t, J = 6.4 Hz, 2H), 2.71 (s, 3H),





2.59-2.44 (m, 2H), 2.36-1.61 (m, 2H), 1.39 (d, J = 6.1 Hz,





6H).


119
509.60
4.60


120
475.12
2.82


121
454.50
1.42
1H NMR (400 MHz, DMSO) δ 7.28-7.20 (m, 2H),





7.05 (d, J = 4.1 Hz, 1H), 6.97 (d, J = 9.1 Hz, 1H), 6.17 (d, J = 4.2 Hz,





1H), 4.73-4.55 (m, 1H), 4.47-4.11 (m, 3H),





3.72-3.28 (m, 2H), 3.28-2.98 (m, 3H), 2.31 (s, 3H),





2.26 (s, 3H), 2.14 (s, 3H), 2.12-1.96 (m, 2H),





1.85-1.64 (m, 2H), 1.29 (d, J = 6.0 Hz, 6H).


122
424.20
1.22
1H NMR (400 MHz, DMSO) δ 7.86 (d, J = 8.4 Hz, 2H),





7.68 (d, J = 8.4 Hz, 2H), 6.58 (d, J = 3.8 Hz, 1H),





6.12 (d, J = 3.9 Hz, 1H), 4.47-4.28 (m, 1H), 3.93 (t, J = 5.8 Hz,





2H), 3.48-3.25 (m, 4H), 3.25-3.07 (m, 5H),





2.27 (s, 3H), 2.23-1.96 (m, 2H), 1.86-1.73 (m, 2H),





1.71-1.63 (m, 4H).


123
511.40
2.70


124
454.50
1.37


125
428.20
0.96


126
522.70
1.64


127
464.50
1.54
1H NMR (400 MHz, DMSO) δ 7.53-7.41 (m, 1H),





7.22-7.10 (m, 2H), 6.61 (d, J = 4.1 Hz, 1H), 6.09 (d, J = 4.0 Hz,





1H), 4.97 (s, 1H), 4.49-4.19 (m, 1H),





3.53-3.01 (m, 3H), 2.96-2.83 (m, 2H), 2.83-2.70 (m, 1H),





2.55 (s, 3H), 2.01-1.61 (m, 4H), 1.51 (s, 6H), 1.43 (s, 6H).


128
464.50
4.17
1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 2.1 Hz, 1H),





7.37 (dd, J = 8.4, 2.1 Hz, 1H), 7.27-7.24 (m, 1H),





6.96 (d, J = 8.5 Hz, 1H), 6.20 (d, J = 4.5 Hz, 1H), 4.57 (s,





1H), 4.20 (s, 2H), 3.94 (s, 3H), 3.63 (s, 2H), 3.32 (s,





1H), 1.92 (s, 2H), 1.78 (s, 2H), 1.18 (s, 6H), 0.97 (s,





1H).


129
484.50
1.50


130
512.40
1.68


131
492.20
1.84


132
476.50
1.39
1H NMR (400 MHz, DMSO) δ 7.27 (d, J = 7.9 Hz, 1H),





6.99 (d, J = 1.4 Hz, 1H), 6.97-6.90 (m, 1H),





6.62-6.53 (m, 1H), 6.18-6.05 (m, 1H), 4.58-4.18 (m, 2H),





3.93-3.76 (m, 5H), 3.62 (d, J = 4.2 Hz, 2H), 3.54-3.02 (m,





5H), 2.49-2.26 (m, 1H), 2.01-1.63 (m, 4H), 1.27 (s,





6H).


133
466.40
2.99
1H NMR (400 MHz, CDCl3) δ 7.68-7.61 (m, 2H),





7.04-6.97 (m, 1H), 6.29 (s, 1H), 4.70 (dt, J = 12.1, 6.1 Hz,





1H), 4.53 (s, 1H), 3.93 (t, J = 5.7 Hz, 2H), 3.55 (s, 2H),





3.30 (s, 3H), 2.42 (s, 3H), 2.23-1.92 (m, 4H), 1.43 (d, J = 6.1 Hz,





6H).


134
479.50
1.42


135
456.50
1.45


136
548.30
1.30
1H NMR (400 MHz, DMSO) δ 7.09 (d, J = 4.3 Hz, 1H),





7.05-6.92 (m, 3H), 6.17 (d, J = 4.3 Hz, 1H),





4.67-4.51 (m, 1H), 4.47-4.02 (m, 3H), 3.77 (s, 3H),





3.65-3.28 (m, 2H), 3.28-2.95 (m, 3H), 2.28 (s, 3H),





2.17-1.97 (m, 2H), 1.86-1.67 (m, 2H), 1.31-1.24 (m, 15H).


137
482.40
1.28
1H NMR (400 MHz, CDCl3) δ 7.34-7.29 (m, 2H),





6.84 (d, J = 9.0 Hz, 1H), 6.56 (d, J = 3.7 Hz, 1H), 6.02 (d, J = 3.9 Hz,





1H), 4.62-4.52 (m, 1H), 4.51-4.40 (m, 1H),





4.34-4.23 (m, 2H), 4.18 (t, J = 6.5 Hz, 2H),





3.88-3.64 (m, 1H), 3.55-3.31 (m, 2H), 2.85 (s, 6H),





2.62-2.42 (m, 2H), 2.22 (s, 3H), 1.70-1.54 (m, 2H), 1.35 (d, J = 6.0 Hz,





6H).


138
507.40
6.05


139
492.30
1.55


140
410.20
0.80


141
498.70
2.97


142
494.50
1.50
1H NMR (400 MHz, DMSO) δ 7.39 (d, J = 8.7 Hz, 2H),





7.27-7.17 (m, 1H), 6.97 (d, J = 8.7 Hz, 2H), 6.49 (d, J = 4.6 Hz,





1H), 4.55-4.15 (m, 3H), 4.03 (t, J = 6.6 Hz,





2H), 3.76-2.94 (m, 5H), 2.30 (s, 3H), 2.21-1.97 (m,





2H), 1.94-1.69 (m, 3H), 1.62 (q, J = 6.7 Hz, 2H),





0.93 (d, J = 6.6 Hz, 6H).


143
492.50
1.73


144
468.70
1.42
1H NMR (400 MHz, DMSO) δ 8.02 (d, J = 1.1 Hz, 1H),





7.86 (d, J = 8.4 Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H),





6.58 (d, J = 3.4 Hz, 1H), 6.14 (d, J = 3.9 Hz, 1H),





4.26-4.14 (m, 1H), 3.79 (t, J = 5.9 Hz, 2H), 3.50-3.23 (m, 5H),





3.18-3.04 (m, 1H), 2.26-1.76 (m, 9H), 1.60-1.36 (m,





2H), 0.56-0.35 (m, 4H).


145
537.40
2.89


146
508.70
1.61


147
414.17
2.22


148
494.50
1.36
1H NMR (400 MHz, DMSO) δ 7.06-6.90 (m, 3H),





6.57 (d, J = 3.6 Hz, 1H), 6.11 (d, J = 3.9 Hz, 1H),





4.68-4.50 (m, 1H), 3.83-3.63 (m, 5H), 3.18-2.78 (m, 4H),





2.41-2.20 (m, 1H), 2.13-1.87 (m, 5H), 1.61-1.34 (m, 2H),





1.26 (d, J = 6.0 Hz, 6H), 1.24-1.19 (m, 3H).


149
480.30
1.76


150
450.50
1.28
1H NMR (400 MHz, DMSO) δ 7.27 (d, J = 7.9 Hz, 1H),





6.98 (d, J = 1.2 Hz, 1H), 6.96-6.87 (m, 1H), 6.58 (s,





1H), 6.12 (s, 1H), 4.62-4.19 (m, 2H), 4.01-3.85 (m,





2H), 3.81 (s, 3H), 3.62 (s, 2H), 3.55-2.94 (m, 5H),





2.36-2.01 (m, 5H), 1.86-1.59 (m, 2H), 1.27 (s, 6H).


151
480.40
2.97


152
468.30
1.91


153
526.50
1.42


154
526.20
1.50


155
470.50
1.70


156
480.50
0.65
1H NMR (400 MHz, DMSO) δ 8.46 (s, 1H), 7.61 (t, J = 52.4 Hz,





1H), 7.42 (s, 1H), 6.63 (d, J = 4.0 Hz, 1H),





6.03 (d, J = 4.0 Hz, 1H), 4.50-4.29 (m, 1H), 3.76-3.39 (m,





2H), 3.27-3.07 (m, 1H), 3.03-2.88 (m, 2H),





2.88-2.76 (m, 1H), 2.65 (s, 3H), 2.08-1.66 (m, 4H), 1.44 (s,





6H).


157
497.50
4.05
1H NMR (400 MHz, DMSO) δ 7.05 (d, J = 1.7 Hz, 1H),





7.01 (d, J = 8.0 Hz, 1H), 6.93 (dd, J = 8.0, 1.8 Hz, 1H),





6.58 (d, J = 3.1 Hz, 1H), 6.12 (d, J = 3.9 Hz, 1H),





4.32 (s, 1H), 3.93 (t, J = 5.5 Hz, 2H), 3.76 (s, 3H),





3.58-3.35 (m, 2H), 3.35-3.29 (m, 2H), 3.22-3.02 (m, 1H),





2.28 (s, 3H), 2.11 (s, 2H), 1.76 (t, J = 11.1 Hz, 2H), 1.29 (s,





9H).


158
480.50
1.36
1H NMR (400 MHz, CDCl3) δ 8.41 (s, 1H), 7.35 (t, J = 40.0 Hz,





1H), 7.09 (s, 1H), 6.55 (d, J = 3.7 Hz, 1H),





5.97 (d, J = 3.9 Hz, 1H), 4.63 (s, 1H), 3.95 (t, J = 5.3 Hz,





2H), 3.83 (s, 1H), 3.62 (s, 1H), 3.28 (s, 2H), 2.71 (s,





3H), 2.12 (s, 2H), 2.03-1.76 (m, 4H).


159
469.50
1.12
1H NMR (400 MHz, DMSO) δ 7.47 (d, J = 2.1 Hz, 1H),





7.30 (dd, J = 8.4, 2.2 Hz, 1H), 7.26-7.18 (m, 1H),





6.99 (d, J = 8.6 Hz, 1H), 6.49 (d, J = 4.6 Hz, 1H), 5.06 (t, J = 5.7 Hz,





1H), 4.75-4.59 (m, 1H), 4.48 (d, J = 5.7 Hz,





2H), 4.44-4.15 (m, 3H), 3.83-2.94 (m, 5H), 2.31 (s,





3H), 2.21-2.00 (m, 2H), 1.94-1.72 (m, 2H), 1.28 (d, J = 6.0 Hz,





6H).


160
494.50
1.44


161
422.50
1.21


162
476.50
1.04


163
428.21
2.32
1H NMR (400 MHz, DMSO) δ 7.36-7.22 (m, 3H),





6.97 (d, J = 8.4 Hz, 1H), 6.48 (d, J = 4.6 Hz, 1H),





4.86-4.72 (m, 1H), 4.43-4.02 (m, 1H), 3.82 (s, 3H),





3.76-3.39 (m, 1H), 3.40-3.29 (m, 2H), 3.29-2.97 (m, 2H),





2.34-2.13 (m, 7H), 2.06-1.88 (m, 2H), 1.81-1.61 (m, 1H),





1.30 (d, J = 6.0 Hz, 3H).


164
464.50
1.53
1H NMR (400 MHz, DMSO) δ 7.24 (d, J = 6.6 Hz, 2H),





6.97 (d, J = 9.2 Hz, 1H), 6.58 (d, J = 3.8 Hz, 1H),





6.14 (d, J = 3.9 Hz, 1H), 4.64 (dt, J = 12.1, 6.1 Hz, 1H),





4.06 (t, J = 5.9 Hz, 2H), 3.90 (s, 2H), 3.51 (t, J = 6.0 Hz, 2H),





2.14 (s, 3H), 1.83 (t, J = 11.8 Hz, 2H), 1.29 (d, J = 6.0 Hz,





6H).


165
475.30
2.04


166
412.10
1.41


167
480.30
1.49
1H NMR (400 MHz, CDCl3) δ 7.06 (d, J = 1.8 Hz, 1H),





7.00 (dd, J = 8.2, 1.9 Hz, 1H), 6.93 (d, J = 8.2 Hz, 1H),





6.56 (d, J = 3.8 Hz, 1H), 5.96 (d, J = 3.9 Hz, 1H),





4.53 (s br, 1H), 4.42-4.23 (m, 4H), 4.06 (s br, 2H), 3.91 (s,





3H), 3.71 (s br, 1H), 3.54 (s br, 1H), 3.43-3.25 (m, 3H),





2.42 (s, 3H), 2.15 (s br, 2H), 1.86 (s br, 2H).


168
536.10
1.58


169
511.26
1.00
1H NMR (400 MHz, CDCl3) δ 7.06 (d, J = 1.8 Hz, 1H),





7.05-6.98 (m, 1H), 6.88 (d, J = 8.2 Hz, 1H), 6.55 (d, J = 3.3 Hz,





1H), 6.15 (d, J = 3.9 Hz, 1H), 4.57 (d, J = 6.1 Hz,





1H), 4.19-4.10 (m, 2H), 3.88 (m, s, 5H), 3.79 (s,





2H), 3.70-3.52 (m, J = 31.5 Hz, 2H), 3.11 (s, 2H),





2.24 (s, 3H), 1.92-1.75 (m, 2H), 1.38 (d, J = 6.1 Hz, 6H).


170
494.70
1.70
1H NMR (400 MHz, DMSO) δ 7.27-7.19 (m, 1H),





7.12-6.98 (m, 3H), 6.51 (d, J = 4.6 Hz, 1H), 4.82-4.69 (m,





1H), 4.46-4.38 (m, 2H), 4.31-4.23 (m, 2H), 3.80 (s,





3H), 3.62-3.39 (m, 1H), 3.38-3.30 (m, 2H),





3.30-3.08 (m, 2H), 2.94-2.72 (m, 2H), 2.17-2.07 (m, 1H),





2.05-1.51 (m, 3H), 1.35 (d, J = 6.4 Hz, 3H).


171
564.70
1.60
1H NMR (400 MHz, DMSO) δ 7.77-7.68 (m, 4H),





7.58-7.46 (m, 4H), 7.43-7.37 (m, 1H), 7.29-7.18 (m, 1H),





6.51 (d, J = 4.6 Hz, 1H), 4.56-4.32 (m, 1H), 4.25 (t, J = 5.6 Hz,





2H), 3.63-3.21 (m, 4H), 3.21-2.98 (m, 1H),





2.31 (s, 3H), 2.27-1.98 (m, 2H), 1.95-1.78 (m, 2H).


172
482.50
1.63


173
504.50
1.58
1H NMR (400 MHz, DMSO) δ 7.30-7.19 (m, 3H),





6.97 (d, J = 9.0 Hz, 1H), 6.21 (d, J = 4.3 Hz, 1H),





4.73-4.55 (m, 1H), 4.36-3.82 (m, 1H), 3.82-3.42 (m, 1H),





3.42-3.15 (m, 2H), 3.08 (s, 2H), 2.41 (s, 3H), 2.40 (s, 3H),





2.14 (s, 3H), 2.13-1.95 (m, 2H), 1.86-1.66 (m, 2H),





1.59 (s, 6H), 1.29 (d, J = 6.0 Hz, 6H).


174
452.50
1.53
1H NMR (400 MHz, DMSO) δ 7.45 (d, J = 8.7 Hz, 2H),





7.30-7.18 (m, 1H), 7.11 (d, J = 8.8 Hz, 2H), 6.49 (d, J = 4.6 Hz,





1H), 4.82 (q, J = 8.9 Hz, 2H), 4.54-4.12 (m,





3H), 3.61-2.95 (m, 5H), 2.30 (s, 3H), 2.26-1.77 (m,





4H).


175
504.50
1.55


176
500.50
1.34


177
410.50
1.38


178
507.50
1.54


179
466.50
1.41


180
512.20
1.07


181
466.50
1.46
1H NMR (400 MHz, DMSO) δ 7.27-7.20 (m, 2H),





7.10 (d, J = 4.2 Hz, 1H), 6.97 (d, J = 9.2 Hz, 1H), 6.18 (d, J = 4.2 Hz,





1H), 4.71-4.59 (m, 1H), 4.48-4.09 (m, 3H),





3.72-3.28 (m, 3H), 3.28-2.95 (m, 3H), 2.27 (s, 3H),





2.14 (s, 3H), 2.13-1.93 (m, 2H), 1.81-1.64 (m, 2H),





1.29 (d, J = 6.0 Hz, 6H), 1.05 (d, J = 6.8 Hz, 6H).


182
452.70
1.58


183
456.30
0.87
1H NMR (400 MHz, CDCl3) δ 7.37-7.29 (m, 2H),





7.14-7.06 (m, 2H), 6.29 (s, 1H), 4.59 (s, 1H), 3.92 (t, J = 5.7 Hz,





2H), 3.64 (s, 1H), 3.45 (s, 1H), 3.25 (d, J = 39.3 Hz,





3H), 2.41 (s, 3H), 2.27-1.86 (m, 5H), 1.63 (s, 1H),





1.06-0.93 (m, 2H), 0.72 (dt, J = 6.6, 4.7 Hz, 2H).


184
436.30
1.44


185
490.30
1.61


186
510.70
1.39


187
500.50
2.44


188
498.50
3.07


189
408.26
2.48


190
466.50
1.41


191
498.23
1.14


192
459.15
1.58


193
454.50
2.30


194
513.50
1.32


195
427.21
1.42
1H NMR (400 MHz, CDCl3) δ 8.27 (d, J = 2.3 Hz, 1H),





7.62 (d, J = 9.0 Hz, 1H), 7.52 (s, 1H), 7.39 (dd, J = 8.5,





2.7 Hz, 1H), 7.00 (s, 1H), 6.53 (d, J = 4.1 Hz, 2H),





5.95 (d, J = 3.8 Hz, 2H), 4.52 (s, 2H), 3.95 (dd, J = 23.5, 10.2 Hz,





4H), 3.63-3.44 (m, 4H), 3.40-3.16 (m, 4H),





2.80 (s, 3H), 2.39 (s, 4H), 2.28-2.15 (m, 2H), 2.06 (s, 2H),





1.92 (s, 3H), 1.40 (s, 10H), 1.25 (s, 2H).


196
451.30
1.32


197
524.50
1.38


198
479.50
1.49
1H NMR (400 MHz, DMSO) δ 7.28-7.19 (m, 2H),





7.09 (d, J = 4.3 Hz, 1H), 6.97 (d, J = 9.2 Hz, 1H), 6.17 (d, J = 4.3 Hz,





1H), 4.70-4.56 (m, 1H), 4.51-4.04 (m, 3H),





3.83-3.28 (m, 2H), 3.28-2.91 (m, 3H), 2.27 (s, 3H),





2.14 (s, 3H), 2.13-1.96 (m, 2H), 1.84-1.66 (m, 2H),





1.29 (d, J = 6.0 Hz, 6H), 1.27 (s, 9H).


199
466.40
1.48


200
451.50
1.31
1H NMR (400 MHz, CDCl3) δ 7.21 (dt, J = 4.2, 2.1 Hz,





1H), 7.19 (d, J = 1.4 Hz, 1H), 7.08 (dd, J = 8.2, 2.0 Hz,





1H), 6.67 (d, J = 8.2 Hz, 1H), 6.16 (d, J = 4.5 Hz, 1H),





4.57 (s, 1H), 4.35 (t, J = 6.0 Hz, 2H), 3.76 (s, 1H),





3.52 (s, 1H), 3.32 (t, J = 6.0 Hz, 2H), 3.28 (s, 1H), 2.40 (s,





3H), 2.21 (s, 3H), 2.19-2.02 (m, 2H), 2.00 (s, 1H),





1.97-1.64 (m, 2H).


201
436.30
1.30
1H NMR (400 MHz, DMSO) δ 7.47 (d, J = 2.1 Hz, 1H),





7.28 (dd, J = 8.4, 2.1 Hz, 1H), 6.99 (d, J = 8.6 Hz, 1H),





6.60 (d, J = 3.5 Hz, 1H), 6.16-6.03 (m, 1H), 5.07 (t, J = 5.6 Hz,





1H), 5.02-4.72 (m, 1H), 4.72-4.59 (m, 1H),





4.48 (d, J = 5.6 Hz, 2H), 4.18-4.01 (m, 1H),





3.96-3.26 (m, 5H), 3.21-2.90 (m, 2H), 2.30 (s, 3H),





2.26-2.12 (m, 1H), 1.98-1.75 (m, 1H), 1.28 (d, J = 6.0 Hz, 6H).


202
484.40
4.78


203
480.30
1.55


204
430.50
1.28


205
458.10
2.27


206
469.50
2.74


207
450.50
1.29


208
540.50
1.44


209
430.17
2.69


210
465.14
3.62


211
500.50
1.46


212
480.30
1.52
1H NMR (400 MHz, DMSO) δ 7.61 (d, J = 7.8 Hz, 1H),





7.03-6.92 (m, 2H), 6.58 (d, J = 3.9 Hz, 1H), 6.12 (d, J = 3.9 Hz,





1H), 5.00 (s, 1H), 4.45-4.22 (m, 1H), 3.93 (t,





J = 5.8 Hz, 2H), 3.82 (s, 3H), 3.57-3.02 (m, 5H),





2.27 (s, 3H), 2.24-1.98 (m, 2H), 1.86-1.67 (m, 2H), 1.48 (s,





6H).


213
466.20
1.24


214
512.70
1.65


215
516.50
2.62


216
522.22
1.33


217
498.70
2.62


218
512.20
1.15


219
438.28
2.55


220
427.20
2.15


221
386.15
2.32
1H NMR (400 MHz, CDCl3) δ 7.28-7.20 (m, 2H),





6.82 (d, J = 8.0 Hz, 1H), 6.53 (d, J = 3.7 Hz, 1H),





5.97-5.86 (m, 1H), 4.56 (dt, J = 12.1, 6.0 Hz, 1H), 4.08 (d, J = 8.9 Hz,





1H), 3.62-3.13 (m, 4H), 2.21 (s, 3H),





2.18-1.84 (m, 2H), 1.78-1.40 (m, 4H), 1.35 (d, J = 6.0 Hz, 6H),





1.27 (d, J = 3.9 Hz, 3H), 0.87 (s, 1H).


222
450.40
1.50


223
478.50
1.65


224
386.15
2.36


225
456.70
1.29
1H NMR (400 MHz, DMSO) δ 7.37 (t, J = 7.7 Hz, 1H),





7.26-7.15 (m, 2H), 6.56 (s, 1H), 6.19 (d, J = 4.0 Hz,





1H), 4.44 (s, 1H), 4.42-4.21 (m, 1H), 3.97 (t, J = 5.7 Hz,





2H), 3.41 (s, 2H), 3.30-3.21 (m, 1H), 3.10 (s, 1H),





2.71 (s, 2H), 2.28 (s, 3H), 2.22-2.10 (m, 1H),





2.10-1.95 (m, 1H), 1.86-1.71 (m, 2H), 1.25 (s, 1H), 1.09 (s,





6H).


226
518.30
1.46
1H NMR (400 MHz, CDCl3) δ 7.12-7.03 (m, 2H),





6.91 (d, J = 8.6 Hz, 1H), 6.56 (d, J = 3.8 Hz, 1H), 6.03 (d, J = 3.9 Hz,





1H), 4.67-4.54 (m, 1H), 4.54-4.39 (m, 1H),





4.38-4.23 (m, 2H), 4.18 (t, J = 6.5 Hz, 2H), 3.89 (s,





3H), 3.84-3.63 (m, 1H), 3.50-3.32 (m, 2H), 2.85 (s,





6H), 2.66-2.44 (m, 2H), 1.72-1.48 (m, 2H), 1.39 (d, J = 6.1 Hz,





6H).


227
523.60
4.94
1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 8.3 Hz, 2H),





7.45 (d, J = 8.3 Hz, 2H), 6.51 (s, 1H), 4.03 (s, 2H),





3.51 (d, J = 111.0 Hz, 5H), 2.65-2.45 (m, 6H), 2.39 (ddd, J = 12.6,





9.5, 7.5 Hz, 3H), 2.19-1.86 (m, 4H), 1.72 (dt, J = 10.1,





7.5 Hz, 1H), 1.55 (s, 5H).


228
482.40
1.43


229
432.13
2.06


230
454.23
2.22
1H NMR (400 MHz, DMSO) δ 8.13-8.00 (m, 1H),





7.32-7.19 (m, 2H), 6.97 (d, J = 9.1 Hz, 1H), 6.60-6.51 (m,





1H), 4.69-4.57 (m, 1H), 4.32-3.38 (m, 2H),





3.38-3.20 (m, 2H), 3.14 (s, 2H), 2.39 (s, 3H), 2.14 (s, 3H),





2.13-1.94 (m, 2H), 1.89-1.68 (m, 2H), 1.53 (s, 6H),





1.29 (d, J = 6.0 Hz, 6H).


231
506.50
1.67


232
496.40
1.74
1H NMR (400 MHz, DMSO) δ 7.39 (d, J = 8.7 Hz, 2H),





7.30-7.17 (m, 1H), 6.95 (d, J = 8.7 Hz, 2H), 6.49 (d, J = 4.6 Hz,





1H), 4.74-4.59 (m, 1H), 4.50-4.04 (m, 3H),





3.76-2.94 (m, 5H), 2.30 (s, 3H), 2.22-1.94 (m, 2H),





1.94-1.74 (m, 2H), 1.28 (d, J = 6.0 Hz, 6H).


233
464.50
1.52


234
432.50
1.15


235
478.50
1.41


236
530.15
1.66
1H NMR (400 MHz, DMSO) δ 7.44 (d, J = 8.1 Hz, 2H),





7.39 (d, J = 8.1 Hz, 2H), 7.26-7.20 (m, 1H), 6.50 (d, J = 4.6 Hz,





1H), 4.55 (s, 2H), 4.47-4.30 (m, 1H),





4.29-4.19 (m, 2H), 3.67 (t, J = 6.1 Hz, 2H), 3.46-3.24 (m,





4H), 3.18-3.00 (m, 1H), 2.70-2.53 (m, 2H), 2.30 (s,





3H), 2.25-1.76 (m, 4H).


237
532.30
1.70


238
450.50
1.40


239
478.50
1.53


240
518.30
1.64


241
466.50
1.42
1H NMR (400 MHz, CDCl3) δ 7.59-7.53 (m, 2H),





7.47-7.42 (m, 2H), 6.30 (s, 1H), 4.61 (s, 1H), 3.93 (s, 2H),





3.62 (s, 1H), 3.49 (s, 2H), 3.31 (s, 3H), 2.64-2.51 (m,





2H), 2.51-2.31 (m, 5H), 2.17 (s, 2H), 2.11-1.89 (m,





4H), 1.80-1.64 (m, 1H), 1.56 (s, 1H).


242
466.50
2.45
1H NMR (400 MHz, DMSO) δ 7.51 (d, J = 2.1 Hz, 1H),





7.38 (dd, J = 8.5, 2.1 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H),





7.09 (d, J = 4.3 Hz, 1H), 6.17 (d, J = 4.3 Hz, 1H),





4.81-4.67 (m, 1H), 4.45-4.20 (m, 1H), 4.15 (t, J = 5.8 Hz,





2H), 3.60-3.28 (m, 2H), 3.27-2.96 (m, 3H), 2.27 (s,





3H), 2.17-1.94 (m, 2H), 1.87-1.72 (m, 2H), 1.31 (d, J = 6.0 Hz,





6H), 1.27 (s, 9H).


243
486.40
1.44


244
515.40
4.81


245
532.50
1.19
1H NMR (400 MHz, CDCl3) δ 8.02 (d, J = 7.9 Hz, 1H),





7.48-7.35 (m, 2H), 6.95 (d, J = 4.1 Hz, 1H), 6.01 (d, J = 4.0 Hz,





1H), 4.67-4.49 (m, 1H), 4.35 (t, J = 5.9 Hz,





2H), 3.64-3.37 (m, 2H), 3.37-3.20 (m, 4H), 2.72 (s,





3H), 2.40 (s, 3H), 2.38 (s, 3H), 2.31-2.14 (m, 1H),





2.14-2.02 (m, 1H), 1.99-1.83 (m, 1H), 1.78-1.64 (m, 1H),





1.32 (d, J = 6.8 Hz, 6H).


246
472.20
0.96


247
466.20
1.96


248
499.20
1.43


249
484.70
2.50


250
436.50
1.38


251
470.50
1.34


252
484.20
1.08


253
504.50
1.22
1H NMR (400 MHz, CDCl3) δ 7.64 (t, J = 8.0 Hz, 1H),





7.29-7.26 (m, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.13 (d, J = 11.9 Hz,





1H), 6.21 (s, 1H), 4.60 (s, 1H),





4.43-4.01 (m, 2H), 3.65 (s, 2H), 3.28 (s, 1H), 2.04 (s, 2H),





1.92-1.72 (m, 2H), 1.65 (s, 6H), 1.19 (s, 6H), 0.99 (s, 1H).





(OH not observed).


254
496.70
1.41


255
494.50
2.99


256
432.50
1.49


257
482.50
1.20
1H NMR (400 MHz, CDCl3) δ 7.02 (d, J = 1.8 Hz, 1H),





6.98 (dd, J = 8.2, 1.8 Hz, 1H), 6.92 (d, J = 8.2 Hz, 1H),





6.49 (s, 1H), 4.61 (s, 1H), 4.04 (d, J = 10.3 Hz, 1H),





4.02-3.94 (m, 3H), 3.88 (s, 3H), 3.75 (d, J = 43.7 Hz,





1H), 3.43 (s, 1H), 3.30 (s, 2H), 3.25-3.07 (m, 1H),





2.44 (s, 5H), 2.01 (s, 2H), 1.56 (d, J = 13.8 Hz, 4H), 1.49 (s,





3H).


258
532.50
1.73
1H NMR (400 MHz, CDCl3) δ 7.06 (d, J = 1.9 Hz, 1H),





7.00 (dd, J = 8.2, 1.9 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H),





6.54 (d, J = 3.3 Hz, 1H), 6.11 (d, J = 4.0 Hz, 1H),





4.57 (dt, J = 12.2, 6.1 Hz, 1H), 4.09-4.02 (m, 2H),





3.97-3.90 (m, 2H), 3.88 (s, 3H), 3.83-3.75 (m, 3H), 3.74 (s,





3H), 3.04-2.89 (m, 2H), 1.87 (dt, J = 14.0, 5.8 Hz, 2H),





1.38 (d, J = 6.1 Hz, 6H), 1.30-1.23 (m, 1H).


259
510.70
1.89


260
442.20
2.40
1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 8.4 Hz, 1H),





7.13 (d, J = 8.5 Hz, 1H), 6.47 (s, 1H), 4.68-4.51 (m,





2H), 3.99 (dd, J = 16.4, 10.5 Hz, 3H), 3.54 (t, J = 12.8 Hz,





1H), 3.27 (ddd, J = 36.4, 19.3, 9.5 Hz, 3H),





2.48 (dd, J = 28.6, 8.7 Hz, 8H), 2.06 (d, J = 13.3 Hz, 1H),





1.89 (d, J = 14.8 Hz, 1H), 1.59 (s, 1H), 1.37 (d, J = 6.0 Hz,





6H).


261
485.05
3.02


262
468.70
2.48
1H NMR (400 MHz, CDCl3) δ 7.29 (s, 1H), 7.27 (d, J = 2.1 Hz,





1H), 6.83 (d, J = 8.0 Hz, 1H), 6.56 (d, J = 3.8 Hz,





1H), 5.97 (d, J = 3.9 Hz, 1H), 4.53 (s br, 1H, OH),





4.10-3.94 (m, 2H), 3.84 (s, 2H), 3.62 (m br, J = 74.5 Hz,





2H), 3.37 (t, J = 6.0 Hz, 3H), 2.41 (s, 3H), 2.30 (s,





3H), 2.17 (m br, J = 15.0 Hz, 2H), 1.85 (s br, 3H),





1.40 (s, 6H).


263
480.70
1.33


264
468.50
1.37


265
485.50
1.17
1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.1 Hz, 1H),





7.25-7.16 (m, 3H), 6.17 (d, J = 4.5 Hz, 1H),





4.68-4.53 (m, 1H), 4.35 (t, J = 5.9 Hz, 2H), 3.65 (s, 1H), 3.51 (n,





1H), 3.34 (t, J = 5.6 Hz, 2H), 3.24 (s, 1H), 2.61 (s, 3H),





2.41 (s, 3H), 2.18 (s, 1H), 2.06 (s, 1H), 1.93 (s, 1H),





1.73 (s, 1H), 1.70 (s, 1H), 1.66 (s, 6H).


266
478.30
1.38


267
450.50
1.25


268
466.14
1.74


269
426.50
1.27


270
512.20
1.84
1H NMR (400 MHz, DMSO) δ 10.48 (s, 1H), 7.39 (d, J = 8.1 Hz,





1H), 7.30-7.16 (m, 1H), 6.99 (d, J = 1.8 Hz,





1H), 6.88 (dd, J = 8.1, 1.9 Hz, 1H), 6.48 (d, J = 4.6 Hz,





1H), 4.45-4.29 (m, 1H), 4.29-4.16 (m, 2H),





3.58-2.96 (m, 5H), 2.30 (s, 3H), 2.25-1.68 (m, 4H).


271
456.50
1.44


272
462.50
1.32


273
422.50
1.32


274
513.70
1.36


275
400.13
2.61


276
436.50
1.37


277
458.50
1.46


278
380.17
1.97
1H NMR (400 MHz, DMSO) δ 7.29-7.17 (m, 2H),





6.96 (d, J = 9.1 Hz, 1H), 6.04-5.88 (m, 2H), 4.69-4.57 (m,





1H), 4.46-3.92 (m, 1H), 3.86-3.72 (m, 2H),





3.72-3.55 (m, 2H), 3.42-2.95 (m, 5H), 2.24 (s, 3H), 2.14 (s,





3H), 2.11-1.91 (m, 2H), 1.78-1.57 (m, 2H), 1.29 (d, J = 6.0 Hz,





6H).


279
464.50
1.32
1H NMR (400 MHz, DMSO) δ 7.29-7.19 (m, 2H),





7.02-6.92 (m, 1H), 6.61 (d, J = 4.0 Hz, 1H), 6.08 (d, J = 4.0 Hz,





1H), 4.71-4.58 (m, 1H), 4.46-4.08 (m, 1H),





3.65-3.00 (m, 3H), 2.91 (d, J = 6.7 Hz, 2H), 2.77 (t, J = 7.2 Hz,





1H), 2.14 (s, 3H), 1.98-1.63 (m, 4H), 1.43 (s, 6H),





1.29 (d, J = 6.0 Hz, 6H).


280
464.50
6.18


281
429.50
1.12
1H NMR (400 MHz, DMSO) δ 7.76 (dd, J = 8.6, 2.0 Hz,





1H), 7.69 (d, J = 1.9 Hz, 1H), 7.32 (d, J = 8.7 Hz, 1H),





7.08 (d, J = 4.1 Hz, 1H), 6.20 (d, J = 4.2 Hz, 1H),





4.48-4.23 (m, 1H), 4.14 (t, J = 5.8 Hz, 2H), 3.94 (s, 3H),





3.53-3.29 (m, 2H), 3.23 (t, J = 5.5 Hz, 2H), 3.19-2.96 (m,





1H), 2.28 (s, 3H), 2.23-1.89 (m, 2H), 1.89-1.70 (m,





2H), 1.43 (s, 3H), ? 0.99-0.94 (m, 2H), 0.66-0.61 (m,





2H).


282
490.50
1.47


283
471.50
1.06


284
492.30
1.78


285
435.20
2.02


286
442.40
1.45


287
498.20
1.09


288
561.80
1.76


289
547.50
1.22


290
448.50
1.57


291
479.30
1.53


292
394.22
2.22


293
505.50
1.39


294
446.26
2.27


295
500.24
1.22


296
485.05
3.58


297
423.30
1.19
1H NMR (400 MHz, DMSO) δ 7.91 (d, J = 8.0 Hz, 1H),





7.58-7.46 (m, 2H), 6.58 (d, J = 3.4 Hz, 1H), 6.12 (d, J = 3.9 Hz,





1H), 4.43-4.29 (m, 1H), 3.93 (t, J = 5.8 Hz,





2H), 3.46-3.21 (m, 6H), 3.18-3.05 (m, 1H), 2.65 (s,





3H), 2.27 (s, 3H), 2.23-1.70 (m, 4H), 1.12 (t, J = 7.4 Hz,





3H).


298
484.40
2.46
1H NMR (400 MHz, DMSO) δ 7.05 (d, J = 1.9 Hz, 1H),





7.01 (d, J = 8.1 Hz, 1H), 6.92 (dd, J = 8.1, 1.9 Hz, 1H),





6.59-6.53 (m, 1H), 6.19 (d, J = 4.0 Hz, 1H), 4.33 (s,





1H), 3.97 (t, J = 5.7 Hz, 2H), 3.76 (s, 3H),





3.62-3.34 (m, 2H), 3.31-2.99 (m, 3H), 2.28 (s, 3H), 2.11 (s, 2H),





1.84-1.71 (m, 2H), 1.29 (s, 9H).


299
530.50
1.56


300
540.50
1.41


301
428.23
1.93
1H NMR (400 MHz, DMSO) δ 7.35 (d, J = 8.2 Hz, 2H),





7.28 (d, J = 8.2 Hz, 2H), 6.73 (d, J = 4.0 Hz, 1H),





6.22 (d, J = 4.1 Hz, 1H), 4.47-4.24 (m, 1H), 4.12 (t, J = 5.8 Hz,





2H), 3.55-3.37 (m, 1H), 3.37-3.26 (m, 3H),





3.20 (s, 3H), 3.18-2.98 (m, 1H), 2.58-2.51 (m, 1H), 2.29 (s,





3H), 2.25-1.91 (m, 2H), 1.88-1.63 (m, 7H),





1.53-1.14 (m, 5H).


302
470.50
1.55


303
554.20
1.34


304
442.10
2.47


305
448.50
0.83


306
466.50
1.41
1H NMR (400 MHz, DMSO) δ 7.47 (d, J = 7.9 Hz, 1H),





7.24-7.12 (m, 2H), 6.60 (d, J = 3.7 Hz, 1H), 6.20 (d, J = 3.9 Hz,





1H), 4.97 (s, 1H), 4.27-4.08 (m, 1H),





4.08-3.93 (m, 2H), 3.51-3.13 (m, 5H), 2.54 (s, 3H),





2.42-2.13 (m, 2H), 1.97-1.68 (m, 3H), 1.51 (s, 6H),





0.68-0.47 (m, 4H).


307
476.40
3.77


308
450.50
1.61


309
436.22
1.75


310
505.30
1.55


311
492.30
1.44
1H NMR (400 MHz, CDCl3) δ 7.36 (t, J = 8.2 Hz, 1H),





7.25 (dd, J = 4.9, 2.7 Hz, 1H), 6.76 (dd, J = 8.6, 2.3 Hz,





1H), 6.62 (dd, J = 11.5, 2.4 Hz, 1H), 6.19 (d, J = 4.5 Hz,





1H), 4.66 (d, J = 13.4 Hz, 1H), 4.30-4.08 (m, 2H),





3.83 (s, 3H), 3.68-3.54 (m, 1H), 3.49 (d, J = 13.0 Hz, 1H),





3.25 (t, J = 13.0 Hz, 1H), 2.07-1.96 (m, 1H), 1.85 (t, J = 16.3 Hz,





2H), 1.70 (d, J = 12.7 Hz, 1H), 1.21 (s, 3H),





1.14 (s, 3H), 0.96 (s, 1H).


312
468.30
1.45


313
468.70
2.38


314
438.50
1.43
1H NMR (400 MHz, CDCl3) δ 7.25-7.19 (m, 1H),





7.02 (d, J = 1.8 Hz, 1H), 6.98 (dd, J = 8.2, 1.9 Hz, 1H),





6.88 (d, J = 8.2 Hz, 1H), 6.17 (d, J = 4.2 Hz, 1H), 4.57 (s,





1H), 4.56 (dd, J = 12.2, 6.1 Hz, 1H), 4.35 (t, J = 5.5 Hz,





2H), 3.88 (s, 3H), 3.74 (s, 1H), 3.34 (t, J = 5.2 Hz, 2H),





3.34 (s, 2H), 2.42 (s, 3H), 2.14 (s, 2H), 1.84 (s, 2H),





1.38 (d, J = 6.1 Hz, 6H).


315
494.50
1.45
1H NMR (400 MHz, DMSO) δ 7.26 (s, 1H), 7.18 (dd, J = 23.4,





7.8 Hz, 2H), 6.57 (s, 1H), 6.12 (d, J = 3.0 Hz, 1H),





5.25 (s, 1H), 4.85 (d, J = 1.1 Hz, 1H), 4.33 (s, 1H),





3.93 (s, 2H), 3.09 (s, 1H), 2.30 (s, 3H), 2.27 (s, 3H), 2.01 (s,





3H), 1.75 (s, 2H).


316
432.70
1.68
1H NMR (400 MHz, DMSO) δ 7.05-6.93 (m, 3H),





6.58 (d, J = 3.8 Hz, 1H), 6.13 (d, J = 3.9 Hz, 1H),





4.65-4.53 (m, 1H), 4.31-3.92 (m, 1H), 3.84-3.73 (m, 5H),





3.60-3.20 (m, 5H), 3.16-3.03 (m, 1H), 2.17-1.69 (m, 8H),





1.58-1.35 (m, 2H), 1.26 (d, J = 6.0 Hz, 6H).


317
506.40
3.47


318
450.20
0.99


319
392.50
1.37
1H NMR (400 MHz, CDCl3) δ 7.02 (d, J = 1.9 Hz, 1H),





6.98 (dd, J = 8.2, 1.9 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H),





6.53 (d, J = 3.8 Hz, 1H), 5.91 (d, J = 3.8 Hz, 1H),





4.57 (dt, J = 12.2, 6.1 Hz, 1H), 4.08 (d, J = 8.8 Hz, 1H),





3.88 (s, 3H), 3.67-3.18 (m, 5H), 2.27-1.86 (m, 2H), 1.65 (s,





3H), 1.38 (d, J = 6.1 Hz, 6H), 1.27 (d, J = 5.9 Hz, 3H),





0.79 (s, 1H).


320
466.30
1.24


321
438.20
1.16


322
437.20
0.89


323
428.15
2.27


324
498.50
1.66


325
512.50
1.71


326
548.70
1.24
1H NMR (400 MHz, DMSO) δ 7.08-6.95 (m, 3H),





6.65 (d, J = 3.7 Hz, 1H), 6.33 (d, J = 3.9 Hz, 1H),





4.96-4.68 (m, 1H), 4.68-4.53 (m, 1H), 4.08-3.98 (m, 1H),





3.90-3.84 (m, 1H), 3.77 (s, 3H), 3.74-3.51 (m, 2H),





3.47-3.35 (m, 1H), 3.35-3.28 (m, 2H), 3.28-3.11 (m, 1H),





2.32 (s, 3H), 2.13-1.86 (m, 2H), 1.27 (d, J = 6.0 Hz,





6H).


327
484.60
2.75
1H NMR (400 MHz, DMSO) δ 7.04-6.90 (m, 3H),





6.57 (d, J = 3.5 Hz, 1H), 6.07 (d, J = 3.9 Hz, 1H),





4.66-4.52 (m, 1H), 4.06-3.82 (m, 2H), 3.77 (s, 3H),





3.61-3.11 (m, 5H), 2.30-2.21 (m, 4H), 2.17-1.66 (m, 3H),





1.42 (d, J = 7.0 Hz, 3H), 1.26 (d, J = 6.0 Hz, 6H).


328
480.20
3.02


329
440.30
1.41


330
442.12
2.25


331
435.50
1.28
1H NMR (400 MHz, DMSO) δ 7.28-7.20 (m, 2H),





6.91 (d, J = 9.0 Hz, 1H), 6.59 (d, J = 3.6 Hz, 1H), 6.20 (d, J = 3.9 Hz,





1H), 4.65 (s, 1H), 4.25-3.91 (m, 3H), 3.73 (s,





2H), 3.65-3.09 (m, 5H), 2.36-2.14 (m, 5H),





1.92-1.68 (m, 3H), 1.23 (s, 6H), 0.66-0.46 (m, 4H).


332
506.20
3.81
1H NMR (400 MHz, DMSO) δ 7.29-7.18 (m, 2H),





7.02-6.92 (m, 1H), 6.60 (d, J = 3.5 Hz, 1H), 6.20 (d, J = 3.9 Hz,





1H), 4.70-4.53 (m, 1H), 4.27-3.90 (m, 3H),





3.72-3.04 (m, 5H), 2.42-2.18 (m, 2H), 2.14 (s, 3H),





1.90-1.64 (m, 3H), 1.29 (d, J = 6.0 Hz, 6H), 0.68-0.48 (m,





4H).


333
476.30
7.37


334
434.25
2.57


335
452.10
1.15


336
510.70
1.32
1H NMR (400 MHz, DMSO) δ 7.38-7.27 (m, 1H),





7.27-7.16 (m, 2H), 6.62 (d, J = 4.1 Hz, 1H), 6.11 (d, J = 4.0 Hz,





1H), 4.75-4.63 (m, 1H), 4.41-4.13 (m, 1H),





3.59-2.99 (m, 3H), 2.90 (d, J = 6.3 Hz, 2H), 2.77 (t, J = 7.2 Hz,





1H), 1.99-1.69 (m, 4H), 1.43 (s, 6H), 1.30 (d, J = 6.0 Hz,





6H).


337
468.70
5.63


338
424.20
0.95
1H NMR (400 MHz, DMSO) δ 7.36 (d, J = 8.1 Hz, 2H),





7.29-7.14 (m, 3H), 6.50 (d, J = 4.6 Hz, 1H),





4.53-4.13 (m, 3H), 3.62-2.96 (m, 5H), 2.53-2.46 (m, 2H),





2.30 (s, 3H), 2.25-1.93 (m, 2H), 1.93-1.74 (m, 3H),





0.87 (d, J = 6.6 Hz, 6H).


339
462.20
1.78


340
528.06
3.63


341
470.50
1.51


342
410.14
1.98


343
499.30
1.27


344
448.50
1.53
1H NMR (400 MHz, CDCl3) δ 8.43 (d, J = 1.5 Hz, 1H),





7.69-7.51 (m, 2H), 6.53 (d, J = 3.4 Hz, 1H), 5.95 (d, J = 3.5 Hz,





1H), 4.64-4.45 (m, 1H), 4.08-3.92 (m, 2H),





3.92-3.74 (m, 1H), 3.61-3.25 (m, 4H), 2.70 (q, J = 7.6 Hz,





2H), 2.39 (s, 3H), 2.28-1.82 (m, 4H), 1.28 (t, J = 7.6 Hz,





3H).


345
407.00
2.23


346
462.50
1.20
1H NMR (400 MHz, DMSO) δ 7.80 (d, J = 8.1 Hz, 1H),





7.51 (s, 1H), 7.46 (d, J = 8.4 Hz, 1H), 6.58 (d, J = 3.7 Hz,





1H), 6.12 (d, J = 3.9 Hz, 1H), 4.35 (d, J = 12.4 Hz,





1H), 3.93 (t, J = 5.5 Hz, 2H), 3.47-3.31 (m, 4H),





3.11 (t, J = 12.8 Hz, 1H), 2.76 (s, 6H), 2.58 (s, 3H), 2.27 (s,





3H), 2.18 (d, J = 12.5 Hz, 1H), 2.01 (d, J = 13.8 Hz,





1H), 1.84-1.69 (m, 2H).


347
499.30
1.36


348
544.02
3.17


349
478.50
1.29
1H NMR (400 MHz, DMSO) δ 7.59-7.40 (m, 1H),





7.24-7.08 (m, 2H), 6.60 (d, J = 3.5 Hz, 1H), 6.10 (s, 1H),





5.21-4.36 (m, 3H), 4.18-3.97 (m, 1H), 3.91-3.64 (m,





2H), 3.63-2.93 (m, 4H), 2.54 (s, 3H), 2.38-2.11 (m,





4H), 1.93-1.68 (m, 1H), 1.51 (s, 6H).


350
468.20
4.52


351
408.10
1.24


352
463.10
1.07


353
452.20
1.69


354
486.30
1.78


355
492.50
1.70
1H NMR (400 MHz, DMSO) δ 10.44 (s, 2H),





7.30-7.23 (m, 2H), 7.04-6.97 (m, 1H), 6.74 (d, J = 3.5 Hz, 1H),





6.50 (s, 1H), 4.66 (sept, J = 6.0 Hz, 1H), 4.32-4.17 (m,





2H), 4.18-3.88 (m, 1H), 3.81-3.60 (m, 5H),





2.35-2.19 (m, 2H), 2.19-2.07 (m, 2H), 2.16 (s, 3H), 1.30 (d,





J = 6.0 Hz, 6H).


356
436.50
1.39


357
495.50
1.43
1H NMR (400 MHz, DMSO) δ 7.52 (d, J = 8.3 Hz, 2H),





7.38 (d, J = 8.3 Hz, 2H), 7.28-7.19 (m, 1H), 6.50 (d, J = 4.6 Hz,





1H), 5.08 (s, 1H), 4.49-4.30 (m, 1H), 4.24 (t,





J = 5.6 Hz, 2H), 3.55-3.23 (m, 4H), 3.21-3.00 (m,





1H), 2.30 (s, 3H), 2.25-1.96 (m, 2H), 1.95-1.77 (m,





2H), 1.43 (s, 6H).


358
464.50
1.29


359
506.20
1.05


360
564.70
1.54


361
462.70
1.69
1H NMR (400 MHz, CDCl3) δ 8.62 (s, 1H), 7.03 (d, J = 1.9 Hz,





1H), 6.98 (dd, J = 8.2, 1.9 Hz, 1H), 6.89 (dd, J = 8.3,





2.4 Hz, 1H), 6.59 (dd, J = 28.9, 3.6 Hz, 1H),





6.17 (dd, J = 112.7, 4.0 Hz, 1H), 4.59 (dt, J = 12.1, 6.1 Hz,





1H), 4.08 (dd, J = 18.9, 5.5 Hz, 3H), 3.88 (d, J = 1.9 Hz,





3H), 3.36 (s, 2H), 2.41 (s, 2H), 2.14 (d, J = 49.0 Hz,





2H), 1.39 (d, J = 6.1 Hz, 6H).


362
480.30
4.65


363
502.30
2.46


364
452.50
1.52


365
421.30
1.20


366
504.50
1.85


367
440.50
1.31
1H NMR (400 MHz, DMSO) δ 7.77-7.58 (m, 1H),





7.36-7.10 (m, 3H), 6.22 (d, J = 4.2 Hz, 1H), 5.35 (s, 1H),





4.43-4.24 (m, 1H), 4.22-4.09 (m, 2H), 3.46-3.27 (m,





2H), 3.27-2.94 (m, 3H), 2.62-2.53 (m, 1H), 2.26 (s,





3H), 2.21-1.88 (m, 2H), 1.88-1.68 (m, 2H), 1.49 (s,





6H), 0.95-0.67 (m, 4H).


368
454.50
1.22


369
512.40
1.74
1H NMR (400 MHz, CDCl3) δ 7.62 (t, J = 8.1 Hz, 1H),





7.18 (dd, J = 8.0, 1.5 Hz, 1H), 7.12 (dd, J = 11.9, 1.5 Hz,





1H), 6.53 (d, J = 3.8 Hz, 1H), 5.94 (d, J = 3.9 Hz,





1H), 4.54 (s br, 1H), 3.99 (d br, J = 5.9 Hz, 2H), 3.57 (s





br, 2H), 3.33 (t, J = 6.0 Hz, 2H), 3.27 (s br, 1H), 2.38 (s,





3H), 2.19 (s br, 1H), 2.14-2.01 (m, 2H), 1.90 (s br, 1H),





1.72 (s br, 1H), 1.65 (s, 6H).


370
454.30
1.23
1H NMR (400 MHz, CDCl3) δ 8.40 (s, 1H),





7.45-7.20 (m, 1H), 7.08 (s, 1H), 6.55 (d, J = 3.4 Hz, 1H), 5.98 (d, J = 3.8 Hz,





1H), 4.58 (s, 1H), 4.00 (s, 3H), 3.81 (s, 1H),





3.62 (s, 1H), 3.37 (t, J = 5.8 Hz, 2H), 2.72 (s, 3H),





2.41 (s, 3H), 2.28-2.06 (m, 2H), 1.99 (t, J = 11.6 Hz, 2H).


371
483.70
1.22
1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 1.9 Hz, 1H),





6.98 (dd, J = 8.2, 1.9 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H),





6.54 (d, J = 3.7 Hz, 1H), 5.93 (d, J = 3.8 Hz, 1H),





4.56 (dd, J = 12.2, 6.1 Hz, 1H), 4.52 (s, 1H), 3.94 (s, 2H),





3.88 (s, 3H), 3.69 (s, 1H), 3.47 (s, 2H), 3.27 (s, 2H),





1.87 (s, 4H), 1.38 (d, J = 6.1 Hz, 6H). (NH is not





observed.)


372
452.50
1.21


373
508.40
1.47


374
456.50
1.47


375
508.40
1.66


376
438.50
1.54
1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 1.9 Hz, 1H),





7.64 (dd, J = 8.5, 2.1 Hz, 1H), 7.28-7.22 (m, 1H),





7.05 (d, J = 8.6 Hz, 1H), 6.20 (d, J = 4.5 Hz, 1H), 4.61 (s,





1H), 4.20 (s, 2H), 3.95 (s, 3H), 3.70 (s, 2H), 3.34 (s,





1H), 1.97 (s, 2H), 1.79 (s, 2H), 1.18 (s, 6H), 0.97 (s,





1H).


377
518.20
1.69


378
502.50
1.03


379
501.30
1.60


380
466.20
1.92
1H NMR (400 MHz, DMSO) δ 7.86-7.81 (m, 2H),





7.69-7.64 (m, 2H), 7.55 (q, J = 4.8 Hz, 1H), 6.59-6.55 (m,





1H), 6.19 (d, J = 4.0 Hz, 1H), 4.37 (d, J = 12.5 Hz, 1H),





3.97 (t, J = 5.8 Hz, 2H), 3.46-3.33 (m, 2H),





3.31-3.23 (m, 2H), 3.12 (t, J = 12.6 Hz, 1H), 2.44 (d, J = 4.9 Hz,





3H), 2.28 (s, 3H), 2.23-2.14 (m, 1H), 2.06-1.98 (m,





1H), 1.80 (t, J = 13.3 Hz, 2H).


381
521.50
1.35


382
410.21
2.12


383
500.24
1.24
1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 7.8 Hz, 1H),





7.21 (dd, J = 12.0, 4.2 Hz, 2H), 6.29 (s, 1H), 4.59 (s,





1H), 3.92 (s, 2H), 3.72 (q, J = 7.0 Hz, 3H), 3.61 (s, 1H),





3.46 (s, 1H), 3.30 (s, 2H), 3.19 (s, 1H), 2.75-2.61 (m,





2H), 2.48-2.35 (m, 8H), 2.25-2.06 (m, 3H), 1.99 (s,





2H), 1.72 (dtt, J = 10.7, 8.9, 5.2 Hz, 2H), 1.24 (t, J = 7.0 Hz,





5H).


384
480.20
1.34
1H NMR (400 MHz, DMSO) δ 7.01 (d, J = 1.4 Hz, 1H),





7.00-6.93 (m, 2H), 6.56 (s, 1H), 6.18 (d, J = 4.0 Hz,





1H), 4.42-4.33 (m, 1H), 4.26 (s, 1H), 3.97 (t, J = 5.8 Hz,





2H), 3.77 (s, 3H), 3.59 (s, 2H), 3.31-2.85 (m, 3H),





2.28 (s, 3H), 2.10 (s, 2H), 1.76 (t, J = 13.3 Hz, 2H),





1.71-1.50 (m, 2H), 1.22 (d, J = 6.1 Hz, 3H), 0.92 (t, J = 7.4 Hz,





3H).


385
530.50
1.56


386
416.13
2.51


387
420.22
1.81


388
422.20
2.02


389
446.20
1.59


390
484.70
2.55


391
510.70
1.63


392
484.30
1.33


393
454.30
1.72
1H NMR (400 MHz, DMSO) δ 7.26-7.19 (m, 2H),





6.96 (d, J = 9.1 Hz, 1H), 6.90 (d, J = 4.0 Hz, 1H), 6.20 (d, J = 4.0 Hz,





1H), 4.63 (hept, J = 6.0 Hz, 1H), 4.53-4.06 (m,





1H), 3.97 (t, J = 5.6 Hz, 2H), 3.38-2.87 (m, 5H),





2.27 (s, 3H), 2.14 (s, 3H), 2.11-1.95 (m, 2H), 1.83-1.65 (m,





2H), 1.28 (d, J = 6.0 Hz, 6H).


394
407.70
1.32


395
468.70
2.61


396
552.50
1.56


397
484.70
2.82
1H NMR (400 MHz, DMSO) δ 7.51 (d, J = 2.0 Hz, 1H),





7.38 (dd, J = 8.5, 2.0 Hz, 1H), 7.20 (d, J = 8.5 Hz, 1H),





7.05 (d, J = 4.1 Hz, 1H), 6.18 (d, J = 4.1 Hz, 1H),





4.80-4.67 (m, 1H), 4.46-4.08 (m, 3H), 3.62-3.30 (m, 2H),





3.30-2.97 (m, 3H), 2.31 (s, 3H), 2.27 (s, 3H),





2.21-1.91 (m, 2H), 1.89-1.69 (m, 2H), 1.31 (d, J = 6.0 Hz,





6H).


398
444.40
1.21


399
514.70
1.37


400
384.21
2.16
1H NMR (400 MHz, CDCl3) δ 7.32 (t, J = 7.5 Hz, 1H),





7.20-7.12 (m, 2H), 6.49 (s, 1H), 4.61 (s, 1H), 3.99 (s,





2H), 3.72 (q, J = 7.0 Hz, 3H), 3.68-3.09 (m, 5H),





2.85 (s, 2H), 2.43 (d, J = 17.8 Hz, 5H), 2.07 (s, 1H), 1.94 (s,





1H), 1.60 (s, 1H), 1.47-1.30 (m, 2H), 1.25 (dd, J = 11.5,





4.4 Hz, 11H).


401
502.10
1.48
1H NMR (400 MHz, DMSO) δ 7.53-7.38 (m, 4H),





7.27-7.14 (m, 2H), 7.14-6.96 (m, 4H), 6.49 (d, J = 4.6 Hz,





1H), 4.48-4.28 (m, 1H), 4.24 (t, J = 5.8 Hz, 2H),





3.65-3.23 (m, 4H), 3.23-2.94 (m, 1H), 2.31 (s, 3H),





2.23-1.95 (m, 2H), 1.95-1.75 (m, 2H).


402
498.30
1.63


403
412.50
1.45


404
496.40
1.79
1H NMR (400 MHz, CDCl3) δ 7.06-6.95 (m, 2H),





6.93-6.85 (m, 1H), 6.63 (d, J = 4.0 Hz, 1H), 5.91 (d, J = 4.0 Hz,





1H), 4.57 (dt, J = 12.1, 6.1 Hz, 1H), 3.88 (s, 3H),





3.49 (s, 3H), 2.96 (s, 2H), 1.84 (s, 4H), 1.59 (s, 2H),





1.51 (s, 6H), 1.38 (d, J = 6.1 Hz, 6H).


405
480.30
1.78


406
436.09
2.50


407
424.50
1.03


408
490.50
1.79
1H NMR (400 MHz, DMSO) δ 7.39 (d, J = 8.7 Hz, 2H),





7.26 (dd, J = 4.4, 2.2 Hz, 1H), 6.97 (d, J = 8.7 Hz, 2H),





6.55 (d, J = 4.6 Hz, 1H), 4.33 (s, 1H), 4.11 (s, 2H),





4.03 (t, J = 6.6 Hz, 2H), 3.52 (s, 2H), 3.24 (s, 1H), 2.27 (s,





1H), 1.94-1.83 (m, 2H), 1.83-1.67 (m, 3H), 1.62 (q, J = 6.7 Hz,





2H), 1.08 (s, 6H), 0.93 (d, J = 6.6 Hz, 6H).


409
506.00
1.94
1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 7.7 Hz, 1H),





7.07-6.96 (m, 2H), 6.29 (s, 1H), 5.30 (s, 0H), 4.62 (s,





1H), 3.90 (d, J = 10.6 Hz, 5H), 3.50 (dd, J = 80.7, 48.4 Hz,





6H), 2.50 (ddd, J = 13.9, 8.6, 5.6 Hz, 2H),





2.45-2.32 (m, 5H), 2.17 (s, 2H), 2.12-1.91 (m, 8H), 1.63 (dt,





J = 15.7, 8.6 Hz, 2H).


410
496.30
1.36


411
496.70
1.34
1H NMR (400 MHz, DMSO) δ 7.01 (d, J = 1.2 Hz, 1H),





7.00-6.93 (m, 2H), 6.56 (s, 1H), 6.18 (d, J = 4.0 Hz,





1H), 4.42-4.33 (m, 1H), 4.33-4.02 (m, 1H), 3.97 (t, J = 5.7 Hz,





2H), 3.77 (s, 3H), 3.59 (s, 2H), 3.20 (t, J = 20.2 Hz,





3H), 2.28 (s, 3H), 2.10 (s, 2H), 1.76 (t, J = 13.5 Hz,





2H), 1.71-1.51 (m, 2H), 1.22 (d, J = 6.1 Hz, 3H),





0.92 (t, J = 7.4 Hz, 3H).


412
530.50
1.57


413
444.20
0.94


414
450.14
2.53


415
489.50
2.26


416
440.19
1.82


417
440.50
1.38


418
438.50
1.44
1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 2.0 Hz, 1H),





7.40 (dd, J = 8.5, 2.1 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H),





6.56 (d, J = 3.8 Hz, 1H), 6.02 (d, J = 3.8 Hz, 1H),





5.92 (s, 1H), 4.69-4.54 (m, 1H), 4.41-4.20 (m, 2H), 4.15 (t,





J = 6.6 Hz, 2H), 4.06-3.56 (m, 2H), 3.41 (t, J = 6.5 Hz,





2H), 2.72 (s, 3H), 2.56-2.44 (m, 2H), 2.44-1.48 (m,





2H), 1.40 (d, J = 6.1 Hz, 6H).


419
513.20
5.54
1H NMR (400 MHz, CDCl3) δ 7.25 (dd, J = 9.6, 2.6 Hz,





3H), 6.80 (d, J = 9.0 Hz, 1H), 6.49 (s, 1H), 4.60 (s, 1H),





4.06 (q, J = 7.0 Hz, 2H), 3.99 (s, 2H), 3.72 (q, J = 7.0 Hz,





2H), 3.32 (s, 4H), 2.43 (d, J = 20.3 Hz, 5H), 2.23 (s,





3H), 2.01 (s, 2H), 1.58 (s, 1H), 1.44 (t, J = 7.0 Hz, 3H),





1.25 (dd, J = 8.8, 5.2 Hz, 4H).


420
470.50
1.71


421
506.50
1.41


422
471.10
1.42


423
492.50
1.77


424
434.19
2.62


425
392.20
1.97


426
522.50
2.19
1H NMR (400 MHz, CDCl3) δ 7.38-7.28 (m, 1H),





6.72 (d, J = 8.3 Hz, 1H), 6.59 (d, J = 11.7 Hz, 1H), 6.53 (d, J = 3.7 Hz,





1H), 5.95-5.84 (m, 1H), 4.68-4.46 (m, 2H),





4.07 (dd, J = 11.6, 5.2 Hz, 1H), 3.66-3.14 (m, 5H),





2.29-1.47 (m, 4H), 1.35 (d, J = 5.9 Hz, 6H),





1.31-1.22 (m, J = 6.1 Hz, 3H), 1.19-0.77 (m, 1H).


427
454.40
1.36
1H NMR (400 MHz, CDCl3) δ 7.08 (d, J = 1.9 Hz, 1H),





7.02 (dd, J = 8.2, 1.9 Hz, 1H), 6.87 (d, J = 8.3 Hz, 1H),





6.55 (d, J = 3.1 Hz, 1H), 6.15 (d, J = 3.9 Hz, 1H),





4.56 (dt, J = 12.2, 6.1 Hz, 1H), 4.13 (t, J = 4.4 Hz, 2H),





3.88 (s, 3H), 3.92-3.84 (m, 2H), 3.79 (s, 2H), 3.63 (s, 2H),





3.22-2.96 (m, 2H), 2.46 (dd, J = 14.4, 7.5 Hz, 2H),





1.82 (s, 2H), 1.38 (d, J = 6.1 Hz, 6H), 1.17 (t, J = 7.3 Hz,





3H).


428
508.70
1.83
1H NMR (400 MHz, DMSO) δ 6.97 (q, J = 8.3 Hz, 3H),





6.62 (d, J = 3.6 Hz, 1H), 6.37 (d, J = 3.9 Hz, 1H),





4.59 (dt, J = 12.1, 6.0 Hz, 1H), 4.09-3.97 (m, 1H), 3.84 (s,





1H), 3.76 (s, 3H), 3.06 (s, 1H), 2.69 (s, 2H), 2.19 (s,





3H), 2.07 (s, 1H), 1.87 (d, J = 27.8 Hz, 2H), 1.26 (d, J = 6.0 Hz,





6H), 1.11 (t, J = 7.2 Hz, 1H), 0.88 (s, 3H).


429
480.50
1.28


430
382.16
2.33


431
455.50
2.70


432
464.20
1.08
1H NMR (400 MHz, DMSO) δ 7.43 (s, 2H), 7.25 (dd, J = 4.5,





2.2 Hz, 1H), 6.50 (d, J = 4.6 Hz, 1H),





4.73-4.64 (m, 1H), 4.39 (d, J = 12.7 Hz, 1H), 4.11 (s, 2H), 3.76 (d,





J = 12.7 Hz, 1H), 3.51 (t, J = 12.3 Hz, 1H), 3.21 (t, J = 11.2 Hz,





1H), 2.34 (s, 3H), 2.29 (s, 1H), 1.94-1.78 (m,





3H), 1.68 (d, J = 12.4 Hz, 1H), 1.31 (d, J = 6.0 Hz, 6H),





1.09 (d, J = 12.1 Hz, 6H).


433
493.30
1.67


434
480.30
1.36


435
466.50
1.34


436
472.30
2.95


437
506.50
1.84


438
493.20
1.26


439
496.70
1.52


440
468.20
1.03


441
498.50
1.26


442
539.50
1.38
1H NMR (400 MHz, CDCl3) δ 7.01 (d, J = 1.9 Hz, 1H),





6.97 (dd, J = 8.2, 1.9 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H),





6.53 (d, J = 3.5 Hz, 1H), 5.94 (d, J = 3.7 Hz, 1H),





4.56 (dq, J = 12.2, 6.1 Hz, 1H), 4.52-4.34 (m, 1H),





4.05-3.94 (m, 2H), 3.87 (s, 3H), 3.69 (s, 1H), 3.50 (s, 1H),





3.34 (s, 1H), 3.34 (t, J = 5.7 Hz, 2H), 2.39 (s, 3H),





2.13 (s, 2H), 1.84 (s, 2H), 1.38 (d, J = 6.1 Hz, 6H).


443
466.50
1.23


444
507.50
1.68


445
468.70
1.42


446
468.70
1.47


447
464.30
1.18


448
437.50
1.21


449
546.70
1.55
1H NMR (400 MHz, DMSO) δ 7.88 (d, J = 7.9 Hz, 1H),





7.71 (d, J = 8.0 Hz, 1H), 7.45 (s, 1H), 7.42 (d, J = 8.1 Hz,





1H), 6.58 (d, J = 3.6 Hz, 1H), 6.12 (d, J = 3.8 Hz,





1H), 4.35 (d, J = 11.4 Hz, 1H), 3.96-3.86 (m, 2H),





3.45-3.34 (m, 2H), 3.29-3.19 (m, 3H), 3.17-3.01 (m, 1H),





2.60 (s, 3H), 2.27 (s, 3H), 2.22-2.10 (m, 1H),





2.06-1.95 (m, 1H), 1.84-1.67 (m, 2H), 0.97 (d, J = 6.5 Hz,





6H).


450
513.30
1.37
1H NMR (400 MHz, DMSO) δ 7.52 (d, J = 8.3 Hz, 2H),





7.36 (d, J = 8.3 Hz, 2H), 6.60 (d, J = 3.8 Hz, 1H),





6.20 (d, J = 3.9 Hz, 1H), 5.07 (s, 1H), 4.26-4.09 (m, 1H),





3.98 (t, J = 5.8 Hz, 2H), 3.51-3.13 (m, 5H),





2.43-2.12 (m, 2H), 1.95-1.69 (m, 3H), 1.43 (s, 6H),





0.63-0.50 (m, 4H).


451
462.20
3.29


452
415.50
1.06


453
483.20
1.12


454
438.50
1.36
1H NMR (400 MHz, DMSO) δ 7.28-7.17 (m, 1H),





7.06-6.95 (m, 3H), 6.50 (d, J = 4.6 Hz, 1H), 4.65-4.51 (m,





1H), 4.48-4.05 (m, 3H), 3.78 (s, 3H), 3.67-2.99 (m,





5H), 2.30 (s, 3H), 2.18-1.98 (m, 2H), 1.94-1.75 (m,





2H), 1.25 (d, J = 6.0 Hz, 6H).


455
494.50
1.44
1H NMR (400 MHz, DMSO) δ 7.47 (d, J = 8.7 Hz, 1H),





7.21-7.14 (m, 2H), 7.05 (d, J = 4.1 Hz, 1H), 6.18 (d, J = 4.2 Hz,





1H), 4.97 (s, 1H), 4.43-4.25 (m, 1H), 4.18 (t,





J = 5.8 Hz, 2H), 3.54-3.29 (m, 2H), 3.29-3.19 (m,





2H), 3.18-2.99 (m, 1H), 2.54 (s, 3H), 2.31 (s, 3H),





2.26 (s, 3H), 2.19-1.94 (m, 2H), 1.86-1.66 (m, 2H), 1.51 (s,





6H).


456
424.20
0.90


457
382.50
0.91
1H NMR (400 MHz, CDCl3) δ 7.01 (d, J = 1.8 Hz, 1H),





6.96 (dd, J = 8.2, 1.9 Hz, 1H), 6.87 (d, J = 8.3 Hz, 1H),





6.63 (d, J = 3.5 Hz, 1H), 6.06 (d, J = 2.2 Hz, 1H),





4.92 (t, J = 6.3 Hz, 1H), 4.56 (dt, J = 12.1, 6.1 Hz, 1H),





4.36 (s, 1H), 3.87 (s, 3H), 3.76 (s, 3H), 3.50 (d, J = 50.0 Hz,





5H), 2.33 (s, 3H), 2.28 (s, 1H), 2.06 (s, 1H), 1.86 (s,





2H), 1.38 (d, J = 6.1 Hz, 6H).


458
524.70
1.87
1H NMR (400 MHz, DMSO) δ 7.76 (dd, J = 8.6, 2.0 Hz,





1H), 7.70 (d, J = 1.9 Hz, 1H), 7.33 (d, J = 8.7 Hz, 1H),





7.28-7.19 (m, 1H), 6.49 (d, J = 4.6 Hz, 1H),





4.52-4.15 (m, 3H), 3.94 (s, 3H), 3.59-2.96 (m, 5H), 2.31 (s, 3H),





2.26-1.78 (m, 4H).


459
504.50
1.59
1H NMR (400 MHz, DMSO) δ 7.29-7.19 (m, 2H),





6.98 (d, J = 9.1 Hz, 1H), 6.63 (d, J = 3.9 Hz, 1H), 6.29 (d, J = 4.0 Hz,





1H), 4.71-4.56 (m, 1H), 4.05 (t, J = 5.0 Hz,





2H), 3.99-3.79 (m, 2H), 3.78-3.44 (m, 7H),





2.98-2.73 (m, 2H), 2.14 (s, 3H), 1.91-1.72 (m, 2H), 1.29 (d,





J = 6.0 Hz, 6H).


460
494.20
6.64
1H NMR (400 MHz, DMSO) δ 7.46 (d, J = 2.1 Hz, 1H),





7.29 (dd, J = 8.4, 2.2 Hz, 1H), 6.98 (d, J = 8.6 Hz, 1H),





6.60-6.50 (m, 1H), 6.18 (d, J = 4.0 Hz, 1H), 5.05 (t, J = 5.7 Hz,





1H), 4.72-4.58 (m, 1H), 4.48 (d, J = 5.7 Hz,





2H), 4.43-4.14 (m, 1H), 3.97 (t, J = 5.7 Hz, 2H),





3.82-3.42 (m, 1H), 3.40-2.91 (m, 4H), 2.29 (s, 3H),





2.22-2.01 (m, 2H), 1.86-1.65 (m, 2H), 1.27 (d, J = 6.0 Hz,





6H).


461
516.50
1.26


462
438.20
2.57


463
518.30
1.51
1H NMR (400 MHz, Acetone) δ 7.99-7.93 (m, 2H),





7.76-7.70 (m, 2H), 6.61-6.54 (m, 1H), 6.18 (d, J = 4.1 Hz,





1H), 4.52 (d, J = 10.5 Hz, 1H), 4.10 (t, J = 5.9 Hz,





2H), 3.63-3.41 (m, 4H), 3.24 (t, J = 11.3 Hz, 1H),





2.43 (s, 3H), 2.38-2.11 (m, 2H), 1.99-1.84 (m, 2H), 1.33 (s,





9H).


464
548.70
1.46


465
422.30
0.80


466
484.07
2.75


467
562.70
1.67
1H NMR (400 MHz, DMSO) δ 7.47-7.38 (m, 2H),





7.27-7.19 (m, 1H), 6.46 (d, J = 4.6 Hz, 1H), 4.76-4.62 (m,





1H), 4.46-4.30 (m, 1H), 4.24 (t, J = 5.9 Hz, 2H),





3.87-3.68 (m, 1H), 3.46-3.25 (m, 3H), 3.19-2.98 (m, 1H),





2.35 (s, 3H), 2.31 (s, 3H), 2.26-1.97 (m, 2H),





1.95-1.72 (m, 2H), 1.30 (d, J = 6.0 Hz, 6H).


468
479.50
1.47
1H NMR (400 MHz, CDCl3) δ 7.59-7.49 (m, 2H),





7.48-7.37 (m, 2H), 6.50 (s, 1H), 4.64 (s, 1H), 4.00 (s, 2H),





3.72 (q, J = 7.0 Hz, 2H), 3.48 (d, J = 126.2 Hz, 5H),





2.46 (s, 5H), 2.07 (s, 1H), 1.88 (d, J = 33.9 Hz, 2H),





1.59 (s, 7H), 1.24 (dd, J = 9.2, 4.8 Hz, 4H).


469
470.50
1.36


470
494.50
1.48


471
488.50
1.65


472
403.15
1.35


473
408.26
2.32
1H NMR (400 MHz, CDCl3) δ 7.38 (t, J = 8.2 Hz, 1H),





6.73 (d, J = 8.5 Hz, 1H), 6.68-6.50 (m, 2H),





6.06-5.71 (m, 2H), 4.61-4.50 (m, 1H), 4.46-4.30 (m, 2H),





4.15 (t, J = 6.3 Hz, 2H), 4.11-3.93 (m, 1H), 3.59 (t, J = 5.2 Hz,





1H), 3.50-3.33 (m, 2H), 2.79-2.65 (m, 3H),





2.58-2.39 (m, 2H), 2.36-1.47 (m, 2H), 1.35 (d, J = 6.0 Hz,





6H).


474
497.40
5.17


475
468.60
6.38


476
408.50
1.20


477
440.50
1.28


478
500.24
1.24


479
507.14
2.56


480
576.70
1.69


481
462.50
0.94


482
500.50
1.45


483
498.70
2.94


484
442.70
1.28


485
465.50
1.29


486
498.50
1.39
1H NMR (400 MHz, DMSO) δ 7.44 (d, J = 8.0 Hz, 1H),





7.29-7.12 (m, 3H), 6.50 (d, J = 4.6 Hz, 1H), 4.69 (s,





1H), 4.49-4.17 (m, 3H), 3.61-2.94 (m, 5H), 2.53 (s,





3H), 2.30 (s, 3H), 2.24-1.59 (m, 12H).


487
504.50
1.49


488
436.50
1.42


489
514.22
1.27


490
465.50
1.34
1H NMR (400 MHz, DMSO) δ 10.67 (s, 1H), 7.44 (d, J = 2.0 Hz,





1H), 7.32-7.21 (m, 2H), 6.99 (d, J = 8.3 Hz,





1H), 6.56 (d, J = 4.6 Hz, 1H), 5.76 (s, 1H), 4.14 (s, 1H),





4.10 (s, 2H), 3.53 (s, 1H), 2.26 (s, 1H), 1.88 (td, J = 13.1,





4.4 Hz, 2H), 1.73 (d, J = 13.9 Hz, 2H), 1.08 (s,





6H).


491
470.20
0.96
1H NMR (400 MHz, DMSO) δ 7.89 (d, J = 8.0 Hz, 1H),





7.58-7.47 (m, 2H), 6.60 (d, J = 3.4 Hz, 1H), 6.21 (d, J = 3.9 Hz,





1H), 4.29-4.14 (m, 1H), 3.98 (t, J = 5.8 Hz,





2H), 3.55-3.44 (m, 1H), 3.44-3.16 (m, 5H), 2.65 (s,





3H), 2.43-2.14 (m, 2H), 1.94-1.68 (m, 3H), 1.17 (d, J = 6.8 Hz,





6H), 0.65-0.48 (m, 4H).


492
524.20
3.40


493
456.50
1.34


494
492.40
1.86


495
450.30
1.64


496
510.70
1.31


497
394.30
1.08
1H NMR (400 MHz, DMSO) δ 7.85-7.39 (m, 3H),





6.65-6.51 (m, 1H), 6.17-6.05 (m, 1H), 4.51-4.32 (m, 1H),





3.92 (t, J = 5.7 Hz, 2H), 3.55-3.38 (m, 1H),





3.41-3.24 (m, 3H), 3.25-2.97 (m, 2H), 2.42-2.29 (m, 3H),





2.26 (s, 3H), 2.24-2.15 (m, 1H), 2.13-1.51 (m, 3H),





1.17 (d, J = 6.8 Hz, 6H).


498
498.20
2.37
1H NMR (400 MHz, DMSO) δ 7.29 (dd, J = 24.6, 8.1 Hz,





4H), 6.58 (d, J = 3.7 Hz, 1H), 6.12 (d, J = 3.9 Hz,





1H), 4.35 (s, 1H), 3.92 (t, J = 5.8 Hz, 2H), 3.42 (s, 1H),





3.10 (s, 1H), 2.68 (s, 2H), 2.27 (s, 3H), 2.07 (s, 1H),





1.75 (s, 2H), 1.07 (s, 6H).


499
450.50
1.18


500
526.50
1.35
1H NMR (400 MHz, DMSO) δ 7.39 (d, J = 8.7 Hz, 2H),





7.28-7.17 (m, 1H), 6.97 (d, J = 8.7 Hz, 2H), 6.49 (d, J = 4.6 Hz,





1H), 4.50-4.04 (m, 3H), 3.78 (d, J = 6.5 Hz,





2H), 3.68-2.91 (m, 5H), 2.30 (s, 3H), 2.19-1.93 (m,





3H), 1.91-1.75 (m, 2H), 0.98 (d, J = 6.7 Hz, 6H).


501
478.50
1.67
1H NMR (400 MHz, CDCl3) δ 7.98-7.93 (m, 2H),





7.63-7.57 (m, 2H), 7.22 (dd, J = 4.3, 2.1 Hz, 1H), 6.17 (d, J = 4.4 Hz,





1H), 4.69-4.57 (m, 1H), 4.36 (t, J = 5.7 Hz,





2H), 3.57 (t, J = 10.0 Hz, 1H), 3.49-3.39 (m, 1H),





3.34 (t, J = 5.3 Hz, 2H), 3.29 (s, 1H), 2.41 (s, 3H), 2.25 (d, J = 13.3 Hz,





1H), 2.08 (d, J = 16.5 Hz, 1H), 1.95 (t, J = 13.8 Hz,





1H), 1.72 (t, J = 13.9 Hz, 1H), 1.36 (s, 9H).


502
526.30
1.45


503
451.30
1.34


504
435.26
1.19


505
532.50
1.61


506
466.50
1.53


507
410.21
2.09


508
526.50
1.40


509
508.50
1.74
1H NMR (400 MHz, DMSO) δ 7.28-7.18 (m, 1H),





7.06-6.93 (m, 3H), 6.49 (d, J = 4.6 Hz, 1H), 4.49-4.16 (m,





3H), 4.11-4.00 (m, 4H), 3.77-3.39 (m, 1H),





3.38-3.26 (m, 3H), 3.24-2.88 (m, 1H), 2.30 (s, 3H),





2.21-1.95 (m, 2H), 1.93-1.73 (m, 2H), 1.40-1.26 (m, 6H).


510
494.70
1.48


511
450.50
1.67


512
402.25
2.29


513
498.30
2.96


514
527.25
1.38
1H NMR (400 MHz, DMSO) δ 7.95 (d, J = 8.0 Hz, 1H),





7.54-7.48 (m, 2H), 6.58 (d, J = 3.4 Hz, 1H), 6.12 (d, J = 3.9 Hz,





1H), 4.36 (d, J = 12.9 Hz, 1H), 3.93 (t, J = 5.6 Hz,





2H), 3.46-3.32 (m, 2H), 3.31-3.27 (m, 2H),





3.25 (s, 3H), 3.12 (t, J = 11.9 Hz, 1H), 2.67 (s, 3H), 2.27 (s,





3H), 2.18 (d, J = 13.7 Hz, 1H), 2.01 (d, J = 14.5 Hz,





1H), 1.85-1.69 (m, 2H).


515
470.50
1.13
1H NMR (400 MHz, DMSO) δ 7.34-7.12 (m, 1H),





7.12-6.93 (m, 3H), 6.50 (d, J = 4.5 Hz, 1H), 4.52-4.14 (m,





3H), 3.89-3.71 (m, 5H), 3.69-2.94 (m, 5H), 2.31 (s,





3H), 2.24-1.95 (m, 3H), 1.95-1.72 (m, 2H), 0.98 (d, J = 6.7 Hz,





6H).


516
508.70
1.61


517
554.10
1.52


518
466.30
0.99


519
394.22
2.19


520
450.10
2.03


521
422.50
1.30


522
466.50
3.36
1H NMR (400 MHz, DMSO) δ 7.47 (d, J = 8.7 Hz, 1H),





7.22-7.13 (m, 2H), 7.09 (d, J = 4.3 Hz, 1H), 6.17 (d, J = 4.3 Hz,





1H), 4.97 (s, 1H), 4.47-4.24 (m, 1H), 4.15 (t,





J = 5.9 Hz, 2H), 3.53-3.29 (m, 2H), 3.28-3.18 (m,





2H), 3.16-2.97 (m, 1H), 2.54 (s, 3H), 2.27 (s, 3H),





2.19-1.93 (m, 2H), 1.88-1.62 (m, 2H), 1.51 (s, 6H), 1.27 (s,





9H).


523
466.40
1.18


524
478.50
1.66


525
480.50
4.06


526
475.12
3.70


527
415.50
1.03
1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 2.1 Hz, 1H),





7.32 (dd, J = 8.4, 2.1 Hz, 1H), 7.22 (dd, J = 4.3, 2.1 Hz,





1H), 6.96 (d, J = 8.6 Hz, 1H), 6.16 (d, J = 4.4 Hz, 1H),





4.61 (dt, J = 12.2, 6.1 Hz, 1H), 4.56 (s, 1H), 4.35 (t, J = 5.8 Hz,





2H), 3.78-3.40 (m, 2H), 3.34 (s, 1H), 3.34 (t, J = 5.4 Hz,





2H), 2.41 (s, 3H), 2.14 (s, 2H), 1.83 (s, 2H),





1.40 (d, J = 6.1 Hz, 6H).


528
498.30
1.61


529
498.30
1.53


530
430.17
2.69


531
446.22
2.08
1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 8.5 Hz, 2H),





7.58 (d, J = 8.4 Hz, 2H), 6.95 (d, J = 4.2 Hz, 1H),





6.02 (d, J = 4.1 Hz, 1H), 5.02 (s, 1H), 4.67-4.48 (m, 1H),





4.35 (t, J = 5.9 Hz, 2H), 3.66-3.36 (m, 2H),





3.36-3.21 (m, 3H), 2.40 (s, 3H), 2.38 (s, 3H), 2.32-2.16 (m, 2H),





2.16-2.00 (m, 1H), 2.00-1.84 (m, 1H), 1.82-1.66 (m,





1H), 0.71-0.57 (m, 4H).


532
471.40
0.88
1H NMR (400 MHz, CDCl3) δ 7.32-7.28 (m, 2H),





6.92-6.79 (m, 1H), 6.55 (d, J = 3.8 Hz, 1H), 6.02 (d, J = 3.9 Hz,





1H), 5.90 (s, 1H), 4.63-4.51 (m, 1H),





4.35-4.19 (m, 2H), 4.15 (t, J = 6.6 Hz, 2H), 4.00-3.56 (m, 2H),





3.41 (t, J = 6.5 Hz, 2H), 2.71 (s, 3H), 2.53-2.44 (m,





2H), 2.22 (s, 3H), 2.18-1.38 (m, 2H), 1.35 (d, J = 6.0 Hz,





6H).


533
493.40
5.60
1H NMR (400 MHz, DMSO) δ 7.89 (d, J = 8.0 Hz, 1H),





7.55-7.46 (m, 2H), 5.99 (d, J = 3.5 Hz, 1H), 5.93 (d, J = 3.6 Hz,





1H), 4.39-4.24 (m, 1H), 3.83-3.72 (m, 2H),





3.71-3.56 (m, 2H), 3.55-3.42 (m, 1H), 3.42-3.20 (m,





4H), 3.20-3.05 (m, 1H), 2.64 (s, 3H), 2.24 (s, 3H),





2.19-2.09 (m, 1H), 2.02-1.91 (m, 1H), 1.79-1.62 (m, 2H),





1.17 (d, J = 6.8 Hz, 6H).


534
512.70
1.11
1H NMR (400 MHz, DMSO) δ 7.05 (d, J = 4.2 Hz, 1H),





7.03-6.94 (m, 3H), 6.18 (d, J = 4.1 Hz, 1H),





4.66-4.53 (m, 1H), 4.50-4.11 (m, 3H), 3.77 (s, 3H),





3.70-3.29 (m, 2H), 3.28-3.02 (m, 3H), 2.31 (s, 3H), 2.27 (s, 3H),





2.18-1.96 (m, 2H), 1.86-1.67 (m, 2H), 1.26 (d, J = 6.0 Hz,





6H).


535
440.60
1.00


536
506.50
1.62


537
464.50
1.59


538
494.70
1.51


539
446.17
2.28


540
486.50
2.17


541
510.17
2.18
1H NMR (400 MHz, DMSO) δ 7.27-7.18 (m, 2H),





6.97 (d, J = 9.1 Hz, 1H), 6.73 (d, J = 4.0 Hz, 1H), 6.21 (d, J = 4.1 Hz,





1H), 4.72-4.54 (m, 1H), 4.46-4.01 (m, 3H),





3.80-3.37 (m, 1H), 3.36-3.26 (m, 3H), 3.20 (s, 3H),





3.17-2.89 (m, 1H), 2.29 (s, 3H), 2.14 (s, 3H),





2.14-1.96 (m, 2H), 1.84-1.64 (m, 2H), 1.29 (d, J = 6.0 Hz,





6H).


542
460.50
1.36
1H NMR (400 MHz, DMSO) δ 7.28-7.18 (m, 2H),





6.98 (d, J = 9.1 Hz, 1H), 6.60 (d, J = 3.8 Hz, 1H), 6.10 (s,





1H), 5.15-4.76 (m, 1H), 4.68-4.57 (m, 1H),





4.52-4.19 (m, 1H), 4.17-4.00 (m, 1H), 3.90-3.73 (m, 2H),





3.60-2.96 (m, 4H), 2.30 (s, 3H), 2.26-2.18 (m, 1H),





2.14 (s, 3H), 1.93-1.75 (m, 1H), 1.29 (d, J = 6.0 Hz,





6H).


543
468.20
6.35
1H NMR (400 MHz, CDCl3) δ 6.89-6.73 (m, 2H),





6.56 (d, J = 3.1 Hz, 1H), 5.96 (d, J = 3.9 Hz, 1H), 4.53 (s br,





1H), 4.50-4.41 (m, 1H), 4.02 (s, 2H), 3.89 (s, 3H),





3.60 (d, J = 45.1 Hz, 2H), 3.36 (t, J = 6.0 Hz, 2H),





3.34-3.19 (m, 1H), 2.41 (s, 3H), 2.18 (s, 2H), 1.83 (d, J = 51.6 Hz,





2H), 1.34 (d, J = 6.1 Hz, 6H).


544
484.30
1.59


545
480.50
1.30


546
454.50
1.49
1H NMR (400 MHz, DMSO) δ 7.04-6.91 (m, 3H),





5.99 (d, J = 3.5 Hz, 1H), 5.92 (d, J = 3.6 Hz, 1H),





4.65-4.52 (m, 1H), 4.44-3.95 (m, 1H), 3.82-3.71 (m, 5H),





3.71-3.55 (m, 2H), 3.43-2.97 (m, 5H), 2.24 (s, 3H),





2.13-1.92 (m, 2H), 1.78-1.59 (m, 2H), 1.26 (d, J = 6.0 Hz,





6H).


547
480.30
1.17


548
495.06
3.68


549
452.50
1.16


550
452.30
1.32
1H NMR (400 MHz, DMSO) δ 7.06-6.89 (m, 3H),





6.60 (d, J = 3.8 Hz, 1H), 6.15 (d, J = 3.9 Hz, 1H),





4.68-4.47 (m, 1H), 4.46-3.89 (m, 1H), 3.77 (s, 3H), 3.70 (s, 2H),





3.66-2.78 (m, 3H), 2.09 (s, 1H), 1.95-1.52 (m, 4H),





1.26 (d, J = 6.0 Hz, 6H), 1.09 (s, 6H).


551
480.40
1.35


552
486.50
1.40


553
518.20
1.67
1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 7.6 Hz, 1H),





6.99 (dd, J = 7.6, 1.4 Hz, 1H), 6.97 (d, J = 1.2 Hz, 1H),





6.48 (s, 1H), 4.63 (d, J = 11.1 Hz, 1H), 4.58 (s, 2H),





3.98 (t, J = 5.4 Hz, 2H), 3.86 (s, 3H), 3.75 (t, J = 6.7 Hz,





2H), 3.62 (s, 1H), 3.45 (s, 1H), 3.37-3.24 (m, 2H),





3.18 (s, 1H), 2.58-2.33 (m, 8H), 2.08 (d, J = 12.8 Hz, 1H),





2.01 (d, J = 4.6 Hz, 2H), 1.89 (d, J = 12.4 Hz, 1H).


554
568.40
1.86


555
512.20
1.27


556
493.50
1.52
1H NMR (400 MHz, DMSO) δ 7.92 (d, J = 8.3 Hz, 2H),





7.73 (d, J = 8.2 Hz, 2H), 7.32-7.23 (m, 1H), 6.57 (d, J = 4.6 Hz,





1H), 4.51-4.32 (m, 1H), 4.18-4.00 (m, 2H),





3.63-3.38 (m, 2H), 3.38-3.15 (m, 2H), 2.29 (s, 1H),





2.01-1.57 (m, 4H), 1.17 (d, J = 6.8 Hz, 6H), 1.12 (s,





3H), 1.04 (s, 3H).


557
526.50
1.38


558
440.20
1.76


559
434.25
2.64


560
484.70
1.71


561
501.50
1.31
1H NMR (400 MHz, CDCl3) δ 7.42-7.35 (m, 2H),





6.92-6.86 (m, 2H), 6.29 (s, 1H), 4.58 (dt, J = 12.1, 6.1 Hz,





1H), 3.93 (s, 2H), 3.30 (s, 3H), 2.42 (s, 3H), 2.09 (s,





4H), 1.56 (s, 1H), 1.35 (d, J = 6.1 Hz, 7H).


562
454.50
2.85


563
502.10
2.01


564
496.20
1.20


565
482.50
1.46


566
492.50
1.61


567
504.20
1.11


568
454.50
1.44
1H NMR (400 MHz, DMSO) δ 10.45 (s, 2H), 8.06 (d, J = 2.4 Hz,





1H), 7.90 (d, J = 8.3 Hz, 2H), 7.71 (d, J = 8.2 Hz,





2H), 6.79-6.73 (m, 1H), 6.51 (s, 1H),





4.32-4.15 (m, 3H), 3.80-3.59 (m, 4H), 3.57-3.42 (m, J = 37.6 Hz,





1H), 2.44-2.28 (m, 1H), 2.28-2.10 (m, 4H),





0.54-0.47 (m, 2H), 0.44-0.36 (m, 2H).


569
483.50
1.12
1H NMR (400 MHz, DMSO) δ 7.34-7.17 (m, 3H),





6.92 (d, J = 9.0 Hz, 1H), 6.49 (d, J = 4.6 Hz, 1H), 4.65 (s,





1H), 4.49-4.10 (m, 3H), 3.73 (s, 2H), 3.69-2.93 (m,





5H), 2.30 (s, 3H), 2.21 (s, 3H), 2.18-1.94 (m, 2H),





1.93-1.73 (m, 2H), 1.23 (s, 6H).


570
508.70
1.42
1H NMR (400 MHz, DMSO) δ 7.43 (s, 1H), 7.24 (t, J = 8.8 Hz,





3H), 7.02-6.93 (m, 1H), 6.58 (d, J = 3.7 Hz,





1H), 6.14 (d, J = 3.9 Hz, 1H), 4.64 (dt, J = 12.1, 6.0 Hz,





1H), 3.97 (s, 2H), 3.57 (s, 4H), 3.32 (s, 3H), 3.08 (s,





2H), 2.14 (s, 4H), 1.80 (s, 2H), 1.29 (d, J = 6.0 Hz, 6H).


571
493.30
1.79


572
454.23
2.08
1H NMR (400 MHz, DMSO) δ 8.24 (s, 1H), 7.47 (s, 1H),





7.26-7.17 (m, 1H), 6.45 (d, J = 4.6 Hz, 1H),





4.86-4.73 (m, 1H), 4.43-4.29 (m, 1H), 4.29-4.18 (m, 2H),





3.89-3.72 (m, 1H), 3.45-3.21 (m, 3H), 3.18-3.00 (m, 1H),





2.31 (s, 3H), 2.25-2.13 (m, 4H), 2.07-2.00 (m, 1H),





1.90-1.74 (m, 2H), 1.32 (d, J = 6.0 Hz, 6H).


573
479.50
1.49


574
506.30
1.50


575
482.50
1.37


576
514.20
1.34


577
436.10
2.08


578
442.70
1.38
1H NMR (400 MHz, DMSO) δ 7.42 (d, J = 7.6 Hz, 1H),





7.05-6.92 (m, 2H), 6.58 (d, J = 3.8 Hz, 1H), 6.12 (d, J = 4.0 Hz,





1H), 5.06 (d, J = 5.2 Hz, 1H), 4.51 (d, J = 4.8 Hz,





2H), 4.34 (s, 1H), 4.06 (q, J = 6.8 Hz, 2H), 3.93 (s,





2H), 3.10 (s, 1H), 2.27 (s, 3H), 2.05 (d, J = 19.9 Hz,





3H), 1.76 (s, 2H), 1.33 (t, J = 6.9 Hz, 3H).


579
452.50
1.17
1H NMR (400 MHz, DMSO) δ 7.26-7.19 (m, 2H),





6.97 (d, J = 9.1 Hz, 1H), 6.57 (d, J = 3.5 Hz, 1H), 6.11 (d, J = 3.9 Hz,





1H), 4.64 (sept, J = 6.0 Hz, 1H), 4.51-4.07 (m,





1H), 3.92 (t, J = 5.8 Hz, 2H), 3.80-3.40 (m, 1H),





3.34-3.28 (m, 2H), 3.26-3.00 (m, 2H), 2.28 (s, 3H), 2.14 (s,





3H), 2.13-1.98 (m, 2H), 1.73 (t, J = 11.5 Hz, 2H),





1.29 (d, J = 6.0 Hz, 6H).


580
450.50
1.47


581
462.20
1.07
1H NMR (400 MHz, DMSO) δ 7.31 (d, J = 8.8 Hz, 2H),





7.27-7.17 (m, 1H), 6.92 (d, J = 8.9 Hz, 2H), 6.49 (d, J = 4.6 Hz,





1H), 4.36-3.57 (m, 4H), 3.35-3.27 (m, 3H),





3.27-3.16 (m, 5H), 2.30 (s, 3H), 2.20-1.99 (m, 2H),





1.93-1.75 (m, 2H), 1.69-1.49 (m, 6H).


582
489.50
1.20
1H NMR (400 MHz, DMSO) δ 7.28-7.22 (m, 2H),





6.95 (d, J = 8.8 Hz, 1H), 6.57 (d, J = 3.8 Hz, 1H), 6.11 (d, J = 3.9 Hz,





1H), 4.54 (t, J = 5.2 Hz, 1H), 4.07 (t, J = 6.2 Hz,





2H), 3.92 (t, J = 5.7 Hz, 2H), 3.58 (dd, J = 11.5, 6.2 Hz,





2H), 2.28 (s, 3H), 2.16 (s, 3H), 2.07 (s, 1H), 1.88 (p, J = 6.2 Hz,





2H), 1.75 (d, J = 10.7 Hz, 2H).


583
466.10
1.22
1H NMR (400 MHz, DMSO) δ 12.01 (s, 1H), 8.06 (s,





1H), 7.90 (d, J = 8.0 Hz, 2H), 7.75-7.63 (m, 2H),





6.78 (s, 1H), 6.55 (s, 1H), 4.42-4.18 (m, 2H), 4.18-3.85 (m,





2H), 3.70-3.52 (m, 3H), 3.36-3.16 (m, 1H),





2.90-2.63 (m, 3H), 2.37-1.96 (m, 5H), 0.54-0.46 (m, 2H),





0.43-0.35 (m, 2H).


584
497.50
1.16


585
518.30
1.47


586
440.24
1.87


587
512.50
1.26


588
526.50
1.72


589
526.20
1.33


590
402.15
2.25
1H NMR (400 MHz, DMSO) δ 7.47 (d, J = 8.7 Hz, 1H),





7.22-7.12 (m, 2H), 7.06 (d, J = 4.2 Hz, 1H), 6.17 (d, J = 4.2 Hz,





1H), 4.97 (s, 1H), 4.43-4.25 (m, 1H), 4.19 (t,





J = 5.9 Hz, 2H), 3.52-3.29 (m, 2H), 3.27-3.19 (m,





2H), 3.19-2.97 (m, 1H), 2.73 (q, J = 7.4 Hz, 2H),





2.54 (s, 3H), 2.26 (s, 3H), 2.20-1.93 (m, 2H), 1.87-1.61 (m,





2H), 1.51 (s, 6H), 1.04 (t, J = 7.4 Hz, 3H).


591
438.40
1.24


592
478.50
1.67
1H NMR (400 MHz, DMSO) δ 7.47 (d, J = 8.7 Hz, 1H),





7.19-7.12 (m, 2H), 5.99 (d, J = 3.5 Hz, 1H), 5.93 (d, J = 3.6 Hz,





1H), 4.96 (s, 1H), 4.39-4.18 (m, 1H), 3.77 (t,





J = 5.8 Hz, 2H), 3.63 (q, J = 11.2 Hz, 2H),





3.49-3.30 (m, 2H), 3.29-3.22 (m, 2H), 3.20-2.99 (m, 1H),





2.54 (s, 3H), 2.24 (s, 3H), 2.16-1.91 (m, 2H), 1.77-1.56 (m,





2H), 1.50 (s, 6H).


593
464.50
1.04
1H NMR (400 MHz, DMSO) δ 10.45 (s, 2H), 9.47 (s,





1H), 7.02 (s, 1H), 6.92 (d, J = 7.5 Hz, 1H), 6.83 (d, J = 8.1 Hz,





1H), 6.75 (s, 1H), 6.51 (s, 1H), 4.24 (s, 2H),





3.80 (s, 4H), 3.69 (s, 4H), 2.20 (d, J = 40.3 Hz, 4H).


594
410.50
0.95


595
450.50
1.50


596
532.50
1.76
1H NMR (400 MHz, DMSO) δ 9.54 (s, 1H),





7.29-7.16 (m, 1H), 7.10 (d, J = 7.9 Hz, 1H), 6.81 (d, J = 1.4 Hz,





1H), 6.76 (dd, J = 7.5, 1.5 Hz, 1H), 6.48 (d, J = 4.6 Hz,





1H), 4.48-4.27 (m, 1H), 4.27-4.17 (m, 2H),





3.67-3.41 (m, 1H), 3.41-3.21 (m, 3H), 3.21-2.93 (m, 1H),





2.30 (s, 3H), 2.19-1.97 (m, 5H), 1.93-1.68 (m, 2H).


597
436.30
1.32
1H NMR (400 MHz, DMSO) δ 7.29-7.15 (m, 2H),





6.97 (d, J = 9.1 Hz, 1H), 6.60 (d, J = 3.8 Hz, 1H), 6.14 (d, J = 3.9 Hz,





1H), 4.71-4.54 (m, 1H), 4.42-3.97 (m, 1H),





3.70 (s, 2H), 3.61-3.38 (m, 1H), 3.26-3.15 (m, 1H),





3.06-2.73 (m, 1H), 2.14 (s, 3H), 2.08 (s, 1H),





1.88-1.56 (m, 4H), 1.29 (d, J = 6.0 Hz, 6H), 1.09 (s, 6H).


598
464.40
1.53


599
470.24
2.68


600
567.50
1.65


601
424.50
1.35


602
488.30
1.72


603
440.50
1.47


604
458.24
2.34


605
427.30
1.18


606
440.24
1.82
1H NMR (400 MHz, DMSO) δ 7.06 (d, J = 4.2 Hz, 1H),





7.03-6.93 (m, 3H), 6.17 (d, J = 4.2 Hz, 1H),





4.66-4.53 (m, 1H), 4.45-4.11 (m, 3H), 3.77 (s, 3H),





3.69-3.29 (m, 2H), 3.29-2.94 (m, 3H), 2.73 (q, J = 7.4 Hz, 2H),





2.27 (s, 3H), 2.18-1.92 (m, 2H), 1.86-1.67 (m, 2H),





1.26 (d, J = 6.0 Hz, 6H), 1.04 (t, J = 7.4 Hz, 3H).


607
454.20
1.32


608
484.50
1.48


609
454.23
2.08


610
492.30
1.60


611
493.50
1.65
1H NMR (400 MHz, CDCl3) δ 7.28-7.22 (m, 3H),





6.83 (d, J = 8.2 Hz, 1H), 6.20 (d, J = 4.5 Hz, 1H), 4.57 (s,





1H), 4.19 (s, 2H), 3.86 (s, 3H), 3.77 (s, 1H), 3.38 (n,





2H), 2.23 (s, 3H), 1.97 (s, 2H), 1.76 (s, 2H), 1.18 (s,





6H), 0.98 (s, 1H).


612
464.50
1.50


613
410.50
1.31
1H NMR (400 MHz, DMSO) δ 7.04-6.88 (m, 3H),





6.57 (d, J = 3.4 Hz, 1H), 6.07 (d, J = 3.9 Hz, 1H),





4.66-4.50 (m, 1H), 4.06-3.81 (m, 2H), 3.77 (s, 3H),





3.63-3.43 (m, 1H), 3.35-3.28 (m, 3H), 3.27-3.09 (m, 1H),





2.34-2.20 (m, 4H), 2.20-1.64 (m, 3H), 1.42 (d, J = 7.0 Hz,





3H), 1.26 (d, J = 6.0 Hz, 6H).


614
480.40
3.08


615
438.17
1.97
1H NMR (400 MHz, CDCl3) δ 7.62 (t, J = 8.1 Hz, 1H),





7.19 (dd, J = 8.0, 1.6 Hz, 1H), 7.12 (dd, J = 11.9, 1.6 Hz,





1H), 6.29 (s, 1H), 4.57 (s, 1H), 3.92 (d, J = 5.5 Hz,





2H), 3.59 (s, 1H), 3.48 (s, 1H), 3.30 (s, 3H), 2.42 (s,





3H), 2.16 (s, 2H), 2.07 (d, J = 2.8 Hz, 1H), 2.01 (s, 2H),





1.65 (d, J = 0.8 Hz, 6H), 1.55 (s, 1H).


616
472.50
2.50


617
520.50
1.65


618
438.40
1.12


619
470.50
1.51


620
430.20
0.81


621
541.29
1.25
1H NMR (400 MHz, CDCl3) δ 7.01 (d, J = 1.9 Hz, 1H),





6.97 (dd, J = 8.2, 1.9 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H),





6.31 (d, J = 3.9 Hz, 1H), 5.91 (d, J = 3.8 Hz, 1H),





4.61-4.49 (m, 3H), 4.16 (t, J = 5.1 Hz, 2H), 3.87 (s, 3H),





3.69 (s, 1H), 3.49 (s, 1H), 3.37-3.18 (m, 2H), 2.82 (t, J = 12.9 Hz,





2H), 2.40 (s, 3H), 2.13 (s, 2H), 1.86 (s, 1H),





1.73 (d, J = 12.0 Hz, 3H), 1.50-1.42 (m, 1H), 1.38 (d, J = 6.1 Hz,





6H), 1.34-1.14 (m, 5H), 0.90 (d, J = 6.8 Hz,





6H).


622
551.70
1.61


623
478.30
1.20


624
442.12
2.26


625
400.13
2.49


626
426.21
2.81


627
504.50
1.41


628
476.30
0.92


629
436.50
1.41
1H NMR (400 MHz, DMSO) δ 7.57-7.40 (m, 1H),





7.23-7.09 (m, 2H), 6.60 (d, J = 3.5 Hz, 1H), 6.10 (s, 1H),





5.15-4.35 (m, 3H), 4.15-4.05 (m, 1H), 3.90-3.67 (m,





2H), 3.61-2.96 (m, 4H), 2.55 (s, 3H), 2.39-2.14 (m,





4H), 1.97-1.68 (m, 1H), 1.51 (s, 6H).


630
468.40
4.54
1H NMR (400 MHz, DMSO) δ 7.34 (d, J = 8.0 Hz, 2H),





7.27 (d, J = 8.1 Hz, 2H), 6.47 (s, 1H), 6.15-6.00 (m,





1H), 5.94 (d, J = 3.7 Hz, 1H), 5.28-5.06 (m, 1H),





4.42-4.17 (m, 1H), 3.86 (t, J = 5.8 Hz, 2H), 3.50-3.30 (m,





2H), 3.29-3.21 (m, 2H), 3.20-2.98 (m, 1H),





2.58-2.45 (m, 1H), 2.25 (s, 3H), 2.18-1.89 (m, 2H),





1.88-1.57 (m, 7H), 1.53-1.12 (m, 5H).


631
490.20
1.72


632
444.20
0.86


633
464.50
1.37


634
507.40
4.29
1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 2.0 Hz, 1H),





7.32-7.25 (m, 1H), 7.22 (dd, J = 4.4, 2.1 Hz, 1H),





7.04 (d, J = 8.4 Hz, 1H), 6.16 (d, J = 4.5 Hz, 1H), 5.94 (s,





1H), 4.53 (s, 1H), 4.35 (t, J = 6.0 Hz, 2H),





3.82-3.38 (m, 2H), 3.34 (t, J = 6.0 Hz, 2H), 3.29 (s, 1H), 2.41 (s,





3H), 2.13 (s, 2H), 1.81 (s, 2H).


635
456.50
1.34
1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 2.1 Hz, 1H),





7.34 (dd, J = 8.4, 2.1 Hz, 1H), 7.26 (dd, J = 4.0, 1.7 Hz,





1H), 6.94 (d, J = 8.5 Hz, 1H), 6.19 (d, J = 4.5 Hz, 1H),





4.57 (s, 1H), 4.19 (s, 2H), 4.14 (q, J = 7.0 Hz, 2H),





3.92-3.09 (m, 3H), 1.96 (s, 2H), 1.83-1.67 (m, 2H), 1.49 (t,





J = 7.0 Hz, 3H), 1.18 (s, 6H), 0.96 (s, 1H).


636
498.30
1.61
1H NMR (400 MHz, CDCl3) δ 7.48-7.35 (m, 2H),





7.02-6.87 (m, 2H), 6.53 (d, J = 3.8 Hz, 1H), 5.94 (d, J = 3.9 Hz,





1H), 5.30 (s, 1H), 4.49 (s, 1H), 4.17-3.93 (m, 2H),





3.82 (s, 2H), 3.76-3.13 (m, 5H), 2.39 (s, 3H),





2.28-1.95 (m, 3H), 1.80 (s, 2H), 1.43-1.25 (m, 6H).


637
466.30
1.18


638
489.50
1.57


639
470.50
1.45


640
510.70
1.37


641
444.50
1.33
1H NMR (400 MHz, DMSO) δ 7.29-7.17 (m, 2H),





6.98 (d, J = 9.1 Hz, 1H), 6.60 (d, J = 3.8 Hz, 1H), 6.10 (s,





1H), 5.18-4.74 (m, 1H), 4.73-4.59 (m, 1H),





4.59-4.17 (m, 1H), 4.17-4.03 (m, 1H), 3.90-3.75 (m, 2H),





3.62-2.95 (m, 4H), 2.30 (s, 3H), 2.25-2.16 (m, 1H),





2.14 (s, 3H), 1.94-1.74 (m, 1H), 1.29 (d, J = 6.0 Hz,





6H).


642
468.40
6.38


643
448.50
1.61


644
524.50
1.46


645
506.50
1.48


646
506.50
1.81
1H NMR (400 MHz, DMSO) δ 7.47 (d, J = 8.7 Hz, 1H),





7.21-7.13 (m, 2H), 6.60-6.51 (m, 1H), 6.19 (d, J = 4.0 Hz,





1H), 4.97 (s, 1H), 4.46-4.23 (m, 1H), 3.97 (t, J = 5.5 Hz,





2H), 3.55-3.22 (m, 4H), 3.20-2.96 (m, 1H),





2.54 (s, 3H), 2.28 (s, 3H), 2.23-1.95 (m, 2H),





1.84-1.63 (m, 2H), 1.51 (s, 6H).


647
500.50
2.74


648
417.30
1.17


649
552.50
1.54


650
502.10
2.31
1H NMR (400 MHz, Acetone) δ 8.05-7.94 (m, 2H),





7.77-7.68 (m, 2H), 6.62-6.53 (m, 1H), 6.18 (d, J = 4.0 Hz,





1H), 4.51 (d, J = 8.8 Hz, 1H), 4.16-4.03 (m, 2H),





3.62-3.41 (m, 4H), 3.30-3.16 (m, 1H), 2.75 (ddd, J = 9.6,





6.4, 4.0 Hz, 1H), 2.43 (s, 3H), 2.36-2.11 (m, 2H),





1.92 (t, J = 13.9 Hz, 2H), 1.23 (dd, J = 4.5, 2.4 Hz, 2H),





1.10 (dd, J = 7.9, 2.6 Hz, 2H).


651
535.50
1.41


652
422.10
0.88


653
554.20
1.13


654
514.70
1.41
1H NMR (400 MHz, DMSO) δ 7.41-7.26 (m, 1H),





7.26-7.13 (m, 2H), 6.60 (d, J = 3.8 Hz, 1H), 6.16 (d, J = 3.9 Hz,





1H), 4.80-4.56 (m, 1H), 4.46-4.12 (m, 1H),





3.70 (s, 2H), 3.64-2.81 (m, 3H), 2.09 (s, 1H), 1.93-1.53 (m,





4H), 1.30 (d, J = 6.0 Hz, 6H), 1.09 (s, 6H).


655
468.20
1.45


656
480.50
1.31
1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 7.50 (s, 1H),





6.47 (s, 1H), 4.73-4.59 (m, 2H), 4.03 (d, J = 13.4 Hz,





1H), 3.97 (t, J = 5.8 Hz, 2H), 3.55 (t, J = 12.7 Hz, 1H),





3.39-3.16 (m, 3H), 2.56-2.41 (m, 5H), 2.25 (s, 3H),





2.07 (d, J = 14.2 Hz, 1H), 1.90 (d, J = 14.5 Hz, 1H),





1.68 (s, 1H), 1.39 (d, J = 6.0 Hz, 6H).


657
485.40
1.66
1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 7.9 Hz, 1H),





7.30 (dd, J = 7.9, 1.6 Hz, 1H), 7.24 (s, 1H), 6.53 (d, J = 3.2 Hz,





1H), 5.94 (d, J = 3.9 Hz, 1H), 5.05 (dd, J = 8.4,





5.9 Hz, 2H), 4.84 (dd, J = 7.4, 5.9 Hz, 2H),





4.61-4.41 (m, J = 15.8, 7.9 Hz, 2H), 3.99 (s br, 2H), 3.55 (d br, J = 35.9 Hz,





2H), 3.34 (t, J = 6.0 Hz, 2H), 3.27 (s, 1H),





2.36 (d, J = 20.1 Hz, 3H), 2.26-2.13 (m, 4H), 2.15-2.00 (m,





1H), 1.91 (s, 1H), 1.72 (s, 1H).


658
448.10
1.26


659
454.50
1.71


660
490.50
1.10


661
480.50
1.69


662
506.50
1.55
1H NMR (400 MHz, DMSO) δ 7.34-7.17 (m, 3H),





6.97 (d, J = 8.4 Hz, 1H), 6.49 (d, J = 4.6 Hz, 1H),





4.51-4.09 (m, 3H), 3.82 (s, 3H), 3.69-2.96 (m, 5H), 2.30 (s, 3H),





2.17 (s, 3H), 2.15-1.97 (m, 2H), 1.93-1.74 (m, 2H).


663
450.30
1.49


664
520.50
1.51


665
458.24
2.37


666
515.50
2.49
1H NMR (400 MHz, DMSO) δ 7.05 (d, J = 1.8 Hz, 1H),





7.01 (d, J = 8.1 Hz, 1H), 6.92 (dd, J = 8.1, 1.9 Hz, 1H),





6.60 (d, J = 3.7 Hz, 1H), 6.16 (d, J = 3.9 Hz, 1H),





4.50-4.08 (m, 1H), 3.77 (s, 3H), 3.70 (s, 2H), 3.63-2.76 (m,





3H), 2.09 (s, 1H), 1.92-1.57 (m, 4H), 1.29 (s, 9H),





1.09 (s, 6H).


667
494.40
1.45
1H NMR (400 MHz, CDCl3) δ 7.15 (d, J = 7.7 Hz, 1H),





6.95-6.89 (m, 2H), 6.29 (s, 1H), 4.60 (s, 1H), 3.92 (t, J = 5.7 Hz,





2H), 3.86 (d, J = 11.1 Hz, 3H), 3.67 (s, 1H),





3.46 (s, 1H), 3.30 (s, 3H), 2.64 (q, J = 7.5 Hz, 2H),





2.42 (s, 3H), 2.08 (d, J = 57.9 Hz, 4H), 1.60 (s, 1H), 1.19 (t, J = 7.5 Hz,





3H).


668
454.50
1.52


669
539.50
1.35


670
458.13
1.91


671
569.20
1.76


672
468.70
1.54


673
447.30
2.07
1H NMR (400 MHz, DMSO) δ 7.51 (d, J = 2.1 Hz, 1H),





7.38 (dd, J = 8.5, 2.1 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H),





7.11 (d, J = 4.3 Hz, 1H), 6.19 (d, J = 4.2 Hz, 1H),





4.79-4.69 (m, 1H), 4.44-4.13 (m, 3H), 3.61-3.29 (m, 3H),





3.27-2.98 (m, 3H), 2.27 (s, 3H), 2.23-1.90 (m, 2H),





1.85-1.71 (m, 2H), 1.31 (d, J = 6.0 Hz, 6H), 1.05 (d, J = 6.8 Hz,





6H).


674
472.50
1.56


675
464.50
1.39


676
532.50
1.73


677
480.30
1.71


678
432.18
1.94


679
395.18
1.56


680
514.70
1.42


681
454.23
1.81


682
486.30
1.40
1H NMR (400 MHz, DMSO) δ 7.48 (d, J = 8.6 Hz, 1H),





7.22-7.14 (m, 2H), 6.64 (d, J = 3.5 Hz, 1H), 6.30 (d, J = 4.0 Hz,





1H), 4.97 (s, 1H), 4.08-4.00 (m, 2H),





3.98-3.42 (m, 9H), 2.98-2.71 (m, 2H), 2.55 (s, 3H),





1.93-1.71 (m, 2H), 1.51 (s, 6H).


683
494.20
4.87


684
450.30
1.17


685
476.50
1.36
1H NMR (400 MHz, DMSO) δ 7.26 (dd, J = 4.5, 2.2 Hz,





1H), 7.02 (d, J = 1.5 Hz, 1H), 7.01-6.95 (m, 2H),





6.56 (d, J = 4.6 Hz, 1H), 4.33 (s, 1H), 4.10 (s, 2H), 4.01 (t, J = 6.7 Hz,





2H), 3.78 (s, 3H), 3.57 (s, 2H), 3.27 (s, 1H),





2.26 (s, 1H), 1.95-1.83 (m, 2H), 1.83-1.66 (m, 3H),





1.62 (q, J = 6.7 Hz, 2H), 1.08 (s, 6H), 0.93 (d, J = 6.6 Hz,





6H).


686
536.40
1.88
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 7.5 Hz, 1H),





7.03-6.95 (m, 2H), 6.49 (s, 1H), 4.73 (s, 2H), 4.64 (d, J = 10.9 Hz,





1H), 3.98 (t, J = 5.5 Hz, 2H), 3.95-3.82 (m,





5H), 3.60 (s, 1H), 3.47 (d, J = 11.9 Hz, 1H),





3.37-3.26 (m, 2H), 3.20 (d, J = 11.6 Hz, 1H), 2.58-2.31 (m, 5H),





2.08 (d, J = 13.6 Hz, 1H), 2.02-1.99 (m, 2H), 1.90 (d, J = 13.3 Hz,





1H), 1.62 (s, 1H).


687
553.80
1.85
1H NMR (400 MHz, DMSO) δ 7.34 (d, J = 8.1 Hz, 2H),





7.27 (d, J = 8.1 Hz, 2H), 7.25-7.20 (m, 1H), 6.50 (d, J = 4.6 Hz,





1H), 4.49-4.29 (m, 2H), 4.24 (t, J = 5.7 Hz,





2H), 3.54-3.24 (m, 4H), 3.20-2.97 (m, 1H), 2.68 (s,





2H), 2.30 (s, 3H), 2.25-1.73 (m, 4H), 1.07 (s, 6H).


688
478.50
1.38


689
512.70
1.33
1H NMR (400 MHz, DMSO) δ 7.02-6.93 (m, 3H),





6.60 (d, J = 3.4 Hz, 1H), 6.20 (d, J = 3.9 Hz, 1H),





4.67-4.51 (m, 1H), 4.24-3.91 (m, 3H), 3.77 (s, 3H),





3.69-3.12 (m, 5H), 2.38-2.11 (m, 2H), 1.93-1.68 (m, 3H),





1.26 (d, J = 6.0 Hz, 6H), 0.64-0.49 (m, 4H).


690
492.50
6.09


691
425.30
0.91
1H NMR (400 MHz, CDCl3) δ 7.24-7.14 (m, 2H),





6.99 (t, J = 8.4 Hz, 1H), 6.53 (d, J = 3.8 Hz, 1H), 5.91 (d, J = 3.5 Hz,





1H), 4.59 (dt, J = 12.1, 6.1 Hz, 1H), 4.09 (d, J = 8.9 Hz,





1H), 3.78-3.17 (m, 5H), 2.28-1.86 (m, 2H),





1.63 (s, 3H), 1.38 (d, J = 6.1 Hz, 6H), 1.28 (d, J = 4.8 Hz,





3H), 0.78 (s, 1H).


692
454.50
1.52


693
514.50
1.53


694
458.20
1.00


695
496.70
1.58


696
402.25
2.15
1H NMR (400 MHz, DMSO) δ 7.54 (d, J = 2.0 Hz, 1H),





7.43 (dd, J = 8.5, 2.1 Hz, 1H), 7.25-7.21 (m, 1H),





7.20 (d, J = 8.6 Hz, 1H), 6.49 (d, J = 4.6 Hz, 1H),





4.47-4.16 (m, 3H), 3.90 (s, 3H), 3.69-2.92 (m, 5H), 2.30 (s, 3H),





2.19-1.95 (m, 2H), 1.95-1.74 (m, 2H).


697
470.50
1.47


698
432.13
2.12


699
454.28
2.12


700
470.50
1.31


701
480.50
1.19


702
524.50
1.33


703
428.16
1.66
1H NMR (400 MHz, DMSO) δ 7.27-7.19 (m, 2H),





7.05 (d, J = 4.2 Hz, 1H), 6.97 (d, J = 9.2 Hz, 1H), 6.16 (d, J = 4.2 Hz,





1H), 4.64 (hept, J = 5.9 Hz, 1H), 4.50-4.01 (m,





3H), 3.74-3.28 (m, 2H), 3.28-2.90 (m, 3H), 2.73 (q, J = 7.4 Hz,





2H), 2.27 (s, 3H), 2.14 (s, 3H), 2.12-1.95 (m,





2H), 1.85-1.63 (m, 2H), 1.29 (d, J = 6.0 Hz, 6H),





1.04 (t, J = 7.4 Hz, 3H).


704
438.40
1.48
1H NMR (400 MHz, CDCl3) δ 7.26 (dd, J = 5.4, 1.8 Hz,





2H), 6.97 (d, J = 1.6 Hz, 1H), 6.92 (dd, J = 7.9, 1.6 Hz,





1H), 6.19 (d, J = 4.5 Hz, 1H), 4.64 (s, 1H),





4.34-4.04 (m, 2H), 3.88 (s, 3H), 3.77 (s, 1H), 3.57 (s, 1H), 3.27 (s,





1H), 2.01 (s, 1H), 1.93-1.62 (m, 3H), 1.37 (s, 9H),





1.18 (s, 6H), 0.98 (s, 1H).


705
506.50
1.80


706
516.30
2.02


707
497.20
1.18
1H NMR (400 MHz, DMSO) δ 8.02 (s, 1H), 7.86 (d, J = 8.3 Hz,





2H), 7.67 (d, J = 8.3 Hz, 2H), 6.61 (d, J = 3.9 Hz,





1H), 6.21 (d, J = 3.9 Hz, 1H), 4.29-4.12 (m, 1H),





3.98 (t, J = 5.8 Hz, 2H), 3.50-3.17 (m, 5H),





2.43-2.09 (m, 3H), 1.99-1.68 (m, 3H), 0.65-0.35 (m, 8H).


708
523.40
3.83


709
466.50
1.22


710
416.50
1.35


711
482.70
1.35


712
479.20
1.14
1H NMR (400 MHz, CDCl3) δ 7.27 (dd, J = 8.6, 2.3 Hz,





2H), 6.83 (d, J = 8.1 Hz, 1H), 6.48 (s, 1H), 4.60 (s, 1H),





3.98 (t, J = 5.7 Hz, 2H), 3.85 (s, 3H), 3.72 (dd, J = 13.8,





7.0 Hz, 2H), 3.30 (s, 5H), 2.42 (d, J = 14.8 Hz, 5H),





2.23 (s, 3H), 2.15-1.82 (m, 2H), 1.58 (s, 2H), 1.25 (dd, J = 8.8,





5.2 Hz, 4H).


713
456.40
1.59


714
436.30
1.24


715
436.30
1.09
1H NMR (400 MHz, DMSO) δ 7.83 (d, J = 8.4 Hz, 2H),





7.66 (d, J = 8.4 Hz, 2H), 7.55 (s, 1H), 6.58 (d, J = 3.2 Hz,





1H), 6.12 (d, J = 3.9 Hz, 1H), 4.36 (d, J = 12.8 Hz,





1H), 3.93 (t, J = 5.7 Hz, 2H), 3.46-3.33 (m, 2H),





3.31-3.24 (m, 2H), 3.19-3.05 (m, 1H), 2.44 (s, 3H), 2.27 (s,





3H), 2.18 (d, J = 12.9 Hz, 1H), 2.02 (d, J = 13.9 Hz,





1H), 1.87-1.70 (m, 2H).


716
471.50
1.07


717
500.20
1.28


718
436.30
0.98
1H NMR (400 MHz, CDCl3) δ 7.02 (d, J = 1.8 Hz, 1H),





6.98 (dd, J = 8.2, 1.9 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H),





6.66 (d, J = 3.8 Hz, 1H), 6.15 (d, J = 3.9 Hz, 1H),





4.57 (dt, J = 12.1, 6.0 Hz, 1H), 4.40-4.30 (m, 1H), 4.19 (dd,





J = 11.9, 3.8 Hz, 1H), 3.88 (s, 3H), 4.03-3.56 (m, 5H),





3.40 (s, 2H), 3.28 (dd, J = 13.5, 5.2 Hz, 1H), 2.37 (s, J = 20.5 Hz,





3H), 2.34 (s, 1H), 2.04 (s, 1H), 1.86 (s, 2H),





1.38 (d, J = 6.1 Hz, 6H).


719
496.40
2.65


720
440.50
1.36
1H NMR (400 MHz, DMSO) δ 7.34 (t, J = 8.2 Hz, 1H),





6.90-6.79 (m, 2H), 6.59 (d, J = 3.8 Hz, 1H), 6.09 (d, J = 3.6 Hz,





1H), 4.79-4.53 (m, 1H), 4.48-4.21 (m, 1H),





3.70 (s, 2H), 3.61-3.42 (m, 1H), 3.28-2.84 (m, 2H),





2.13 (s, 1H), 1.87-1.55 (m, 4H), 1.27 (d, J = 6.0 Hz,





6H), 1.11 (s, 3H), 1.06 (s, 3H).


721
468.40
1.49
H NMR (400.0 MHz, CDCl3) δ 7.02-6.97 (m, 2H),





6.87 (d, J = 8.2 Hz, 1H), 6.53 (s, 1H), 5.99 (s, 1H), 4.54 (qn,





J = 6.1 Hz, 1H), 4.04 (s, 2H), 3.88 (s, 3H), 3.34 (s, 2H),





2.92 (d, J = 5.3 Hz, 4H), 2.40 (s, 3H), 2.14 (s, 2H),





1.82 (s, 2H) and 1.41-1.35 (m, 6H) ppm.


722
516.50
1.28
1H NMR (400 MHz, DMSO) δ 7.28-7.19 (m, 2H),





7.01-6.93 (m, 1H), 6.62 (d, J = 3.6 Hz, 1H), 6.22 (d, J = 3.0 Hz,





1H), 4.64 (dt, J = 12.1, 6.1 Hz, 1H), 4.01 (s, 2H),





3.41 (d, J = 37.7 Hz, 11H), 3.14 (d, J = 20.8 Hz, 3H),





2.87 (s, 3H), 2.14 (s, 4H), 1.86 (s, 2H), 1.29 (d, J = 6.0 Hz,





6H).


723
521.50
1.87
1H NMR (400 MHz, DMSO) δ 7.09-6.96 (m, 3H),





6.65 (d, J = 3.5 Hz, 1H), 6.33 (d, J = 3.3 Hz, 1H),





4.94-4.72 (m, 1H), 4.70-4.54 (m, 1H), 4.07-3.82 (m, 2H),





3.77 (s, 3H), 3.75-3.46 (m, 2H), 3.48-3.29 (m, 3H),





3.24-3.13 (m, 1H), 2.32 (s, 3H), 2.17-1.85 (m, 2H), 1.27 (d,





J = 6.0 Hz, 6H).


724
484.60
2.73


725
501.50
1.47


726
518.30
1.58


727
480.50
4.03


728
526.25
1.59


729
466.12
2.80


730
452.20
1.23


731
433.70
0.92


732
478.17
2.53


733
490.20
1.00


734
428.16
2.06


735
478.20
1.03


736
470.50
2.46


737
476.50
0.98
1H NMR (400 MHz, CDCl3) δ 7.26-7.22 (m, 1H),





7.22-7.02 (m, 1H), 6.79-6.70 (m, 2H), 6.17 (s, 1H), 4.70 (d,





J = 11.6 Hz, 1H), 4.30-4.07 (m, 2H), 3.81 (s, 3H),





3.56-3.45 (m, 1H), 3.45-3.34 (m, 1H), 3.31-3.15 (m, 1H),





2.44-2.23 (m, 3H), 2.02-1.93 (m, 1H), 1.89-1.71 (m,





2H), 1.71-1.60 (m, 1H), 1.21 (s, 3H), 1.13 (s, 3H),





0.96 (s, 1H).


738
464.50
1.49


739
596.50
1.71


740
462.50
1.71
1H NMR (400 MHz, CDCl3) δ 7.06 (d, J = 1.8 Hz, 1H),





7.00 (dd, J = 8.2, 1.9 Hz, 1H), 6.88 (d, J = 8.3 Hz, 1H),





6.54 (d, J = 3.2 Hz, 1H), 6.11 (d, J = 4.0 Hz, 1H),





4.57 (dt, J = 12.2, 6.1 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H),





4.09-4.03 (m, 2H), 3.97-3.91 (m, 2H), 3.88 (s, 3H),





3.85-3.71 (m, 3H), 2.97 (s, 2H), 1.91-1.82 (m, 2H),





1.77-1.66 (m, 1H), 1.38 (d, J = 6.1 Hz, 6H), 1.32 (t, J = 7.1 Hz,





3H).


741
524.40
1.96


742
491.50
1.56
1H NMR (400 MHz, DMSO) δ 7.52 (d, J = 8.3 Hz, 2H),





7.36 (d, J = 8.3 Hz, 2H), 6.60-6.53 (m, 1H), 6.19 (d, J = 4.0 Hz,





1H), 5.07 (s, 1H), 4.44-4.24 (m, 1H), 3.97 (t,





J = 5.7 Hz, 2H), 3.52-3.22 (m, 4H), 3.22-2.98 (m,





1H), 2.28 (s, 3H), 2.23-1.95 (m, 2H), 1.85-1.67 (m,





2H), 1.43 (s, 6H).


743
486.50
1.14


744
454.70
1.36


745
466.50
3.47
1H NMR (400 MHz, DMSO) δ 7.48 (d, J = 8.5 Hz, 1H),





7.42 (d, J = 8.5 Hz, 1H), 7.26-7.14 (m, 1H), 6.47 (d, J = 4.6 Hz,





1H), 4.47-4.28 (m, 1H), 4.24 (t, J = 5.9 Hz,





2H), 3.86 (s, 3H), 3.81-3.67 (m, 1H), 3.42-3.35 (m,





1H), 3.35-3.29 (m, 2H), 3.21-2.99 (m, 1H), 2.37 (s,





3H), 2.31 (s, 3H), 2.24-2.12 (m, 1H), 2.12-1.98 (m,





1H), 1.98-1.70 (m, 2H).


746
451.30
1.28


747
484.50
1.54
1H NMR (400 MHz, DMSO) δ 7.87-7.60 (m, 1H),





7.60-7.33 (m, 1H), 7.33-7.06 (m, 2H), 6.54 (d, J = 4.8 Hz,





1H), 5.35 (s, 1H), 4.30-4.06 (m, 1H), 3.62-3.03 (m,





5H), 2.46 (s, 3H), 2.24-1.77 (m, 4H), 1.62 (s, 6H),





1.49 (s, 6H).


748
510.70
1.65


749
468.30
1.91


750
464.30
1.11
1H NMR (400 MHz, DMSO) δ 7.89 (d, J = 8.0 Hz, 1H),





7.59-7.45 (m, 2H), 6.58 (d, J = 3.7 Hz, 1H), 6.12 (d, J = 3.9 Hz,





1H), 4.45-4.27 (m, 1H), 3.93 (t, J = 5.8 Hz,





2H), 3.57-3.43 (m, 1H), 3.43-3.01 (m, 5H), 2.65 (s,





3H), 2.27 (s, 3H), 2.23-1.65 (m, 4H), 1.17 (d, J = 6.8 Hz,





6H).


751
454.30
1.47
1H NMR (400 MHz, CD3CN) d 7.12 (d, J = 1.8 Hz, 1H),





7.07 (d, J = 8.0 Hz, 1H), 7.01 (dd, J = 8.0, 1.8 Hz, 1H),





6.60 (d, J = 3.4 Hz, 1H), 6.07 (d, J = 3.7 Hz, 1H),





4.42 (s, 1H), 4.12 (dd, J = 1.6, 0.9 Hz, 1H), 4.01 (t, J = 6.0 Hz,





2H), 3.85 (s, 3H), 3.79 (d, J = 1.7 Hz, 1H),





3.67-3.40 (m, 2H), 3.36 (t, J = 5.6 Hz, 2H), 3.20 (s, 1H),





2.36 (s, 3H), 2.18 (s, 2H), 2.00 (d, J = 0.7 Hz, 3H), 1.83 (s,





2H).


752
582.20
1.66









Assays for Detecting and Measuring NaV Inhibition Properties of Compound

E-VIPR Optical Membrane Potential Assay Method with Electrical Stimulation

Sodium channels are voltage-dependent proteins that can be activated by inducing membrane voltage changes by applying electric fields. The electrical stimulation instrument and methods of use are described in Ion Channel Assay Methods PCT/US01/21652, herein incorporated by reference and are referred to as E-VIPR. The instrument comprises a microtiter plate handler, an optical system for exciting the coumarin dye while simultaneously recording the coumarin and oxonol emissions, a waveform generator, a current- or voltage-controlled amplifier, and a device for inserting electrodes in well. Under integrated computer control, this instrument passes user-programmed electrical stimulus protocols to cells within the wells of the microtiter plate.
24 hours before the assay on E-VIPR, HEK cells expressing human NaV subtype, like NaV 1.7, are seeded in 384-well poly-lysine coated plates at 15,000-20,000 cells per well. Other subtypes are performed in an analogous mode in a cell line expressing the NaV of interest. HEK cells are grown in media (exact composition is specific to each cell type and NaV subtype) supplemented with 10% FBS (Fetal Bovine Serum, qualified; GibcoBRL #16140-071) and 1% Pen-Strep (Penicillin-Streptomycin; GibcoBRL #15140-122). Cells are grown in vented cap flasks, in 90% humidity and 10% CO2, to 100% confluence. They are usually split by trypsinization 1:10 or 1:20, depending on scheduling needs, and grown for 2-3 days before the next split.
Reagents and Solutions
100 mg/mL Pluronic F-127 (Sigma #P2443), in dry DMSO
Compound Plates: 384-well round bottom plate, e.g. Corning 384-well Polypropylene Round Bottom #3656
Cell Plates: 384-well tissue culture treated plate, e.g. Greiner #781091-1B
10 mM DiSBAC6(3) (Aurora #00-100-010) in dry DMSO
10 mM CC2-DMPE (Aurora #00-100-008) in dry DMSO
200 mM ABSC1 in H2O
Bath 1 buffer. Glucose 10 mM (1.8 g/L), Magnesium Chloride (Anhydrous), 1 mM (0.095 g/L), Calcium Chloride, 2 mM (0.222 g/L), HEPES 10 mM (2.38 g/L), Potassium Chloride, 4.5 mM (0.335 g/L), Sodium Chloride 160 mM (9.35 g/L).
Hexyl Dye Solution: Bath 1 Buffer+0.5% β-cyclodextrin (make this prior to use, Sigma #C4767), 8 μM CC2-DMPE+2.5 μM DiSBAC6(3). To make the solution Add volume of 10% Pluronic F127 stock equal to volumes of CC2-DMPE+DiSBAC6(3). The order of preparation is first mix Pluronic and CC2-DMPE, then add DiSBAC6(3) while vortexing, then add Bath 1+β-Cyclodextrin.
Assay Protocol
1) Pre-spot compounds (in neat DMSO) into compound plates. Vehicle control (neat DMSO), the positive control (20 mM DMSO stock tetracaine, 125 μM final in assay) and test compounds are added to each well at 160× desired final concentration in neat DMSO. Final compound plate volume will be 80 μL (80-fold intermediate dilution from 1 μL DMSO spot; 160-fold final dilution after transfer to cell plate). Final DMSO concentration for all wells in assay is 0.625%.
2) Prepare Hexyl Dye Solution.
3) Prepare cell plates. On the day of the assay, medium is aspirated and cells are washed three times with 100 μL of Bath 1 Solution, maintaining 25 μL residual volume in each well.
4) Dispense 25 μL per well of Hexyl Dye Solution into cell plates. Incubate for 20-35 minutes at room temp or ambient conditions.
5) Dispense 80 μL per well of Bath 1 into compound plates. Acid Yellow-17 (1 mM) is added and Potassium Chloride can be altered from 4.5 to 20 mM depending on the NaV subtype and assay sensitivity.
6) Wash cell plates three times with 100 μL per well of Bath1, leaving 25 μL of residual volume. Then transfer 25 uL per well from Compound Plates to Cell Plates. Incubate for 20-35 minutes at room temp/ambient condition
7) Read Plate on E-VIPR. Use the current-controlled amplifier to deliver stimulation wave pulses for typically 9 seconds and a scan rate of 400 Hz. A pre-stimulus recording is performed for 0.5 seconds to obtain the un-stimulated intensities baseline. The stimulatory waveform is applied for 9 seconds followed by 0.5 seconds of post-stimulation recording to examine the relaxation to the resting state. The stimulatory waveform of the electrical stimulation is specific for each cell type and can vary the magnitude, duration and frequency of the applied current to provide an optimal assay signal.
Data Analysis
Data are analyzed and reported as normalized ratios of background-subtracted emission intensities measured in the 460 nm and 580 nm channels. Background intensities are then subtracted from each assay channel. Background intensities are obtained by measuring the emission intensities during the same time periods from identically treated assay wells in which there are no cells. The response as a function of time is then reported as the ratios obtained using the following formula:




  
    R
    ⁡
    
      (
      t
      )
    
  
  =
  
    
      (
      
        
          intensity
          
            460
            ⁢
            
              
            
            ⁢
            nm
          
        
        -
        
          background
          
            460
            ⁢
            
              
            
            ⁢
            nm
          
        
      
      )
    
    
      (
      
        
          intensity
          
            580
            ⁢
            
              
            
            ⁢
            nm
          
        
        -
        
          background
          
            580
            ⁢
            
              
            
            ⁢
            nm
          
        
      
      )
    
  




The data is further reduced by calculating the initial (Ri) and final (Rf) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period. The response to the stimulus R=Rf/Ri is then calculated and reported as a function of time.
Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as tetracaine, and in the absence of pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above. The compound antagonist activity A is defined as:




  A
  =
  
    
      
        R
        -
        P
      
      
        N
        -
        P
      
    
    *
    100.
  




where R is the ratio response of the test compound

Electrophysiology Assays for NaV Activity and Inhibition of Test Compounds
Patch clamp electrophysiology was used to assess the efficacy and selectivity of sodium channel blockers in dorsal root ganglion neurons. Rat neurons were isolated from the dorsal root ganglions and maintained in culture for 2 to 10 days in the presence of NGF (50 ng/ml) (culture media consisted of NeurobasalA supplemented with B27, glutamine and antibiotics). Small diameter neurons (nociceptors, 8-12 μm in diameter) have been visually identified and probed with fine tip glass electrodes connected to an amplifier (Axon Instruments). The “voltage clamp” mode has been used to assess the compound's IC50 holding the cells at −60 mV. In addition, the “current clamp” mode has been employed to test the efficacy of the compounds in blocking action potential generation in response to current injections. The results of these experiments have contributed to the definition of the efficacy profile of the compounds.
IonWorks Assays.
Sodium currents were recorded using the automated patch clamp system, IonWorks (Molecular Devices Corporation, Inc.). Cells expressing Nav subtypes are harvested from tissue culture and placed in suspension at 0.5-4 million cells per mL Bath 1. The IonWorks instrument measures changes in sodium currents in response to applied voltage clamp similarly to the traditional patch clamp assay, except in a 384-well format. Using the IonWorks, dose-response relationships were determined in voltage clamp mode by depolarizing the cell from the experiment specific holding potential to a test potential of about 0 mV before and following addition of the test compound. The influence of the compound on currents are measured at the test potential.
1-Benzazepin-2-One Binding Assay
The sodium channel inhibiting properties of the compounds of the invention can also be determined by assay methods described in Williams, B. S. et al., “Characterization of a New Class of Potent Inhibitors of the Voltage-Gated Sodium Channel NaV 1.7,” Biochemistry, 2007, 46, 14693-14703, the entire contents of which are incorporated herein by reference.
The exemplified compounds of Table 1 herein are active against one or more sodium channels as measured using the assays described herein above as presented in Table 3.







TABLE 3







IC50: +++ <= 2.0 μM< ++ <= 5.0 μM < +










Cmpd.
Binned Activity



No.
Data














1
++



2
+++



3
+



4
+



5
+++



6
+++



7
+++



8
+++



9
+++



10
+++



11
+++



12
+++



13
+++



14
+++



15
+++



16
++



17
+++



18
+++



19
+++



20
+++



21
+



22
+



23
+++



24
++



25
+



26
++



27
+++



28
+++



29
+++



30
+



31
++



32
+++



33
+++



34
+++



35
+++



36
+



37
+++



38
++



39
+++



40
+++



41
+++



42
+



43
+



44
++



45
+++



46
+++



47
+++



48
+++



49
+++



50
+++



51
+++



52
+



53
+++



54
++



55
+++



56
+++



57
+++



58
+++



59
+++



60
+



61
++



62
+++



63
+



64
+++



65
+++



66
+++



67
+



68
++



69
+++



70
+++



71
+++



72
+++



73
++



74
++



75
+++



76
+



77
+++



78
++



79
+



80
+++



81
+++



82
+++



83
+++



84
+++



85
+++



86
+



87
+++



88
++



89
+++



90
+++



91
+++



92
+++



93
+++



94
++



95
+++



96
+++



97
+++



98
+++



99
++



100
+++



101
+++



102
+++



103
+++



104
+



105
+++



106
+++



107
+++



108
++



109
+



110
+++



111
+



112
+++



113
+++



114
+++



115
+++



116
+



117
+++



118
+++



119
+++



120
++



121
+



122
+++



123
+++



124
+++



125
++



126
++



127
+++



128
+++



129
+++



130
++



131
+++



132
+++



133
+++



134
+++



135
+++



136
+++



137
+++



138
+++



139
+



140
+++



141
+++



142
+++



143
+++



144
+++



145
+



146
+++



147
++



148
+++



149
+++



150
+++



151
+++



152
+++



153
+



154
++



155
+



156
+++



157
+



158
+++



159
++



160
+++



161
+++



162
+++



163
+



164
+++



165
+++



166
+



167
+++



168
+++



169
+++



170
+



171
+++



172
+++



173
+++



174
+++



175
+++



176
++



177
+



178
+



179
++



180
+++



181
+++



182
+++



183
+++



184
++



185
+++



186
+++



187
+++



188
+++



189
+++



190
+++



191
+++



192
+



193
+++



194
+++



195
+



196
+



197
+++



198
+++



199
+++



200
+++



201
+++



202
++



203
+++



204
+



205
+



206
+++



207
+++



208
+++



209
+++



210
++



211
+++



212
+++



213
+++



214
+++



215
+++



216
+++



217
+++



218
+



219
+++



220
++



221
+



222
+++



223
++



224
+



225
+



226
+++



227
+



228
+++



229
++



230
+++



231
+



232
+++



233
+++



234
+



235
+++



236
+++



237
+++



238
+++



239
+



240
+++



241
+



242
+++



243
+++



244
+++



245
+++



246
+



247
+++



248
+++



249
+++



250
+++



251
+++



252
+



253
+++



254
+++



255
+++



256
+



257
+++



258
+++



259
+++



260
++



261
+++



262
+++



263
+++



264
+++



265
+++



266
+++



267
++



268
+



269
+++



270
+++



271
+



272
++



273
++



274
+++



275
++



276
+++



277
+++



278
+



279
+++



280
+++



281
+++



282
+++



283
++



284
+++



285
++



286
+++



287
++



288
+++



289
+++



290
+++



291
+++



292
+



293
+



294
+++



295
+



296
+++



297
+++



298
+++



299
+++



300
+++



301
+



302
++



303
+



304
+++



305
+++



306
++



307
+++



308
+++



309
+



310
+



311
+++



312
+++



313
+++



314
+++



315
+++



316
+++



317
++



318
+++



319
+



320
+++



321
+



322
+++



323
+



324
+++



325
+++



326
+++



327
+++



328
+



329
++



330
++



331
+



332
+++



333
+++



334
+



335
+++



336
+++



337
+++



338
+++



339
+++



340
+++



341
+++



342
+



343
+++



344
++



345
+



346
+++



347
+++



348
+++



349
+++



350
+++



351
+



352
++



353
+++



354
+++



355
+++



356
+++



357
+++



358
++



359
+++



360
+++



361
+++



362
+



363
+++



364
+



365
+++



366
+++



367
+++



368
+++



369
+++



370
+++



371
+++



372
+++



373
+++



374
+



375
+++



376
++



377
+++



378
+++



379
+++



380
+++



381
+++



382
++



383
++



384
+++



385
+++



386
+++



387
+++



388
+



389
+++



390
+++



391
+



392
++



393
+



394
++



395
+++



396
+++



397
+++



398
+++



399
++



400
+



401
+++



402
++



403
+



404
+++



405
+++



406
++



407
++



408
+++



409
+++



410
+++



411
+++



412
+++



413
+++



414
++



415
+++



416
+



417
+



418
+++



419
+++



420
+++



421
+



422
+++



423
+++



424
+++



425
+



426
+++



427
+++



428
+++



429
++



430
+



431
++



432
++



433
+++



434
+



435
++



436
+++



437
+++



438
+++



439
+++



440
+



441
+++



442
+++



443
+++



444
+++



445
+++



446
++



447
+



448
+++



449
+++



450
+++



451
+



452
++



453
++



454
+



455
+++



456
++



457
+



458
++



459
+++



460
+++



461
+++



462
+++



463
+++



464
+++



465
+



466
+++



467
+++



468
+++



469
++



470
+++



471
+++



472
+



473
+



474
++



475
+++



476
+++



477
+++



478
+



479
++



480
+++



481
+++



482
++



483
+++



484
+++



485
+++



486
+++



487
+++



488
+++



489
+++



490
+++



491
+++



492
+++



493
+++



494
+++



495
+++



496
++



497
+



498
+++



499
+++



500
+++



501
+++



502
+



503
+++



504
+



505
+++



506
++



507
+



508
+++



509
+++



510
+++



511
+



512
++



513
+++



514
+



515
+



516
+++



517
+++



518
+++



519
+



520
+++



521
+++



522
+++



523
+++



524
+++



525
+++



526
+++



527
+



528
+++



529
+



530
+++



531
+++



532
+



533
+++



534
+



535
+



536
++



537
+++



538
+++



539
+



540
+



541
+++



542
+



543
+++



544
+++



545
++



546
+++



547
+



548
+++



549
+++



550
+++



551
+++



552
+++



553
+++



554
+++



555
+++



556
+++



557
+++



558
+



559
+++



560
+++



561
+++



562
+++



563
+++



564
+++



565
++



566
+++



567
+++



568
+++



569
+++



570
+++



571
++



572
+++



573
+++



574
+++



575
+++



576
+++



577
+



578
++



579
+++



580
+++



581
++



582
+++



583
+++



584
+++



585
+++



586
++



587
+++



588
+



589
+++



590
++



591
+++



592
+++



593
+++



594
+



595
+++



596
+



597
+



598
+++



599
+++



600
+++



601
+++



602
+++



603
+



604
+++



605
+



606
+



607
++



608
+++



609
++



610
+++



611
+++



612
+++



613
+



614
+



615
+



616
+++



617
+++



618
+



619
+++



620
++



621
+++



622
++



623
+++



624
++



625
+



626
+++



627
+++



628
+++



629
+++



630
+++



631
+



632
+++



633
+



634
+



635
++



636
+++



637
++



638
+++



639
+++



640
++



641
+++



642
+++



643
+++



644
+++



645
+++



646
+++



647
+++



648
+++



649
+++



650
+++



651
+++



652
+



653
++



654
+++



655
+++



656
+++



657
+++



658
+++



659
+



660
+++



661
+++



662
+++



663
+++



664
+++



665
+++



666
+++



667
+++



668
+++



669
+++



670
+



671
+++



672
+++



673
+++



674
+++



675
+++



676
+++



677
+



678
++



679
++



680
+++



681
++



682
+



683
+++



684
+



685
+++



686
+++



687
+++



688
+++



689
+



690
+++



691
+++



692
+++



693
+++



694
++



695
+++



696
+



697
+++



698
++



699
+++



700
+++



701
+++



702
+++



703
+



704
+++



705
+++



706
+++



707
+++



708
+++



709
+++



710
+++



711
+++



712
+++



713
++



714
+



715
+++



716
+++



717
+++



718
++



719
++



720
+



721
+++



722
+++



723
+++



724
+++



725
+



726
+++



727
+++



728
+++



729
+++



730
+++



731
++



732
+++



733
+++



734
+



735
+++



736
+++



737
+++



738
+++



739
+



740
+++



741
+++



742
++



743
+++



744
+++



745
+++



746
+++



747
+++



748
+



749
++



750
+



751
+++



752
+++










Many modifications and variations of the embodiments described herein may be made without departing from the scope, as is apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only.

## Claims

1. A compound of formula I:




or a pharmaceutically acceptable salt thereof,
wherein, independently for each occurrence:
R1 is H, C1-C8 alkyl, C3-C8 cycloalkyl, halo, CN, NR8SO2R8, SO2R8, SR8, SOR8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, heterocycloalkyl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8, or two R1 taken together form an oxo group;
R2 is H, C1-C8 alkyl, halo, C1-C8 haloalkyl, CN, OH, SO2R8, SR8, SOR8, COR8, CO2R8, CON(R8)2, SO2N(R8)2, CF3, CHF2, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, CF2, or NR8;
R3 is H, C1-C8 alkyl, C3-C8 cycloalkyl, CO2R8, COR8, COH, CON(R8)2, CF3, CH2CF3, CH2CHF2, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8;
R4 is H, C1-C8 alkyl, halo, C3-C8 cycloalkyl, wherein up to two CH2 units may be replaced by O, CO, S, SO, SO2, or NR8, or 2 R4 taken together form a fused 3 to 7 membered cycloalkyl ring;
R8 is H, C1-C8 alkyl, CF3, C3-C8 cycloalkyl, fluoroalkyl, aryl, heteroaryl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR, or 2 R8 taken together with the atoms to which they are attached form a ring;
R9 is H, CF3, CO2R, OH, aryl, heteroaryl, C3-C8 cycloalkyl, heterocycloalkyl, N(R)2, NRCOR, CON(R)2, CN, halo, or SO2R;
R is H, C1-C8 alkyl, aryl, heteroaryl, C3-C8 cycloalkyl, or heterocycloalkyl;
A is an aryl optionally substituted with one or more of C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, C3-C8 cycloalkoxy, halo, CN, OH, OR8, N(R8)2, NR8SO2R8, OSO2R8, SO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CHF2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C3-C8)-(R9)p wherein p is 1 or 2 and wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8;
or wherein two adjacent substituents on A together with the carbons to which they are attached form a ring comprising up to 2 heteroatoms;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, or 3; and
o is 0, 1, 2, 3, or 4.

2. The compound of claim 1, wherein A is




wherein:
R5 is H, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, halo, CN, OH, OR8, N(R8)2, NR8SO2R8, SO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CHF2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8;
R6 is H, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, C3-C8 cycloalkoxy, halo, CN, OH, OR8, N(R8)2, NR8SO2R8, SO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8;
R7 is H, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, halo, CN, OH, OR8, N(R8)2, NR8SO2R8, SO2R8, OSO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C3-C8)-(R9)p, wherein p is 1 or 2 and wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8; or
two occurrences of R5 and R6, or R6 and R7 are both C1-C8 alkyl and together with the carbons to which they are attached form an optionally substituted ring comprising up to 2 heteroatoms.

3. The compound of claim 2, wherein R5 is H, C1-C8 alkyl, C1-C8 alkoxy, halo, OCF3, OCHF2, R9, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR7.

4. The compound of claim 2, wherein R5 is H, CH3, OCH3, OCF3, OPh, Ph, OCHF2, or F.

5. The compound of claim 2, wherein R6 is H, C1-C8 alkyl, C1-C8 alkoxy, halo, R9, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8.

6. The compound of claim 2, wherein R6 is H, CH3, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, CF3, CN, Ph, SO2CH3, OH, CH(CH3)2, OCH2CH2CH2CH3, F, Cl, or CH2OH.

7. The compound of claim 2, wherein R7 is H, C1-C8 alkyl, C1-C8 alkoxy, SO2R8, OSO2R8, SO2N(R8)2, R9, OCHF2, OCF3, or a straight chain, branched, or cyclic (C3-C8)-(R9)p, wherein p is 1 or 2 and wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8.

8. The compound of claim 2, wherein R7 is H, CH3, CH2CH3, tBu, Cl, F, OH, C(═CH2)CH3, OC(═CH2)CH3, OCH3, OCH2CH2CH2CH3, CH2OH, OCH2CH2OH, OCH2CH2CH2OH, OtBu, OCH(CH3)(CH2CH3), OCH2C(CH3)2OH, C(CH3)2OH, CH2C(CH3)2OH, CH(OH)CH(CH3)2, C(CH3)2CH2OH, OCH2CH2CH(CH3)2, OCH2CH2CH3, OCH(CH3)2, OCH2CH2OCH3,




SO2CH3, SO2tBu, SO2CH2CH3, SO2CH2CH(CH3)2, SO2CH(CH3)2,




SO2NH(CH3), SO2NH(CH(CH3)2), SO2NH(CH2CH3), SO2NH(CH(CH3)2), SO2N(CH3)2,




OPh, Ph,




OCH2CH2OCH3, CH(CH3)2, SO2N(CH2CH2CH3)2, CH2CH2CH2CH3, CH2CH2CH3, OCH2CH2CH2CH3, CH2OPh,




OCH2Ph, CH2CH2CH2CH2CH3, OCH2CH3, OCH2CH(CH3)2, CH2Ph,




CCCH2OCH3, SO2CHF2, OCF3,




OCHF2,




CH2CH(CH3)2, OCH2tBu,




OCH2CF3,




CH2OCH2CH2CF3, CH2OCH2CF3, SO2CF3, C(CH3)2CH2CH3, C(CH2CH3)3, CH(OCH2CF3)2,




CF3, OCH2C(CH3)2F,




CH(OH)CH2OCH2CF3, CH(OCH2CF3)CH2OH, OSO2CF3,




or OCH2CH2OCF3.

9. The compound of claim 2, wherein




is:

10. The compound of claim 1, wherein the compound has formula IA:



wherein:
R2 is H, C1-C8 alkyl, halo, C1-C8 haloalkyl, CN, OH, SO2R8, SR8, SOR8, COR8, CO2R8 , CON(R8)2, SO2N(R8)2, CF3, CHF2, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, CF2, or NR8;
R3 is H, C1-C8 alkyl, CO2R8, COR8, COH, CON(R8)2, CF3, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with CF2, O, CO, S, SO, SO2 or NR8;
R6 is H, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, C3-C8 cycloalkoxy, halo, CN, OH, OR8, N(R8)2, NR8SO2R8, SO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8;
R7 is H, C1-C8 alkyl, C3-C8 cycloalkyl, C1-C8 alkoxy, halo, CN, OH, OR8, N(R8)2, NR8SO2R8, SO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8.

11. The compound of claim 10, wherein R2 is H, COCF3, COtBu, Cl, COCH3, CF2CF3, CH2CF3, CF3, CN, Br, COCH(CH3)2, COCH2CH3, CH(OH)CF3, SO2CH3,




COPh,

12. The compound of claim 10, wherein R3 is H, CH3, CH2CH3, CH2CH2OCH3, CH2CH2OH, CH2CO2CH2CH3, CH2CON(CH3)2, CH2CONH2, CH2CN, benzyl, cyclobutyl, CH2CH(CH2)2, CH(CH2)2, CH2CF3, CH2CHF2, COCH3, COCH2CH3, CO2CH3, CO2CH2CH3, COH, CONH(CH3)2, or CONHCH3.

13. The compound of claim 10, wherein R6 is H, CH3, OCH3, OCH2CH3, OCH2CH2CH3, OCH(CH3)2, CF3, CN, Ph, SO2CH3, OH, CH(CH3)2, OCH2CH2CH2CH3, F, Cl, or CH2OH.

14. The compound of claim 10, wherein R7 is H, CH3, CH2CH3, tBu, Cl, F, OH, C(═CH2)CH3, OC(═CH2)CH3, OCH3, OCH2CH2CH2CH3, CH2OH, OCH2CH2OH, OCH2CH2CH2OH, OtBu, OCH(CH3)(CH2CH3), OCH2C(CH3)2OH, C(CH3)2OH, CH2C(CH3)2OH, CH(OH)CH(CH3)2, C(CH3)2CH2OH, OCH2CH2CH(CH3)2, OCH2CH2CH3, OCH(CH3)2, OCH2CH2OCH3,




SO2CH3, SO2tBu, SO2CH2CH3, SO2CH2CH(CH3)2, SO2CH(CH3)2,




SO2NH(CH3),), SO2NH(CH(CH3)2), SO2NH(CH2CH3), SO2NH(CH(CH3)2), SO2N(CH3)2,




OPh, Ph,




OCH2CH2OCH3, CH(CH3)2, SO2N(CH2CH2CH3)2, CH2CH2CH2CH3, CH2CH2CH3, OCH2CH2CH2CH3, CH2OPh,




OCH2Ph, CH2CH2CH2CH2CH3, OCH2CH3, OCH2CH2CH2CH3, CH2Ph




CCCH2OCH3, SO2CHF2,OCF3,




OCHF2,




CH2CH(CH3)2, OCH2tBu,




OCH2CF3,




CH2OCH2CH2CF3, CH2OCH2CF3, SO2CF3, C(CH3)2CH2CH3, C(CH2CH3)3, CH(OCH2CF3)2,




CF3, OCH2C(CH3)2F,




CH(OH)CH2OCH2CF3, CH(OCH2CF3) CH2OH, OSO2CF3,




or OCH2CH2OCF3.

15. The compound of claim 10, wherein the




moiety is:

16. The compound of claim 1, wherein, independently for each occurrence:
R1 is H, C1-C6 alkyl, C3-C8 cycloalkyl, halo, CN, NR8SO2R8, SO2R8, SR8, SOR8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, heterocycloalkyl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8, or two R1 taken together form an oxo group, or a 3 to 7 membered fused cycloalkyl ring, or a 3 to 7 membered spirocyclic ring;
R2 is H, C1-C6 alkyl, C1-C6 haloalkyl, CN, OH, SO2R8, SR8, SOR8, CO2R8, CON(R8)2, SO2N(R8)2, CF3, CHF2, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, CF2, or NR8;
R3 is H, C1-C6 alkyl, C3-C8 cycloalkyl, CO2R8, COR8, COH, CON(R8)2, CF3, CH2CF3, CH2CHF2, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8;
R4 is H, C1-C6 alkyl, halo, C3-C8 cycloalkyl, wherein up to two CH2 units may be replaced by O, CO, S, SO, SO2, or NR8, or 2 R4 taken together form a fused 3 to 7 membered cycloalkyl ring;
R8 is H, C1-C6 alkyl, CF3, C3-C8 cycloalkyl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR, or 2 R8 taken together with the atoms to which they are attached form a ring;
R9 is H, CF3, CO2R, OH, aryl, heteroaryl, C3-C8 cycloalkyl, heterocycloalkyl, N(R)2, NRCOR, CON(R)2, CN, or SO2R;
R is H, C1-C6 alkyl, aryl, heteroaryl, C3-C8 cycloalkyl, or heterocycloalkyl.

17. The compound of claim 1, wherein R1 is C1-C8 alkyl or two R1 taken together with the atoms to which they are attached form a 3 to 7 membered fused cycloalkyl or spirocyclic ring.

18. The compound of claim 1, wherein R1 is CH3 or two R1 taken together form a fused cyclohexyl ring.

19. The compound claim 1, wherein R2 is H, C1-C8 alkyl, halo, CF3, CN, COR8, CON(R8)2, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, CF2, or NR8.

20. The compound of claim 1, wherein R2 is COCF3, COtBu, Cl, COCH3, CF2CF3, CH2CF3, CF3, CN, Br, COCH(CH3)2, COCH2CH3, CH(OH)CF3, SO2CH3,




COPh,

21. The compound of claim 1, wherein R3 is H, C1-C8 alkyl, CO2R8, COR8, COH, CON(R8)2 or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8.

22. The compound of claim 1, wherein R3 is H, CH3, CH2CH3, CH2CH2OCH3, CH2CH2OH, CH2CO2CH2CH3, CH2CON(CH3)2, CH2CONH2, CH2CN, benzyl, cyclobutyl, CH2CH(CH2)2, CH(CH2)2, CH2CF3, CH2CHF2, COCH3, COCH2CH3, CO2CH3, CO2CH2CH3, COH, CONH(CH3)2, or CONHCH3.

23. The compound of claim 1, wherein R4 is H, halo, or C1-C8 alkyl.

24. The compound of claim 1, wherein R4 is H, F, or CH3.

25. The compound of claim 1, wherein m is 0, 1, or 2.

26. The compound of claim 1, wherein n is 0, 1, or 2.

27. The compound of claim 1, wherein o is 0 or 1.

28. The compound of claim 1, wherein the compound is selected from the following table:

















1


 






2


 






3


 






4


 






5


 






6


 






7


 






8


 






9


 






10


 






11


 






12


 






13


 






14


 






16


 






17


 






18


 






19


 






20


 






23


 






24


 






25


 






26


 






27


 






28


 






29


 






30


 






31


 






32


 






33


 






34


 






35


 






36


 






37


 






38


 






39


 






40


 






41


 






42


 






43


 






45


 






46


 






47


 






48


 






50


 






51


 






52


 






53


 






54


 






55


 






56


 






57


 






58


 






59


 






60


 






61


 






62


 






64


 






65


 






66


 






67


 






68


 






69


 






70


 






71


 






72


 






73


 






74


 






75


 






76


 






77


 






78


 






79


 






80


 






81


 






82


 






83


 






84


 






85


 






86


 






87


 






88


 






89


 






90


 






91


 






92


 






93


 






94


 






95


 






96


 






97


 






98


 






99


 






100


 






101


 






102


 






103


 






104


 






105


 






106


 






107


 






108


 






109


 






111


 






112


 






113


 






114


 






115


 






117


 






118


 






119


 






120


 






121


 






122


 






123


 






124


 






125


 






126


 






127


 






128


 






129


 






130


 






131


 






132


 






133


 






134


 






135


 






136


 






137


 






138


 






139


 






140


 






141


 






142


 






143


 






144


 






145


 






146


 






147


 






148


 






149


 






150


 






151


 






152


 






153


 






154


 






155


 






156


 






158


 






160


 






161


 






163


 






164


 






165


 






166


 






167


 






168


 






169


 






170


 






171


 






172


 






173


 






174


 






175


 






176


 






177


 






179


 






180


 






181


 






182


 






183


 






184


 






185


 






186


 






187


 






188


 






189


 






190


 






191


 






192


 






193


 






194


 






195


 






197


 






199


 






201


 






202


 






203


 






204


 






205


 






207


 






208


 






209


 






210


 






211


 






212


 






213


 






214


 






215


 






216


 






217


 






218


 






219


 






220


 






221


 






222


 






223


 






224


 






225


 






226


 






227


 






228


 






229


 






230


 






231


 






232


 






233


 






234


 






235


 






236


 






237


 






238


 






239


 






240


 






241


 






242


 






243


 






244


 






245


 






246


 






247


 






249


 






250


 






251


 






252


 






253


 






254


 






255


 






256


 






257


 






258


 






259


 






260


 






262


 






263


 






264


 






265


 






266


 






267


 






268


 






269


 






270


 






271


 






272


 






273


 






274


 






275


 






276


 






277


 






278


 






279


 






280


 






281


 






282


 






283


 






284


 






285


 






286


 






287


 






288


 






289


 






290


 






292


 






294


 






295


 






296


 






298


 






299


 






300


 






301


 






302


 






303


 






304


 






306


 






307


 






308


 






309


 






310


 






311


 






312


 






313


 






314


 






315


 






316


 






317


 






318


 






319


 






320


 






321


 






323


 






324


 






325


 






326


 






327


 






328


 






329


 






330


 






332


 






333


 






334


 






335


 






336


 






337


 






338


 






339


 






340


 






341


 






342


 






343


 






344


 






347


 






348


 






349


 






350


 






351


 






352


 






353


 






354


 






355


 






356


 






358


 






359


 






360


 






361


 






362


 






363


 






364


 






366


 






367


 






368


 






369


 






370


 






372


 






373


 






374


 






375


 






376


 






377


 






380


 






381


 






382


 






383


 






384


 






385


 






386


 






387


 






388


 






389


 






390


 






391


 






393


 






394


 






395


 






396


 






397


 






398


 






399


 






400


 






401


 






402


 






403


 






404


 






405


 






406


 






407


 






408


 






409


 






410


 






411


 






412


 






413


 






414


 






415


 






416


 






417


 






418


 






419


 






420


 






421


 






423


 






424


 






425


 






426


 






427


 






428


 






429


 






430


 






432


 






434


 






435


 






436


 






437


 






439


 






440


 






441


 






442


 






443


 






445


 






446


 






447


 






449


 






450


 






451


 






452


 






454


 






455


 






456


 






457


 






458


 






459


 






460


 






461


 






462


 






463


 






464


 






466


 






467


 






469


 






470


 






471


 






472


 






473


 






474


 






475


 






476


 






477


 






478


 






479


 






480


 






482


 






483


 






484


 






486


 






487


 






488


 






489


 






491


 






492


 






493


 






494


 






495


 






496


 






497


 






498


 






499


 






500


 






501


 






502


 






504


 






505


 






506


 






507


 






508


 






509


 






510


 






511


 






512


 






513


 






514


 






515


 






516


 






517


 






519


 






520


 






521


 






522


 






523


 






524


 






525


 






526


 






528


 






529


 






530


 






531


 






532


 






533


 






534


 






535


 






536


 






537


 






538


 






539


 






540


 






541


 






542


 






543


 






544


 






545


 






546


 






547


 






548


 






549


 






550


 






551


 






552


 






553


 






554


 






555


 






557


 






558


 






559


 






560


 






561


 






562


 






563


 






564


 






565


 






566


 






567


 






568


 






569


 






570


 






571


 






572


 






574


 






575


 






576


 






577


 






578


 






579


 






580


 






582


 






583


 






584


 






585


 






586


 






587


 






588


 






589


 






590


 






591


 






592


 






593


 






594


 






595


 






596


 






597


 






598


 






599


 






600


 






601


 






602


 






603


 






604


 






606


 






607


 






608


 






609


 






610


 






612


 






613


 






614


 






615


 






616


 






617


 






618


 






619


 






620


 






621


 






622


 






623


 






624


 






625


 






626


 






627


 






629


 






630


 






631


 






632


 






633


 






634


 






635


 






636


 






637


 






639


 






640


 






641


 






642


 






643


 






644


 






645


 






646


 






647


 






649


 






650


 






651


 






653


 






654


 






655


 






656


 






658


 






659


 






661


 






662


 






663


 






664


 






665


 






666


 






667


 






668


 






669


 






670


 






671


 






672


 






674


 






675


 






676


 






677


 






678


 






679


 






680


 






681


 






682


 






683


 






685


 






686


 






687


 






688


 






689


 






690


 






692


 






693


 






694


 






695


 






696


 






697


 






698


 






699


 






700


 






701


 






702


 






703


 






704


 






705


 






706


 






708


 






709


 






710


 






711


 






713


 






714


 






715


 






716


 






717


 






719


 






720


 






721


 






722


 






723


 






724


 






726


 






727


 






728


 






730


 






732


 






733


 






734


 






735


 






736


 






738


 






739


 






740


 






741


 






742


 






743


 






744


 






745


 






747


 






748


 






749


 






750


 






751


 






752

29. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

30. A method of inhibiting a voltage-gated sodium ion channel in:
a patient; or
a biological sample;
comprising administering to the patient, or contacting the biological sample, with the compound of claim 1.

31. The method of claim 30, wherein the voltage-gated sodium ion channel is NaV 1.7.

32. A compound of formula I:




or a pharmaceutically acceptable salt thereof,
wherein, independently for each occurrence:
R1 is H, C1-C6 alkyl, C3-C8 cycloalkyl, halo, CN, NR8SO2R8, SO2R8, SR8, SOR8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, heterocycloalkyl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8, or two R1 taken together form an oxo group;
R2 is H, C1-C6 alkyl, C1-C6 haloalkyl, CN, OH, SO2R8, SR8, SOR8, CO2R8, CON(R8)2, SO2N(R8)2, CF3, CHF2, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, CF2, or NR8;
R3 is H, C1-C6 alkyl, C3-C8 cycloalkyl, CO2R8, COR8, COH, CON(R8)2, CF3, CH2CF3, CH2CHF2, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8;
R4 is H, C1-C6 alkyl, halo, C3-C8 cycloalkyl, wherein up to two CH2 units may be replaced by O, CO, S, SO, SO2, or NR8, or 2 R4 taken together form a fused 3 to 7 membered cycloalkyl ring;
R8 is H, C1-C6 alkyl, CF3, C3-C8 cycloalkyl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR, or 2 R8 taken together with the atoms to which they are attached form a ring;
R9 is H, CF3, CO2R, OH, aryl, heteroaryl, C3-C8 cycloalkyl, heterocycloalkyl, N(R)2, NRCOR, CON(R)2, CN, or SO2R;
R is H, C1-C6 alkyl, aryl, heteroaryl, C3-C8 cycloalkyl, or heterocycloalkyl;
A is an aryl optionally substituted with one or more of C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C3-C8 cycloalkoxy halo, CN, OH, OR8, N(R8)2, NR8SO2R8, SO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CHF2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8;
or wherein two substituents on A together with the carbon atoms to which they are attached form a ring comprising up to 2 heteroatoms;
m is 0, 1, 2, 3, or 4;
n is 0, 1, 2, or 3; and
o is 0, 1, 2, 3, or 4.

33. The compound of claim 32, wherein the compound has formula IA:



wherein:
R2 is C1-C6 alkyl, C1-C6 haloalkyl, CN, OH, SO2R8, SR8, SOR8, CO2R8, CON(R8)2, SO2N(R8)2, CF3, CHF2, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2, CF2, or NR8;
R3 is H, C1-C6 alkyl, CO2R8, COR8, COH, CON(R8)2, CF3, or a straight chain, branched, or cyclic (C1-C8)-R9 wherein up to two CH2 units may be replaced with O, CO, S, SO, SO2 or NR8;
R6 is H, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, C3-C8 cycloalkoxy, halo, CN, OH, OR8, N(R8)2, NR8SO2R8, SO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8;
R7 is H, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkoxy, halo, CN, OH, OR8, N(R8)2, NR8SO2R8, SO2R8, SOR8, SR8, CO2R8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, OCF3, OCHF2, R9, heterocycloalkyl, heterocycloalkoxy, aryl, heteroaryl, or a straight chain, branched, or cyclic (C3-C8)-R9 wherein up to three CH2 units may be replaced with O, CO, S, SO, SO2, or NR8.

34. The compound of claim 32, wherein the




moiety is selected from:

35. The compound of claim 32, wherein the compound is selected from the following table:

















1


 






2


 






3


 






4


 






6


 






7


 






8


 






9


 






10


 






11


 






12


 






13


 






14


 






15


 






16


 






17


 






18


 






19


 






21


 






22


 






23


 






24


 






25


 






26


 






27


 






28


 






31


 






33


 






35


 






36


 






37


 






38


 






39


 






40


 






41


 






42


 






43


 






44


 






45


 






46


 






48


 






49


 






50


 






53


 






54


 






55


 






56


 






57


 






59


 






61


 






62


 






63


 






64


 






66


 






68


 






69


 






70


 






71


 






72


 






73


 






74


 






76


 






77


 






78


 






79


 






80


 






81


 






82


 






83


 






84


 






85


 






87


 






89


 






90


 






91


 






92


 






93


 






95


 






96


 






97


 






98


 






99


 






100


 






102


 






103


 






104


 






105


 






106


 






107


 






108


 






109


 






113


 






114


 






116


 






117


 






118


 






119


 






120


 






121


 






122


 






123


 






124


 






125


 






126


 






127


 






128


 






129


 






130


 






132


 






133


 






135


 






136


 






137


 






138


 






139


 






140


 






141


 






142


 






143


 






144


 






145


 






148


 






149


 






150


 






151


 






152


 






153


 






155


 






156


 






157


 






158


 






159


 






161


 






162


 






164


 






165


 






166


 






167


 






168


 






169


 






170


 






171


 






172


 






173


 






177


 






179


 






180


 






181


 






182


 






184


 






186


 






187


 






188


 






190


 






191


 






192


 






193